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Abstract 
 
Cardiovascular disease, the single greatest killer in the western world, is credited with 
causing 48% of all deaths worldwide and is of huge economic importance in healthcare 
provision. The cardiac troponins are definitive indicators of cardiovascular disease and 
elevated levels of cardiac troponin I (cTnI) are highly-specific for cardiovascular damage.  
Using a specific targeting strategy, a panel of novel antibodies were successfully generated 
against key epitopes in cTnI that are of paramount importance for specific cardiovascular 
disease detection. Panels of both monoclonal and recombinant antibodies were generated 
and fully characterised. This approach required a combination of high-throughput assay 
screening with „state-of-the-art‟ multiplexed surface-plasmon resonance-based 
instrumentation. The selected antibodies were demonstrated to outperform current 
commercially available reagents. 
In addition, inherent difficulties associated with the use and expression of cardiac troponin 
I, the key target analyte, were investigated in detail and alternative recombinant constructs 
developed and evaluated. 
The antibodies ultimately selected were chosen for their applicability for integration on to a 
point-of-care risk-chip for cardiovascular disease determination due to their specificity, 
high affinity and genetic tailoring for deployment on a microfluidic device. This stage 
involved close collaboration with clinical and industrial partners and the commercial 
feasibility and performance of the antibodies are now under evaluation. 
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Chapter 1: Introduction 
 
  
  
1–2 
 
  
1.1 The immune system 
 
The immune system functions as a surveillance mechanism against infectious organisms 
and/or their toxic products. It can be characterised by two mechanisms; non-adaptive 
(innate) and adaptive (acquired) immunity [1]. Non-adaptive immunity is a general non-
specific response to foreign molecules and includes systems such as phagocytosis 
(macrophages), cell lysis (natural killer cells) and a host of chemical and physical elements 
[1, 2]. The key difference between the two mechanisms is the adaptive immunity‟s ability 
to improve and refine its response following exposure to antigens. Adaptive immunity is 
mediated mainly by the B-lymphocytes, a sub-group of white blood cells, which are 
responsible for the secretion of immunoglobulins. Terminally differentiated B-cells give 
rise to memory B-cells that immediately recognise an antigen post primary exposure and 
plasma cells, which are responsible for the secretion of antigen-specific antibodies [2-4]. 
 
1.1.1 Innate immunity  
 
Innate immunity is the body‟s first line of defence and consists of anatomic barriers and 
physiological barriers. Anatomic barriers, such as the skin and mucous membranes, prevent 
passive transfer of organisms. Physiological barriers including enzymes present in saliva 
and tears and the acidic nature of the stomach offer resistance to infection. Should these 
initial defences be overwhelmed a number of elements of the internal innate immune 
system become activated, such as those outlined in Table 1.1-1. 
 
Table 1.1-1: Cellular elements of the internal innate immune system 
Cell Action 
Mast  Pathogen defence, wound healing and recruitment of macrophages/neutrophils. 
Natural killer  Function to kill „non-self‟ cells. 
Phagocytes Engulf invading matter and recruitment of chemokines. 
Neutrophils Inhibit growth of bacteria and fungi. 
Dendritic  Antigen presentation to the adaptive immune system. 
Table adapted from [2]. 
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1.1.2 Acquired immunity 
 
The adaptive immune system is an antigen-specific system capable of mounting a cell-
mediated and humoral immune response. The adaptive immune system is only found in 
gnathostomata and confers immunological memory. T- and B-cells are the two major 
lymphocyte sub-groups associated with the adaptive immune system and are derived from 
hematopoietic cells within the bone marrow. T-cells play a role in cell-mediated responses 
and can be further categorised into helper and killer T-cells. Helper T-cells direct cells of 
the immune system whereas in contrast killer T-cells directly interact and destroy marked 
cells. B-cells function in the humoral response and recognise specific antigens via receptors 
on their surface (antibodies). One category of activated B-cells, called plasma cells, 
functions to secrete antigen-specific antibodies into the circulatory system. 
 
1.1.3 Antibody structure  
 
The terms immunoglobulin and antibody are used widely and interchangeably. The term 
“antibody” refers to a molecule that binds a known antigen while the term 
“immunoglobulin” describes this group of proteins irrespective of whether their antigen is 
known or not [1]. Immunoglobulins circulate freely in an individual‟s serum and control the 
humoral clearance of invading antigens. Antibodies are a family of glycoproteins that share 
structural and functional properties. There are five classes of immunoglobulin which are 
distinguished by their heavy chains; IgA, IgG, IgM, IgD and IgE and the properties of each 
are summarised in Table 1.1-2. 
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Table 1.1-2: Summary of the properties and function of antibody isotypes 
Isotype Form Action 
IgA Mono-, di-, trimer  Found in mucosal secretions. 
IgG Monomer 
Activates complement and involved in opsonisation and antibody-
dependent cell-mediated cytotoxicity (ADCC). 
IgM Pentamer 
Activates complement and is first isotype released in response to 
antigen. 
IgD Monomer B-cell receptor. 
IgE Monomer Allergic response by binding to mast cell surfaces. 
Table adapted from [1]. 
 
Class-switching of the heavy chains during gene rearrangement dictates the isotype of the 
immunoglobulin. There are two types of light chains, κ and λ, which combine with the 
heavy chain to form the complete antibody molecule [5]. IgG is the predominant class of 
antibody produced during the matured immune response (approximately 70% of the 
polyclonal antibody serum pool). However, IgM is the first antibody secreted in response to 
primary exposure (approximately 10% of the polyclonal serum pool). The basic structure of 
an immunoglobulin is outlined in Figure 1.1-1 and the more detailed ribbon structure is 
illustrated by Figure 1.1-2. The antibody molecule consists of four polypeptide chains, two 
heavy (H) chains each with a molecular weight of 50kDa and two light (L) chains of 25kDa 
each linked by disulphide bridges at the „hinge‟ region. The chains have both constant I and 
variable (V) regions. The heavy chain has one variable region (VH) and three constant 
regions (CH1, CH2 and CH3). The light chain has one variable region (VL) and one constant 
region (CL) [5]. The antibody molecule has several distinct regions. The Fc region consists 
of three domains; CH1, CH2 and CH3 that confer effector functions, such as complement 
activation, on the antibody. The Fab region is separated from the Fc by the flexible „hinge‟ 
region and Fv consists of the variable domains (VL and VH) that bring together the hyper-
variable regions of the antibody, known as the complementarity determining regions 
(CDRs). The antibody constant domains are conserved with only small differences in 
sequence found across the various antibody classes. The CDRs however, exhibit a high 
level of sequence diversity [6].  
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Figure 1.1-1: Overview of the basic immunoglobulin structure  
A typical IgG antibody molecule (~150kDa). The immunoglobulin is composed of two identical heavy 
chains consisting of constant (CH1, CH2, and CH3) and variable (VH) domains, associated by a disulphide 
bond (double red lines) at the „hinge‟ region of the molecule. The light chain consist of a constant (CL) and 
a variable (VL) domain that are linked with the heavy chain via a disulphide bond (single red lines). The 
molecule has three distinct regions. The variable fragment (Fv) determines the antigen-binding specificity 
of the antibody molecule and the antigen binding sites are indicated by the yellow triangles. Specificity is 
dictated by the complementarity determining regions (CDRs). The antigen binding fragment (Fab) contains 
the Fv and is separated by the hinge region from the crystallisable fragment (Fc). The Fc domain 
incorporates the carbohydrate element of the molecule (red dots) and confers effector functions on the 
antibody. 
 
Figure 1.1-2: Ribbon structure of IgG molecule 
Here the arrangement of the antiparallel-β strands is clearly illustrated and the stabilisation of the molecule 
via intra-strand hydrogen bonding is indicated. This image was downloaded online from [7]. 
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1.1.4 Antibody diversity  
 
At any point in time a huge number of different antibodies circulate within the serum of an 
individual. The human species is capable of generating 10
11
 different antibody molecules in 
response to multiple antigens. The diversity of antibodies in the immune system is achieved 
by gene recombination and somatic hyper-mutation (SHM) of the encoding genes [8]. An 
example of the encoding gene segments is outlined in Figure 1.1-3. In vertebrate genomes, 
there are 11 constant (CH), 123-129 variable (VH), 27 diverse (DH) and 9 joining (JH) gene 
segments that combine to encode the heavy chains. During B-cell development, the 
immunoglobulin loci undergo rearrangements [9]. Within the heavy chain locus, the VH-
DH-JH rearrange and this exon becomes linked to a combination of CH segments during 
transcription. Subsequently, the mRNA is translated into the immunoglobulin isotype 
specific to the lymphocyte. A similar chain of events occurs for the κ and λ loci, with the 
absence of D segments.  
The diversity introduced into the antibody population by these rearrangements is increased 
further by SHM, a process that introduces errors into the genes encoding the variable 
regions of the individual B-cells [10]. During a very narrow time frame of B-cell 
proliferation the locus undergoes an extremely high rate of mutation, predominantly base 
substitution [10], approximately one million times higher than the spontaneous rate of 
mutation across the genome [11, 12]. The introduction of random mutations results in 
antibodies that lose their affinity for the antigen and undergo cell death, or generates 
advantageous antibodies, where there is an affinity increase and subsequent proliferation of 
the associated antibody-producing clone of lymphocytes. 
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Figure 1.1-3: Genes encoding for human antibodies  
Immunoglobulin loci: Heavy chain (chromosome 14), κ light chain (chromosome 2) and λ light chain 
(chromosome 22). Variable (V), constant I, joining (J) and diverse (D) segments are shown. In the heavy 
chain locus the V-D-J segments are recombined in immature B-cells and linked by splicing to Cμ to produce 
mRNA encoding for IgM or Cδ to give mRNA encoding for IgD. mRNA encoding IgG is produced by 
splicing leading to recombination of Cγ2, Cγ4, Cε and Cα2 by deletion of the other five CH segments. This 
figure was adapted from [5, 9]. 
 
Exquisite specificity combined with the ability to refine and tailor antibody bio-physical 
properties has immense applications in therapeutics and diagnostics. Gargantuan advances 
in molecular biology and novel applications of antibody technologies have propelled 
antibody-based diagnostics forward. Biosensors is an area experiencing intense research to 
improve both patient diagnosis and prognosis and also areas such as environmental 
monitoring, counterterrorism, water monitoring, illicit drugs and food protection to name 
but a few.  
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1.2 Biosensors 
1.2.1 Introduction 
 
A biosensor can be described as a transducer that incorporates a biological recognition 
component as the key functional element. It consists of three main components as 
illustrated in Figure 1.2-1: the biorecognition element, the transducer and the signal display 
or readout [13]. The transduction system converts the interaction of the analyte with the 
biorecognition element to a measurable signal which is then visualised on a readout or 
display. Biosensors are powerful tools for the analysis of biomolecular interactions in 
clinical, biochemical and environmental analyses [14]. In the context of a medical setting, 
biosensors have the potential to provide rapid, real-time and accurate results in accident and 
emergency departments or at the physician‟s office. A typical example of this is the in vitro 
measurement of glucose (near patient) in diabetic patients [15]. The area of antibody-based 
sensors, with emphasis on improvements in antibody production and tailoring for the 
design of biosensors, is crucial for the next generation of useful sensor devices. 
 
 
Figure 1.2-1: Components of a biosensor 
a) Analyte interaction with the biorecognition element: this is facilitated by the specificity of the 
immobilised antibody for its cognate antigen (purple). Other biorecognition elements include enzymes, 
lectins, receptors and microbial cells. 
b) Signal transduction: converts the interaction of the analyte with the immobilised antibody into a 
quantifiable signal. 
c) Readout: shows the specific signal generated (yellow = non-specific analyte). 
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1.2.2 Antibodies and their significance in biosensor development 
 
The “enzyme electrode”, demonstrated by Clark and Lyons in 1962, was the first biosensor. 
This device coupled glucose oxidase to an amperometric electrode for monitoring oxygen 
levels in blood [16]. In 1987, Vo-Dinh and co-workers showed that antibodies could be 
utilised in situ for the detection of a chemical carcinogen in a fibre optic-based 
immunosensor [17]. Antibodies have since proven their worth as powerful tools for 
diagnostic applications, as illustrated by Table 1.2-1. Essentially, the specificity of the 
biosensor depends on the biorecognition element, which is capable of „sensing‟ the 
presence of an analyte [13, 14]. Immunosensors utilising antibody-based recognition 
elements, have been developed on a wide range of transduction platforms for a multitude of 
analytes. The transducer element translates the selective recognition of the analyte into a 
quantifiable signal and thus, has a major influence on sensitivity [18]. Transduction 
approaches include electrochemical, piezoelectric and optical systems [19]. 
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Table 1.2-1: Examples of antibody-based biosensors 
Transducer Analyte detected Antibody form Ref. 
Electrochemical    
 Potentiometric Terbuthylazine Monoclonal [20] 
  Hepatitis B surface antigen Not specified [21] 
  Diphtherotoxin  Monoclonal [22] 
 Amperometric E. coli O157:H7 Polyclonal [23] 
  Carcinoembryonic antigen (CEA) Not specified [24] 
  Aflatoxin M1 Monoclonal [25] 
  Progesterone Monoclonal [26] 
 Impedance Listeria monoctogenes (Internalin B) Polyclonal [27] 
Piezoelectric    
  E. coli O157:H7 Polyclonal [28] 
  Canine IgG isoforms Monoclonal [29] 
  Cocaine derivative (BZE-DADOO) Polyclonal [30] 
  Atrazine Monoclonal [31] 
  Bacillus anthracis Polyclonal [32] 
  Francisella tularensis Polyclonal [33] 
Optical    
 SPR Urediniospores Monoclonal [34] 
  Polychlorinated biphenyls Monoclonal [35] 
  Vitellogenin (Carp) Monoclonal [36] 
  Campylobacter jejuni Polyclonal [37] 
  Listeria monocytogenes Monoclonal [38] 
  Okadaic acid Polyclonal [39] 
 Resonant Mirror Listeria monocytogenes Monoclonal [40] 
 TIRF Testosterone (also RIfS) Monoclonal [41] 
  Carbohydrates (maltose and panose) Monoclonal [42] 
 RIfS Estrone Polyclonal [43] 
  Tuberculosis (also interferometry) Monoclonal [44] 
  Cell adhesion Monoclonal [45] 
 OWLS Trifluralin Polyclonal [46] 
  Sulfamethazine Not specified [47] 
 Interferometry Atrazine Monoclonal [48] 
  Hepatitis B virus surface antigen Not Specified [49] 
 Ellipsometry Mycotoxin T-2 (TIRE also QCM) Mono-and polyclonal [50] 
  Salmonella typhimurium Monoclonal [51] 
 Fibre Optic Listeria monocytogenes (Imaging) Polyclonal [52] 
  Bacillus anthracis (evanescent wave FO) Not Specified [53] 
  Raptor™ - biothreat (e.g. B. anthracis) Various monoclonal Abs [54] 
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Antibodies are ideal biorecognition elements due to their exquisite specificities and strong 
affinities for cognate antigens.  Figure 1.2-2 presents an overview of the generation of 
polyclonal [55, 56], monoclonal [56, 57] and recombinant antibodies [58, 59] from 
immunised repertoires. Antibodies have had numerous successful applications in the area of 
diagnostics with monoclonal and polyclonal antibodies exploited in many biosensors, as 
illustrated by Table 1.2-1. Polyclonal antibodies are derived from multiple plasma cells and 
monoclonal antibodies are derived from a single clonal hybridoma, all of which have 
terminally differentiated in response to an antigen [4, 55]. Recombinant antibodies, 
discussed at length in section 5.1, are the product of genetic manipulation of antibody 
genes. The specific characteristics of polyclonal, monoclonal and recombinant antibodies 
are outlined in Table 1.2-2. While each have relative advantages the modular nature of 
recombinant antibodies make them highly attractive for tailored antibody development. 
 
Table 1.2-2: Characteristics of poly-, mono- and recombinant antibodies 
 Polyclonal Monoclonal  Recombinant 
Ease of production  ++++ +++ +++ 
Low Cost ++++ ++ +++ 
Stability
1
 +++ ++ ++ 
Commercial availability ++++ +++ + 
Ease of immobilisation ++++ ++++ +++++ 
Sensitivity (affinity) +++ ++++ +++++ 
Potential to engineer affinity - - (unless convert to rAb) +++++ 
 
                                                 
1
 Stability of the recombinant antibody is dependent on the format  
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Figure 1.2-2: Overview of the routes to antibody generation 
This image illustrates the basic route to antibody generation including poly-, mono-, and recombinant 
pathways. LOD; limit of detection, LOQ; limit of quantitation. 
 
Key parameters exist for the successful exploitation of antibodies in sensor-based analysis 
and recombinant antibody technology represents a viable avenue for molecular evolution 
and specific-tailoring to address these key parameters (discussed in detail in sections 5.1 
and 6.1). The ability to generate and tailor highly-specific antibodies for diagnostic 
applications has huge potential to meet the current challenges facing high-sensitivity rapid 
cardiovascular disease diagnosis in accident and emergency rooms. 
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1.3 Cardiovascular disease 
1.3.1 Overview 
 
Cardiovascular disease (CVD) is the biggest single killer in the western world [60, 61]. In 
Europe, CVD is responsible for over 4.3 million deaths, a staggering 48% of all deaths. The 
healthcare and associated costs of the disease are estimated at €192 billion per year, an 
average of €233 per EU resident [62]. CVD is also reported as the most frequent cause for 
hospitalisation in developed countries [63]. Improvements in the diagnosis, prognosis and 
treatment of cardiac disease can have an impact on patient outcome alleviating hospital 
congestion and reducing the costs of the disease on the health services [60, 61, 64]. 
Acute coronary syndrome (ACS) refers to disease of the coronary arteries and is discussed 
in detail in section 1.3.2. The diagnosis of ACS is one of the most difficult challenges that 
medical practitioners face [65]. The ability to diagnose a patient presenting with acute chest 
pain is imperative to the patient‟s outcome. In fact, a large number of malpractice payments 
for emergency department physicians are due to failure in diagnosis of acute myocardial 
infarction (AMI) which can be also referred to as myocardial infarction (MI) and is 
commonly known as heart attack [66, 67]. A major problem which currently faces the use 
of conventional biomarkers is that they are often not useful for diagnosis at the time of the 
patient‟s arrival to the accident and emergency department [65]. The world health 
organisation (WHO) developed a definition of AMI in 1997. This definition required two of 
the three following criteria to be satisfied; chest pain (myocardial ischemia), 
electrocardiography (ECG) irregularities and detectable laboratory changes [65]. In 2000, 
the definition of AMI was re-defined by the European Society of Cardiology and the 
American College of Cardiology joint committee to place greater emphasis on the role of 
biomarkers in the diagnosis of MI and AMI (Table 1.3-1). In 2007, a joint consensus 
document from the European Society of Cardiology (ESC), the American College of 
Cardiology Foundation (ACCF), the American Heart Association (AHA) and the World 
Heart Foundation (WHF) further revised the definition. This revision added the weight of 
additional scientific and clinical experiences to the 2000 definition [68, 69]. 
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Table 1.3-1: Definition of myocardial infarction (MI). Criteria for acute, evolving or recent MI 
Any of the following criteria: 
a) Typical rise and gradual fall (troponin) or more rapid rise and fall (CK-MB) of biochemical 
markers of myocardial necrosis with at least one of the following; 
i. Ischemic symptoms. 
ii. Development of pathological Q-waves in the ECG. 
iii. ECG changes indicative of ischemia (ST segment elevation).  
iv. Coronary artery intervention (angioplasty).  
b) Pathological findings of MI. 
Table adapted from [70]. 
 
1.3.2 Pathophysiology 
 
“Almost all MI’s are as a result of coronary atherosclerosis and generally with 
superimposed coronary thrombosis” [71]. 
 
Numerous clinical symptoms become evident after the disruption of a coronary plaque and 
are collectively referred to as ACS [66]. Atherosclerotic plaque rupture, the underlying 
basis for ACS [64], is illustrated in Figure 1.3-1. Atherogenesis causes the development of 
atheromatous coronary artery plaques, a process which begins quite early in life [67], 
characterised by the remodelling of the arteries and the accumulation of fatty acid 
substances [64, 72]. There are several genetic and lifestyle factors which lead to increased 
risk; sex (especially male), advanced age, diabetic conditions, smoking and a family history 
of coronary disease [67, 72]. Intra-coronary thrombosis has long been associated with AMI 
[73] and the importance of stabilising the plaque to prevent rupture has become 
increasingly pivotal to ACS treatment [64, 74]. Lesions which tend to rupture have a large 
lipid core overlaid by a fibrous cap. Owing to the ongoing inflammatory response, matrix 
degradation and cell death destabilises the plaque and subsequent rupture occurs at the 
shoulder where the fibrous cap is thin [74, 75]. The rupture of this lipid rich structure 
exposes blood to procoagulants triggering thrombosis (Figure 1.3-1) [64, 74].  
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Figure 1.3-1: Atherogenesis leading to thrombosis formation 
Plaque rupture leads to intracoronary thrombosis, where the thrombus restricts blood flow and this 
restriction is often asymptomatic. During ischemia the resulting restriction in the supply of oxygen to the 
myocardium can lead to unstable angina and subsequently a necrotic state, causing irreversible damage. 
This image was taken from [76] and adapted from [67]. 
 
Clinicians divide patients presenting with AMI into those with Q-wave and those with non-
Q-wave infarct, which is based on the ECG pattern. Q-waves indicate the loss of 
electrically functioning cells and refers to a transmural infarction while a non-Q-wave ECG 
refers to a subendocardial infarction. The classification of ACS by ECG pattern is shown in 
Figure 1.3-2 and outlines the difficulties in diagnosing AMI on the basis of ECG alone. 
This asserts the absolute requirement for biochemical markers to differentiate between 
patients exhibiting Q-wave or non-Q-wave infarct and unstable angina. The treatment for 
non-ST-elevation-myocardial infarction (NSTEMI) and ST-elevation-myocardial infarction 
(STEMI) varies dramatically and the correct categorisation is imperative [66].  Medically, 
the ST segment refers to the period from the end of ventricular depolarisation to the 
beginning of ventricular repolarisation on the ECG. The ischemic discomfort felt during 
NSTEMI can be unstable angina, but may also become much more serious and cause 
irreversible myocardial damage (non-Q-wave-MI) [70].  
After the initial myocardial infarction there is a reduction in cardiac output and the 
increased pressure on the heart results in heart failure. The body attempts to maintain 
cardiac output and blood flow to the extremities using several mechanisms. These include 
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the adrenergic nervous system, the angiotensin (rennin-aldosterone) system, inflammatory 
cytokines and growth factors [77]. These mechanisms cause a difference in gene expression 
resulting in disadvantageous functional and structural changes, a process known as left 
ventricular remodelling [77]. This structural and functional change of the myocytes leads to 
systolic and diastolic dysfunction. Changes in the myocardium (dilated and ischemic 
cardiomyopathy) result in hypertrophy and a heart chamber with reduced contractibility due 
to dilation [77]. These events and those leading to myocardial infarction give rise to new 
strategies for biochemical marker development [63, 65-67, 70, 72, 77, 78] and highlights 
the necessity for biochemical markers to help guide intervention and positively impact 
prognosis. 
 
 
Figure 1.3-2: Route to the classification of acute coronary syndrome by electrocardiography pattern 
a) The majority of patients presenting with ischemic discomfort where there is no ST elevation in the 
ECG are experiencing unstable angina or non-ST-elevation-myocardial infarction (NSTEMI), which 
does not evolve Q-waves in ECG. 
b) Patients presenting with ST-elevation (STEMI) ultimately go on to develop Q-wave myocardial 
infarction, but a minority may develop non-Q-wave myocardial infarction.  
This figure was adapted from [70, 71]. 
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1.3.3 Biomarkers of cardiovascular disease 
1.3.3.1 Overview 
 
In 1954, La Due et al. demonstrated use of the first biochemical marker, serum glutamic 
oxalaoacetic transaminase, to investigate transmural myocardial injury [79]. Since then an 
explosion of interest and research in both the clinical and analytical development of more 
suitable biomarkers of ACS has ensued [80, 81]. Combined with a better understanding of 
the pathophysiology of ACS, advances in proteomics and genomics are providing new 
biomarkers for exploitation as analytical tools in diagnosis and treatment of patients [81]. 
Biochemical markers of cardiac injury have a pivotal role in a clinical setting for the 
effective diagnosis, treatment, prognosis and risk stratification of patients presenting with 
symptoms of AMI [67]. Accordingly, widespread research aimed to indentify unique 
biochemical markers and also to integrate those markers into detection systems for use in 
point-of-care devices (POC). This has reduced the need for laboratory testing and provides 
rapid, accurate and precise results [67].  
 
1.3.3.2 The ‘golden’ biomarker 
 
The specificity of the marker for the target organ, the heart, is of crucial importance for 
clinical diagnosis. Other key attributes of an ideal marker are summarised in Table 1.3-2. 
The size of a prospective biomarker is important as it controls the rate of release during a 
cardiovascular event and the kinetics of that release has an impact on the speed of diagnosis 
[78, 80]. The location of the biomarker determines its rate of release with structural proteins 
appearing in the blood slower than cytoplasmic ones [80]. Prolonged persistence of a 
biomarker in circulation is of diagnostic value for patients presenting late, after the early 
markers return to normal levels [60, 80]. To ensure cardiovascular specificity, the 
concentration of the biomarker must be high in cardiac tissue with relatively low 
concentrations in non-cardiac related tissues [66, 80]. The distribution of the biomarker 
within the body under normal physiological and in pathological conditions is of 
considerable importance. The use of biomarkers for infarction sizing is beneficial for 
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prognosis as the extent of biomarker release may be correlated to the degree of necrosis, 
indicating its severity [66, 80]. The necessity to differentiate between reversible (ischemia) 
and irreversible damage (necrosis), combined with positive outcomes from the physicians 
intervention and defining a risk score, are paramount [66]. Ultimately, any new biomarkers 
require thorough evaluation within a large, statistically relevant cohort of clinical studies 
before being accepted into clinical practice [66]. Unfortunately, no one biochemical marker 
identified to date meets all the criteria outlined in Table 1.3-2 [60, 80]. Therefore, it is 
necessary to examine multiple markers of cardiovascular injury to aid current standard 
practices in accident and emergency departments. This movement towards multiplexed 
assays is currently under enthusiastic investigation [81, 82]. 
 
Table 1.3-2: The characteristics of an ideal biochemical marker 
Characteristic Notes 
Size [67] 
Small markers are released faster from injured tissue and undergo 
rapid clearance. 
Localisation [67] 
Soluble cytoplasmic markers are desirable as they appear in the 
blood stream more rapidly than structural markers. 
High sensitivity [83] 
Early diagnosis due to early release of the marker. 
Prolonged presence in the serum for late diagnosis (longer half-life). 
High specificity [83] 
Present only in myocardial tissues. 
Not present in non-afflicted individuals. 
Allow differentiation between ischemia and necrosis [67]. 
Analytical characteristics [83] 
Detectable and measurable by a low cost assay. 
Ease of test procedure. 
Rapid analysis. 
Sufficient sensitivity and precision. 
Clinical characteristics 
Release of marker directly proportional to the size of the injury. 
Peak levels reached soon after injury to provide diagnosis time [67]. 
Results that can dictate/influence intervention. 
Results that can improve patient outcome. 
Adapted from [60, 65, 67, 83]. 
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1.3.3.3 Clinical considerations 
 
Before discussing the current and emerging biomarkers, clinical considerations must be 
taken into account. Biomarkers need to provide useful, reliable and accurate information for 
clinicians and physicians alike. 
The necessity for serial sampling in the diagnosis of ischemia and/or necrosis is vital due to 
the rapid changes in biomarker concentration with respect to time and extent of injury 
which is currently recommended by established guidelines [61, 63, 67, 78, 81, 84]. Single 
sampling gives low sensitivity for AMI diagnosis due to the differing release kinetics of 
each biomarker [67], implying that a single measurement may be early or late for AMI 
detection leading to misdiagnosis [60]. By monitoring the serum levels over time the 
biomarker concentration profile can indicate the extent of cardiac damage or if the 
therapeutic intervention was effective. Any rapid change in the concentration of a 
biomarker is in response to some cardiac event or is indicative of the potential onset of a 
cardiovascular event and may improve the speed at which medical intervention is taken for 
a patient presenting with suspected AMI (measurement time from symptom onset) [63]. 
The development of point-of-care devices would have a huge impact on the serial 
measurement of biomarkers allowing physicians to analyse the patients‟ sera without the 
need for complete laboratory testing hence, greatly improving the intervention decision 
process taken. 
The development of multi-marker detection systems is necessary [82, 85] due to the 
complex series of events leading up to, during and after AMI combined with the variance 
between symptom onset and presentation at A&E from patient to patient [66]. The National 
Academy of Clinical Biochemistry (NACB) Standards of Laboratory Practice recommends 
that at least two biochemical markers be utilised for the diagnosis of AMI (one early 
marker and one definitive marker) [60, 86] and these sentiments are reflected in the 
ACCF/AHA guidelines [84]. As demonstrated in Figure 1.3-3, the Academy recommends 
that; (a) an early marker which appears in the blood stream ≤6 hours after symptom onset 
and, (b) a definitive marker appearing 6-9 hours after symptom onset which is both a 
definitive indicator of AMI and provides a large diagnostic window to be used to 
effectively diagnose AMI [86]. 
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Figure 1.3-3: The release kinetics of biomarkers during acute coronary syndrome  
Biomarker appearance versus time after symptom onset. Graph taken from [86]. 
Legend: 
Peak A: Myoglobin release after AMI, 
Peak B: Cardiac troponin release after AMI. 
Peak C: Creatine kinase myocardium specific isoform (CK-MB) release after AMI. 
 
 
1.3.3.4 Current and emerging biomarkers  
 
Ultimately, the goal of employing biochemical markers is in the prevention of a minor 
infarction and a reduction in the associated mortality rate [66].  Key factors influencing this 
are the information available to physicians, the speed at which the injury is detected and the 
intervention taken [78]. Presently, conventional biomarkers are commonly non-diagnostic 
at the time of patient presentation [65]. Figure 1.3-4 indicates the stages of AMI and the 
markers released. The biomarkers that are upstream of cardiac tissue necrosis are of 
particular interest to prevent AMI developing. However, due to their relatively new status 
as biomarkers the necessity to definitively identify the occurrence of AMI remains 
(accepted definitive markers are the troponins).  
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Figure 1.3-4: Biochemical markers released during acute coronary syndrome  
Various stages of AMI from the initial formation of the plaque, its destabilisation, subsequent rupture and 
thrombosis leading to ischemia culminating in myocardial cell death and ventricular overload. Each stage of 
the AMI releases biological entities which have potential as biochemical markers for diagnosis. Adapted 
from [78, 83, 87]. 
 
 
To date, assays detecting the established biomarkers primarily indicate myocardial necrosis 
[78]. The clinically accepted biomarkers of AMI are; the troponins (which are the preferred 
[69]), CK-MB (Mass assay [69]) and myoglobin (potentially outdated [81]) [60, 78, 84]. 
The properties of these biomarkers are summarised in Table 1.3-3. 
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Table 1.3-3: Current cardiovascular biomarkers and their associated properties 
Biomarker 
Size 
kDa 
Cardio- 
Specificity 
Role in 
ACS 
Value 
Elevation 
Period* 
POC-test 
[78]
 
Myoglobin 17.8 Low 
Early MI, 
Re-infarction 
NPV
1 
1-48 
hrs 
Cardiac STATus, 
Cardiac M-Test, 
RAMP Reader, 
Life Lite, 
Stratus CS. 
CK-MB 85 Yes Re-infarction Rule in 
24-36 
hrs 
Cardiac STATus, 
Stratus CS, 
RAMP Reader, 
Life Lite. 
Troponin I 23.9 
Very 
 High 
Necrosis 
Definitive, 
Risk 
Stratification 
2-4 hrs up to 
4-7 
days 
i-STAT, 
RAMP Reader, 
AlphaDx, 
Life Lite, 
Stratus CS, 
Architect TnI, 
Vitrous TnI-ES, 
Access Accu TnI. 
Troponin T 37 High Necrosis 
Definitive, 
Risk 
Stratification 
2-4hrs up 
to10-14 days 
CARDIAC T-Test. 
This table was prepared from [66, 67, 78]. * Initial elevation to return to normal. 
1
NPV: Negative predictive 
value. 
 
Myoglobin, a haemeprotein, is located in the cytoplasm of both cardiac and skeletal muscle 
cells [80]. Myoglobin is released rapidly into circulation as early as one hour from the onset 
of symptoms (Table 1.3-3) and has a high negative predictive value (NPV) for AMI  due to 
its low molecular weight and location within the cell [60, 78, 80]. NPV represents accurate 
determination of the number of patients with a negative result who are diagnosed correctly 
and myoglobin has value as a „rule out‟ biomarker. Myoglobin‟s specificity is 
compromised by its identical amino acid composition in both cardiac and skeletal tissues 
and its appearance in patients with renal insufficiency [80]. However, myoglobin is still 
recognised as a useful early marker of myocardial damage as a negative predictive 
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biomarker [70, 81, 86]. Myoglobin may also identify low grade ACS patients at additional 
risk, for example detection of a non-cardiovascular disease [81]. 
Cytoplasmic creatine kinase (CK) is a dimer composed of M (muscle) or B (brain) subunits 
that associate to form CK-MM (striated muscle), CK-MB (predominantly myocardium) and 
CK-BB (brain, stomach and liver) [80]. The normal function of CK is to provide high 
energy phosphate molecules, from creatine, which is used in contractile tissues. Early 
successful assays included CK-MB-specific mass and CK-MB subtype measurement. The 
characteristics of each is summarised in Table 1.3-4. 
CK-MB isoform was considered the gold standard in AMI diagnosis until 1995, however, 
its specificity is limited, like myoglobin, due to its role in skeletal muscle damage [60, 67, 
78]. CK-MB remains a useful tool, especially in multi-marker analysis, for the assessment 
of re-infarction [60].  
 
Table 1.3-4: Creatine kinase characteristics 
Marker Cardiac Specific 
Initial Elevation 
(Hours) 
Duration of Elevation 
(Hours) 
Total CK No 4-8 36-48 
CK-MB mass Yes 3-4 24-36 
CK-MB subtypes Yes 2-4 16-24 
 
The troponin complex (Figure 1.3-5) consists of three proteins that function in the 
regulation of striated muscle contraction. In the complex, calcium mediates the interaction 
between actin and myosin in the thin filament [80]. The TnI and TnT subunits have both 
skeletal (sTnI, sTnT) and cardiac isoforms (cTnI, cTnT) that have differing amino acid 
sequences and immunological activities while TnC has no cardiac specific isoform [80]. 
Cardiac Troponin I and T which are proteins of the sarcomeric pool are widely recognised 
as the gold standard biomarkers for AMI diagnosis which also impact the patient prognosis, 
risk stratification and guide therapeutic intervention [60, 65, 66, 68, 69]. The cardiac 
troponins (cTn) are markers of myocyte necrosis and take several hours to reach peak 
elevation after the onset of ischemia (Table 1.3-3) [67]. As indicated by Figure 1.3-3, cTn 
has a prolonged elevation period providing a large temporal diagnostic window and the 
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peak concentration can be closely correlated to the size of the infarction [60]. The elevation 
of cTn occurs 2 to 4 hours after onset of symptoms (Table 1.3-3) and this initial release can 
be attributed to their cytosolic pool with the prolonged elevation due to the structural 
release of the regulatory proteins [81, 82]. The circulating forms of cardiac troponin found 
are listed in Table 1.3-5. The variance in circulating forms of the structural cTn complex 
and its constituents gives rise to complications in the rational design of an antibody 
targeting strategy due to the inaccessibility or cloaking of epitopes, the formation of 
complexes and interference from other serum proteins to exposed regions of the protein. 
Currently, cTnI is credited with greater discriminatory value compared to cTnT. The 
detection limits for assays detecting cTnI in patient samples is sub-40pg/mL and so 
represents a significant challenge in terms of  the design of the assay and its components 
[66]. 
 
 
Figure 1.3-5: Actin-Tropomyosin-Troponin complex 
The complex regulates calcium-mediated muscle contraction. The Troponin T (TnT) subunit anchors the 
troponin complex to tropomyosin. The TnI subunit inhibits actomyosin ATPase activity and thus modulates 
the interaction of actin with myosin. The TnC subunit, common to both striated and cardiac muscle, binds 
calcium [67, 80]. 
 
Table 1.3-5: Circulating cTn forms 
cTnT cTnI* 
Free cTnT (major form) TnI/TnC (major form) 
TnT/TnI/TnC complex 
TnT fragments Free TnI (minor form) 
TnT/TnI complex (minor form) 
This table was adapted from [80]. *cTnI exists in these forms in phosphorylated, oxidised and reduced states. 
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1.4 Thesis aims and objectives 
 
The principal aim of this research is the production, characterisation and development of 
antibodies for the early detection of cardiac disease by addressing the issues surrounding 
the ultra-sensitive detection of cardiac Troponin I (cTnI). 
To achieve these outcomes several key objectives need to be realised:  
1. Development of antibodies based on synthetic-epitope targeting immunisation 
regimes developed by rational, knowledge-based antigen design strategies. 
2. Use of this approach  to investigate the generation of antibodies by the exploitation 
of monoclonal and recombinant antibody technologies for targeting key epitopes of 
interest, underpinned by rigorous selection and screening methodologies 
incorporating high-throughput surface plasmon resonance-based instrumentation.  
3. Efficient characterisation of the generated epitope-specific antibodies by the 
development and use of modified forms of the antigen. 
4. Tailoring, modifying and refining the generated antibodies for highly-specific roles 
in novel point-of-care platforms. 
In addition, work was undertaken to elucidate the three dimensional structure of avian 
scFvs using advanced crystallographic studies including large-scale production and 
purification of scFvs, high-throughput screening and systematic optimisation of conditions 
for crystal formation.  
Ultimately, the overall requirement is to generate high-affinity, high-sensitivity anti-cTnI 
epitope-specific antibodies to facilitate the development of a novel next generation ultra-
sensitive point-of-care-device capable of detecting cTnI at less than 40pg/mL in whole 
blood samples. 
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2.1 Materials 
2.1.1 Equipment 
 
Instrument Manufacturer 
  
Nanodrop™ ND-1000 
NanoDrop Technologies, Inc.,  
3411 Silverside Rd 100BC,  
Wilmington,  
DE19810-4803,  
USA. 
  
Gene Pulser Xcell™  
 
Trans-Blot® Semi-dry transfer cell 
 
Bio-Rad PowerPac HC: 250V/3.0A/300W 
Bio-Rad Laboratories, Inc.,  
2000 Alfred Nobel Drive,  
Hercules,  
California 94547,  
USA. 
  
Tecan® Safire 2™ plate reader 
 
Tecan® Sunrise™ plate reader 
Tecan Group Ltd.,  
Seestrasse 103,  
CH-8708 Männedorf,  
Switzerland. 
  
PX2 thermal cycler 
Thermo Electron Corporation,  
81 Wyman Street,  
Waltham,  
MA 02454,  
USA. 
  
G-Storm™ PCR machine 
GRI Ltd., 
Gene House, 
Queenborough Lane, 
Rayne,  
Braintree, 
Essex CM77 6TZ, 
United Kingdom. 
  
 
Biacore™ 3000 and 4000 
AKTA Explorer FPLC System 
 
GE Healthcare Bio-Sciences AB,  
SE-751 84 Uppsala,  
Sweden. 
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Clifton stirred water bath 
Nickel – Electro Ltd., 
Oldmixon Crescent, 
Weston-super-Mare, 
North Somerset BS24 9BL, 
United Kingdom. 
  
Ohaus Explorer balance 
Ohaus Europe GmbH, 
Heuwinkelstrasse 3, 
CH-8606 Nänikon, 
Switzerland. 
  
Heraeus Biofuge Pico 
Kendro Laboratory Products International 
Sales, 
Hanau, 
Germany.  
  
Stuart Scientific See-saw rocker SSL4 
Lennox Laboratory Supplies Ltd., 
John F Kennedy Drive, 
Naas Road, 
Dublin 12, 
Ireland. 
  
Priorclave tactrol 2 autoclave 
Priorclave Ltd.,  
129/131 Nathan Way,  
West Thamesmead Business Park,  
London SE28 0AB,  
United Kingdom. 
  
Eppendorf refrigerated centrifuge 
   Model 5810R 
      Rotors: F45-30-11 (14,000rpm) 
                    A-4-62 (4,000rpm) 
New Brunswick Scientific U725 (-80
o
C ) 
Eppendorf UK Limited 
Endurance House,  
Vision Park Histon, 
Cambridge CB24 9ZR, 
United Kingdom. 
  
Orbi-Safe TS Netwise orbital shaker 
 
37
o
C static incubator 
Sanyo Europe Ltd.,  
18 Colonial Way,  
Watford WD24 4PT,  
United Kingdom. 
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Inverted Microscope  
Leica BMIL 
Laboratory Instruments & Supplies (I) Ltd. 
Pamaron House, 
Ballybin Road, 
Ashbourne, 
Ireland. 
  
Thermo Steri-cycle CO2 incubator 
 
Hearaeus Hera-safe Laminar flow cabinet 
 
Thermo Orion pH meter: Model 420A+ 
Thermo Scientific, 
12-16 Sedgeway Business Park, 
Witchford, 
Cambridgeshire CB6 2HY, 
United Kingdom. 
  
Liquid Nitrogen (LN2) Cryogenic storage  
LS750 
Jencons Scientific, 
800 Bursca Dr., 
Suite 801Bridgeville, 
PA 15017, 
USA. 
  
Plate Washer ELx405 
BioTek U.S. - World Headquarters, 
100 Tigan Street, 
Winooski,  
VT 05404, 
USA. 
 
2.1.2 Chemicals 
 
All chemicals were of the highest possible quality and sourced from Sigma-Aldrich 
(Sigma-Aldrich Ireland Limited, Vale Road, Arklow, Wicklow, Ireland.) or Fisher 
Scientific (Fisher Scientific Ireland, Suite 3, Plaza 212, Blanchardstown Corporate Park 2 
Ballycoolin, Dublin 15, Ireland.) unless stated otherwise. 
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2.1.3 Cells 
 
Table 2.1-1 details the mammalian cell lines and Table 2.1-2 outlines the E. coli cell types 
and their genotypes that were utilised in the course of this thesis. 
 
Table 2.1-1: Mammalian cell lines 
Cell Line Description Catalogue Supplier 
Sp2/0-Ag14 Mouse myeloma, lymphoblast CRL-1581 ATCC 
 
 
Table 2.1-2: E. coli cells and genotypes 
Cell Line Genotype Catalogue Brand 
XL1 Blue 
recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 
lac [F´ proAB lacIqZΔM15 Tn10 (Tetr)]. 
200249 Stratagene 
Top10F´ 
F´[lacIq Tn10 (TetR)] mcrA Δ(mrr-hsdRMS-
mcrBC) Φ80lacZΔM15 ΔlacX74 recA1 araD139 
Δ(ara-leu)7697 galU galK rpsL endA1 nupG. 
C3030-03 Invitrogen 
dcm
-
/dam
- 
(dam13::Tn9 (Cam
R
), dcm-6)(endA) (hsdR2) 
(mcrA, mcrB1 ) (fhuA31) 
C2925H NEB 
Top10 
F- mcrA Δ(mrr-hsdRMS-mcrBC) φ80lacZΔM15 
ΔlacX74 recA1 araD139 Δ(araleu) 7697 galU 
galK rpsL (StrR) endA1 nupG 
C4040-10 Invitrogen 
BL21 (DE3) F– ompT hsdSB(rB–, mB–) gal dcm (DE3) 70235-3 Novagen 
BL21 (DE3) 
 pLysS 
F– ompT hsdSB(rB–, mB–) gal dcm (DE3) pLysS 
(CamR) 
70236-3 Novagen 
Origami 2 (DE3) 
Δ(ara-leu)7697 ΔlacX74 ΔphoA PvuII phoR 
araD139 ahpC galE galK rpsL F′[lac+ lacIq pro] 
(DE3) gor522::Tn10 trxB (Str
R
, Tet
R
) 
71408-3 Novagen 
Tuner (DE3) F
–
 ompT hsdSB (rB
–
 mB
–
) gal dcm lacY1(DE3) 70726-3 Novagen 
Rosetta2 F
-
 ompT hsdSB(rB
-
 mB
-
) gal dcm pRARE2 (Cam
R
) 71402-3  Novagen 
 
  
2–6 
 
  
2.1.4 Media and buffers 
2.1.4.1 Media used for the growth of mammalian cells 
 
All cell culture reagents were of the highest possible quality, tested for cell culture and 
sourced from Sigma-Aldrich (Sigma-Aldrich Ireland Limited, Vale Road, Arklow, 
Wicklow, Ireland.) or Fisher Scientific (Fisher Scientific Ireland, Suite 3, Plaza 212, 
Blanchardstown Corporate Park 2 Ballycoolin, Dublin 15, Ireland.) unless stated otherwise. 
 
Media Component Composition 
   
SP2/0 Ag14 Growth 
DMEM (- L-Glutamine) 500mL 
Foetal Calf Serum (FCS) 10% (v/v) 
L-Glutamine (200mM) 2mM 
   
DMEM w/o FCS 
DMEM (- L-Glutamine) 500mL 
L-Glutamine (200mM) 2mM 
Sodium Pyruvate (100mM) 1mM 
NEAA (100X) 1(X) 
25µg/ml Gentamicin 25μg/mL 
   
DMEM + FCS 
DMEM (- L-Glutamine) 500mL 
FCS 10% (v/v) 
L-Glutamine (200mM) 2mM 
Sodium Pyruvate (100mM) 1mM 
NEAA (100X) 1(X) 
25µg/ml Gentamicin 25μg/mL 
   
Selection Media (HAT) 
DMEM + FCS 500mL 
HAT Medium (100X) 1X 
Briclone (Archport)
2
 5% (v/v) 
   
Cloning Media (HT)  
DMEM + FCS 500mL 
HT Medium (100X) 1X 
Briclone (Archport) 5% (v/v) 
                                                 
2
 Briclone is a media additive for use in the fusion stages of hybridoma development promoting the outgrowth 
of new hybrids. The IL-6 rich conditioned media is collected from a human cell line and Briclone is a 
registered product of Archport, DCU.   
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2.1.4.2 Media used for the growth of bacterial cells 
 
Media Component Composition 
   
Luria Broth (LB) 
Tryptone 10g/L 
Yeast extract 5g/L 
NaCl 10g/L 
   
Super Broth (SB) 
MOPS 10g/L 
Tryptone 30g/L 
Yeast extract 20g/L 
   
Terrific Broth (TB) 
(Completed with 100mL TB salts*) 
Tryptone 12g/900mL 
Yeast extract 24g/900mL 
Glycerol 4mL/900mL 
   
TB Salts* 
KH2PO4 2.31g/100mL 
K2HPO4 12.54g/100mL 
   
Super Optimal Catabolite (SOC) 
Tryptone 20g/L 
Yeast extract 5g/L 
KCl 2.5mM 
NaCl 0.5g/L 
MgCl2 20mM 
Glucose 20mM 
 
 
2.1.4.3 Media additives used for the growth of bacterial cells 
2.1.4.3.1 Antibiotics 
 
Antibiotics used for bacterial cell culture were prepared as described below and sterile 
filtered (0.2μm) before use. Antibiotic stocks were retained in aliquots to reduce the 
instances of contamination. 
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Antibiotic Component Composition 
   
100mg/mL (w/v) Carbenicillin  
Carbenicillin salt 500mg 
Molecular grade water 5mL 
   
70 mg/mL (w/v) Kanamycin 
Kanamycin  700mg 
Molecular grade water 10mL 
   
5mg/mL (w/v) Tetracycline 
Tetracycline 50mg 
Molecular grade ethanol  10mL 
 
2.1.4.3.2 Additives 
 
Additives were prepared with autoclaved dH2O as described below and, where possible 
sterile filtered through a 0.2μm syringe filter. 
Media Additive Component Composition 
   
100X 505 
Glycerol 50% (v/v) 
Glucose 5% (w/v) 
dH2O (autoclaved) to 50mL 
   
30% (w/v) Glucose 
Glucose 30% (w/v) 
dH2O (autoclaved) to 50mL 
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2.1.4.4 Buffers 
 
Buffer Component Composition 
   
Phosphate Buffered Saline (PBS) 
NaCl 0.15M 
KCl 2.5mM 
Na2PO4 10mM 
KH2PO4 18mM 
 pH 7.4 
   
5% (w/v) PBS-Milk (PBSM)  
PBS 1X 
Milk marvel 5% (w/v) 
   
0.05% (v/v) PBS-Tween (PBST) 
PBS 1X 
Tween 20 0.05% (v/v) 
   
1% (w/v) PBST-Milk (PBSTM) 
PBST 1X 
Milk marvel  1% (w/v) 
   
10X HBS-EP
+
 (1L) 
0.1M HEPES 23.831g 
1.5M NaCl 87.66g 
30mM EDTA 11.17g 
0.5% (v/v) P20/Tween®20 5mL 
MilliQ H2O to 1L 
   
Tris Buffered Saline (TBS) 
Tris 50mM 
NaCl 150mM 
 pH 8.0 
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2.1.4.5 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
and Western blotting (WB) 
 
12.5%  (w/v) Separation gel  
(1gel: 6mL) 
1M TrisHCl, pH 8.8  1.5mL 
30% (w/v) acrylamide (Acrylagel) 2.5mL 
2% (w/v) methylamine bisacrylamide (Bis-Acrylagel) 1.0mL 
dH2O 934μL  
10% (w/v) sodium dodecyl sulphate (SDS)  30μL 
10% (w/v) Ammonium persulfate (APS) 30μL 
TEMED 6μL 
   
4.5% (w/v) Stacking gel  
(1 gel: 2.5mL) 
1M TrisHCl, pH 6.8  300μL 
30% (w/v) acrylamide (Acrylagel) 375μL 
2% (w/v) methylamine bisacrylamide (Bis-Acrylagel) 150μL 
dH2O 1.74mL 
10% (w/v) sodium dodecyl sulphate (SDS)  24μL 
10% (w/v) APS 24μL 
TEMED 2.5μL 
   
10X electrophoresis buffer 
50mM Tris, pH 8.3 30g 
196mM Glycine 144g 
0.1% (w/v) SDS 10g 
dH2O to 1L 
   
Loading buffer (4 X) 
0.5M Tris, pH 6.8 2.5mL 
Glycerol 2.0mL 
 1-mercaptoethanol 0.5mL 
 20% (w/v) SDS  2.5mL 
 Bromophenol blue 20ppm 
 dH2O 1.25mL 
   
Coomassie stain (500mL) Coomassie blue R-250      1g 
 Methanol 225mL 
 Acetic Acid 50mL 
 dH2O 225mL 
   
Coomassie destain (1L) Acetic Acid 150mL 
 Methanol 200mL 
 dH2O 650mL 
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Transfer Buffer (500mL) Trizma Base 2.4g 
 Glycine 7.2g 
 Methanol 100mL 
 dH2O 400mL 
 
2.1.4.6 Protein purification 
 
Note: Buffers were prepared in 18.2mΩ water and 0.2μm sterile filtered before use. 
 
2.1.4.6.1 Monoclonal antibody purification buffers  
 
Equilibration Buffer 1X PBS 
  
Wash Buffer  0.05% (v/v) PBST  
  
Elution Buffer 0.1M Glycine HCl, pH 2.5 
  
Neutralisation Buffer 1M Tris-HCl, pH 8.5 
 
2.1.4.6.2 Recombinant protein purification buffers 
 
PBS–based buffers 
 
Equilibration Buffer 1X PBS + 150mM NaCl + 10mM Imidazole, pH 8.0 
  
Wash Buffer Equilibration buffer + 0.5% (w/v) Tween®20, pH 8.0 
  
Elution Buffer 100mM NaOAc, pH 4.2 
  
Neutralisation Buffer 10X PBS and 100mM NaOH (1:1) 
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NaH2PO4–based buffers 
 
Equilibration Buffer 50mM NaH2PO4 + 100-300mM NaCl, pH 8.0 
  
Wash Buffer # 1 Equilibration buffer + 10mM Imidazole, pH 8.0 
  
Wash Buffer # 2 Equilibration buffer + 20mM Imidazole, pH 8.0  
  
Elution Buffer 100mM NaOAc, pH 4.2 
  
Neutralisation Buffer 10X PBS and 100mM NaOH (1:1) 
 
Cation exchange buffers 
 
Equilibration Buffer 50mM NaH2PO4 + 100-300mM NaCl, pH 8.0 
  
Elution Buffer 100mM NaOAc, pH 4.2 
  
Neutralisation Buffer 10X PBS and 100mM NaOH (1:1) 
 
Gel filtration buffers for Fast protein liquid chromatography (FPLC) 
 
Gel filtration buffers were composed of 1X PBS or 1X TBS (depending on the intended 
application of the purified protein) supplemented with 0.02% (w/v) NaN3. The buffers were 
prepared and sterile filtered through 0.2μm filter and degassed before use. 
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2.1.5 Commercially sourced kits and solutions 
 
Kit Supplier 
  
Superscript III® Reverse Transcriptase Kit 
(18080-051) 
Platinum® Taq DNA Polymerase High Fidelity 
(11304011) 
Invitrogen Corporation, 
5791 Van Allen Way, 
PO Box 6482, 
Carlsbad,  
California 92008, 
USA. 
  
NucleoTrap®  Gel Extraction Kit 
(636018) 
NucleoBond®  Xtra Midi 
(740410.100) 
MACHEREY-NAGEL GmbH, 
Postfach 10 13 52, 
Neumann Neander Str. 6-8, 
D-52355 Düren, 
Germany. 
  
BugBuster™ Protein Extraction Reagent (70923) 
 
His•Bind® Resin, Ni2+-charged  (71035-25ml) 
Novagen, 
Merck KGaA,  
Darmstadt,  
Germany. 
  
GoTaq® Flexi DNA Polymerase  
(Promega - M8301 ) 
Promega Corporation, 
2800 Woods Hollow Road, 
Madison, 
WI 53711, 
USA. 
  
Amine Coupling Kit 
(BR-1000-50) 
GE Healthcare Ltd., 
Amersham Place, 
Little Chalfont,  
Buckinghamshire,  
HP7 9NA, 
United Kingdom. 
  
Pierce™ Rapid Isotyping Kit plus κ and λ 
(26179) 
Pierce, 
3747 N Meridian Rd, Rockford,  
IL  61101, 
USA.  
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2.1.6 Commercially sourced antibodies 
 
Antibody Species Supplier 
   
Anti-Mouse (whole molecule) HRP   
Anti-polyhistidine (HIS) HRP             
Anti-Mouse-Fc-specific HRP            
Goat 
Mouse 
Goat 
Sigma-Aldrich Ireland Ltd.,  
Vale Road,  
Arklow,  
Wicklow,  
Ireland. 
   
Anti-chicken-IgY-Fc-specific HRP    
Anti-chicken-IgY-Fab HRP              
Anti-chicken-IgY-Fc-specific 
Anti-chicken-IgY-Fab 
Anti-mouse-IgG-Fc-specific 
Goat 
Goat 
Donkey 
Goat 
Chicken 
Gallus Immunotech,  
6570 1st Line West Garafraxa, 
Fergus,  
ON N1M 2W4, 
Canada. 
   
Anti-TnI-19C7  
Anti-TnI-228 
Anti-TnI-16A11 
Mouse 
Mouse 
Mouse 
Hytest,  
Intelligate 6th floor, 
Joukahaisenkatu 6,  
20520,  
Turku, 
Finland. 
   
Anti-Hemagglutinin (HA) HRP Rat 
Roche Diagnostics Ltd., 
Charles Avenue, 
Burgess Hill, 
West Sussex, 
RH15 9RY, 
United Kingdom. 
   
Anti-HA epitope pAb 
(for Biacore™ 4000) 
Rabbit 
Thermo Fisher Scientific Inc., 
3747 N Meridian Rd,  
Rockford,  
IL 61101, 
USA. 
   
Anti-HA-649 Dylight™ Rabbit 
Rockland Immunochemicals Inc.,  
Gilbertsville,  
PA 19525, 
USA. 
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2.1.7 Commercially sourced proteins 
 
Protein Species Cat. Supplier 
    
cTnI Human 1210 
Life Diagnostics Inc.,  
P.O. Box 5205,  
West Chester,  
PA 19380, 
USA. 
    
Protein G  
 
Keyhole limpet Haemocyanin 
(KLH) 
Recombinant 
 
Animal 
derived 
P3296 
 
 
H7017 
Sigma-Aldrich Ireland Ltd.,  
Vale Road,  
Arklow,  
Wicklow,  
Ireland. 
    
NeutrAvidin 
Deglycosylated 
avidin 
31000 
Pierce Protein Research Products, 
3747 N Meridian Rd,  
Rockford IL  61101 , 
USA. 
    
Bovine serum albumin (BSA) 
Animal 
derived 
 
BPE1600 
 
Fisher Scientific Ireland,  
Blanchardstown Corporate Park 2, 
Ballycoolin,  
Dublin 15,  
Ireland. 
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2.1.8 Vectors  
 
Vector Resistance Catalogue Supplier 
    
pET 26b(+) 
pET 28b(+) 
pET 32b(+) 
Kanamycin 
Kanamycin 
Ampicillin 
69862 
69865 
69016 
Novagen, 
Merck KGaA,  
Darmstadt,  
Germany. 
    
pComb3xSS Ampicillin N/A 
Prof. C. Barbas III, 
The Scripps Institute, 
La Jolla, 
San Diego, 
California, 
USA. 
    
pMopac16 Ampicillin N/A 
Andrew Hayhurst, 
University of Texas at Austin,  
Austin,  
TX 78712-1095,  
USA. 
    
pUC57rTnI 
FABP-P1&2 
Ampicillin Custom 
GenScript USA Inc. 
860 Centennial Ave. 
Piscataway,  
NJ 08854, 
USA. 
 
2.2 Licencing 
 
All animal procedures were ethically approved and carried out in accordance with the 
Department of Health and Children licence number B100/3816 under the direction of 
trained animal handlers minimising animal distress. PJC has completed Laboratory Animal 
Science and Training program (LAST) qualifying to handle rodent and avian subjects. All 
animals were handled and treated humanely in the dedicated Bio-Resource Unit (BRU). 
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2.3 Methods  
 
2.3.1 General molecular methods 
2.3.1.1 Ethanol precipitation of DNA 
 
Ethanol precipitation was carried out at -20
o
C overnight (O/N) or at -80
o
C for two hours 
depending on the time requirement. To the 1.5mL tube containing the DNA to be 
precipitated the following was added: 
  0.1X the volume of sodium acetate, pH5.2 
  2X the volume of 100% (v/v) molecular grade ethanol (ice-cold) 
  1μL glycogen (5mg/mL) 
Tubes were agitated and placed at the relevant temperature for the desired length of time. 
The DNA was then pelleted by centrifugation at 14,000rpm for 30 minutes at 4
o
C, washed 
with 70% (v/v) ice-cold ethanol as above, air dried and resuspended in an appropriate 
volume of molecular grade water (mol. G. H2O). 
 
2.3.1.2 Plasmid propagation and purification 
 
An overnight culture (10mL super broth (SB) supplemented with relevant antibiotic) was 
prepared from a single transformed colony, or glycerol stock, and incubated at 37
o
C, while 
shaking at 210rpm. This culture was then used to inoculate 100mL SB (with antibiotic) and 
grown overnight at 37
o
C, while shaking at 210rpm. Bacterial cells were collected by 
centrifugation at 4000rpm at 4
o
C for 30 minutes. The plasmid was then purified using 
NucleoBond® Xtra Midi, as per the manufacturer‟s guidelines. Purified plasmid was 
resuspended in a final volume of 250μL mol. G. H2O and quantified on Nanodrop ND™ 
1000 nucleic acid DNA-50 setting. 
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2.3.1.3 Agarose electrophoresis 
 
Various percentage gels (w/v) were prepared by weighing out the desired amount to give 
the required percentage in grams of agarose. The weighed agarose was added to 1X Tris-
acetate-EDTA (TAE) buffer and heated in a microwave (2-3 minutes) until dissolved, 
allowed to cool, before adding 1X SYBR™ safe DNA gel stain. The gel was then allowed 
to set in the appropriate gel box with the inserted comb. Gel electrophoresis was carried out 
using Bio-Rad PowerPac™ HC in 1X TAE-buffer at 90V for between 20 and 40 minutes. 
 
2.3.1.4 Ligation of DNA into a vector 
 
Ligations were carried out with a number of vector and inserts using the general ligation 
reaction conditions (Table 2.3-1). The weight of vector (X) and insert (Y) to obtain a 1:1 
ratio was determined using Equation 2.3-1. 
 
Equation 2.3-1: 1:1 molar ratio of vector and insert for ligation reactions 
 
 
The ligations were incubated overnight at room temperature (RT) followed by inactivation 
at 65
o
C for 20 minutes and precipitation as described in section 2.3.1.1. The ligations were 
resuspended in 10-20μL pre-heated mol. G. H2O (~60
o
C) post precipitation. 
 
Table 2.3-1: General ligation reaction components 
Component Ligation Control 
Vector DNA Xμg Xμg 
Insert DNA Yμg - 
Ligase Buffer (10X) 1X 1X 
Mol. G. H2O to 100μL to 100μL 
T4 Ligase [400U/μL] 10U/μg 10U/μg 
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2.3.1.5 Preparation of competent cells 
 
Electro-competent cells were prepared freshly when required so as to prevent losses in 
efficiency associated with storage. Prior to preparation cells were streaked onto selective 
agar and additionally assayed on Kanamycin and Carbenicillin plates to ensure no 
contamination due to rogue phage. 
 
2.3.1.5.1 Electro-competent cell preparation 
 
A single colony (E. coli XL1 Blue) was inoculated into 5ml of SB (5μg/mL tetracycline) 
and grown O/N at 37
o
C while shaking at 230rpm. Prior to carrying out any work all 
surfaces and equipment were bleached as thoroughly as possible. Sterile Pasteur pipettes, 
dH2O (autoclaved), 10% (v/v) glycerol (autoclaved) and centrifuge tubes were placed on 
ice at 4
o
C O/N. 500mls of LB media with 0.01M MgCl2 was inoculated with the 5mL O/N 
culture and grown at 37
o
C, while shaking at 230rpm until an OD600 of 0.5 (max) was 
reached (in approx. 2-3 hours or so). The culture vessel was then placed on ice at 4
o
C for 30 
minutes and swirling occasionally. The 500mL culture was divided into 10 x 50mL tubes 
and centrifuged at 3000rpm at 4
o
C for 20 minutes (Eppendorf 5810R). The supernatant was 
discarded and the pellets resuspended in 10mL of ice-cold water using a Pasteur pipette and 
combined into 2 pre-chilled 50mL tubes (100mL). The cultures were centrifuged as before 
and the volume of water used to resuspend the pellets halved (25mL/50mL tube). The cells 
were collected by centrifugation as before, the pellets resuspended in 2 x 10mL ice-cold 
water volumes and combined into one tube. After centrifugation the pellet was re-
suspended in 10mL 10% (v/v) ice-cold glycerol. The cells were again collected by 
centrifugation and re-suspended in 5mL 10% (v/v) ice cold glycerol. The cells were 
centrifuged a final time and re-suspended in 1.5-2.0mL 10% (v/v) glycerol. The cells are 
then ready for electroporation. 
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2.3.1.5.2 Chemically-competent cell preparation 
 
E. coli were treated for the preparation of electro-competent cells (as described section 
2.3.1.5.1). However, all washes were carried out with 0.1M CaCl2 in place of water and 
0.1M CaCl2 with 10% (v/v) glycerol. The cells were dispensed into 50μL aliquots and snap 
frozen using LN2 and stored at -80
o
C. 
For transformation, the cells were removed from -80
o
C storage and placed immediately on 
ice. The vector/ligation to be transformed was also placed on ice and once the cells had 
thawed 1μL of DNA was added to the cells and mixed with gentle agitation. The cells and 
DNA were allowed to stand for one minute before being placed at 42
o
C for 30 seconds. The 
tube was then put on ice for 2 minutes and 150μL pre-warmed super optimal broth (SOC) 
added. The cells were allowed to outgrow for 1 hour at 37
o
C, while shaking at 230rpm 
before both 10μL and 100μL volumes were plated out on LB-selective agar (the antibiotic 
included was dependent on the vector used) and grown O/N, while inverted, at 37
o
C. 
 
2.3.1.6 Preparation of bacterial cell stocks 
 
Cell stocks were prepared in either 1.5mL tubes or 96-well culture plates dependent on the 
numbers required.  
1.5mL tubes: overnight cultures (2mL SB with relevant antibiotic and 1% (v/v) glucose) 
were grown at 37
o
C while shaking at 230rpm and the cells were then collected by 
centrifugation at 4,000rpm at 4
o
C for 20 minutes. The supernatant was then discarded and 
the cells re-suspended in SB media containing 10% (v/v) glycerol and 100μL transferred to 
a number of 1.5mL (screw thread) tubes which were snap frozen in LN2. Cells were then 
stored long term at -80
o
C. 
96 well plates: overnight cultures (150μL SB with relevant antibiotic and 1% (v/v) 
glycerol) were grown at 37
o
C while shaking at 230rpm. The following day 25μL was 
removed for expression in 96-deep well plates and replaced with 25μL 80% (v/v) glycerol 
and placed at -80
o
C for long term storage. 
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2.3.1.7 Lysis of E. coli cells for small-scale analysis and purification  
 
Cells were lysed by a combined Bug Buster™, lysozyme and freeze-thaw treatment regime. 
The cell pellet was resuspended with 1/10 the culture volume (small-scale) or 2.5mL per 1g 
cell paste (large-scale) phosphate buffered saline (PBS) and transferred to the relevant 
number of 2mL tubes (0.75mL/tube). A volume of 0.75mL of 1X Bug Buster™ with 
1mg/mL of lysozyme was then added to each tube and the tubes placed on the platform 
rocker for 20 minutes at room temperature (RT). Post incubation the cells were alternated 
from -80
o
C to 37
o
C for a minimum of three times. Cellular debris was collected by 
centrifugation at 14,000rpm at 4
o
C for 30 minutes and the supernatant separated. The 
supernatant could then be used for sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) by addition of 10μL 4X dye/30μL lysate or the insoluble 
matter tested by resuspension in 4X SDS-PAGE loading dye. To enable purification of 
soluble protein the lysates were pooled together and the volume brought to ~50mL with the 
relevant equilibration buffer (50mL buffer /400mL large-scale induced culture). 
 
2.3.1.8 Optimisation of recombinant protein expression 
 
Optimisation of the expression of various recombinant proteins was undertaken at 
numerous stages throughout this work. Various lengths of induction time and Isopropyl-β-
D-thiogalactoside (IPTG) concentrations were evaluated with a number of different 
constructs, media types and temperatures. All these expression studies can be described by 
the generic flow contained in Figure 2.3-1 with refinements or modifications to the protocol 
noted in the relevant sections. The samples taken were centrifuged and the pellet retained at 
-80
o
C until required. The cell pellets were treated similarly during lysis and loading onto 
SDS-PAGE gels for side-by-side comparison with an un-induced cell control (0mM IPTG). 
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Figure 2.3-1: Generic time course experiment for expression of recombinant proteins 
A single colony or glycerol stock was inoculated in 6mL of medium containing antibiotic and 1% (v/v) 
glucose and grown O/N at 37
o
C, while shaking at 230rpm. It was then sub-cultured into fresh media 
containing antibiotic only and grown until an OD600 ~0.6 was reached. This starter culture was then employed 
to inoculate 50mL of media (with antibiotics) into a 250mL flask which was subsequently grown until the  
OD600 reached ~ 0.6. At this stage the cultures were induced with various concentrations of IPTG at a defined 
temperature (X) and 1mL samples taken at two time points (A and B).  
 
2.3.1.9 Purification of produced recombinant proteins 
 
Numerous purification strategies were undertaken for the recombinant proteins generated. 
The cells were grown and expressed as described in the relevant section and lysed, as 
described in 2.3.1.7. The choice of buffers also varied and specific buffers for particular 
purifications are contained within the relevant section. The buffer recipes for recombinant 
protein purification can be found in section 2.1.4.6.2. 
His• Bind® Ni2+ charged resin (Novagen) slurry (1-2mL) was added to a 10mL 
chromatography column and allowed to settle, corresponding to a 0.5-1mL resin bed. The 
resin was washed thoroughly with 10-15 column volumes (CV) equilibration buffer. The 
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lysate volume was adjusted to ~50mL with equilibration buffer (while 30μL sample was 
taken and retained for analysis – unfiltered lysate) and was then passed through 0.45μm and 
0.20μm syringe filters (a 30μL sample was taken and retained for analysis – filtered lysate). 
The cleared lysate was then applied to the column and a sample of the „flow-through‟ was 
retained for SDS-PAGE and Western blotting (WB) analysis. The column was then washed 
with 10CV wash buffer (or combination of wash buffers depending on the buffer table) and 
samples retained for analysis (W1 up to W3). The retained protein was then eluted with 
4mL elution buffer into 1mL neutralisation buffer or 10 x 150μL neutralisation buffer in 
1.5mL tubes. The 5mL eluted sample, or protein-containing samples, were then buffer 
exchanged against PBS (with 0.02% (w/v) NaN3) using a Vivaspin 6 column with an 
appropriate molecular weight cut-off. The protein content of the purified sample was 
determined and the protein stored at -20
o
C in several aliquots. A sample of the pure protein, 
unfiltered and filtered lysates, „flow-through‟ and washes were then analysed by SDS-
PAGE and WB. 
 
2.3.1.10 Preparation of helper-phage  
 
A 5mL overnight culture (SB + 5μg/mL tetracycline) was prepared and grown at 37oC 
while shaking at 230rpm. The following day the culture was subcultured into 10mL SB 
containing 5μg/mL tetracycline and grown for 2 hours. The cells were then infected with 
10μL VCSM13 (1x1011pfu/mL – Stratagene) and grown for 2 hours at 37oC with shaking at 
230rpm. The phage-infected culture was then transferred to a 2L baffled flask containing 
400mL SB (70μg/mL Kanamycin) and shaking continued at 37oC O/N. The culture was 
decanted into two 250mL centrifuge bottles and centrifuged at 4000rpm at 4
o
C for 15 
minutes.  The „phage-rich‟ supernatant was collected and pasteurised (70oC for 20 minutes) 
followed by clarification by centrifugation at 4000rpm at 4
o
C for 15 minutes. The phage 
was ready to use or was precipitated (by addition 4% (w/v) PEG8000 and 3% (w/v) NaCl) on 
ice for 1 hour followed by centrifugation at 10,000rpm for 20 minutes at 4
o
C. The pelleted 
phage was then resuspended in 1% (w/v) PBS-BSA with 0.02% (w/v) NaN3 and stored at -
80
o
C until required. 
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2.3.1.11 SDS-PAGE  
 
Assessment of the commercial antigen quality and protein purifications steps were carried 
out by SDS-PAGE and Western blot (WB) analysis using the buffers described in section 
2.1.4.5.  
Proteins were separated using 12.5% (w/v) SDS-PAGE gels to analyse purity and to 
determine the apparent molecular weight. The gel consisted of a resolving gel (12.5%) and 
a stacking gel (4.5%). The resolving and stacking gels were prepared as described in 
section 2.1.4.5. These gels were left to polymerise between two clean glass plates. After the 
stacking gel was poured, a comb was inserted to make wells in preparation for loading of 
the protein samples. The samples were prepared by adding appropriate volumes of 4X gel 
loading buffer and deionised water. A 20μg quantity of each protein sample in a total 
volume of 10μL or lysate diluted with loading buffer to 1X in a volume of 10μL, were 
added into each well. The gels were placed in an electrophoresis apparatus (Bio-Rad) and 
submerged in electrophoresis buffer. The apparatus was attached to a power supply and a 
voltage of 150V was applied to the gel for 15 minutes followed by 200V for 45 minutes. 
The gels were allowed to run until the tracker dye had reached the bottom of the gel, taking 
approximately 1 hour. The gels were then removed and stained using Coomassie stain for 
20-60 minutes before destaining using Coomassie destain. The destain solution was 
changed 2-3 times (until the background non-specific staining was removed). 
 
2.3.1.12 Western blotting 
 
Where a Western blot was required the SDS-PAGE gels were setup and run as described in 
section 2.3.1.11 with one SDS-PAGE gel being placed in transfer buffer (section 2.1.4.5) in 
place of the Coomassie blue stain. The gel, absorbent paper and nitrocellulose (cut to the 
gel dimensions) were all placed in the transfer buffer for 10 minutes. 
A four layer sandwich consisting of filter paper, nitrocellulose membrane, SDS-PAGE gel 
and filter paper was assembled. All air bubbles were removed by carefully rolling each of 
the layers with a disposable plate spreader. Proteins were transferred from the acrylamide 
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gel to the nitrocellulose using a Trans-Blot®Semi-Dry Transfer cell (Bio-Rad) at 15V for 
21 minutes. The nitrocellulose membrane was then carefully transferred into a large 
weighing boat containing 20mL of 5% (w/v) PBS milk (PBSM) solution and blocked for 2 
hours at room temperature or at 4°C overnight with agitation. Any excess blocking solution 
was removed from the membrane via two washes with PBS. Next, the blocked membrane 
was incubated with 10mL of 1% (w/v) PBSM solution with 0.05% (v/v) tween20 (PBSTM) 
containing a 1 in 2,000 dilution of the relevant primary antibody for 1 hour at RT with 
gentle agitation. The antibody solution was then discarded and the membrane washed in 
PBST (x3) and PBS (x3). Next, a 1 in 2,000 dilution of a specific secondary antibody was 
prepared in 10mL of 1% (w/v) PBSTM and again incubated with the membrane at RT for 1 
hour with agitation. The antibody solution was then discarded and the membrane washed in 
PBST (x3) and PBS (x3). Development of the specific complex was achieved via the 
addition of liquid 3, 3', 5, 5'-tetramethylbenzidine (TMB) substrate and stopped by multiple 
washes with distilled water.   
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2.3.2 Cardiac Troponin I antigen  
2.3.2.1 Quality of commercially sourced antigen 
 
Assessment of the commercial antigen quality was carried out by SDS-PAGE and WB 
using the buffers as described in section 2.1.4.5, while applying the methodology described 
in sections 2.3.1.11 and 2.3.1.12.  The blot was probed with anti-epitope-1 (19C7), anti-
epitope-2 (228) and anti-epitope-3 HRP-labelled (16A11) antibodies from Hytest, all 
diluted 1 in 2,000 in 1% (w/v) PBSTM. The primary antibodies, with the exception of anti-
epitope-3 HRP-labelled, were detected using an anti-mouse-Fc-specific HRP-labelled 
secondary antibody, diluted as above. 
 
2.3.2.2 Evaluation of protein–based immunisation regimes 
 
The serum from a previously immunised chicken was evaluated for epitope-specificity by 
direct binding enzyme-linked immunosorbent assay (ELISA). The chicken was sensitised 
to the whole cardiac troponin I molecule. cTnI (0.5μg/mL), neutrAvidin (2.5μg/mL), KLH-
peptide-1 (0.5μg/mL) and KLH-peptide-2 (0.5μg/mL) in PBS were coated to a series of 
wells of an ELISA plate O/N at 4
o
C.  The plate was then blocked with 5% (w/v) PBSM for 
1 hour at 37
o
C. Peptide-1-CT, peptide-2-CT, peptide-1-NT and peptide-2-NT (all 
biotinylated C or N-terminal) at 1μM in 1% (w/v) PBSTM were applied to neutrAvidin-
coated wells and incubated as above. The wells were washed with PBST (x3) and PBS 
(x3). The serum was diluted serially from 1 in 2,000 to 1 in 2 million in 1% (w/v) PBSTM 
and applied to the various antigen forms. The plate was incubated and washed, as above, 
followed by application of a 1 in 2,000 dilution of anti-chicken-Fc-specific HRP-labelled 
secondary antibody in 1% (w/v) PBSTM. After incubation and washing the plate was 
incubated with TMB and quenched with 10% (v/v) HCl before determining the absorbance 
at 450nm on the Tecan Sunrise™.  
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2.3.2.3 Recombinant Troponin I 
2.3.2.3.1 Genetic manipulation of designed construct 
 
The TnI gene construct (rTnI - Figure 8.1-2) was designed „in-house‟, codon optimised for 
bacterial expression and commercially synthesised by Genscript (USA). The gene was 
obtained in pUC57 (Figure 8.1-6) and subsequently propagated in dam
-
/dcm
-
 E. coli, as 
described in section 2.3.1.2. The plasmid was purified using the NucleoBond®  Xtra Midi 
kit as per the manufacturer‟s guidelines. The rTnI gene was isolated from the pUC57 vector 
by restriction digest and inserted into pET26b and pET32b to assess the ability to express in 
a soluble form, and purify the protein under non-denaturing conditions. In addition, the 
gene was also placed into the pET28b vector for expression in the cytoplasm of the cell 
which was anticipated to be in an aggregated form. Table 2.3-2 outlines the digestion 
reaction conditions to isolate the rTnI gene from pUC57 and for digestion of the three 
vectors. The reactions were carried out at 37
o
C for 3 hours followed by inactivation of the 
enzymes at 65
o
C for 30 minutes. The rTnI gene was then precipitated, as described in 
section 2.3.1.1 and the vectors further treated by Antarctic phosphatase (addition of 1X 
buffer and 1U/μg enzyme) for 1 hour at 37oC with inactivation at 65oC for 20 minutes. The 
vectors were also precipitated as outlined in section 2.3.1.1. 
 
Table 2.3-2: components of the digestion reaction for rTnI and vectors 
Component pUC 57 rTnI pET26b pET32b pET28b 
Vector  10μg 10μg 10μg 10μg 
Buffer 2 (10X) 1X 1X 1X 1X 
Mol. G. H2O to 100μL to 100μL to 100μL to 100μL 
NcoI [20U/μL] 
HindIII  [20U/μL] 
2U/μg 
2U/μg 
2U/μg 
2U/μg 
2U/μg 
2U/μg 
2U/μg 
2U/μg 
 
The precipitated, digested reactions were resolved on a 0.5% (w/v) agarose gel to excise 
and purify the vector backbones and rTnI gene using the NucleoTrap® Gel Extraction Kit 
as per the manufacturer‟s instructions. The purified components were resuspended in 
~30μL heated mol. G. H2O. The components were then ligated using T4 ligase at a ratio of 
1:1 vector to insert (section 2.3.1.4). 
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2.3.2.3.2 Expression of rTnI in E. coli 
 
Each of the ligation reactions were transformed into BL21 (DE3) pLysS cells (Table 2.1-2) 
using the heat shock transformation protocol (section 2.3.1.5.2). Single colonies were 
obtained on selective agar (dependent on the vector, see section 2.1.8) and grown up in 
2mL SB (with relevant antibiotic) O/N at 37
o
C with shaking at 230rpm. The cultures were 
then subcultured into SB (containing antibiotic) at 10mL scale for induction with 0.5mM 
IPTG or into auto-induction media (non-IPTG) for O/N induction. Post induction cells were 
lysed using Bug Buster™-lysozyme-freeze-thaw method (section 2.3.1.7) and analysed by 
12.5% (w/v) SDS-PAGE and WB (sections 2.3.1.11 and 2.3.1.12). The Western blots were 
probed with anti-HIS HRP-labelled or anti-cTnI-specific antibodies all diluted 1 in 2,000 
with 1% (w/v) PBSTM. Where necessary HRP-labelled secondary antibody diluted as 
above was utilised to detect bound primary antibodies. 
 
2.3.2.3.3 Purification of rTnI 
 
The purification of rTnI in its soluble form was carried out by immobilised metal affinity 
(IMAC) (results not shown) and cation exchange chromatography. Soluble protein was 
extracted from cultures (as described in section 2.3.1.7) and IMAC carried out using the 
buffers delineated in section 2.1.4.6.2, as described in section 2.3.1.9. Cation exchange 
chromatography was carried out using the AKTA Explorer FPLC (GE Healthcare) and a 
HiTrap SP column (GE Healthcare) where 2mL of lysate was injected onto the column at a 
flow rate of 0.5mL minute. The cation exchange buffers listed in section 2.1.4.6.2 were 
used and elution of bound protein was carried out in a stepwise gradient method, written 
using the Unicorn control and evaluation software (GE Healthcare).  
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2.3.2.4 Fusion of epitopes 1 and 2 to fatty acid binding protein 
2.3.2.4.1 Genetic manipulation of designed construct 
 
To overcome the issues encountered with use of many fusion partners and vector-cell 
combinations identified thus far, the epitope 1 and 2 region was expressed as a fusion to the 
DNA sequence encoding human fatty acid binding protein (Val
2
-Glu
132
 – see appendix 
Figure 8.1-1). The gene sequence of heart-type fatty acid binding protein (hFABP) was 
obtained and a serine-glycine linker plus the epitope regions added as a C-terminal fusion 
to the protein. This gene construct was designed and codon optimised followed by 
commercial synthesis in pET28b(+) by Genscript. The vector was then transformed into 
Tuner™ cells by heat shock transformation for identification of positively secreting clones 
(section 2.3.1.5.2).  
 
2.3.2.4.2 Identification of FABP-P1&2 expressing clones 
 
Three clones were assessed for expression of the protein construct by SDS-PAGE and WB 
as described in sections 2.3.1.11 and 2.3.1.12,  in parallel to an equivalently treated 
Tuner™ cell control without plasmid (10mL scale, 0.2mM IPTG for 4 hours at 30oC). The 
clones were probed initially with anti-HIS HRP-labelled (1 in 2,000 in 1% (w/v) PBSTM) 
and a single clone (#2) carried forward for analysis with a range of secondary antibodies. 
For this the SDS-PAGE and subsequent WB were carried out on lanes with the same cell 
lysate sample. The nitrocellulose was blocked and then probed with a battery of specific 
antibodies; anti-FABP (scFv), 2B12 (scFv), Hytest 228, Hytest 19C7 HRP-labelled, 20B3 
mAb and also anti-HIS HRP-labelled which were all diluted 1 in 2,000 in 1% (w/v) 
PBSTM. The scFv were detected with a 1 in 2,000 dilution of an anti-HA HRP-labelled 
secondary antibody and the mAbs with an anti-mouse-Fc-specific HRP-labelled secondary 
antibody. The blot was washed and developed as described in section 2.3.1.12. 
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2.3.2.4.3 Optimisation of expression of FABP-P1&2 
 
To assess the impact of culture time and IPTG concentration a time course (2.5 hours and 5 
hours) at 30
o
C with shaking at 230rpm was undertaken with a range of IPTG concentrations 
(0, 0.01, 0.02, 0.1, 0.2 and 0.5mM) as described in the generic expression optimisation 
method (section 2.3.1.8) and analysed by SDS-PAGE (section 2.3.1.11) and WB (section 
2.3.1.12). For the WB the lysates were probed with an anti-HIS HRP-labelled secondary 
antibody at a 1 in 2,000 dilution in 1% (w/v) PBSTM. 
 
2.3.2.4.4 Optimisation of the purification of FABP-P1&2 
 
A 5mL O/N culture of FABP-P1&2 fusion protein clone#1 (SB with 50μg/mL Kanamycin 
and 1% (v/v) glucose) was used to inoculate a 400mL culture which was allowed to grow at 
37
o
C shaking at 230rpm until an OD600 of ~0.6 was reached. At this point the culture was 
induced with 0.2mM IPTG for 2.5 hours at 30
o
C. The culture was then decanted into 2 x 
250mL tubes and centrifuged at 4,000rpm at 4
o
C for 40 minutes. The collected cell pellet 
was then lysed as described in section 2.3.1.7. Purification was undertaken using the PBS- 
and NaH2PO4-based buffers as outlined in section 2.1.4.6.2 and the generic purification 
methodology delineated in section 2.3.1.9. In this case the purification required significant 
optimisation of the washing strategies as is described in the results section. 
 
2.3.2.4.5 Gel filtration of FABP-P1&2 on an AKTA Explorer FPLC 
 
A S75 (16/60) HiLoad gel filtration column (GE Healthcare) was equilibrated with 1 
column volume (CV) of 1XTBS (1CV = 120mL). A 2mL sample of FABP purified by 
IMAC (1.62mg/mL) applied at a flow rate of 1mL/minute. Fractions were collected after 
0.3CV and until 1.2CV was reached. Protein was monitored online by A280nm using the 
dedicated Unicorn control and evaluation software (GE Healthcare). Protein peaks were 
evaluated and significant protein-containing fractions concentrated to approximately 200μL 
(concentration 11mg/mL).  
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2.3.3 Monoclonal antibody generation 
2.3.3.1 Immunisation of Balb/c mice with synthetic epitope conjugate 
 
cTnI peptide-2-KLH immunisations (200μL) were administered via intraperitoneal (IP) 
injection. On day one, Balb/c mice were immunised with 50μg of the peptide-conjugate in 
500μL PBS emulsified in a 1:1 ratio with 500μL Freund‟s complete adjuvant (FCA). The 
first boost was delivered 3 weeks later by administration of 25μg of peptide-conjugate, 
emulsified 1:1 in Freund‟s incomplete adjuvant (FICA). Subsequent boosts of 12.5μg were 
delivered in alternating 2 and 3 week intervals in the same manner as boost one until a 
sufficient titre was achieved. In preparation for the final boost, the animals were rested for 
4 weeks prior to administration and were sacrificed 7 days post IP injection. The spleens 
(SP) of several mice were harvested for hybridoma production. 
 
2.3.3.2 Anti-serum titre analysis of immune response to epitope-2 of cTnI 
 
cTnI (1μg/mL) and neutrAvidin (2.5μg/mL) were prepared in PBS and 100μL applied to a 
series of wells in duplicate and placed at 4
o
C overnight (O/N) or alternatively at 37
o
C for 1 
hour. Coated plates were then blocked with 5% (w/v) PBSM for 1 hour at 37
o
C. After 
washing with PBS (x2), 1μM peptide-1-CT and peptide-2-CT in 1% (w/v) PBSTM were 
applied to separate series of neutrAvidin-coated wells. The plate was incubated at 37
o
C for 
1 hour and washed with PBST (x3) and PBS (x3). Serial dilutions of serum (tail vein bleed) 
were prepared in 1% (w/v) PBSTM ranging from 1 in 1,000 to 1 in 1million. The prepared 
dilutions were applied in duplicate (100μL) across the cTnI, peptide-1 and peptide-2-coated 
wells. The plate was incubated and washed, as described in the previous step and 100μL of 
a 1 in 2,000 dilution of anti-mouse-Fc-specific HRP-labelled secondary
 
antibody applied to 
all wells. The plate was washed as before and developed with 100μL TMB for 10 minutes 
followed by quenching with 50μL 10% (v/v) HCl. The plate was then read in the Tecan 
sunrise™ plate reader at 450nm. 
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2.3.3.3 Fusion of splenocytes and myeloma 
 
Note: all work was carried out in laminar flow hood employing aseptic technique. Media 
was prepared as described in section 2.1.4.1 and sterile filtered though a 0.2μm filter unit. 
Immediately after harvesting the spleen was perforated in several locations using two 
2.5mL syringe and needles loaded with DMEM w/o FCS in a Petri dish containing 10mL 
of the same medium. The two syringes of media were used in tandem to „flush‟ out the 
lymphocytes from the spleen. The media was removed and placed in a 50mL tube and the 
procedure repeated. The spleen was then crushed using a syringe plunger and washed a 
final time. The collected splenocytes were then centrifuged at 2,000rpm at 4
o
C for 10 
minutes followed by resuspension in 10mL of DMEM w/o FCS. In addition, from four 
T175 (at approximately 75-80% confluence) SP2/0-Ag14 myeloma cells were harvested 
and placed in 40mL DMEM w/o FCS. Both the splenocytes and the myeloma cells were 
pelleted by centrifugation at 2,000rpm at 4
o
C for 10 minutes and washed twice as 
described. After the final wash the cells were counted and viability determined by trypan 
blue exclusion (SP2/0-Ag 14: 2.32x10
7
 and Splenocytes: 1.56x10
8
 cells/mL). The 
splenocytes were mixed in a 6.5:1 ratio with the myeloma cells. The mixed cell population 
was then collected by centrifugation at 1,250rpm at 4
o
C for 10 minutes and washed with 
(DMEM w/o FCS). This was repeated twice after which the supernatant was removed and 
the pellet disrupted by gentle agitation. The cell tube was placed in ice-cold water (ice 
cubes were glass vials containing frozen water). 1.5mL 50% (w/v) PEG was added drop-
wise over 1 minute with constant vigorous swirling in the ice cold water and continued to 
mix vigorously for an additional 90 seconds. The fused cell mix was then clasped tightly in 
the palm of the hand during which 4mL/minute DMEM w/o FCS was added to a volume of 
20mL with constant swirling.  The cell solution was then heated to 37
o
C in a water bath for 
20 minutes and centrifuged at 2,000rpm for 10 minutes at 37
o
C. The pelleted, fused cell 
mix was then resuspended at 1.0 x10
6
 cell/mL in selection media (HAT) (approximately 
179.2mL). About 0.15mL/well of the inner 60-wells of 20x96-well plates was propagated 
and the cells grown at 37
o
C with 5% (v/v) CO2 un-stacked for 7 days without being 
disturbed. 
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2.3.3.4 Analysis of fused hybridoma progeny 
 
Initial analysis of 1170 individual wells post fusion was carried out by a direct binding 
ELISA. Wells were visually examined and scored for the presence of growing 
hybridoma/cell clusters. Wells were also scored for the number of distinct colonies formed 
to identify single cell-derived hybridomas where possible. 
 
2.3.3.4.1 Direct Binding ELISA 
 
Cardiac troponin I (1μg/mL) was coated onto Nunc™ ELISA plates (100μL/well) in PBS 
for 1 hour at 37
o
C (or alternatively overnight at 4
o
C). The solution was ejected from the 
plate and free sites blocked using 5% (w/v) PBSM as above and washed with PBST (x 1) 
and PBS (x 1).  Crude supernatants were diluted 1 in 2 with 1% (w/v) PBSTM and 100μL 
applied to each well. After incubation the plates were washed with PBST (x3) and PBS (x3) 
using a plate washer. Bound secreted IgG was detected using an anti-mouse-Fc-specific-
AP-labelled antibody (1 in 2,000 dilution in 1% (w/v) PBSTM). Secondary antibody was 
removed by washing (as described in the previous step) and colour development achieved 
using p-nitro phenyl phosphate (p-NPP) (12 minutes development time) as a substrate. 
Absorbance was then read using a Tecan Sapphire™ spectrometer at 405nm.   
 
2.3.3.4.2 Epitope-specificity mapping on Biacore™ 4000 
 
Subsequent to identification of positive clones by direct binding ELISA, epitope-specificity 
was confirmed on a Biacore™ 4000 (at the time called the A100). A chip surface was 
prepared by activation of the surface with 1:1 mix of 100mM N-hydroxysuccinimide (NHS) 
and 400mM N-ethyl-N-(dimethyl-aminopropyl) carbodiimide hydrochloride (EDC) for 10 
minutes at a flow rate of 10μL/minute. NeutrAvidin in NaOAc pH4.2 (15μg/mL) was 
immobilised using amine-coupling chemistry with a flow rate 10μL/minute and a contact 
time of 10 minutes followed by capping with 1mM ethanolamine-HCl, pH 8.5 and cleaning 
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of the surface with desorb solution 1 and 2 (GE Healthcare). Individual spots within each of 
the four flow cells were addressed with an excess of biotinylated peptides (1, 2, 3 and 4) 
using the hydrodynamic addressing power of the instrument. Peptide concentrations were 
adjusted to 10μM in 10mM NaOAc, buffer line A placed in water, buffer line B was placed 
in 10mM NaOAc, pH 4.2 and buffer lines 1-4 in HBS-EP
+
 facilitating addressing of the 
spots. The hybridoma supernatants were diluted 1 in 5 with running buffer (HBS-EP
+
) and 
placed in 96-well plates. Analysis was carried out by injection of the diluted supernatants at 
30μL/minute and monitoring the dissociation of the antibodies for 15 minutes post injection 
stop. Binding responses were evaluated using the dedicated BiaEvaluation software and 
antibody-secreting clones ranked by their binding levels and stability early versus stability 
late.  
 
2.3.3.4.3 Competitive ELISA for hybridoma ranking 
 
Two ELISA plates were coated with 0.5μg/mL cTnI in PBS at 4oC O/N. The plates were 
blocked with 5% (w/v) PBSM at 37
o
C for 1 hour. Supernatants for 24 clones were diluted 1 
in 2 with 1% (w/v) PBSTM (1 in 2 A0) and also with 10μM peptide-2 in 1% (w/v) PBSTM 
(1 in 2 competition). The supernatants were also diluted 1 in 5 with 1% (w/v) PBSTM 
before dilution (1 in 2) with 1% (w/v) PBSTM (1 in 10 A0)  and with 10μM peptide-2 in 
1% (w/v) PBSTM (1 in 10 competition). The mixed dilutions were applied to the cTnI-
coated wells and incubated for 1 hour at 37
o
C followed by washing with PBST (x3) and 
PBS (x3). A 1 in 2,000 dilution (1% (w/v) PBSTM) of anti-mouse-Fc HRP-labelled 
secondary antibody was then applied to the wells, incubated and washed as described in the 
previous step. The plate was developed with TMB and quenched with 10% (v/v) HCl 
before reading absorbance at 450nm on the Tecan Sunrise™. 
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2.3.3.4.4 Capture ranking of hybridoma supernatants on Biacore™ 3000 
 
The surface was activated initially by mixing equal volumes of 400mM EDC and 100mM 
NHS and passing the mixture over the sensor surface for 10 minutes at a flow rate of 
5μL/minute. A donkey anti-murine-IgG-Fc-specific antibody (Gallus Immunotech) was 
immobilised (50μg/mL in 10mM NaOAc, pH 4.2) onto the surface of a CM5 dextran chip 
(research grade) (FC: 4) at a flow rate of 5μL/minute for 20 minutes. The surface was then 
capped with 1M ethanolamine HCl, pH 8.5 for 10 minutes. The surface was further cleaned 
with two 30 second injections (30μL/minute flow rate) of 20mM NaOH removing any 
unbound or extraneous material. Conditioned media from the hybridomas was diluted 1 in 
10 in running buffer (1X HBS-EP
+
) and a custom program written on Biacore™ 3000 was 
used to analyse the secreted antibodies. The IgG from the various supernatants was 
captured (flow rate: 10μL/min) and 30nM cTnI (flow rate: 30μL/min) passed over the 
captured monoclonal surface (FC: 4) and FC: 3 to act as a surface online reference. 
Reference subtracted sensorgrams were collected and the surface regenerated with a 30 
second pulse of 10mM H3PO4 (optimised regeneration conditions). 
 
2.3.3.4.5 Sandwich ELISA for cTnI 
 
To perform the sandwich ELISA undiluted supernatant or purified mAb (typically 2-
5g/mL) were coated onto the wells of an ELISA plate at 4
o
C O/N. The plate was blocked 
with 5% (w/v) PBSTM for 1 hour at 37
o
C and washed with PBST (x2).  cTnI of various 
concentrations (a; for the analysis of crude supernatants; 1, 0.5, 0.25, 0.0025 and 0μ/mL 
and b; for purified mAb analysis; serial 1 in 3 dilution from 2000 to 0.3ng/mL) were 
applied to the wells, incubated at 37
o
C for 1 hour and washed with PBST (x3) and PBS 
(x3). MAb 16A11 (anti-peptide-3 HRP-labelled) was diluted 1 in 2,000 in 1% (w/v) PBTM 
and applied across the plate. After incubation and washing as above, the plate was 
developed with TMB and quenched with 10% (v/v) HCl. The absorbance was read at 
450nm on the Tecan Sunrise™. 
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2.3.3.4.6 Isotyping of monoclonal antibody in crude supernatant 
 
Isotype determination was carried out using the Pierce™ Rapid Isotyping kit (catalogue # 
26179) on freshly diluted supernatant as directed by the manufacturer‟s guidelines. The 
presence of control and test lines indicated a valid test.  
 
2.3.3.5 Scale-up and cloning by limiting dilution of screened progeny 
  
Scale-up was carried out daily as required dependent on the specific growth rate of the 
individual clones. From a 96-well format at fusion, the cells were scaled up sequentially as 
illustrated in Figure 2.3-2 and cloned out by limiting dilution a total of three times to ensure 
monoclonality. Wells selected for continued expansion were identified by analysis and the 
cells resuspended in fresh hypoxanthine-aminopterin-thymidine (HAT) media (first scale-
up procedure) or hypoxanthine-thymidine (HT) media (second and subsequent scale-up 
procedures). Cells were then transferred into the appropriate volume of medium for the 
scale (Figure 2.3-2) and placed at 37
o
C with 5% (v/v) CO2 until nearing confluence. Once 
the cells were expanded to T75 scale, selected specific antibody-secreting hybrids were 
cloned by limiting dilution. Using the spent media, the cell monolayer was washed from the 
surface of the flask by pipetting and gentle tapping. The pooled cells were enumerated by 
Trypan blue dye exclusion (section 2.3.3.6.2). Individual clones were then seeded out at 
three cell densities (0.1, 1 and 10 cell/mL) in fresh 150μL HAT/HT media in a 96-well 
plate format and incubated for 7 days at 37
o
C with 5% (v/v) CO2. Single hybridoma-
containing wells were identified from the plates and expanded up to T75 flask scale with 
ongoing performance checking. 
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Figure 2.3-2: Flow diagram of scale-up and cloning by limiting dilution of generated hybridomas 
Illustration of scale-up process indicating culture volumes used.  Clones were serially expanded from 96-well 
master plates through to T75 flasks. At the flask-stage specific antibody-secreting hybrids were cloned by 
limiting dilution. Positives were re-confirmed and scaled up through the process again. This cloning by 
limiting dilution process was carried out three times to ensure monoclonality. 
 
2.3.3.6 General mammalian cell culture methods 
 
All methods involving the use of mammalian cells were carried out aseptically in a Laminar 
flow hood. Cells were grown at 37
o
C with 5% (v/v) CO2 in a humidified atmosphere. 
Adequate precautions and sufficient care were taken to ensure prevention of contamination 
of the cultures and media. The media was prepared using the components listed in section 
2.1.4.1, sterile filtered (0.2μm) and stored at 4oC for one month. Mycoplasma testing was 
carried out on all cell lines, purchased or acquired, not certified as „mycoplasma-free‟ prior 
and, routinely, on all the cell lines held. 
 
2.3.3.6.1 Recovery of frozen mammalian cells 
 
Cells were recovered from LN2 storage by rapid thawing at 37
o
C (clasped in the palm of the 
hand) and transferring to a flask (generally T75) containing 30mL of relevant media 
(dependent on cell line) and incubated at 37
o
C with 5% (v/v) CO2. 
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2.3.3.6.2 Mammalian cell counting and viability determination by trypan blue 
exclusion 
 
Cell counts were performed routinely to assess seeding densities and cell viability. The 
counts were carried out using an improved Neubauer counting chamber. An aliquot of 
resuspended cells (50μL) was diluted 1:5 with fresh media in an eppendorf tube. This 1 in 5 
dilution was further diluted 1:1 with 0.25% (w/v) Trypan blue solution for no longer than 
5-10 minutes. The cells were applied to the counter chamber beneath the cover-slip. Viable 
cells remained uncoloured due to their intact cell membranes. The dye is able to traverse 
the cell membrane in non-viable cells which are stained blue. The count was performed 
under phase contrast on an inverted microscope (Leica DMIL) at 40X magnification. 
 
2.3.3.6.3 Storage of mammalian cell lines  
 
Cells were harvested from 90% confluent flasks (T75/T175) by flushing from the surface 
with an aliquot (~5mL) of the conditioned culture media. The resuspended cells were 
counted (section 2.3.3.6.2) and recovered by centrifugation at 3000rpm at 4
o
C for 10 
minutes. The cells were resuspended in fresh media (DMEM with 50% (v/v) FCS) to give a 
cell density of 2 x 10
6
 cells/mL and this was mixed 1:1 with cryoperservative media 
(DMEM with 50% (v/v) FCS and 8% (v/v) DMSO) to give a final cell density of 1 x 10
6
 
cell/mL in DMEM supplemented with 50% (v/v) FCS and 4% (v/v) DMSO. The cells were 
distributed into 1mL aliquots in screw-threaded cryovials and placed in a Mr. Frosty 
freezing container (filled with pre-chilled isopropanol) at -80
o
C for 12 hours. The vials 
were then transferred to the liquid phase of LN2. 
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2.3.3.7 Purification of anti-epitope-2 monoclonal antibody 
2.3.3.7.1 Protein G purification of 20B3 monoclonal antibody 
 
Protein G sepharose™ fast flow was resuspended in 1mL of 20% (v/v) EtOH in mol. G. 
H2O and allowed to settle in a 10mL column. The buffers required were prepared as 
described in section 2.1.4.6.1. The resin was then washed with 25mL of equilibration 
buffer. Supernatant collected from T175 flasks over a number of days was concentrated 
from approximately 500mL to 5mL with an Amicon® stir cell system (GE Healthcare) 
with a molecular weight cut-off membrane (100kDa). The concentrated supernatant was 
diluted to 10mL with equilibration buffer before application to the column (a 150μL sample 
of the „flow-through‟ was taken for analysis). The column was washed twice with 15CV 
wash buffer (wash 1 and 2). The retained protein was then eluted from the column with 
10mL elution buffer collecting 850μL in 1.5mL tubes containing 150μL neutralisation 
buffer. The fractions containing significant amounts of protein were identified using the 
ND-1000™ and then desalted using a PD-10 column (GE Healthcare). The PD-10 was 
equilibrated with 25mL PBS and a maximum of 3mL of eluted protein applied to the 
column. The „flow-through‟ was discarded and the retained protein eluted with 3.5mL PBS 
in 350μL fractions. The desalted protein fractions were quantified using the ND-1000™ 
and concentrated using a Vivaspin 6 (10kDa cut-off). The final protein determination was 
carried out using the ND-1000™. 
 
2.3.3.7.2 Size exclusion chromatography-HPLC analysis of monoclonal antibody, 
20B3 
 
Size exclusion chromatography was carried out on a Shimadzu HPLC at 20
o
C. 
Column: Phenomenex BioSep-SEC-S200 (300 x 7.80mm) 
System: LC20AB (pump), CT02AC (oven), CBM20A (control), SIL20A (auto 
sampler) and SPD20A (UV detector). 
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Three dilutions of mAb were prepared to generate a strong UV280nm peak. Monoclonal 
antibody 20B3 was adjusted to 0.125, 5 and 495μg/mL in PBS corresponding to total 
protein quantities of 6.25ng, 0.5 and 24.75μg being applied to the column (50μL injection 
volume, 0.5mL/min flow rate). The resulting chromatograms were analysed using the LC 
solution software package. 
 
2.3.3.8 Kinetic analysis of monoclonal antibody on Biacore™ 3000 
 
20B3 (50μg/mL in 10mM NaOAc buffer) was pre-concentrated onto the dextran surface 
over a range of pH values to determine the optimal pH to promote efficient immobilisation. 
The pH of the buffer was adjusted with 10% (v/v) acetic acid to pH values 3.8, 4.0, 4.2, 4.4, 
4.6 and 4.8. 10μL (50μg/mL) of the protein at the respective pH was passed over an un-
modified carboxymethylated dextran chip at a flow rate of 10μL/minute. The pH 
demonstrating the highest response unit (RU) level, hence greatest pre-concentration, was 
employed as the carrier buffer for immobilisation. A surface of 20B3 mAb was then created 
using the immobilisation chemistry and parameters, outlined in section 2.3.3.4.4, resulting 
in a surface of approximately 5000RU. Kinetic analysis was carried out with serial cTnI 
concentrations prepared in HBS-EP
+ 
at a flow rate of 30uL/minute to minimise mass 
transfer limitations.  
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2.3.4 Recombinant antibody generation 
2.3.4.1 Immunisation of chickens 
 
Chicken Designation: Y20.03.09 
cTnI peptide-1-KLH immunisations were administered via 1mL subcutaneous injections. 
On day one, the chickens (adult Leghorn) were immunised with 100μg of the relevant 
peptide-conjugate in 550μL PBS emulsified in a 1:1 ratio with 550μL Freund‟s complete 
adjuvant (FCA). The first boost was delivered 3 weeks later by administration of 75μg of 
peptide-conjugate, emulsified 1:1 in Freund‟s incomplete adjuvant (FICA). Subsequent 
boosts of 50μg were delivered in alternating 2 and 3 week intervals in the same manner as 
boost one until a sufficient titre was achieved. In preparation for the final boost, the animal 
was rested for 4 weeks prior to administration and was sacrificed by lethal injection 
(pentobarbital) and cervical dislocation 7 days post subcutaneous injection. Both bone 
marrow (BM) and spleen (SP) were harvested for library building. 
 
2.3.4.2 Extraction of RNA and cDNA synthesis from chicken 
 
Total RNA was recovered from BM and SP of the immunised chicken (Y20.03.09) by 
chloroform-based extraction carried out immediately after sacrifice. All reagents used are 
molecular grade and all materials treated with RNaze™ Zap where possible. 
All surfaces of the laminar flow unit were decontaminated with 70% (v/v) isopropyl 
alcohol (IPA) and RNase™ ZAP.  SP and BM (x 2 thigh/hip) were processed separately. 
The spleen was placed in 50mL RNase-free tube immediately containing 10mL ice-cold 
Trizol. The bone marrow was first extracted by cutting away the joint knuckles at either end 
of the bone and flushing out as much marrow as possible using a syringe and needle loaded 
with 10mL Trizol reagent. Both BM and SP were homogenised using a homogeniser probe 
(previously precepted, RNase™ Zap washed, rinsed, autoclaved and dried) at 50% output 
for 1 minute followed by 100% output for 20 seconds. 20mL of Trizol was added to both 
tubes and allowed to stand at room temperature (RT) for 5 minutes followed by 
centrifugation at 3,530rpm at 4
o
C for 20 minutes. The supernatant was carefully transferred 
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to a 50mL polypropylene tube and 6mL chloroform was added. The tube was shaken 
vigorously for 15 seconds and left to rest for 15 minutes at RT. After centrifugation at 
12,000rpm at 4
o
C for 25 minutes the upper aqueous layer was carefully pipetted away into 
a 50mL polycarbonate tube (note: a residual layer was left to ensure no protein 
contamination) to which 15mL isopropanol was added and mixed vigorously for 15 
seconds.  After standing at RT for 15 minutes the tube was centrifuged at 12,000rpm at 4
o
C 
for 25 minutes and the supernatant removed from the opaque pellet. The pellet was washed 
twice with 30mL ice-cold 70% (v/v) EtOH at 12,000rpm at 4
o
C for 20 minutes and air-
dried for 2 minutes. Both the BM and SP pellets were resuspended in 500μL mol. G. H2O 
and quantified on Nanodrop ND 1000™ using nucleic acid RNA-40 setting. A sufficient 
aliquot was retained for cDNA synthesis and the remainder was precipitated, as described 
in section 2.3.1.1 for storage at -80
o
C in several aliquots. 
From the total RNA extracted, mRNA was oligo dT primed for cDNA synthesis which was 
carried using Superscript III® reverse transcriptase kit as per manufacturer‟s guidelines. 
The cDNA was stored in 10μL aliquots at -80oC post 1st strand synthesis. 
 
2.3.4.3 pComb3xSS vector preparation 
 
The pComb3 vector series was kindly provided by Carlos Barbas III (Scripps Institute, La 
Jolla, California) under an academic material transfer agreement (MTA). The pComb3xSS 
vector was transformed into competent dam
-
/dcm
- 
E. coli for initial propagation and 
maintenance. An overnight culture (10mL SB supplemented with 12μg/mL tetracycline) 
was prepared from a single transformed colony and incubated at 37
o
C shaking at 230rpm. 
This overnight culture was then used to inoculate 100mL SB (12μg/mL tetracycline) and 
grown O/N at 37
o
C shaking at 230rpm. Bacteria were collected by centrifugation at 
4000rpm at 4
o
C for 30 minutes and the plasmid purified using NucleoBond® Xtra Midi as 
per the manufacturer‟s guidelines. Purified plasmid was resuspended in a final volume of 
250μL mol. G. H2O and quantified on Nanodrop ND™ 1000 nucleic acid DNA-50 setting. 
Purified vector (section 2.3.4.3) was initially verified using the digestion setup outlined in 
Table 2.3-3 and the digested products visualised for verification on a 0.5% (w/v) agarose 
gel (section 2.3.1.1). 
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Table 2.3-3: pComb3xSS vector digestion components 
Component SacI Digest SfiI Digest 
Vector 1μg 1μg 
Buffer 4 (10X) 1X 1X 
BSA (100X) 1X 1X 
Mol. G. H2O to 50μL to 50μL 
SacI [20U/μL] 
SfiI  [20U/μL] 
2U/μg 
- 
- 
2U/μg 
Total Volume 50μL 50uL 
Temperature 37
o
C 50
o
C 
Time 3 hours 3 hours 
 
2.3.4.4 Antibody (scFv) library construction 
 
Antibody construction was carried out as described by Andris-Widhopf and co-workers 
[88, 89]. The initial steps involved in generating the library require the amplification of the 
antibody variable domains from the synthesised cDNA isolated from both the spleen (SP) 
and the bone marrow (BM) of the chicken (Y20.03.09). The primers used for library 
building are those published in Chapter 9 of Phage Display:  a laboratory manual and host-
specific sub chapters [89]. All primers used were those to clone antibody fragments into the 
pComb3x vector series. The list of primers used to construct avian scFv fragments from 
immune libraries introducing the long linker (GGSSRSSSSGGGGSGGGG) between the 
variable heavy and light chains is shown in Table 2.3-4 [88, 89]. All primers were 
commercially synthesised by Integrated DNA Technologies (Interleuvenlaan 12A B-3001 
Leuven, Belgium). The only exceptions were the sequence primer pair that were 
synthesised on demand by Source BioScience DNA Sequencing (Translational Research 
Lab - Room 1.18, Central Pathology Laboratory, St James's Hospital, Dublin 8. Ireland). 
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Table 2.3-4: Avian scFv library PCR primer list 
Primer Name Sequence 5' - 3' 
Variable H 
CSCVHo-FL  
GGT CAG TCC TCT AGA TCT TCC GGC GGT GGT GGC AGC TCC GGT GGT GGC 
GGT TCC GCC GTG ACG TTG GAC GAG 
CSCG-B  CTG GCC GGC CTG GCC ACT AGT GGA GGA GAC GAT GAC TTC GGT CC 
Variable λ 
CSCVK  GTG GCC CAG GCG GCC CTG ACT CAG CCG TCC TCG GTG TC 
CKJo-B GGA AGA TCT AGA GGA CTG ACC TAG GAC GGT CAG G 
SOE Overlap 
CSC-F  GAG GAG GAG GAG GAG GAG GTG GCC CAG GCG GCC CTG ACT CAG 
CSC-B  GAG GAG GAG GAG GAG GAG GAG CTG GCC GGC CTG GCC ACT AGT GGA GG 
Sequence Primers 
Ompseq AAG ACA  GCT ATC GCG ATT GCA G 
gBack GCC CCC TTA TTA GCG TTT GCC ATC 
 
2.3.4.4.1 Variable domain amplification  
 
The first round of PCR involved separate amplification of variable heavy and light chains. 
Initially, the MgCl2 concentration for the reactions was optimised to ensure high-yield 
specific-bands by titration in the concentration range as indicated in Table 2.3-5 followed 
by large-scale synthesis (15X) at the optimised 2.0mM MgCl2 for both VL and VH. 
 
Table 2.3-5: Amplification of avian variable domains from cDNA 
Component Optimisation Reaction (1X) Large-Scale Reaction (1X) 
Go Taq Buffer (10X) 1X 1X 
MgCl2 [25mM] 1.5/2.0/3.4/4.0mM 2.0mM 
Mol. Grade H2O to final volume of 50μL to final volume of 50μL 
dNTP [100mM] 0.1mM 0.1mM 
Forward Primer [60nMol] 30pM 30pM 
Reverse Primer [60nMol] 30pM 30pM 
cDNA 1μL μL 
Polymerase [5U/μL] 1.25U 1.25U 
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The PCRs were carried out under the following cycling parameters in the G-Storm 
thermocycler. 
 
Table 2.3-6: Variable domain amplification PCR cycle parameters 
 
 
Large-scale variable PCR products were resolved on 1.5% agarose gel (section 2.3.1.3). 
Strong bands at 350bp (LC) and 450bp (HC) were excised and purified using NucleoTrap® 
gel extraction kit according to the manufacturer‟s guidelines. Purified products were 
quantified using Nanodrop ND 1000™ using DNA-50 setting. Note: All PCR products 
were eluted from the column in washes of 20μL then followed by an additional 10μL of 
preheated (~70
o
C) molecular grade water. 
  
2.3.4.4.2 Splice-by-overlap extension (SOE) PCR  
 
The second round of PCR „stitched‟ together the variable domains into a single scFv 
construct in the VL-VH orientation. This stitching is possible due to the overlapping „tails‟ 
in the light chain reverse (CKJo-B) and heavy chain forward primers (CSCVHo-FL). This 
was carried out using the overlap primer pair (CSC-F and CSC-B) to complete the 
construct and introduce upstream and downstream SfiI sites for easy transition into the 
vector. In addition „clamp‟ sequences (GAG)6 on these primers promote efficient digestion 
of the PCR products. Platinum® Taq DNA Polymerase High Fidelity (Invitrogen) was 
employed at this stage of library construction and initial optimisation of MgSO4 was carried 
out prior to the large-scale reaction. Table 2.3-7 details the reaction conditions for SOE 
optimisation and the subsequent optimised large-scale reaction. The PCRs were carried out 
under the following cycling parameters in the G-storm thermocycler (Table 2.3-8). 
Stage Step Temperature (
o
C) Times (s) # Cycles 
1 Initial Denature 94
o
C 120 1 
2 
Denaturation 
Annealing 
Extension 
94
o
C 
56
o
C 
72
o
C 
15 
30 
60 
30 
3 Final Extension 72
o
C 600 1 
  
2–46 
 
  
Table 2.3-7: Splice-by-overlap extension PCR 
Component 
Optimisation Reaction 
Concentration (1X) 
Large-Scale Reaction 
Concentration (1X) 
High Fidelity PCR Buffer (10X) 1X 1X 
MgSO4 [50mM] 1.5/2.0/3.4/4.0mM 1.5mM 
Mol. Grade H2O to final volume of 50μL to final volume of 50μL 
dNTP [100mM] 0.1mM 0.1mM 
CSC-F [60nMol] 30pM 30pM 
CSC-B [60nMol] 30pM 30pM 
VL  100ng 100ng 
VH 100ng 100ng 
Polymerase [5U/μL] 1U 1U 
 
Table 2.3-8: SOE amplification PCR cycle parameters 
Stage Step Temperature (
o
C) Times (s) # Cycles 
1 Initial Denature 94
o
C 120 1 
2 
Denaturation 
Annealing 
Extension 
94
o
C 
56
o
C 
68
o
C 
15 
30 
60 
30 
3 Final Extension 68
o
C 600 1 
 
Optimisation reactions for SOE-PCR were visualised on 1.5-2% (w/v) agarose gel (section 
2.3.1.1) to allow determination of the optimal conditions for the large-scale reactions. 
Optimised large-scale reaction products were taken forward for purification. SOE-PCR 
products were purified by resolution on a 2% (w/v) agarose gel (section 2.3.1.1) and 
extracted using the NucleoTrap® gel extraction kit as per the manufacturer‟s instructions. 
The purified products were eluted in 50μL mol. G. H2O per gel slice. 
 
SOE Product Concentration Total DNA 
BM 87.6ng/μL 21.9μg 
SP 131.02ng/μL 32.8μg 
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2.3.4.4.3 Restriction digests of vector and inserts for scFv library construction 
 
Both the purified pComb3xSS and SOE-PCR products from the BM and SP were digested 
in large-scale for ligation of the library (Table 2.3-9). 
  
Table 2.3-9: Large-scale SfiI digestion of scFv library and insert 
Component BM SP pComb3xSS 
DNA 10μg 10μg 20μg 
Buffer 4 (10X) 1X 1X 1X 
BSA (100X) 1X 1X 1X 
Mol. G. H2O to 200μL to 200μL to 200μL 
SfiI  [20U/μL] 36U/μg 36U/μg 6U/μg 
 
All the reactions were incubated at 50
o
C in a G-storm thermocycler for 5 hours. The BM 
and SP were then stored as an ethanol precipitation until required (section 2.3.1.1). Table 
2.3-10 outlines the subsequent treatment of the vector. 
 
Table 2.3-10: Triple digestion and Antarctic phosphatase treatment of vector 
Component pComb3xSS 
XhoI [20U/μL] 
XbaI [20U/μL] 
3U/μg 
3U/μg 
Temperature and Time 37
o
C for 1 hour followed by 65
o
C for 30 minutes 
Antarctic phosphatase buffer (10X) 
Antarctic phosphatase [5U/μL] 
1X 
1U/μg 
Temperature and Time 37
o
C for 30 minutes followed by 65
o
C for 15 minutes 
  
Post triple digestion and Antarctic phosphatase treatment the vector was stored as an 
ethanol precipitation (section 2.3.1.1) until required. All the digested product precipitations 
were completed, as described in section 2.3.1.1. The products were purified by resolution 
on 0.5% (w/v) (pComb3x) or 2% (w/v) (BM and SP) agarose gels, the relevant bands 
  
2–48 
 
  
excised and extracted using NucleoTrap® gel extraction kit as per the manufacturer‟s 
instructions (eluted in 50μL mol. G. H2O). 
 
2.3.4.4.4 Library ligation and transformation 
 
The purified SfiI digested scFv inserts were then ligated into the prepared pComb3x vector 
using T4 ligase (NEB) under the reaction conditions outlined in Table 2.3-11. The reaction 
was carried out overnight at room temperature. The ligations were then deactivated at 65
o
C 
for 20 minutes and ethanol precipitated overnight at -20
o
C as described in section 2.3.1.1. 
 
Table 2.3-11: scFv library ligation reaction components 
Component BM SP Control 
Vector DNA 1.4μg 1.4μg 1.4μg 
Insert DNA 0.7μg 0.7μg - 
Ligase Buffer (10X) 1X 1X 1X 
Mol. G. H2O to 100μL to 100μL to 100μL 
T4 Ligase [400U/μL] 10U/μg 10U/μg 10U/μg 
 
Once the precipitations were completed, the ligation reactions were resuspended in 15μL 
mol. G. H2O for transformation. Transformations were carried out for BM and SP libraries 
separately. Each 15μL library ligation was split into 2 x 7.5μL transformation reactions (4 
in total) to generate the avian anti-peptide-1 library. 
300μL of electro-competent E. coli XL1-blue cells, prepared as per section 2.3.1.5.1, were 
placed into ice-cold 2.5mm electroporation cuvettes (Bio-Rad) and 7.5μL of the library 
ligation added to each 300μL cell aliquot. The cells and DNA were left to stand for 1 
minute after gentle mixing. DNA was electroporated into the cells using the Gene Pulser 
xCell Electroporation system (Bio-Rad) with the following parameters; 2.5kV, 25µF and 
200Ω (τ = 4.0msec). Once electroporation was completed each cuvette was immediately 
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flushed with 1mL SOC media and transferred to a 50mL pre-warmed tube. This was 
followed by a further 1mL wash with SOC. All the electroporated samples (both BM and 
SP ~ 8mLs) were combined into the one 50mL tube and placed at 37
o
C shaking at 230rpm 
for 1 hour. The control ligation (2 x 7.5μL ligation) was also electroporated and treated in 
the same fashion. To both the library and the control 10mL of pre-warmed SB (with 3μL of 
10mg/mL carbenicillin and 30μL of 5mg/mL tetracycline) was added. A 20μL sample of 
the library was removed into 180μL SB for titre determination by plating a 10-fold serial 
dilution range (plated 100μL of 10-3 to 10-6 inclusive on LB-Carbenicillin (50μg/mL) agar 
plates). A 2μL sample was removed from the control library and diluted into 200μL SB 
followed by plating 10μL and 100μL of this 1 in 100 dilution onto LB-Carbenicillin 
(50μg/mL) agar plates. The control was then discarded. The library was then placed at 37oC 
shaking at 230rpm for a further hour after which 4.5μL of Carbenicillin (100mg/mL) was 
added. After incubation for 1 hour at 37
o
C with shaking at 230rpm, 2mL of helper-phage 
(VCSM13: 1.0x10
13
cfu/mL) was added and the library transferred to a 500mL baffled flask 
containing 183mL SB with 92.5μL Carbenicillin (100mg/mL) and 370μL Tetracycline 
(5mg/mL). The culture was left static for 15 minutes followed by incubation for 2 hours as 
described in the previous incubation step. 280μL of Kanamycin (70mg/mL) was added and 
the cultures left to grow at 37
o
C with shaking at 230rpm overnight. At this stage the library 
is displayed on the phage particle and is ready for bio-panning. 
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2.3.4.5 Bio-panning of phage displayed libraries 
2.3.4.5.1 Pre-optimisation of bio-panning conditions  
 
Prior to carrying out any of the bio-panning strategies outlined in the subsequent sections 
the conditions were optimised with available control antibodies to maximise the success of 
the bio-panning stringencies. 
 
2.3.4.5.1.1 Wild-type antigen presentation 
 
The wild-type (WT) library was panned in a highly stringent antigen presentation manner 
using the mAb 20B3 to isolate compatible antibody-pairs for a diagnostic assay format. The 
strategy utilised 20B3 to capture cTnI to be subsequently interrogated by the library. Thus, 
isolating scFv fragments which could bind cTnI epitope-1 in the presence of the mAb 
bound in close proximity. The coating concentration of 20B3 and cTnI capture 
concentration were determined by preparation of a sandwich assay mimicking the 
presentation strategy. 20B3 mAb at 50, 10, 5 and 1μg/mL in PBS was coated in duplicate 
onto wells of an ELISA plate with 2μg/mL of the control mAb (Hytest 228) O/N at 4oC. 
The plate was blocked with 5% (w/v) PBSM for 1 hour at 37
o
C and concentrations of cTnI 
(15, 10, 5, 1, 0.5 and 0μg/mL) in 1% (w/v) PBSTM applied to the capture mAb wells. After 
incubation for 1 hour at 37
o
C and washing (PBST x3 and PBS x3) the captured cTnI was 
detected with a 1 in 2,000 dilution (1% (w/v) PBSTM) of anti-epitope-1 Hytest mAb 19C7 
(HRP-labelled). The plate was incubated and washed as before followed by colour 
development with TMB and quenching with 10% (v/v) HCl after 10 minutes. The 
absorbance was read at 450nm in Tecan Sunrise™ plate reader.   
 
2.3.4.5.1.2 Mutant in-solution peptide concentration optimisation 
 
An „in-solution‟ mode of bio-panning was selected to isolate improved mutants (MT) over 
the WT scFv. To optimise the bio-panning conditions 2μg/mL of purified WT scFv and 
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Hytest 19C7 HRP-labelled mAb were incubated with varying concentrations of biotinylated 
synthetic epitope-1 (10, 1, 0.5, 0.1 and 0nM) in 1% (w/v) PBSTM at 37
o
C shaking for 1 
hour to assess the biotin-peptide-1 concentrations to optimally enrich and suitably 
challenge the library. The peptide-bound antibody was recovered by incubation with 10μL 
streptavidin-coated magnetic beads (NEB), application of a magnet and washing (PBST x3 
and PBS x3). A 1 in 2,000 dilution in 1% (w/v) PBSTM of an anti-HA HRP-labelled 
secondary antibody was applied to the tubes containing scFv, incubated and washed as 
before. The resultant bead-peptide-antibody complexes were then resuspended in TMB and 
after 10 minutes, 100μL of the TMB was transferred to an ELISA plate containing 50μL 
10% (v/v) HCl and the absorbance read at 450nm on the Tecan Sunrise™. 
 
2.3.4.5.2 Phage rescue after each round of bio-panning 
 
Phage rescue is the process carried out at each round of bio-panning to recover the selected 
antibody-displaying phage from culture supernatant. After incubation of the transformed 
library overnight (section 2.3.4.4.4) the phage were isolated by PEG8000 precipitation. This 
was carried out after each round of bio-panning e.g. R0 = transformed library recovery, R1 
= recovered phage after 1
st
 round of bio-panning and so on. The phage-scFv library culture 
was placed in 2 x 250mL or 2 x 85mL (depending on culture volume) centrifuge bottles. A 
1mL sample was removed, centrifuged at 9,000rpm for 5 minutes at RT. The cells and 
supernatant were retained for DNA/soluble antibody analysis if required.  
The centrifuge bottles were centrifuged at 9000rpm for 15 minutes at 4
o
C (Eppendorf 
5810R) after which 4% (w/v) PEG8000 and 3% (w/v) NaCl was added to each supernatant 
after transfer to a set of clean centrifuge bottles. The phage rich supernatant was shaken at 
230rpm for 5 minutes at 37
o
C. The precipitating phage was then put on ice for 30 minutes 
before centrifuging at 9000rpm for 15 minutes at 4
o
C. The supernatant was discarded and 
the tubes dried by inversion for 10 minutes. The phage pellet was then resuspended in 2 x 
1mL of 1mg/mL KLH with 0.02% (w/v) NaN3 in PBS. The phage preparation was then 
transferred to a 2mL micro-centrifuge tube and any residual cellular debris removed by 
centrifugation (full speed for 5 minutes at 4
o
C). 
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2.3.4.5.3 Wild-type scFv bio-panning 
 
To a previously coated (100μL of 5mg/mL 20B3 mAb at 4oC O/N) and blocked (PBSM 5% 
(w/v) 1 hour at 37
o
C) immunotube, 850μL of the rescued phage was added and incubated 
with shaking for 1 hour at RT to deplete the library. Eight wells of a microtitre plate coated 
with 50μg/mL 20B3 mAb (4oC O/N) were blocked with 5% (w/v)  PBSM (1 hour at 37oC) 
to capture 75μg/mL of cTnI (1 hour at 37oC) followed by washes of PBST (x3) and PBS 
(x3). 800μL of the depleted phage library was then applied to the captured protein wells 
(100μL/well) and allowed to interact while shaking for 1 hour at RT. Non-specific phage 
were removed with sequential PBST (200μL/well x 5) and PBS (200μL/well x 5) washes. 
Specific bound phage were eluted by incubation with 100μL/well of 10mg/mL trypsin in 
PBS at 37
oC for 30 minutes. The eluted phage (~800μL) was then infected into 5mL of 
mid-exponential (O.D600 ~0.4) E. coli XL-1 blue for 15 minutes, static at RT. Pre-warmed 
SB media (6mL) containing 1.6μL of Carbenicillin (100mg/mL) was added to the infected 
cells and a 2μL sample diluted in 200μL SB for output titre determination by plating 10μL 
and 100μL of this onto LB-Carbenicillin (50μg/mL) agar plates. The 8mL output library 
was placed at 37
o
C shaking at 230rpm for 1 hour followed by the addition of 2.4μL of 
Carbenicillin (100mg/mL) and incubation at 37
o
C shaking at 230rpm for 1 hour. Helper-
phage (1mL of VCSM13: 1.0 x 10
13
 cfu/mL) was added and the culture transferred to a 
250mL baffled flask containing 92mL SB with 46μL of Carbenicillin (100mg/mL) plus 
184μL of Tetracycline (5mg/mL) and incubated at 37oC with shaking at 230rpm for 2 
hours. In the final step 140μL of Kanamycin (70mg/mL) was added and the culture 
incubated as above overnight. 
An input titre was performed during these incubation steps by addition of 10μL of the 
rescued phage in 90μL SB media and 10-fold serially diluting to 10-9. A 2μL sample of the 
10
-7
, 10
-8
 and 10
-9
 dilutions were infected into mid-exponential phase E. coli XL-1 blue 
(100μL) and plated (50μL) onto LB-Carbenicillin plates (50μg/mL) after static incubation 
at RT for 15 minutes. 
This bio-panning procedure was repeated on successive days (referred to as rounds), 
employing the stringency conditions delineated in Table 2.3-12, to exert selective pressure 
on the library to isolate high-affinity clones. 
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Table 2.3-12: Bio-panning conditions employed for isolating the wild-type anti-epitope-1 scFv 
 O/N Culture 
Volume 
(mL) 
[Capture mAb] 
(μg/mL) 
[cTnI] x (wells) 
(μg/mL) 
Washes 
PBST + PBS 
R1 200 50 75 x 8 5 + 5 
R2 100 50 75 x 4 5 + 5 
R3 100 50 50 x 4 5 + 5 
R4 100 50 25 x 4 5 + 5 
 
2.3.4.5.4 Mutant scFv bio-panning 
 
Solution-phase bio-panning was the mode of selection decided upon for the isolation of 
improved affinity clones from the LC-shuffled scFv library. The library was constructed in 
the same manner as for the WT with the VH being amplified from the WT scFv plasmid by 
PCR as opposed to cDNA. The WT VH was then recombined (by SOE-PCR) with the 
catalogue of light chains (SP and BM) from the original chicken cDNA. At this stage the 
mutant (MT) library construction process was carried out as for the WT where the SfiI 
digested BM and SP LC-shuffled libraries were ligated and transformed as previously 
described and displayed on phage (section 2.3.4.4.4).  From the MT-rescued phage (section 
2.3.4.5.2) 170μL was incubated with 25μL streptavidin-coated magnetic beads to deplete 
the library of non-specific-phage for 1 hour at 37
o
C. The beads were recovered by the 
application of a strong magnet for 2 minutes. The depleted library (150μL) was then 
transferred to a 1.5mL tube previously blocked with 3% (w/v) PBS-BSA. To the tube 50μL 
of 4X concentrated biotinylated peptide-1 (see Table 2.3-13) was added and incubated 
shaking at RT for 45 minutes. Streptavidin-coated magnetic beads (20μL) blocked with 3% 
(w/v) PBS-BSA were added and the library-peptide-bead mix incubated for a further 15 
minutes. Specific-phage were recovered by application of the magnet and the non-specific 
phage-containing supernatant discarded. The bead-peptide-scFv-phage complexes were 
washed by resuspension in 500μL PBST and recovered using the magnet. This washing 
was repeated with PBST x5 and with PBS x5 with the beads being transferred to a clean 
blocked 1.5mL tube after the PBST washes. The phage were eluted with 500μL of 
10mg/mL trypsin in PBS for 30 minutes at RT and the beads recovered using the magnet. 
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The supernatant was then infected into 5mL of mid-exponential (O.D600 ~0.4) E. coli XL-1 
blue for 15 minutes, static at RT.  At this stage, the bio-panning procedure for in-solution 
selection was carried out as described for the WT library bio-panning. The selection 
conditions exerting selective pressure on the mutant library are indicated in Table 2.3-13. 
 
Table 2.3-13: Solution-phase bio-panning conditions for mutant anti-epitope-1 scFv selection 
Round 
4 x Peptide  
Concentration (nM) 
Final Peptide  
Concentration (nM) 
Washes 
PBS +PBST 
1 40 10 5 + 5 
2 4 1 5 + 5 
3 2 0.5 5 + 5 
4 0.4 0.1 5 + 5 
 
2.3.4.6 Polyclonal-phage ELISA for specific antibody-displaying phage 
 
After completion of the bio-panning experiments a polyclonal-phage ELISA was carried 
out to assess the success of the panning conditions and to identify the round in which 
enrichment of phage displaying antigen-specific antibodies had occurred. The ELISAs 
carried out for the WT and MT selection campaigns are described below. 
 
2.3.4.6.1 Wild-type polyclonal-phage ELISA 
 
cTnI (1μg/mL in PBS), neutrAvidin (2.5μg/mL), 20B3 mAb (10μg/mL) and KLH 
(1μg/mL) were coated over a series of wells on an ELISA plate at 4oC overnight. The plate 
was blocked with 5% (w/v) PBSM at 37
o
C for 1 hour. Biotinylated peptide-1 (10μM) was 
applied to the neutrAvidin-coated wells and cTnI (10μg/mL) to a series of the 20B3 mAb-
coated wells (all other wells were placed in PBS). After incubation for 1 hour at 37
o
C the 
plate was washed with PBST (x3) and PBS (x3). Phage from each rescue (round: R0, R1, 
R2, R3 and R4) were diluted 1 in 5 with 1% (w/v) PBSTM and 100μL applied across the 
coated wells for each phage rescue. The plate was incubated and washed as described in the 
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above step and a 1 in 2,000 dilution (1% (w/v) PBSTM) of anti-M13 HRP-labelled 
secondary antibody applied to the wells. After incubation and washing as indicated above, 
the plate was developed with 100μL/well TMB and quenched after 10 minutes with 10% 
(v/v) HCl. The absorbance was read in the Tecan Sapphire™ at 450nm. 
 
2.3.4.6.2 Mutant polyclonal-phage ELISA 
 
A series of wells of an ELISA plate were coated with cTnI (1μg/mL) and KLH-peptide-1 
(1μg/mL) in PBS overnight at 4oC to accommodate the four phage rescues and the WT 
scFv (pure) as a positive control. The entire plate was then blocked with 5% (w/v) PBSM 
for 1 hour at 37
o
C. The phage from each rescue (R0-R4) was diluted 1 in 5 with 1% (w/v) 
PBSTM and 100μL applied across the coated wells. After incubation for 1 hour at 37oC the 
plate was washed with PBST (x3) and PBS (x3). A 1 in 2,000 dilution (1% (w/v) PBSTM) 
of anti-M13 HRP-labelled secondary antibody was applied to the wells. After incubation 
and washing the plate was developed with 100μL/well TMB and quenched after 10 minutes 
with 10% (v/v) HCl. The absorbance was read in the Tecan Sapphire™ at 450nm. 
 
2.3.4.7 Soluble scFv expression and lysis 
 
Once the round corresponding to selective enrichment of the library was identified by the 
polyclonal-phage ELISA, the phage were infected into mid-exponential E. coli Top10F'.  
A small amount of phage (1-20μL) was added to a growing culture of E. coli TOP10F' and 
incubated for 1 hour at 37
o
C, while shaking at 230rpm. The cells were then diluted serially 
from 10
-1
 to 10
-7 
in SB media and plated onto LB-Carbenicillin (50mg/mL) agar plates to 
isolate single colonies. Single colonies were then transferred into the inner 60 wells of a 96-
well plate containing 150μL SB (50μg/mL Carbenicillin and 1% (w/v) glucose). The plate 
was sealed and incubated at 37
o
C shaking at 230rpm overnight. The following day 25μL of 
the O/N cultures was subcultured into 875μL SB (50μg/mL Carbenicillin and 1X 505) in a 
96-deep-well plate and grown for 3 hours at 37
o
C shaking at 230rpm. The individual 
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cultures were then induced with 100μL of 5mM IPTG (final of 0.5mM IPTG) overnight at 
30
o
C shaking at 230rpm. The IPTG-induced single colonies were evaluated for specific-
soluble antibodies by a number of analysis formats that were specific to the WT and MT 
screening campaigns. Prior to analysis the cells were recovered from the conditioned media 
by centrifugation at 4,000rpm for 30 minutes at 4
o
C. The cells were then lysed to release 
the soluble-expressed scFv. The cell pellets were then frozen at -80
o
C for a minimum of 1 
hour. After thawing the cells were resuspended in 500μL PBS containing 1mg/mL 
lysozyme and incubated at RT for 30 minutes. The plate was freeze-thawed a minimum of 
3 times with alternating cycles of -80
o
C and 37
o
C. The cellular debris was collected by 
centrifugation at 4,000rpm for 40 minutes at 4
o
C and the scFv-containing supernatant 
(clarified lysate) removed for analysis. 
 
2.3.5 Screening for anti-epitope-1-specific scFv from bio-panned libraries 
 
Both the WT and MT selected libraries from the bio-panning campaigns described above 
were screened in slightly differing fashions. The screening regimes undertaken for both are 
described separately in this section. 
 
2.3.5.1 Wild-type scFv screening approach 
 
A three pronged analysis was undertaken for the WT scFv screen. This consisted of bio-
panning output-based genetic evaluation, plate-based ELISA and high-throughput (HT)-
based screening which were all applied to exhaustively mine the selected WT library. 
 
2.3.5.1.1 Fingerprint analysis of wild-type clones by restriction mapping 
 
For fingerprint analysis single colonies were selected from the output titre plates from 
round four to allow PCR amplification of the scFv gene. Nineteen individual 1X reactions 
were prepared as outlined in Table 2.3-14. Eighteen colonies were randomly sampled and 
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added to 60μL of mol. G. H2O, boiled and the debris collected by centrifugation (full speed 
at RT). This was then used as the water component specific to each clone for the PCR mix 
(the 19
th
 tube served as a negative control). To all 19 tubes Go Taq polymerase (0.25μL) 
was added and the PCR carried out in a G-storm thermocycler as outlined in Table 2.3-8. 
 
Table 2.3-14: Colony pick PCR master mix 
Component 1X 
Go Taq Buffer (5x) 1X 
MgCl2 [25mM] 2.0mM 
dNTPs [100mM] 0.1mM 
Mol. G. H2O to 49.75μL 
CSC-F [60nM] 30pM 
CSC-B [60nM] 30pM 
 
The amplified scFv genes were resolved on a 2% (w/v) agarose gel (section 2.3.1.3) to 
ascertain the percentage of colonies containing the gene fragment. This was followed by 
digestion with AluI and BstNI to generate a DNA fingerprint for each clone. The digestions 
were setup as delineated in Table 2.3-15 and were carried out for 2 hours at 37
o
C for AluI 
and 60
o
C for BstNI. They were then resolved on a 3% (w/v) agarose gel to visualise the 
patterns. 
 
Table 2.3-15: AluI and BstNI digestion tube setup 
Component AluI BstNI 
SOE PCR Product 8μL 8μL 
Buffer 2 (10X) 1X 1X 
Mol. G. H2O with 1X BSA to 24μL to 24μL 
BstNI [10U/μL] - 5U 
AluI [10U/μL] 5U - 
Total 24μL 24μL 
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2.3.5.1.2 ELISA screening of wild-type clones 
 
After bio-panning to screen for the most sensitive WT scFv, 300 individual colonies were 
selected from round 4 output plates and screened by steady-state and HT-analysis. The 
combined analysis regime provided classical ELISA-based ranking information and 
critically more defined binding analysis using SPR-based HT-instrumentation. 
To initially determine the bio-panning success, the clarified lysates from plate # 1 only 
were assayed in a direct binding ELISA against the cTnI protein (1μg/mL), KLH-peptide-
1 conjugate (1ug/mL) and KLH control (1μg/mL) in PBS coated onto separate plates at 4oC 
O/N. The plates were blocked with 5% (w/v) PBSM for 1 hour at 37
o
C. Lysates were 
freshly prepared, diluted 1 in 3 (1% (w/v) PBSTM) and applied to the cTnI, KLH-peptide-1 
and KLH-coated ELISA plates. The plates were incubated at 37
o
C for 1 hour and washed 
with PBST (x3) and PBS (x3) followed by application of a 1 in 2,000 dilution of anti-HA 
HRP-labelled secondary antibody in 1% (w/v) PBSTM. The secondary antibody was 
incubated and washed as described in the previous step followed by development of colour 
with TMB. The substrate colour was quenched with 10% (v/v) HCl and absorbance read at 
450nm on the Tecan Sunrise™. 
A sandwich assay format was also employed to rank all 300 clones. The 20B3 mAb at 
1μg/mL in PBS was applied to three ELISA plates (inner 60) per scFv plate to be screened 
at 4
o
C O/N. The plates were blocked for 1 hour at 37
o
C with 5% (w/v) PBSM and two 
plates were coated with 6-fold differing concentrations of cTnI (6nM and 36nM) for 1 hour 
at 37
o
C. This left the 3
rd
 plate as a negative control. The plates were washed with PBST 
(x3) and PBS (x3) before adding 100μL/well of freshly prepared and diluted  lysates (1 in 3 
in 1% (w/v) PBSTM) over the three plates. The plates were incubated and washed as 
described in the previous step and a 1 in 2,000 dilution of anti-HA HRP-labelled secondary 
antibody in 1% (w/v) PBSTM was added. The secondary antibody was incubated and 
washed as described above followed by development of colour with TMB. The substrate 
colour was quenched with 10% (v/v) HCl and absorbance read at 450nm on the Tecan 
Sunrise™. 
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2.3.5.1.3 High-throughput ranking of wild-type clones 
 
HT ranking of the lysates was carried out on the Biacore™ 4000 multiplexed surface 
plasmon resonance (SPR)-based instrument. A surface of 6000RU was prepared by amine-
coupling of an anti-HA polyclonal antibody (contact time of 10 minutes) at 15μg/mL in 
10mM NaOAc, pH 4.2, over spots 1, 2, 4 and 5 of the four flow cells on a research grade 
CM5 chip (Biacore, Sweden). The surface was then capped with 1M ethanolamine HCl, pH 
8.5 and cleaned with desorb solution 1 and 2. This prepared surface could remain active for 
several weeks with continuous buffer flow (1X HBS-EP
+
). 
All 300 clones were involved in the analysis which was divided over 4 plates. Clones were 
expressed and prepared, as described in section 2.3.4.7, and diluted 1 in 5 with 1X HBS-
EP
+
. The diluted clones were applied to 96-well plates compatible with the system and 
racked in the dedicated temperature-controlled hotel (20
o
C) and the analysis carried out at 
25
o
C. The diluted bacterial lysates were injected onto spots 1 (clone X) and 5 (clone Y) at a 
flow rate of 10μL/minute for 10 minutes. cTnI (25nM) in 1X HBS-EP+ was then passed 
over the whole surface at a flow rate of 30μL/minute and the active spots (1 and 5) online-
reference subtracted using the reference spots (2 and 4). The surface was regenerated with a 
30 second pulse of 20mM NaOH. Data was acquired at 1Hz/sec collection rate and 
evaluated using the dedicated BiaEvaluation software. The data based on stability (early 
and late) allowing percentage left ranking was prepared and exported, in addition to the 
subtracted sensorgrams. 
 
2.3.5.2 Mutant scFv screening approach 
 
In the case of the MT screening a much more HT-based approach was undertaken given the 
level and amount of quality data that could be acquired, yielding more information on 
kinetic parameters that allowed more efficient and knowledge-based selection of improved 
scFvs. 
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2.3.5.2.1 ELISA analysis of mutant scFv 
 
The initial screening of the 192 clones (2 x 96-well plates) was undertaken in direct binding 
and sandwich ELISA formats. For the direct binding ELISA, a plate was coated with cTnI 
and blocked as described previously (section 2.3.5.1.2) and for the sandwich assay purified 
20B3 mAb was coated and blocked on ELISA plates followed by capture of cTnI 
(1μg/mL). In both cases 192 clones were expressed and lysed as described in section 
2.3.4.7. The lysates were diluted 1 in 3 with 1% (w/v) PBSTM and applied to the direct and 
sandwich assay plates. After incubation for 1 hour at 37
o
C the plates were washed (PBST x 
3 and PBS x 3) and a 1 in 2,000 dilution of anti-HA HRP-labelled secondary antibody in 
1% (w/v) PBSTM added to the plates. The plates were incubated and washed (PBST x 3 
and PBS x 3) followed by colour development with TMB and quenching with 10% (v/v) 
HCl prior to reading absorbance at 450nm on the Tecan Sunrise™. 
 
2.3.5.2.2 High-throughput ranking of mutant scFv 
2.3.5.2.2.1 HT - ‘off-rate’ ranking 
 
A surface of ~6000RU was prepared by amine-coupling of anti-HA antibody as described 
in 2.3.5.1.3.  192 clones were involved in the analysis and the clones were expressed and 
prepared as described in section 2.3.4.7 followed by dilution in 1X HBS-EP
+ 
(1 in 5). The 
diluted clones were analysed as described in section 2.3.5.1.3 with the inclusion of a 0nM 
cTnI concentration into the analyses. Data was acquired at 1Hz/sec collection rate and was 
evaluated using the dedicated BiaEvaluation software. Data based on stability (early and 
late) allowing percentage left ranking was prepared and the curves acquired modelled for 
crude ka and kd values using the 1:1 Langmuir equation with the global fit parameter.  
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2.3.5.2.2.2 HT - ‘2 over 2’ ranking of wild-type and mutant scFv 
 
Two different scFv densities were captured for each clone in a cycle (two clones per cycle: 
spots 1 and 5 – high density and spots 2 and 4 – low density) in the capture approach at 
25
o
C. Diluted lysates (1 in 3 and 1 in 30 in 1X HBS-EP
+
) for a selected group of 15 MT 
clones and the pure WT (1μg/mL and 0.1μg/mL in HBS-EP+) were passed across the chip 
surface at a flow rate of 10μL/minute for 10 minutes. Post scFv capture two concentrations 
of cTnI were passed across the two capture densities (75nM and 25nM) in 1X HBS-EP
+
. 
The data was collected at 1Hz/sec and the surface regenerated after 12 minutes dissociation 
for the next cycle. The data was evaluated using the dedicated BiaEvaluation software 
using the „2 over 2‟ template. Curves were fitted with 1:1 Langmuir binding equation with 
the global fit parameter allowing determination of more precise ka and kd values for the 15 
mutant clones. 
 
2.3.5.2.2.3 Full kinetic profiling of wild-type and mutant scFv 
 
The anti-HA surface prepared on Biacore was readily employed to carry out full kinetic 
profiling of the clones. In this case a clone was captured repeatedly on spot 1 and a second 
clone on spot 5 over the four flow cells (a total of 8 clones). Seven MT clones and the WT 
scFv were taken forward for full kinetic analysis over a significant cTnI concentration 
range [12, 6, 3(x2), 1.5, 0.75. 0.375, 0.1875 and 0nM cTnI]. The run typically took in the 
order of 12-14 hours. The data was collected a 10Hz/sec and allowed acquisition of vast 
amounts of kinetic data to fit with 1:1 Langmuir binding model. Owing to issues with the 
commercial protein the data collected was fitted with a local Rmax to improve the quality of 
the data fits. 
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2.3.6 Inhibition ELISA comparison of wild-type and mutant scFv 
 
Inhibition analysis was carried out to evaluate the WT in comparison to the selected panel 
of MT clones, increasing the confidence in the demonstrated improved sensitivity of the 
clones. 
 
2.3.6.1 Titre 
 
Analysis was carried out with freshly prepared lysates. A plate was coated with 0.5μg/mL 
cTnI in PBS O/N at 4
o
C and blocked with 5% (w/v) PBSTM for 1 hour at 37
o
C. Doubling 
dilutions (1 in 100 to 1 in 204,800) of lysates in 1% (w/v) PBSTM were applied to the 
wells and incubated for 1 hour at 37
o
C. The plate was washed with PBST (x3) and PBS 
(x3) followed by application of a 1 in 2,000 dilution of anti-HA HRP-labelled secondary 
antibody in 1% (w/v) PBSTM. The plate was incubated and washed with PBST (x3) and 
PBS (x3) and colour developed with the addition of TMB followed by quenching with 10% 
(v/v) HCl. Absorbance was read at 405nm using a Tecan Sunrise™ 
 
2.3.6.2 Inhibition 
 
The optimised scFv lysate dilutions (double strength) were diluted 1:1 with free a cTnI 
concentration range (200 to 0.39nM and including zero cTnI in 1% (w/v) PBSTM) and 
incubated at 37
o
C for 1 hour in 1.5mL tubes. The inhibition mix (100μL) was then applied 
to a plate coated with cTnI (0.5μg/mL in PBS) as described for the titre. After 1 hour 
incubation at 37
o
C the plate was washed, the secondary antibody applied and the plate 
absorbance read (as described for the titre determination). Each clone A0 (Absorbance at 
zero cTnI) was divided into the response at each free cTnI concentration resulting in an 
inhibition curve. 
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2.3.7 Full kinetic profiling using fatty acid binding protein fusion 
 
The precise determination of the kinetic constants was important to critically evaluate the 
clones. Despite the issues encountered using the commercial cTnI protein the surrogate 
epitope fusion protein proved invaluable. To carry out the kinetic evaluation the exact 
determination of the FABP-P1&2 fusion concentration was required as for evaluation of 
kinetic interactions exact protein concentrations are necessary to accurately model the data. 
Absorbance measurements are inherently inconsistent and give the total protein 
concentration. In this assay any protein contaminants were not involved in calculation of 
the actual fusion protein concentration. 
 
2.3.7.1 Determination of fatty acid binding protein fusion concentration  
 
The exact concentration of the FABP fusion was determined by an inhibition assay format 
using an „in-house‟ anti-FABP scFv [90] and commercial hFABP (c-hFABP) of known 
concentration. Initially, the optimal scFv concentration for the analysis was determined by 
titration against 0.5μg/mL hFABP in PBS coated onto the wells of an ELISA plate O/N at 
4
o
C. The plate was blocked with 5% (w/v) PBSTM for 1 hour at 37
o
C. Serially diluted scFv 
was then applied to the coated well, incubated for 1 hour at 37
o
C and washed (PBST x 3 
and PBS x3). The bound scFv was detected using a 1 in 2,000 dilution of anti-HA HRP-
labelled secondary antibody in 1% (w/v) PBSTM. From this titre the optimal scFv dilution 
for the inhibition format was determined. In this assay a plate was coated with FABP and 
blocked as described for the titre. The scFv was diluted with a range of c-hFABP 
concentrations incubated in 1.5mL tubes for 1 hour at 37
o
C before transfer to the hFABP-
coated wells. In parallel, the FABP-P1&2 fusion protein was diluted in the same manner 
with the scFv for accurate concentration determination. After incubation and washing the 
bound scFv fraction was detected with the anti-HA HRP-labelled secondary antibody as 
described for the titre above. Using the c-hFABP inhibition curve values a calibration plot 
was generated. This allowed for the unknown (FABP-P1&2) response to be back calculated 
resulting in precise determination of the concentration. The analyses described here were 
carried out in triplicate and on three individual occasions. 
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2.3.7.2 Kinetic evaluation of wild-type and mutant scFv 
 
An anti-HA pAb surface was prepared as previously described (section 2.3.5.1.3) over the 
spots of two flow cells only. This allowed for kinetic characterisation of the WT (180) and 
MT (2B12) in duplicate (spot 1 and spot 5) per kinetic run. Purified WT and MT scFv 
dilutions in 1X HBS-EP
+
 were prepared to obtain a consistent Rmax< 100RU required for 
reliable kinetics. Using these optimised scFv concentrations the FABP-P1&2 fusion was 
adjusted to a suitable concentration range for the kinetics to be carried out [25, 12.5, 6.25, 
3.125(x2), 1.5625, 0.78125, 0.390625 and 0nM]. The kinetic data was collected at the 
higher (10Hz/second) rate and the dedicated BiaEvaluation software utilised to prepare the 
data and fit the kinetic parameters with 1:1 Langmuir binding global fit equation. 
 
2.3.8 Sequence analysis and protein modelling of scFv 
2.3.8.1 Sequence analysis of two selected scFv clones   
 
Sequence analysis was carried out by Source-Bioscience Ireland using the sequence 
primers delineated in Table 2.3-4 from purified plasmids or cell stocks treated by the 
company. The DNA sequence was then translated using the Expasy online translate tool 
(http://www.expasy.ch/tools/dna.html). The amino acid sequence was then aligned using 
ClustalW (http://www.ebi.ac.uk/Tools/msa/clustalw2/) to compare sequences. Aligned 
sequences were exported to PowerPoint and the significant regions highlighted. 
 
2.3.8.2 Protein modelling of two scFv clones  
 
The amino acid sequences for WT and MT clones were submitted to the Web antibody 
modelling server (WAM) at http://antibody.bath.ac.uk/ using the auto align program. As 
this system is for human antibodies the CDRL2 caused errors for the modelling program, 
for that reason the „N‟ residue in the „SNIP‟ sequence of complementarity determining 
region of the light chain (CDRL2) was removed from both the wild-type and mutant clones 
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to allow the program to apply its models. The models were returned as pdb files and viewed 
using the Swiss-PDB deep view program 4.0.1. The structures were energy minimised and 
corrected for side chain clashes using the in program functionality. Following colouring 
and augmentation of the view point the images were saved as high-quality POV Ray scenes 
or bmp files. 
 
2.3.9 Thermal challenge assay for assessment of improved stability 
 
The thermal challenge assay was modified from [91, 92] by incubation of 0.1μg/mL 
(130μL/tube) of the purified scFv in PBS over a range of temperatures. In the G-storm 
thermocycler a gradient was programmed from 47.9
o
C to 72.5
o
C in which the proteins were 
placed for 90 minutes. For both scFvs, an aliquot was retained at RT to act as an unheated 
control. After thermal challenge the 11 heat treated proteins and control were diluted 1 in 4 
in 1% (w/v) PBSTM and applied in triplicate, to a plate previously coated with 0.5μg/mL 
cTnI and blocked with 5% (w/v) PBSTM. The plate was incubated at 37
o
C for 1 hour and 
washed with PBST (x3) and PBS (x3). The bound non-denatured scFv was detected with a 
1 in 2,000 dilution of anti-HA HRP-labelled secondary antibody in 1% (w/v) PBSTM. The 
plate was incubated and washed with PBST (x3) and PBS (x3) and developed with TMB 
followed by quenching with 10% (v/v) HCl. The absorbance was then read on the Tecan 
Sunrise™ at 450nm. The individual responses for each temperature were expressed as a 
percentage retained binding activity and the clones compared at 50% loss of binding 
activity (T50).  
 
2.3.10 Determination of crystal structure 
2.3.10.1 Gel filtration of purified scFv 
 
A S75 (16/60) analytical gel filtration column (GE Healthcare) was equilibrated with 1X 
TBS prepared as described in section 2.3.1.9 (1CV = 50mL). A 0.5mL sample of scFv 180 
(2.0mg/mL) previously purified by IMAC (section 5.2.2.5.3) was applied to the column at a 
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flow rate of 0.5mL/minute. Fractions were collected after 0.3CV until 1CV was reached. 
Protein was monitored online by A280nm using the dedicated Unicorn control and evaluation 
software (GE Healthcare). Protein peaks were evaluated and significant monomeric 
protein-containing fractions concentrated to approximately 150μL in 1X TBS. 
 
2.3.10.2 Coarse screening for optimal crystal formation conditions 
2.3.10.2.1 Manual tray setup 
 
Coarse screening was carried out in 24-well plate format. The concentrated protein was 
centrifuged at 13,000rpm at 4
o
C to remove any formed precipitates or contaminating 
matter. 24-well plates were prepared by application of a ring of petroleum jelly to the 
circumference of each well. 500μL of mother liquor from the Sigma Basic Crystallisation 
Kit for Proteins (catalogue # 82009) conditions 1 to 48 were placed in the appropriate 
number of wells (2 x 24-well plates). A 0.6μL drop of mother liquor was placed in the 
centre of the siliconised glass slides (Hampton Research catalogue # HR3-277) and 0.6μL 
of scFv 180 (at 6mg/mL) was mixed into the mother liquor drop before inversion of the 
slide and sealing of the well using a 1mL pipette tip. All plates were then placed in a 
vibration excluded temperature controlled environment at 20
o
C and monitored daily for 
crystal formation. 
 
2.3.10.2.2 Crystalmation tray setup 
 
As the crystal suite was automated the protein was provided to the facility for robotic 
dispersion of 100nL drops. The concentrated protein was centrifuged at 13,000rpm at 4
o
C 
to remove any formed precipitates or contaminating matter which could block the nano-
needle. 100nL drops of protein were mixed with 100nL drops of mother liquor in the 96 
conditions for the Hampton Research PEG/ION and SaltRx screening kits (Table 8.1-2). 
Plates were housed in temperature controlled racks at 20
o
C and imaged daily. Plates could 
be viewed remotely using the CrystalTrack online software. 
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2.3.10.3 Fine screening to refine optimal crystal formation conditions 
 
Fine screening conditions were prepared for the Sigma Basic Crystallisation Kit condition 
number 40 (0.1M Na-citrate pH 5.6, 20% (v/v) 2-propanol and 20% (w/v) PEG-4000). The 
fine screen was carried out as described in Table 2.3-16. Each Na-citrate at a pH was 
prepared as a 1.8M stock and 28μL added to the corresponding rows of the plate. Each mix 
of salt and organic solvent was prepared individually from stocks of 50% (v/v) 2-propanol 
and 50% (w/v) PEG-4000 in MilliQ water as described in Table 2.3-17. The prepared 
solutions was added to each corresponding column (472μL) and mixed on a plate shaker for 
5 minutes to fully mix the mother liquor. Individual hanging drops were prepared by 
application of 0.6μL of the relevant mother liquor to the siliconised glass slide and mixing 
in 0.6μL of scFv 180 (6mg/mL). The wells were sealed using petroleum jelly and placed at 
20
o
C to incubate. 
 
Table 2.3-16: Layout of the fine screening conditions for scFv 180 crystal formation  
Conditions 1 2 3 4 5 
%  2-propanol  (v/v) 18 19 20 21 22 
%  PEG-4000 (w/v)  18 19 20 21 22 
A Na-Citrate pH 6.0      
B Na-Citrate pH 5.8      
C Na-Citrate pH 5.6      
D Na-Citrate pH 5.4      
 
Table 2.3-17: Preparation of mother liquor for fine screening of crystal conditions 
Final % 
Final volume 
(mL) 
50% (v/v) 2-propanol 
(μL) 
50% (w/v) PEG-4000 
(μL) 
MilliQ Water 
(μL) 
18:18 2.3 828 828 412 
19:19 2.3 874 874 326 
20:20 4.3 1720 1720 430 
21:21 2.3 966 966 134 
22:22 2.3 1012 1012 48 
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2.3.10.4 X-ray diffraction of scFv 180 crystals 
 
Individual crystals from the coarse screens (both manual and automated) were collected in 
a gionometer loop of an appropriate size (decided visually under a microscope) and locked 
onto the gionometer. Using the adjustment screws the crystal was brought into the X-ray 
path. X-ray measurements were made using the Rikagu RU-3HBR rotating anode generator 
with helium purged OSMIC focusing mirrors as an X-ray source. The data was collected 
using an R-AXIS IV++ detector by rotation through 90
o
C. Collected images were data 
processed using a custom written program and displayed as jpeg files for the purposes of 
display in this thesis. 
 
2.3.11 Evaluation of selected scFvs and the industry standard 
 
In this inhibition analysis, the purified WT (180) and MT (2B12) and the Hytest 19C7 
HRP-labelled antibody were titred as described in section 2.3.6.1. The optimal antibody 
dilution was determined and the inhibition carried out as described in section 2.3.6.2 with a 
cTnI concentration range of 5 to 0.0195μg/mL (serially doubling) in 1% (w/v) PBSTM. 
The analysis for each antibody was carried out in duplicate and on three individual 
occasions. 
 
2.3.12 Conversion of scFv to scAb format 
2.3.12.1 Genetic manipulation of scFv construct 
 
pComb3x-based scFv were converted to scAb format by addition of a chicken constant 
domain (Cλ) to the end of the VH chain. To achieve this, the Cλ amplified from chicken 
cDNA was cloned into pMopac16 (Figure 8.1-7) in place of the existing HuCκ designed by 
Dr. Stephen Hearty and carried out by Dr. B. Vijayalakshmi Ayyar. To subclone in the 
pComb3x-scFv into pMopacCλ the SfiI sites needed to be modified to be compatible. This 
was carried out using the primers as outlined in Table 2.3-18. 
  
2–69 
 
  
Table 2.3-18: Primer sequence to transfer pComb3x-based scFv to pMopacCλ 
Primer Name Primer Sequence 
ChiVL-VHPac-F GGA AAT CGC GGC GGC CCA GCC GGC CAT GGC GCT GAC TCA G 
ChiVL-VHPac-R TTA CTC GCG GCC CCC GAG GCC GCA CTA GTG GA 
 
The pMopacCλ and pComb3-based 2B12 and 4G5 vectors were purified as described in 
section 2.3.1.2. The scFvs were modified by PCR using the reaction mix outlined in Table 
2.3-19 in the G-storm thermocycler with the cycle parameters delineated in Table 2.3-20. 
 
Table 2.3-19: Amplification and modification of scFv from pComb3x vector 
Component Large-Scale Reaction Concentration (1X) 
Go Taq Buffer (10X) 1X 
MgCl2 [25mM] 2.0mM 
Mol. Grade H2O to final volume of 50μL 
dNTP [100mM] 0.1mM 
Forward Primer [60nMol] 30pM 
Reverse Primer [60nMol] 30pM 
Plasmid DNA 1μL 
Polymerase [5U/μL] 1.25U 
 
Table 2.3-20: Modified scFv amplification PCR cycle parameters 
 
 
 
 
 
Post large-scale amplification the scFv inserts were purified by resolution on a 2% (w/v) 
agarose and extraction using the NucleoTrap® gel extraction kit as per the manufacturer‟s 
Stage Step Temperature (
o
C) Times (s) # Cycles 
1 Initial Denature 94
o
C 120 1 
2 
Denaturation 
Annealing 
Extension 
94
o
C 
56
o
C 
72
o
C 
15 
30 
60 
30 
3 Final Extension 72
o
C 600 1 
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guidelines. The modified scFvs and pMopacCλ
 
vector were SfiI digested as described in 
Table 2.3-21. 
 
Table 2.3-21: Large-scale SfiI digests of pMopacCλ vector and modified scFv inserts 
Component 2B12 4G5 pMopacCλ 
DNA 10μg 10μg 20μg 
Buffer 4 (10X) 1X 1X 1X 
BSA (100X) 1X 1X 1X 
Mol. G. H2O to 200μL to 200μL to 200μL 
SfiI  [20U/μL] 36U/μg 36U/μg 6U/μg 
 
All the reactions were incubated at 50
o
C in G-storm thermocycler for 5 hours. The scFv 
digests were then stored as an ethanol precipitation until required (section 2.3.1.1). The 
vector was further treated with Antarctic phosphatase (1X Buffer and 1U/μg enzyme) for 1 
hour at 37
o
C followed by inactivation at 65
o
C for 20 minutes. Post digestion and Antarctic 
phosphatase treatment the vector was stored as an ethanol precipitation (section 2.3.1.1).  
All the digested product precipitations were completed, as described in section 2.3.1.1, and 
subsequently purified by resolution on 0.5% (w/v) (vector) or 2% (w/v) (insert) agarose gel, 
followed by excision of the relevant bands and extraction using NucleoTrap® gel 
extraction kit as per the manufacturer‟s instructions (eluted into 50μL mol. G. H2O). The 
modified scFv inserts were ligated into the pMopacCλ vector and transformed into E. coli 
TOP10F' as described in 2.3.1.4.  
 
2.3.12.2 scAb expression analysis 
 
Single colonies were selected and grown up for small-scale analysis as described in 2.3.1.7 
and glycerol stocks prepared as described in 2.3.1.6. The presence of correctly expressed 
protein was identified by direct binding ELISA against KLH-peptide-2 at 1μg/mL 
(2B12_scAb) and neutrAvidin (2.5μg/mL) captured 1μM biotinylated peptide-3 
(4G5_scAb). Both plates were blocked with 5% (w/v) PBSTM and diluted lysates applied 
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(1 in 5). Bound scAb was detected using anti-HIS HRP-labelled secondary antibody. The 
plates were developed using TMB followed by quenching with 10% (v/v) HCl and the 
absorbance read on a Tecan Sunrise™ at 450nm. 
 
2.3.13 Purification of generated recombinant antibodies 
 
Purification of the recombinant antibodies generated followed the generic recombinant 
protein purification protocol in section 2.3.1.9 using the buffer compositions outlined in 
section 2.3.1.9. The clones were grown overnight in 5mL starter cultures (SB with 
50μg/mL Carbenicillin and 1% (w/v) glucose) from glycerol stocks. The 5mL starter 
culture was then used to inoculate 400mL SB (with 50μg/mL Carbenicillin) in a 2L baffled 
flask. The culture was grown at 37
o
C with shaking at 230rpm until an OD600 of ~0.6 was 
reached. At this stage the clones were induced with 0.5mM IPTG O/N at 30
o
C. The induced 
cultures were collected and lysed as described in 2.3.1.7. All proteins (scFv 180, scFv 
2B12, 2B12_scAb, scFv 4G5 and 4G5_scAb) were purified on 1mL settled Ni
2+
 charged 
resin using the PBS-based buffers outlined in section 2.1.4.6.2.  
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Chapter 3: Cardiac Troponin I antigen 
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3.1 Introduction 
 
Prior to any monoclonal antibody generation campaign careful consideration with respect 
to antigen source and quality is advised. The necessity for the epitope-specific strategy 
employed to successfully isolate diagnostically relevant antibodies became apparent and 
strategies to overcome some of the antigen quality-based limitations encountered in 
characterisation of the selected antibodies were required. 
 
3.1.1 Cardiac Troponin I (cTnI) 
 
Cardiac Troponin I is a critical component of calcium mediated muscle contraction in thin 
filament-based Tn-tropomyosin interaction, as described in section 1.3.3.4. Due to its „gold 
standard‟ status for the diagnosis of AMI, the ability to detect ultra-low levels of cTnI is of 
paramount importance. Currently, the new generation of sensitive cTnI assays have 
overcome problems associated with non-specific issues found in first generation devices, 
pushing assay reliability and sensitivity much higher. The associated problems (illustrated 
diagrammatically in Figure 3.1-1) include patient heterophile antibodies, human anti-mouse 
antibodies (HAMA), cTnI auto-antibodies [93] and the varying forms of circulating TnI 
(Table 1.3-5). However, these have largely been overcome by targeting the stable N-
terminal region of cTnI [66]. Major challenges exist for the generation of epitope-specific 
antibodies against cTnI. Directing the immune response to several specific and discrete 
epitopes was a significant challenge. This issue, coupled with the lack of standardised 
reagents for troponin-based diagnostics and suboptimal antigen quality, presented 
significant barriers for screening, characterisation and assay development [66]. 
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Figure 3.1-1: Illustration of the sources of assay interference in the detection of cTnI 
Peptide regions targeted for antibody development are indicated by colour and the IgG symbols. The blue line 
spans the regions prone to degradation (the line thickness represents the severity). The red line indicates the 
areas affected by auto-antibodies, the „*‟ and „>‟ symbols signify regions involved in TnC and cTnT 
interaction, respectively. The „#‟ symbol denotes oxidation sites and the „=‟ symbol those sites that undergo 
phosphorylation. Epitopes 1 to 3 are within the recommended region for cTnI detection. This figure  was 
adapted from [94].   
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3.1.2 Design of cTnI peptides 
 
The initial approach to overcome the problems associated with antigen quality and directing 
the epitope-specificity was introduced early in the immunisation regime. In the primary 
screening of existing whole protein immunised libraries, the synthesis of specific epitope-
associated peptides facilitated evaluation of the selected library for epitope-specific 
antibodies. Figure 3.1-2 A is an alignment of cardiac and skeletal TnI indicating the regions 
of similarity. To a large extent the two proteins are similar and this presents an obstacle for 
specific antibody generation. The N-terminal cardiovascular-specific region was identified 
and subsequently targeted as a key antigen in line with current trends to ensure 
cardiovascular-specificity. Two adjacent peptides, peptide-1 (epitope-1) and peptide-2 
(epitope-2), were designed as outlined in Table 3.1-1, and are overlapping continuous 
regions within the cardio-specific N-terminus of cTnI. For antibody targeting, combined 
with discrimination between skeletal (s) and cTnI, these two epitopes were used in 
conjunction during selection and screening to identify optimal antibody pairs for diagnostic 
purposes. Figure 3.1-2 B illustrates a model of the cTnI molecule indicating the 
conformation of each peptide region in the context of the whole protein.  
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Figure 3.1-2: Cardiac Troponin I amino acid sequence and model 
A) CLUSTAL 2.0.11 multiple sequence alignment of c- and s- TnI 
Amino acid alignment of cTnI (P19429) and sTnI (P48788) using ClustalW at http://www.uniprot.org/ 
Amino acid identity is indicated by the symbols as follows; “*” identical, “:” conserved and “.” semi-
conserved. Epitopes are highlighted on the P19429 sequence and in the cardiac troponin model as follows; 
1: red, 2: gold, 3: green and 4: blue. 
B) cTnI molecule model  
A hypothetical 3D structure of TnI was constructed using SWISS-MODEL [95] and the PDB files 1J1D 
and 1J1E as a templates (release date 15-Jul-2003) [96]. PDB files were viewed using Swiss-PDB Viewer 
program 4.0.1. 
P48788 MGD-------------------------------EEKRNRAITARRQHLKSVMLQIAATE 29
P19429    MADGSSDAAREPRPAPAPIRRRSSNYRAYATEPHAKKKSKISASRKLQLKTLLLQIAKQE 60
*.*                                :*:.:  ::*: :**:::****  *
P48788 LEKEESRREAEKQNYLAEHCPPLHIPGS-MSEVQELCKQLHAKIDAAEEEKYDMEVRVQK 88
P19429    LEREAEERRGEKGRALSTRCQPLELAGLGFAELQDLCRQLHARVDKVDEERYDIEAKVTK 120
**:* ..*..** . *: :* **.:.*  ::*:*:**:****::* .:**:**:*.:* *
P48788 TSKELEDMNQKLFDLRGKFKRPPLRRVRMSADAMLKALLGSKHKVCMDLRANLKQVKKED 148
P19429    NITEIADLTQKIFDLRGKFKRPTLRRVRISADAMMQALLGARAKESLDLRAHLKQVKKED 180
. .*: *:.**:**********.*****:*****::****:: * .:****:********
P48788    TEKERDLRDVGDWRKNIEEKSGMEGRKKMFESES 182
P19429    TEKEN--REVGDWRKNIDALSGMEGRKKKFES-- 210
****.  *:********:  ******** ***  
A 
B 
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The amino acid composition of each peptide and its associated properties are summarised 
in Table 3.1-1. These peptides were synthesised commercially by Anaspec with N-terminal 
conjugation to biotin. Due to the reasons outlined in section 3.2.2, peptides 1 and 2 were 
synthesised using C-terminal conjugation chemistry to include KLH (CT-peptide-1- or -2 -
KLH) and biotin conjugation (CT-peptide-1- or -2-B).  
 
Table 3.1-1: Cardiac Troponin I peptides 
Peptide 
Amino acid 
residue 
MW (Da) Theoretical  pI Amino Acid Sequence 
1 39-50 1372 11.26 KISASRKLQLKT 
2 24-40 2005 10.00 NYRAYATEPHAKKKSKI 
3 79-93 1485 3.79 QPLELAGLGFAELQ 
4 169-180 1452 9.70 RAHLKQVKKEDT 
 
3.1.3 Recombinant antigen expression 
 
The expression of recombinant proteins in E. coli is of considerable importance for a 
significant number of biological fields and applications including proteomics, structural 
genomics and vaccines. The widespread use of E. coli as a host for heterologous protein 
production has come about due to gargantuan improvements in our understanding of 
transcription, translation and protein folding in the organism. These leaps have been made 
possible by improved genetic tools at the disposal of scientists intermixed with much good 
fortune [97]. E. coli is advantageous in many respects including; its growth on inexpensive 
carbon sources, rapid biomass accumulation, suitability for high-density fermentations and 
relatively simple scale-up. E. coli is not without its disadvantages and is typically only 
suited to expression of soluble proteins that do not require complex post-translational 
modifications. In addition, incorrect conformation, degradation and aggregation may 
commonly occur, complicating expression [98].  
The choice of expression vector and E. coli host is of considerable importance, impacting 
on the quality, quantity and purification potential of the recombinant protein. Many 
expression vectors exist and each has a wealth of experience and publications supporting 
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their use for numerous applications.  These vector systems rely on the use of „good‟ 
promoter systems. Typical characteristics of a good promoter include high potency and 
capability to reach expression levels in excess of the 10-30% of the total protein content 
[99].  Many of these promoters are based on or around the lac operon. Indeed, despite some 
of its disadvantages it is still widely and successfully adopted to drive heterologous protein 
expression. Both the lac and lacUV5 are weak promoters and tend to be extremely useful to 
achieve graded expression of recombinant proteins in conjunction with the non-
hydrolysable analogue, isopropyl-β-D-1-thiogalactopyranoside (IPTG). The tac and trc are 
synthetic promoters that comprise of the -35 region of the trp promoter and the -10 region 
of the lac promoter. The tac and trc promoters differ by a single base pair between the two 
regions and are relatively strong promoters, routinely achieving specific protein content of 
15-30% of the total cell protein content [97]. To circumvent the leakiness of the lac-based 
promoters repression can be achieved by lacI
Q 
which is a single point mutation of the 
chromosomal lacI promoter in the host strain. This causes a 5-10 fold increase in the 
number of lacI repressor molecules available in the cell allowing efficient repression of 
protein expression until induced by IPTG. 
The pET system of vectors were developed from the original vectors constructed by Studier 
and co-workers [100] and commercially developed by Novagen [101]. The system allows 
cloning of target genes downstream of the bacteriophage T7 late promoter. These medium 
copy number plasmids require T7 RNA polymerase that is engineered into E. coli by 
prophage (λDE3), is controlled by the lacUV5 promoter and is inducible by IPTG. In this 
powerful system, very high target protein concentrations can be achieved (up to 50%) due 
to the synthesis of large amounts of mRNA. This expression mechanism is not without 
disadvantages as such high levels of mRNA can cause ribosome destruction and cell death. 
In addition, leaky T7 polymerase expression may contribute to plasmid and/or expression 
instability [97].  In an already crowded environment, where a protein exits a ribosome 
every 35 seconds and macromolecule concentrations can elevate to 300-400mg/mL, this 
high-level of expression can contribute to protein misfolding and the formation of inclusion 
bodies [98]. To mitigate against these events strategies have evolved including co-
expression of phage T7 lysozyme and insertion of lac operator sequence downstream of the 
plasmid-encoded T7 promoter. In the former strategy, T7 lysozyme is encoded on a 
plasmid (pLysS and pLysE) and inhibits T7 RNA polymerase, repressing expression of T7 
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RNA polymerase-dependent genes. In the latter strategy, the inclusion of a chromosomal 
copy of the lac repressor gene (lacI) allows repression of both the lacUV5 and T7 
promoters integrated with segments of the lac (T7lac - Figure 3.1-3) [102].  
In combination with these numerous strategies to control induction, the vectors encode 
several other components such as leader sequences, fusions to promote expression or 
stability, purification and affinity tags. Leader/signal sequences (e.g. ompA and pelB) mark 
the protein for export to the periplasm via the sec-dependent transport pathway (vector: 
pET26b+). Numerous other signal sequences and mediators exist in the pET 
armamentarium and a full listing of the components of the pET vectors can be found in the 
pET system manual [102]. Three pET vectors were exploited in the course of heterologous 
expression of the various forms of recombinant TnI (rTnI), pET 26b+, 28b+ and 32b+.  
The above mentioned technologies were exploited for the successful cloning, heterologous 
expression and purification of recombinant forms of the cTnI protein in conjunction with 
the methodologies outlined in section 2.3.2 
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Figure 3.1-3: Control and production of  recombinant protein expression by T7lac  
The E. coli host strain are lysogens of bacteriophage DE3 and contain a chromosomal copy of the T7 RNA 
polymerase gene (white) in addition to fragments of DNA encoding the lacI gene (green) and the lacUV5 
promoter (black). The lac repressor (red and purple) acts on the lacUV5 promoter on the host chromosome 
repressing T7 RNA polymerase transcription. Additionally, it acts on the T7lac promoter (grey) in the pET 
vector to block transcription of the target gene (yellow) by T7 RNA polymerase. Upon induction with IPTG 
translation of the T7 RNA polymerase gene by E. coli polymerase provides T7 RNA polymerase to interact 
with the T7lac promoter and express the target gene.   
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3.2 Results 
3.2.1 cTnI antigen quality 
 
SDS-PAGE and Western blot (WB) analysis of the cTnI commercially sourced from Life 
Diagnostics allowed for the antigen quality to be evaluated (section 2.3.2.1). As illustrated 
in Figure 3.2-1 on SDS-PAGE a single band was observed for cTnI. However, when 
probed with three industry gold standard antibodies by WB numerous bands were observed 
at higher and lower molecular weights, suggesting aggregation and degradation of the 
antigen was a factor. This was likely to be exasperated by the purification process where 
the buffer contains significant levels of urea and EDTA, which can lead to carbamylation, 
and thus is not representative of the naturally occurring circulating forms of cTnI [66]. 
 
 
Figure 3.2-1: 12.5 (w/v) SDS-PAGE and Western blot of commercially available cTnI 
Top: SDS-PAGE, bottom: WB. The commercially sourced cTnI was loaded onto lanes of the SDS-PAGE and 
WB probing was performed using three industry „gold‟ standard monoclonal antibodies available from Hytest 
(19C7; peptide-1. 228; peptide-2 and 16A11; peptide-3.  Monoclonal antibodies 19C7 and 228 were detected 
using an anti-mouse HRP-conjugated secondary antibody. 16A11 was directly HRP-conjugated facilitating 
direct detection. PR
+
: Prestained protein ladder. 
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3.2.2 Initial immunisations with whole cTnI 
 
Immunisations of a chicken were previously performed with the whole cTnI protein. 
Subsequently, a library was constructed and bio-panned against the immobilised cTnI 
protein (Dr. Stephen Hearty and co-workers). This library showed a poor spread of epitope-
specificity which was analysed for by solid-phase ELISA against the designed peptides and 
the library exclusively yielded anti-peptide-3 scFvs (4G5- see section 5.3).  
Potential epitope-1 and -2-specificity was evaluated from the chickens serum taken at 
expiry (section 2.3.2.2). Figure 3.2-2 is the serum titration result for the synthetic peptides 
in various forms. Reactivity for epitopes-1 and -2 was analysed in C- and N-terminal 
conjugation strategies to biotin. Additionally, the peptides C-terminal conjugated to KLH 
and the cTnI protein were included in the analysis. 
When comparing the C- and N-terminal conjugated peptide-2, Figure 3.2-2 shows the 
major difference in the animal‟s response to the conjugation terminus of the peptide. The 
antiserum to the C-terminally conjugated peptide-2 (both biotin and KLH) had a relatively 
high titre. However, the N-terminal conjugated peptide-2 (to biotin) did not show a titre. 
This suggests that the conjugation terminus impacted the display of the synthetic epitope to 
the antibodies available in the serum. Peptide-1 binding responses were not observed for 
either the N- and C-terminal conjugation chemistries.  
Overcoming this demonstrated lack of epitope-specificity was the main goal of the work 
presented in this thesis. To overcome the limited epitope spread, synthetic epitope-based 
immunisations were employed throughout and this approach was successful for antibody 
generation.  
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Figure 3.2-2: Evaluation of immune response to the synthesised peptides from a chicken immunised 
with cTnI 
The serum from a chicken previously immunised with cTnI (commercial protein) and from which an anti-
cTnI scFv library was constructed was tested for its antibody reactivity to the synthetic peptide epitopes. The 
serum was titrated in a typical serum ELISA format against the cTnI protein and various formulations of the 
synthetic epitopes and a control, neutrAvidin. Peptide-1 and -2 were assayed in N-terminal (NT) and C-
terminal (CT) conjugations to biotin and also as CT-KLH conjugates. Specific IgY was detected using an 
anti-chicken IgY-Fc-specific antibody labelled with HRP. 
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3.2.3 Recombinant Troponin I 
 
Due to the demonstrated antigen quality issues the availability of a recombinant form of the 
cTnI protein would be advantageous and was investigated to provide a stable and consistent 
antigen. Full length cTnI, minus the initial regulatory region, was expressed and purified in 
work carried out by others, independently [103], and more typically co-expressed with TnC 
and cTnT in E. coli [104-106]. Initial efforts sought to achieve soluble expression of the 
truncated Troponin I protein (rTnI) as an ideal antigen. This was the most logical and 
desired construct as it would have approximated the natural isoform well. To this end a 
gene construct was designed and synthesised. 
 
3.2.3.1 Cloning strategy for recombinant Troponin I 
 
A gene construct was synthesised commercially by Genscript (USA, Inc.), following 
optimisation for expression in E. coli. It contained the amino acid sequence shown in 
Figure 3.2-3. The construct was flanked by BamHI and HindIII sites for cloning into the 
pUC57 vector. Subsequently, the NcoI-HindIII sites were used to transfer the gene into a 
pET expression vector. The gene was designed without the 28 amino acid N-terminal 
regulatory sequence of cTnI which is known to hinder its expression in E. coli [104, 105]. 
The N-terminal methionine sets the frame for translation and results in cleavage of the 
signal sequence from the protein in vectors that transport the protein to the periplasm. The 
N–terminal alanine, exposed due to proteolytic cleavage of the leader sequence, was 
selected by accounting for the “N-terminal amino acid rule for E. coli” and both Met and 
Ala are known to be stabilising in terms of protein degradation [107]. 
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Figure 3.2-3: Design and amino acid composition of the rTnI gene 
This is the gene sequence that was synthesised with BamHI (blue shading) and HindIII (purple shading) 
restriction sites for insertion of the gene into pUC57. Sub-cloning via the NcoI (red shaded) and HindIII 
restriction sites was carried out into a number of pET vectors. Peptide 1-4 are coloured (1: Red, 2: Gold, 3: 
Green and 4: Blue). 
 
3.2.3.2 Results 
 
The rTnI gene (pUC57 - Figure 8.1-6) was transformed into dcm
-
/dam
-
 E. coli, propagated 
and plasmid purified, as described in section 2.3.1.2. Subsequently, the gene was prepared 
for transfer into the pET26b vector by restriction digest (section 2.3.2.3.1). Post digestion, 
the rTnI gene (~600bp) and pET26b vector (~5.4kb) were resolved (Figure 3.2-4), purified 
by gel extraction, ligated and transformed into BL21(DE3)pLysS cells. Additionally, the 
gene was ligated into pET32b(+) and pET28b(+) and transformed into the same cell type. 
 
 
Figure 3.2-4: rTnI gene cloning from the maintenance vector into an expression vector 
The restriction digestions were analysed by 0.5% (w/v) agarose gel electrophoresis. Lane 1: undigested 
pUC57 containing the rTnI gene. Lane 2: double NcoI and HindIII digested pUC57 with a drop out band at 
approximately 600bp (expected 582bp). Lane 3: pET26b(+) vector. Lane 4: double NcoI and HindIII digested 
pET26b(+). 1kb
+
: DNA ladder. 
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Expression of the protein from individual clones (section 2.3.2.3.2) was screened for by 
SDS-PAGE and WB using the Hytest 16A11 HRP-labelled mAb (anti-epitope-3) and the 
anti-HIS HRP-labelled antibody as probes. Figure 3.2-5 shows specific bands at a slightly 
higher molecular weight (~27kDa) than was expected (~24kDa). However, this apparent 
molecular weight increase is a known phenomenon in electrophoresis of TnI [103] due to 
the very high positive charge at neutral pH. In both Western blots specific bands were 
observed suggesting correct heterologous expression of the construct.  
Purification of the expressed protein sought to exploit the hexa-HIS-tag by IMAC (section 
2.3.2.3.3). Repeated attempts to purify the protein from E. coli lysate were unsuccessful 
despite extensive efforts at optimisation of the buffers, purification steps and lysis 
conditions (results not shown). Some success was experienced using cation exchange 
(section 2.3.2.3.3) due to the extremely high positive charge of cTnI at neutral pH. 
However, attempts to drive the expression levels higher, in larger scale protein production, 
did not result in increased levels of protein from the purification. The expression of rTnI 
also became variable, possibly due to the toxicity of the protein to the E. coli host leading 
to plasmid instability.   
The relatively poor expression of rTnI as a soluble antigen was not overly surprising as the 
high pI of the protein was anticipated to be problematic to express in E. coli. Recombinant 
TnI was expressed readily as inclusion bodies from E. coli when cloned into the pET28b(+) 
vector. When cloned into this expression vector (removing the associated solubility 
enhancing fusions) large protein quantities could be expressed as insoluble protein as 
illustrated in Figure 3.2-6. The challenge outlined in this chapter was to develop an easily 
solubilised antigen free of modifications due to harsh denaturants (e.g. urea) that would be 
required to solubilise the protein for purification under denaturing conditions. Despite its 
successful expression as an inclusion body in its current form the antigen was not as what 
was required and the recombinant antigen strategy was further refined.  
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Figure 3.2-5: Western blot detection of rTnI secreting clones 
Western blots were prepared from SDS-PAGE of E. coli lysates and probed with anti-HIS HRP-labelled (A) 
and anti-epitope3 HRP-labelled (B) antibodies. Specific bands were visualised at approximately 27kDa for 
the soluble protein. PR
+
: Prestained protein ladder. Lanes 1-7: individual clones expressing the protein.  
 
Figure 3.2-6: Expression of rTnI as an inclusion body in the pET28b vector 
The expression of rTnI in the pET28b(+) vector in BL21pLysS cells. The cell control was the BL21pLysS 
cells without the vector. Both the test and control were induced and prepared in a similar fashion. „Insol‟ and 
„sol‟ labels are the insoluble and the soluble protein fractions, respectively. The soluble fraction was obtained 
by lysis of the cells and removal of the cellular debris by centrifugation. The insoluble fraction was prepared 
from the soluble fraction pellet. The SDS-PAGE (A) and transferred WB (B) show the presence of the protein 
(rTnI) in the insoluble fraction which is relatively pure, but is absent in the soluble fraction. PR
+
: Prestained 
protein ladder 
  
A B
A 
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3.2.3.3 Conclusion and adaption of the cloning strategy 
 
rTnI was successfully cloned into and expressed in E. coli. However, its purification by 
IMAC was not feasible from the soluble expressed protein fraction. This suggested that the 
HIS-tag may have been associated with some region of the rTnI protein and was 
unavailable to interact with the nickel resin. Purification by cation exchange 
chromatography protocol could not be achieved with the soluble protein. Attempts to re-
express these clones proved unsuccessful suggesting plasmid instability due to the toxicity 
of the protein. It must also be noted that the rTnI gene was also examined in pET32b+ 
vector as an alternative strategy (results were not shown). With marginally greater success 
in the IMAC purification, where the rTnI bound to the column, the eluted protein was 
truncated and highly contaminated. Polishing steps to isolate the rTnI by cation exchange 
were unsuccessful in this construct which may have been impacted by the presence of the 
S·tag and Trx·tag as fusions to the protein altering the overall charge. Soluble fusions and 
leader sequences in this case did not lend themselves to improving the quality or solubility 
of the recombinant protein. The cytoplasmic expression of rTnI in pET28b yielded 
inclusion bodies of relatively high-purity. This was not the ideal means of protein isolation, 
as the re-folding of proteins is not a trivial exercise. This methodology was further 
complicated by the use of harsh denaturants, such as urea. The use of urea can potentially 
cause disadvantageous modifications to the protein, for example, carbomylation resulting in 
a protein preparation that was not representative of native antigen. To simplify the issue, it 
was decided to heavily truncate the TnI gene to be expressed removing the highly-charged 
regions which are involved in interactions with cTnT and TnC. 
  
  
3–18 
 
  
3.2.4 Expression of epitope 1 and 2 regions as a fusion to the fatty acid 
binding protein (FABP) 
 
It was discovered in our laboratory that a small cytoplasmic human protein, heart-type fatty 
acid binding protein (h-FABP), was notable for its high level of expression and ease of 
purification. Hence, it was proposed as an optimal fusion partner to assist the expression of 
the epitope-1 and -2 regions of TnI in a more efficient way than the multiple tags 
introduced by the pET vector systems. 
 
3.2.4.1 Cloning strategy for the FABP fusion construct 
 
Owing to the small size of the combined epitope region (27 amino acids), to effectively 
express it in E. coli, a strategy to fuse it to a „carrier‟ protein was adopted using h-FABP. 
The small size (14.8kDa) and cytoplasmic nature of the protein was beneficial coupled with 
the availability of several high-affinity antibodies to the protein which could aid detection 
and if required purification [90]. A gene construct was designed „in-house‟ (section 
2.3.2.4.1) and synthesised commercially by Genscript (USA, Inc.) as illustrated 
diagrammatically in Figure 3.2-7. FABP was linked to the N-terminus of the epitope-1 and 
-2 regions via a flexible serine-glycine linker which is well tolerated in E. coli. Within the 
construct restriction enzyme sites provide directionality to the gene for cloning into the 
expression vector (NcoI and NotI) and modularity allowing insertion of different 
linker/non-linker variants (BamHI, SacI and NotI). With no requirements for the formation 
of disulphide bonds the gene was cloned into pET28b+ (Figure 8.1-4) removing the N-
terminal His·Tag and T7·Tag by virtue of the NcoI restriction site. Transformation was 
carried out into E. coli Tuner™ (DE3) cells, which are LacZY BL21 mutants (Novagen) 
and uptake IPTG in a uniform fashion allowing homogenous expression of vectors under 
control of T7lac promoter. The biophysical properties of the expressed protein are 
summarised in Table 3.2-1. 
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Figure 3.2-7: Schematic overview of FABP peptide 1 and 2 fusion construct 
The epitope one and two region gene was synthesised as fusion protein to heart-type fatty acid binding protein 
(h-FABP) joined by a flexible linker (GGSSRSSSSGGGSGGGG) and cloned into the pET28b+ vector 
encoding a hexa-histidine tag via NcoI and NotI restriction sites. The SacI and BamHI restriction sites 
facilitate any further utility of this vector construct as an expression partner. The amino acid sequence for the 
gene in the pET28b vector is shown, as colour coded in the diagrammatic representation. 
 
Table 3.2-1: Biochemical properties of FABP-P1&2 fusion protein 
Molecular Weight (kDa) 20.89 
Number of Amino Acids 192 
Estimated pI 9.19 
Charge at pH7.00 7.3 
Extinction Coefficient at 280nm (M
-1
 cm
-1
) 16500 
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3.2.4.2 Screening, expression and purification 
 
Initial selection of colonies post transformation was carried out by SDS-PAGE and WB 
(section 2.3.2.4.2). Three clones were taken forward to screening and compared in parallel 
to Tuner™ cells containing no plasmid. All the selected clones were tested with and 
without induction by IPTG on 12.5% (w/v) SDS-PAGE and WB (Figure 3.2-8). From the 
initial screening SDS-PAGE gel, over expression bands were observed in the induced 
clones at an apparent MW above 15kDa (suggested to be 20.8kDa expected band) with no 
bands in the un-induced cells combined with complete absence in un-transformed Tuner™ 
cells. The specificity of this band was confirmed by a WB transfer probed with an anti-HIS 
HRP-labelled antibody. To further evaluate the reactivity of the expressed fusion protein a 
series of SDS-PAGE and WB were performed in parallel on one selected clone (clone # 1), 
which was taken forward due to its marginally greater apparent expression in Figure 3.2-8. 
In these Western blots, six available antibodies were utilised to probe the protein. In Figure 
3.2-9 broad bands were observed for virtually all the antibodies used, save the anti-HIS 
HRP-labelled probe. This suggested that there may have been some truncation of the 
protein possibly due to degradation in lysate (lysate was retained at 4
o
C O/N), but more 
likely due to premature termination of translation of the protein. However, the discrete anti-
HIS band was encouraging as the C-terminal HIS-tag resides at the end of the full-length 
protein permitting purification on IMAC of only the correctly expressed full-length protein.  
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Figure 3.2-8: Initial screening of FABP-P1&2-expressing clones 
The vector was transformed into Tuner™ cells and three clones were compared to an un-transformed Tuner™ 
cell control in a small-scale expression experiment (10mL SB, 0.2mM IPTG, 4 hours at 30
o
C) by SDS-PAGE 
(A). All clones were tested in un-induced (UN) and induced (IND) states. For all three selected clones over-
expression bands (approx. 20kDa apparent molecular weight) were observed in the IND lanes only as verified 
in WB (B) using an anti-HIS HRP-labelled probe. In addition, the Tuner™ control shows no over-expression 
bands. The molecular weight was assigned by comparison to the prestained protein ladder (PR
+
). 
 
Figure 3.2-9: SDS and WB analysis of antibody reactivity with expressed FABP-P1&2 fusion 
Analysis was carried out using a battery of anti-cTnI-epitope antibodies. SDS-PAGE (LHS) of clone # 1 
induced and lysed. Multiple transfers of the resolved lysate were prepared in series and probed with various 
antibodies; anti-FABP („in-house‟), Hytest control antibodies 19C7 (epitope 1) and 228 (epitope 2), „in-
house‟ anti-epitope antibodies (20B3 – epitope-2 and 2B12 – epitope-1) and the anti-purification tag antibody 
(anti-HIS). 19C7 and anti-HIS were both HRP-labelled facilitating direct detection. MAbs 228 and 20B3 were 
detected using an anti-mouse HRP-labelled secondary antibody and the recombinant antibodies (anti-FABP 
and 2B12) were detected using anti-HA HRP-labelled secondary antibody. PR
+
: Prestained protein ladder. 
A 
 
 
 
 
B 
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To ensure maximal protein expression to support efficient purification yields a small-scale 
study of the effect of IPTG concentration and induction time was carried out at 30
o
C 
(section 2.3.2.4.3). From Figure 3.2-10 it was concluded that irrespective of IPTG 
concentration after 5 hours induction, the protein expressed well, but the appearance of a 
slightly increased MW band was observed. From the 2.5 hour induction profile, an IPTG 
concentration independent expression profile was observed, where even minimal IPTG 
concentration fully turned on protein expression. This was likely as a result of the uniform 
uptake of IPTG by the Tuner™ cells due to the lacZY mutation. Marginally more protein 
appeared to be expressed at 0.2mM IPTG and this was adopted as one of the optimal 
conditions for large-scale expression.   
 
 
Figure 3.2-10:  Optimisation of expression of the selected FABP-P1&2 clone 
The IPTG concentration and length of induction time were examined by SDS-PAGE (I) and WB (II). Samples 
were taken at two time points; 2.5 hours (A) and 5.0 hours (B) over a range of IPTG concentrations (0-
0.5mM) as indicated above the lanes. SDS-PAGE of the cytoplasmic cell extractions were subsequently WB 
transferred and probed with anti-HIS HRP-labelled detection antibody. PR
+
: Prestained protein ladder. 
 
 
A 
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The protein was expressed in large-scale and then purified by IMAC as detailed in section 
2.3.2.4.4. Initial purifications were hampered by removal of the protein from the column by 
simply washing in PBS-based wash buffers. Adoption of NaH2PO4 buffers for purification 
(with the removal of Tween®20) followed by optimisation of both salt and imidazole 
concentration proved more efficient than the PBS-based buffers (Figure 3.2-11). 
Subsequently, large-scale purification yielded 1.68mg/mL (3.3mg total from a 400mL 
culture) of fusion protein as determined by absorbance (280nm) measurement. The purified 
fusion protein was visualised on SDS-PAGE, transferred to nitrocellulose and probed with 
commercial and in-house antibodies for purity. The anti-epitope-1 (Hytest 19C7 and 2B12), 
anti-epitope-2 (Hytest 228 and 20B3) antibodies were used in a WB confirming specificity 
as illustrated in Figure 3.2-12. Some additional bands were visible, but a high proportion of 
the desired MW protein was purified. Polishing steps to improve the purity were 
undertaken at this stage to reduce the number of bands in combination with an alternative 
purification strategy, cation exchange chromatography. However, when carried out with 
crude lysate another similarly charged protein bound to and eluted from the exchange 
column. This strategy from crude lysate was inefficient, but could easily be combined with 
an initial IMAC purification to form a two step purification protocol. When combined with 
gel filtration chromatography, the protein preparation was found to be extremely pure and 
to exist predominantly as a monomeric fraction (even after prolonged storage at -20
o
C). 
Figure 3.2-13 is the gel filtration profile for the fusion protein, as described in section 
2.3.2.4.5. In this case the purity was ≥98% and suitable for kinetic studies. Prior to this, 
precise measurement of the concentration of protein was necessary. This was carried out 
using hFABP from a commercial source (c-hFABP) and the anti-hFABP clone (H2) in an 
inhibition assay (section 2.3.7.1). The inhibition assay was carried out at a pre-determined 
antibody dilution by titration and a standard curve constructed by inhibition of binding to 
the immobilised hFABP with free c-hFABP. Prepared dilutions of the purified FABP-P1&2 
fusion were assayed in parallel allowing determination of the true protein concentration 
from the standard curve. An average of 56.86±3.56μM (n=3) FABP-P1&2 fusion was 
calculated which equated to a true protein concentration of 1.19±0.07mg/mL. The correct 
determination of protein concentration was critical for its use in 1:1 interaction kinetics 
where the concentration of the analyte is crucial for accurate kinetic constant analysis.  
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Figure 3.2-11: Optimisation of salt and imidazole concentration for purification of FABP-P1&2 fusion 
SDS-PAGE analysis of the purification conditions was carried out. The lanes are labelled as follows; PR
+
: 
Prestained protein ladder, UFL: unfiltered lysate, FL: flow-through, F1: flow-through, W1-3: washes 1-3 and 
Pure: purified fraction 
A) Variation of the salt concentration with a fixed imidazole concentration (10mM). W1: 100mM, W2: 
150mM, W3: 300mM NaCl. Little difference was observed greater than 100mM NaCl. However, 
some higher MW bands were present in the pure fraction. To overcome the presence of these bands 
imidazole concentration was optimised. 
B)  Variation of the concentration imidazole in the wash buffers at 100mM NaCl. W1: 10mM, W2: 
15mM and W3: 20mM imidazole. These modified buffers yielded pure protein without any 
contaminating bands. In this case the use of increasingly stringent washing caused some loss of the 
desired protein. However, this was countered by the relatively pure protein fraction collected.  
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Figure 3.2-12: Large-scale, optimised purification of recombinant FABP-P1&2 protein by IMAC 
The protein was purified by IMAC adopting the optimised NaH2PO4-based buffers and yielded a pure fraction 
by SDS-PAGE analysis. Furthermore, the presence of FABP-P1&2 fusion protein was confirmed by WB 
using the epitope-specific antibodies available, as labelled on the image. PR
+
: Prestained protein ladder. 
 
Figure 3.2-13: Gel filtration elution profile of recombinant FABP-P1&2 protein 
The purified protein was applied to a HiLoad S75 16/60 gel filtration column at a flow rate of 1mL/minute in 
1X PBS buffer containing 0.02% (w/v) NaN3. The image is cropped to show only the volumes where the 
fractions were collected and the peaks observed. At 62.90mL the peak maximum was reached and 
demonstrated the FABP-P1&2 fusion protein to be highly soluble and stable. 
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3.3 Chapter conclusions 
 
At the onset of the project a previously existing, whole protein immunised, avian library 
was available and screened using the custom designed cTnI peptides to evaluate the spread 
of epitope-specificity. This library exclusively yielded anti-epitope-3 or undefined epitope 
anti-cTnI antibodies (section 5.3). To assess the coverage of other non-immuno-dominant 
epitopes in this library the serum was titred against the C- and N-terminally conjugated 
peptides. This comprehensively demonstrated that there was no specificity for epitope one, 
but potentially specific-antibodies for epitope two (only in the C-terminal conjugated 
peptide form). The terminus of conjugation is typically arbitrarily assigned, but sequences 
from N-terminal regions of a protein are recommended to be conjugated via their C-
terminus and vice versa. It cannot be definitively concluded that the whole protein-based 
immunisation approach did not contain antibodies specific to the epitope-1 region, rather 
that the strategy did not elicit antibodies capable of recognising both the native and 
synthetic variants of the epitope. The likelihood of extracting conformationally-sensitive 
epitope-specific antibodies from this library for epitope-2 was severely diminished, as the 
bio-panning experiments would have to be carried out using the synthetic peptide. Indeed, 
numerous blocking bio-panning experiments (using anti-epitope-3 antibodies bound to 
cTnI) were undertaken to increase the likelihood of extracting anti-epitope-2 scFv which 
failed to isolate the required antibodies. Immunising with a protein and screening against a 
peptide epitope potentially fails to enrich for conformation-specific recombinant antibodies, 
as was seen in this case. The library described here was bio-panned against the cTnI protein 
and the unpanned library was only available as a cell stock not a cDNA stock. With 
differing levels of representation for each clone (i.e. each cell) in the transformed library, 
amplification from cell-stocks can often introduce a bias due to differences in the specific-
growth rate of the cells. The best bio-panning experiments are carefully built upon efficient 
amplification of the genes into the vector, transformation and immediate display on the 
phage for bio-panning. While numerous factors affect various stages of that process (e.g. 
mRNA quality, PCR and transformation efficiency) moving immediately into the bio-
panning experiments ensures that the representation of each of the antibodies displayed is 
not affected by cell-storage.  
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Immunisation strategies based on the use of the synthetic epitopes conjugated to a carrier 
protein (e.g. KLH) improve the chances of accessing those conformation-specific 
antibodies by bio-panning with the native protein and numerous examples of successful 
peptide immunisation strategies are available [108, 109] particularly in the area of vaccine 
development [110-112]. This strategy of synthetic epitope immunisation was adopted 
successfully and led to the development of both hybridoma (anti-epitope 2 – section 4.2) 
and recombinant antibodies (anti-epitope 1 – section 5.2) with potential applications in 
cTnI diagnostic platforms. 
Overcoming the issues linked to the quality of the available antigen (section 3.2.1) was a 
significant challenge and the use of recombinant antigen expression proved to be a 
successful strategy that led to the efficient characterisation of the selected antibodies 
(section 5.2). The use of recombinant protein expression technologies is wide-spread with 
many examples of successes and at least as many, if not more, failures. The strategy proved 
multifaceted due to a number of intrinsic factors primarily surrounding the expression and 
purification of a difficult-to-express, highly charged, human protein in E. coli. Despite 
overcoming some of these barriers with truncated cTnI expression, downstream purification 
was a significant issue. This resulted in strategies that sequentially reduced the length of the 
protein to be expressed, culminating in successful expression and, crucially, purification of 
the epitope 1 and 2 regions as a fusion to FABP. The fusion protein proved to be a readily 
expressed and purified protein which was highly stable even after prolonged storage.  The 
successful isolation of the FABP-P1&2 fusion protein permitted accurate characterisation 
of the developed antibodies with a soluble, stable and consistent representative antigen.  
Broadly speaking, the availability of vast amounts of bioinformatic, structural and genetic 
information surrounding many human and animal proteins is unprecedented. A knowledge-
driven and rational approach to epitope targeting is not only a possibility, but is strongly 
advised in light of such quality information being readily accessible. The source and 
availability of quality antigen prior to attempting to generate any antibody is paramount and 
is a widely accepted key factor. To rationally target specific epitopes multiple versions of 
an antigen are hugely beneficial and a prerequisite to highly-specific antibody generation: i) 
for immunisation, ii) to perform selections or screening campaigns with a different form of 
the antigen than was immunised and iii) to rigorously characterise the generated antibodies 
in multiple approaches. While not all antibody generation campaigns require such absolute 
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and dedicated epitope-specificity, it is of particular importance in the development of 
sensitive assays using novel antibodies in a clinical-diagnostic setting. 
The approach to antigen development undertaken was dictated by the specific assay 
requirements; compatible sandwich assay pairs that were specific to absolutely defined 
epitopes on a human structural protein. The process was initially instigated due to the poor 
epitope spread found with cTnI protein-based immunisations and led to substantial 
optimisation of the procedures followed, including synthetic-peptide chemistry for antigen 
generation and recombinant methodologies for protein expression. The experience gives 
one an appreciation for the complexity of the process, but the successful application of the 
approach to antibody generation validates the feasibility of the strategy and the thought 
processes and stratagems needed for difficult to work with or scarcely available antigen. 
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Chapter 4: Monoclonal Antibodies  
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4.1 Introduction  
4.1.1 Hybridoma technology 
 
Nobel laureates (1984) Kolher and Milstein invented what has become the most freely 
available and hence, widely used method to generate monoclonal antibodies [113]. 
Hybridoma technology was exploited to generate anti-epitope-2-specific antibodies from a 
murine repertoire.  
Hybridoma generation involves the immortalisation of B-lymphocytes, harvested from 
mice immunised with a specific antigen, by fusion with a myeloma cell to generate a stable 
hybrid cell line with characteristics of both parental cells. This hybridoma gains 
immortality from the myeloma parent and specific antibody production capacity from the 
lymphocyte parent (Figure 4.1-1).  The most widely used fusion partners are Sp2/0-Ag14 
[114] and P3X63Ag8.653 [115] and both were selected from a mouse lineage deficient in 
hypoxanthine-guanine phosphoribosyltransferase (HGPRT
-
). Fusion is most commonly 
mediated by the addition of polyethylene glycol (PEG) [116] and the fusion itself is a 
multifaceted process that includes cell agglutination, membrane fusion and cell swelling 
[117]. Often the optimal environmental conditions are variant leading to degrees of fusion 
efficiency that is largely thought to be affected by efficient cell-pairing [118]. More 
efficient strategies to fuse cells have developed, for example, bringing single lymphocytes 
in close contact with myeloma (cell pairing) and microfluidic control of this process [119].  
Chromosome exchange occurs between the parent cells and following fusion, a 
heterogeneous mixture of myeloma cells, lymphocytes and many fusions of myeloma-
myeloma, lymphocyte-lymphocyte and myeloma-lymphocyte are generated. To isolate 
hybridomas resulting from lymphocyte-myeloma fusions the following approach, involving 
a selective propagation regime based on the Hypoxanthine-Aminopterin and Thymidine 
(HAT) system, is adopted (Figure 4.1-2). This ensures that only correctly fused, potentially 
antibody-secreting clones are selected for. In addition, selecting for correctly fused 
myeloma-lymphocytes must also take into account the degree of genetic instability in the 
newly formed hybrid. Segregation of the chromosomes occurs at distinct periods, one 
occurring rapidly during the initial propagation of the fusions and another after prolonged 
culture [120]. With respect to mouse monoclonal hybrids this equates to large-scale loss of 
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hybrids in the initial scale-up followed by gradual decline in antibody-producing hybrids 
with increasing expansion. To counter the initial rapid segregation of chromosomes large 
numbers of positive clones are carried through the screening process. One of the main 
challenges in the procedure is the screening and characterisation of multiple potential 
antibody-producing clones in a rapid and judicious manner (Figure 4.1-1).  
Figure 4.1-3 illustrates the concept of „cloning by limiting dilution‟ which is vital for the 
isolation of clones derived from a single parental hybridoma. The methodology involves 
seeding the cells at such a range of densities as to maximise the probability of a single cell 
being distributed in a single well. This approach assumes that the majority of wells seeded 
(at ≤ 1cell/well) do not demonstrate cell growth and Poisson-distribution dictates that the 
wells demonstrating growth contain single cells. The nature of cells disrupts this 
mathematical approach (due to clumping for example) and so cloning by limiting dilution 
must be carried out repeatedly to ensure monoclonality [99].  
In parallel, the screening process must be designed to closely mimic the eventual analytical 
format that will be used to ensure the antibodies effectiveness in that format. The process of 
scale-up, specificity analysis and stability of the newly formed hybrids requires serious 
consideration. High-throughput interaction analysis systems offer an attractive means to 
assess the binding characteristics of secreted hybridoma-derived antibodies and provides 
valuable information to support the selection process e.g. on SPR–based instruments [121] 
or microarrays [122-124].  
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Figure 4.1-1: Schematic overview of mouse monoclonal antibody production 
From an immunised mouse, B-lymphocytes are isolated and fused with a mouse myeloma cell line (Sp2/0-
Ag14) creating a series of hybrid cells. Screening of the hybridoma pool is carried out to ensure only specific 
functional hybridomas are taken to the next stage of scale-up. Subsequently, specific clones are further 
characterised before expansion to purify the selected antibody. 
 
Figure 4.1-2: HAT selection for B-cell-myeloma fusions 
Aminopterin blocks the de novo synthesis of purines (1). The enzyme HGPRT can incorporate Hypoxanthine, 
a source of purine precursors, into mature purines (2). Additionally, thymidine synthesis is blocked so an 
exogenous source of thymidine is provided which is absorbed by the cell and phosphorylated for inclusion 
into DNA synthesis (3). Therefore, only clones which are HGPRT
+
 can propagate in this system and only 
immortalised hybridomas can survive prolonged culture. 
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Figure 4.1-3: Schematic overview of identification and isolation of stable hybridomas  
From the fusion master plate, positive wells are identified by a functional assay for the antigen of interest. 
Those clones secreting antibody of the required specificity, combined with other additional properties, are 
expanded from a 96-well format through to flasks of increasing size. Cells are harvested and plated at low 
concentrations to achieve one cell per well. This process must be carried out several times to ensure 
monoclonality.  Preservation of positive hybridoma populations at numerous stages in the expansion process 
is necessary. The need to screen regularly to ensure continuous secretion of specific antibodies is of crucial 
importance. 
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4.1.2 Surface plasmon resonance (SPR) 
 
The use of surface plasmon resonance (SPR)-based optical biosensors has seen tremendous 
growth over the last two decades, and this trend is predicted to continue as the technology 
becomes more accessible and its applications more diverse. SPR has emerged as the 
foremost and favoured technology for monitoring molecular interactions, due ostensibly to 
the fact that binding events can be monitored in „real-time‟ and without the requirement for 
ancillary labels (Figure 4.1-4). These key attributes facilitate accurate kinetic 
measurements, rapid analysis times, reduced additional costs and possible heterogeneities 
or other complications associated with labelling of interactants.  
SPR is a quantum electromagnetic phenomenon as a result of the interaction of light with 
free electrons at a metal-dielectric interface (surface plasmons) [125]. Most SPR-based 
instruments are designed in the Kretschmann configuration using a prism coupled to a 
dielectric metal e.g. gold (Figure 4.1-4) [126]. In this common and efficient arrangement, a 
metal film is deposited directly on top of a prism. P-polarised light from a light source 
(LED at 760nm in Biacore™ instruments) is incident on the surface (red wedge) after 
passing through the prism at an angle of incidence greater than the critical angle (θc) 
causing total internal reflection (TIR) to occur [125]. When the light vector matches the 
surface plasmon wave propagation vector, energy from the incident light couples into the 
surface plasmon wave leading to an enhancement of the evanescent field and a 
corresponding reduction in the reflected light (black line which is referred to as a minimum 
observed or θSPR). The minimum angle change (ΔθSPR) is a function of mass changes at the 
surface caused by molecular binding events. ΔθSPR is the baseline minimum angle (θSPR1 – 
solid black line) change after interaction between a ligand and analyte (θSPR2 – dashed black 
line) and is reported as a change in response units (RU) in real-time [99].  
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Figure 4.1-4: Overview of the surface plasmon resonance biosensor configuration 
(A) Binding of analyte to ligand immobilised on the sensor chip surface is monitored in „real-time‟ and the 
binding profile is reported as a „sensorgram‟ as shown in (B). In the sensorgram buffer flow over the 
antibody-coupled surface establishes a baseline response. The continuous injection of analyte allows for 
association (binding) to occur. After the sample injection is finished, buffer flow is restored and dissociation 
(unbinding) is monitored. Regeneration restores the surface to baseline level (not shown). Interaction kinetics 
and binding affinities can be extrapolated readily from the resultant sensorgram data. RU: Response unit. 
 
The simplest interaction is the 1:1 binding event, which can be described for immobilised 
ligand (A) binding to cognate analyte (B) forming a complex (AB) as illustrated by 
Equation 4.1-1. ka is the association rate and kd is the dissociation rate (see Table 4.1-1 for 
detailed explanation) [127].  
 
Equation 4.1-1: 1:1 binding interaction for analytes A and B forming the complex AB 
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Table 4.1-1: Definitions of biophysical determinants for bio-molecular interactions 
 Definition Description Proportionality Units 
ka 
Association rate  constant 
(also referred to as „on-rate‟) 
No. of AB complexes 
formed per unit time at unit 
concentration of A and B. 
Affinity  ka M
-1
s
-1
 
kd 
Dissociation rate constant 
(also referred to as „off-rate‟) 
No. of AB complexes 
dissociating per unit time. 
Affinity  1/kd s
-1
 
KA Equilibrium association constant 
Affinity propensity to 
association of A + B 
KA = ka/kd= 
[AB]/[A]+[B] 
M
-1
 
KD Equilibrium dissociation constant 
Affinity contribution to 
stability of AB complex 
KD = kd/ka = 
([A]+[B])/[AB] 
M 
 
The value of truly high-throughput (HT) systems for studying bio-molecular interactions is 
discussed in section 5.1.10 with respect to recombinant libraries. HT-screening using SPR 
is also invaluable for the screening of hybridomas. The first use of such parallel screening 
on Biacore™ 4000 (known as the A100 at the time) was in the characterisation of 
hybridoma supernatants [121]. Biacore™ (GE Healthcare) is the predominant manufacturer 
of the SPR systems found in many research laboratories, due to its substantial market 
penetration, and the range of instruments that have developed since the first system in 1990. 
For these reasons, our lab has three Biacore™ instruments: 1000, 3000 and 4000. The 1000 
and 3000 systems are low volume analysis systems and were typically used to evaluate a 
maximum of 20 clones in the process of this work. The HT and diverse nature of the 4000 
made it the predominant workhorse for screening for specific antibodies from both 
hybridoma progenies and recombinant antibody libraries.  
The strategies and technologies outlined above were combined with the methodologies 
delineated in section 2.3.3, to isolate epitope-specific antibody-secreting hybridoma clones. 
The synthetic-epitope immunisation regime was favoured for, with functional screening of 
the hybridomas using the cTnI protein. This permitted screening and isolation of 
hybridomas producing anti-cTnI-specific antibodies by a „data-rich‟ selection approach. 
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4.2 Results of the generation and isolation of a monoclonal antibody 
against epitope-2 of cTnI 
 
Hybridoma technology was employed and evaluated as an approach to isolate anti-cTnI-
epitope-specific antibodies from murine repertories. A strategy to isolate a stable, antibody-
producing, specific hybridoma was developed based upon a successful immunisation 
strategy using the synthetic peptide-2 as antigen. To enhance the probability of isolating an 
antibody that was capable of binding the native protein, the initial screening of the 
hybridomas was carried out by solid-phase ELISA against intact native cTnI. In 
conjunction with this, epitope-specificity studies were carried out using the Biacore™ 4000 
and „off-rate‟ kinetics determined using the Biacore™ 3000. In combination, this approach 
provided accurate, high-quality, „data-rich‟ information to rank the individual antibody-
secreting hybridomas and judiciously aid in the selection process for the best candidate 
antibodies. 
 
4.2.1 Immunisation of Balb/c mice with synthetic-epitope-2 conjugate 
 
Balb/c mice were immunised with peptide-2 conjugated to KLH (section 2.3.3.1) and the 
antiserum produced was found to react specifically with the native epitope presented in the 
context of the cTnI protein (Figure 4.2-1), as confirmed by ELISA (section 2.3.3.2). To 
ensure that the response was specific for the synthetic epitope and not the linker, a negative 
control peptide was included. The ELISA showed a very high serum titre (cTnI: 1 in 1 
million and peptide 2: >1 in 1 million) and the extracted spleen cells from the associated 
animal were used for hybridoma generation, as described in section 2.3.3.3. 
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Figure 4.2-1: Anti-serum response in KLH-peptide-2-sensitised mouse 
The commercial cTnI protein and neutrAvidin were coated onto the wells of a microtitre plate and blocked 
with 5% (w/v) PBSM. Subsequently, biotinylated peptide 1 and 2 were applied to a separate series of the 
neutrAvidin-coated wells. Antiserum was titrated from 1 in 100 to 1 in 1,000,000 in 1% (w/v) PBSTM and 
mouse IgG detected using a commercial anti-mouse-Fc-specific HRP-labelled secondary antibody. The 
response profile generated showed antibodies-specific for the required epitope in both its synthetic (peptide 2) 
and native (cTnI) forms. 
 
4.2.2 Clone selection by data-rich screening 
 
To strategically evaluate each clone in a judicious manner, a multi-platform analysis regime 
was employed with the initial focus on epitope- (on Biacore™ 4000) and protein-specificity 
(by ELISA and Biacore™ 3000). These core requirements were supplemented by further 
analysis based on functional assay screening (sandwich ELISA) and evaluation of antibody 
expression levels (section 2.3.3.4). 
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4.2.2.1 Epitope and protein-specificity screening 
 
Post fusion 19.5 plates were prepared and analysed by direct binding ELISA (section 
2.3.3.4.1) to identify specific antibody-secreting hybrids. The time between test and 
decision was typically in the order of 24 hours for ELISA-based analysis. In a steady-state 
analysis such as this, the signals obtained are due to unknown combinations of intrinsic 
affinity and the relative abundance of the secreted antibody in the supernatant [128]. 
However, as a starting point in the analysis it was a suitable method to identify potential 
positive antibody-secreting clones in the wells. To reduce the number of wells to a 
manageable level an absorbance level of 0.4A.U was applied as a cut-off limit. This yielded 
112 clones to be carried forward for further analysis as illustrated in Figure 4.2-2. 
 
 
Figure 4.2-2: First screen of antibody-secreting hybridomas by a direct binding ELISA 
Analysis of crude supernatants was carried out against the cTnI protein to assess for conformation-specific 
anti-epitope-2 antibodies. cTnI was coated onto wells of an ELISA plate at 1μg/mL followed by blocking. 
Diluted supernatants were applied to individual wells and specific murine IgG detected with an anti-mouse-
alkaline phosphatase (AP)-labelled secondary antibody. The red line indicates the 0.4A.U. cut-off limit that 
was applied. 
 
  
4–12 
 
  
Peptide-specificity analysis was then carried out using the Biacore™ 4000 (then known as 
the A100) as described in section 2.3.3.4.2. This analysis confirmed epitope-specificity and 
eliminated issues with reactivity against the other cTnI synthetic peptides and linker 
chemistries. Figure 4.2-3 is an illustration of the screening experiment setup where four 
hybridoma supernatants per cycle were interrogated against the 4 peptides and a surface 
control. For each antibody, 5 independent sensorgrams were collected per cycle. 
  
 
Figure 4.2-3: Biacore™ 4000 flow cell setup for epitope-specificity mapping of generated hybrids 
Peptides 1, 2, 3 and 4 were immobilised on the outer spots of the flow cell with spot 3 retained as a surface 
control. 
A) Crude supernatants diluted in running buffer are applied across the flow cell, where association 
occurs (insert sensorgram). 
B) Hybridomas binding to immobilised peptide-2 and their subsequent dissociation were monitored for 
12 minutes post injection. 
This diagram illustrates binding of one hybridoma. In reality four hybridomas per cycle were interrogated 
generating curves for each spot (five per hybridoma) resulting in substantial data to rank the hybridomas. 
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The peptide-specificity maps collected at each stage of expansion were paired with direct 
binding ELISA data to ensure the isolation of specific antibody-secreting clones. Figure 
4.2-4 shows the binding response levels for the 112 selected clones from the initial whole 
protein screen. A significant number of clones can be seen to bind exclusively to the spot 
where peptide-2 was immobilised.  
 
 
Figure 4.2-4: Epitope-specificity screening for anti-cTnI epitope-specific antibodies on Biacore™ 4000 
Crude antibody-containing supernatants were diluted in buffer and each passed over the four peptides and a 
surface reference. The binding responses for each antibody for the peptides were plotted for the 112 
hybridomas selected previously by the cTnI protein binding ELISA. A significant number of the antibodies 
reacted with the peptide-2 and crucially showed no cross reactivity with the other peptides. 
 
Following scale-up to 48-well plate scale, the clones were retested by a direct binding 
ELISA (Figure 4.2-5) and the positives were reanalysed for peptide-specificity (Figure 
4.2-6). Figure 4.2-5 demonstrates a dramatic loss of binding for several clones possibly due 
to chromosome loss or growth competition from other non-secreting cells present in the 
wells. This highlights the importance of examining each clone at each stage of scale-up. 
The epitope-specificity was also re-analysed to ensure no shift in the binding profile. Figure 
4.2-6 shows retention of specificity for the majority of the clones. From this paired analysis 
data 24 clones were taken forward and expanded up to 24-well plate scale. 
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Figure 4.2-5: Direct binding ELISA to confirm retention of positivity at 48-well plate scale of 
hybridoma expansion 
Direct binding to cTnI was carried out to assess retention of positivity post scale-up from 96- to 48-well plate 
format. A number of positive clones showed loss of binding either due to instability of the chromosomes or 
due to competition from other non-secreting clones in the wells. 
 
Figure 4.2-6: Epitope-specificity of expanded clones at the 48-well plate stage of hybridoma scale-up 
Positive clones from the direct binding ELISA analysis were re-assessed for peptide-specificity on the 
Biacore™ 4000. Many of the strong binding clones retained their epitope-specificity. Crude supernatants 
were again diluted in running buffer (HBS-EP
+
) and binding responses assessed as described previously. 
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The format of analysis was then expanded, after scale-up from 48-well to 24-well plates, to 
include competitive ELISA (section 2.3.3.4.3). Figure 4.2-7 shows that binding to cTnI 
could be almost completely abolished by an excess of free peptide-2. The crude 
supernatants (two dilutions) were incubated with and without free peptide and assayed 
against the cTnI protein. The absorbances at zero free peptide concentration (A0) were 
compared to a „one-shot‟ excess of free peptide aimed to completely reduce binding. This 
approach was employed as there was no reliable way to quantify the amount of secreted 
IgG in the supernatants without titration. Titration was possible, but for large numbers of 
clones it is inherently cumbersome. This „one-shot‟ competition assay allowed for 
evaluation of 24 clones in one analysis at two supernatant dilutions. The collected data 
indicated that all clones were sensitive to free peptide thus indicating competition for 
binding and hence, cTnI specificity. 
 
  
4–16 
 
  
 
Figure 4.2-7: Competitive ELISA comparison of twenty-four selected hybridomas 
Twenty four positive clones were evaluated for their sensitivity to the free peptide at the 24-well plate scale. 
cTnI was coated onto wells of an ELISA plate. Crude supernatants were diluted 1 in 2 and 1 in 10 with 1% 
(w/v) PBSTM (A0) and 10μM free peptide-2 (Comp) before being applied to the cTnI-coated wells. 
Absorbance without competitive antigen and signal reduction due to free antigen were plotted side by side for 
both dilutions of supernatant. It can be seen that all the clones were sensitive to the presence of free peptide 
antigen which competed for binding at both supernatant dilutions. cTnI bound mAb was detected using an 
anti-mouse HRP-labelled secondary antibody. 
 
Until this stage of expansion all assumptions made were based on direct binding formats. 
Since affinity is a ratio of the thermodynamic constants ka and kd (Table 4.1-1) a method to 
examine at least one of these constants for ranking was required. The ka constant is 
concentration dependent and therefore ranking guided by this parameter in crude samples 
was not feasible. kd is independent of concentration and was examined in a stability study 
by monitoring the formation of an antibody-peptide binding event and its subsequent 
dissociation over a relatively long time period. Examination of the percentage left (% left, 
see Equation 4.2-1) for each of the selected hybridomas permitted ranking by evaluation of 
a parameter related to their affinity rather than basic binding assay. Table 4.2-1 outlines the 
stability early response (immediately after association) and stability late response (after 12 
minutes dissociation) with the calculated percentage left values for each of the hybridomas 
in comparison to a commercial monoclonal antibody (Hytest 228).  
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Table 4.2-1: Ranking of hybridomas by percentage left 
Clone Clone # Stability Early (RU) Stability Late (RU) % Left 
1D9 5 180.13 154.90 86.00 
1.E.6 7 75.30 57.33 76.13 
1.E.10 9 87.85 63.38 72.14 
2C2 14 127.45 103.70 81.37 
3F10 20 127.10 107.78 84.80 
4C9 24 71.25 52.55 73.75 
4D7 25 83.18 55.65 66.91 
4G3 29 123.60 101.50 82.12 
5G11 34 119.98 96.75 80.64 
6.E.10 40 160.35 136.85 85.34 
8.E.11 54 96.70 72.95 75.44 
8G4 55 386.13 361.80 93.70 
8G7 56 234.83 212.15 90.34 
9C4 57 90.85 66.33 73.00 
11C10 69 253.25 228.45 90.21 
13D6 78 168.20 141.70 84.24 
13F9 81 97.73 72.45 74.14 
13G4 82 238.68 214.40 89.83 
14G6 86 158.55 130.28 82.17 
15C6 87 108.68 81.73 75.20 
18C4 103 130.60 105.98 81.14 
18F8 106 142.88 112.75 78.92 
18G2 107 123.23 95.65 77.62 
20B3 111 453.28 426.43 94.08 
Hytest 228 - 250.73 250.63 99.96 
 
Figure 4.2-8 graphically maps the relationship between binding early and late, as described 
in Table 4.2-1. The clones can be observed to lie quite close to the ideal (100% left) with 
four clones showing percentage left values >90%. These clones (highlighted in red) were 
prioritised for continued expansion and cloning by limiting dilution.  
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Figure 4.2-8: Biacore™ 4000 high-throughput percentage left ranking of anti-peptide-2 hybridomas 
Plot of stability early versus stability late. Binding levels at a time-point early in the dissociation phase were 
collected and compared to a later time-point, after 12 minutes dissociation. The diagonal blue line represents 
100% left, which is indicative of no dissociation of the antibody-antigen interaction. 
 
4.2.2.2 Capture ranking of Hybridoma clones on Biacore™ 3000 
 
With the number of clones reduced to a manageable number the format of the analysis was 
refined further to acquire more „assay relevant data‟. As the final assay format is intended 
to be a sandwich assay, the selected mAb must function as an efficient capture antibody. 
The antibody selected must therefore recognise the antigen in a solution-dictated 
conformation which can often differ from the conformation adopted when the protein is 
absorbed onto polystyrene plates. To achieve this, four clones were evaluated on the 
Biacore™ 3000 in a low volume analysis. Figure 4.2-9 outlines the two flow cell 
experimental setup. In both flow cells, a surface was prepared using an anti-mouse Fc-
specific antibody as described in section 2.3.3.4.4. The active surface captured mAbs from 
crude supernatants after which a fixed cTnI concentration (30nM) was passed over both 
flow cells. In this setup the reference cell allows for any contributions of non-specific cTnI 
binding to be subtracted. This analysis was limited somewhat as the dissociation for each 
mAb off of the capture antibody was not subtracted. However, this dissociation was 
constant for each of the hybrids and permitted ranking based on percentage left analysis. 
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Figure 4.2-9: Biacore™ 3000 'off-rate' ranking flow cell setup 
A commercial mouse-specific monoclonal antibody (red) was utilised to capture the Fc portion of the anti-
peptide 2 monoclonal antibodies from crude supernatants (yellow). cTnI was then passed over the captured 
monoclonal antibodies and the Fc-specific capture antibody which was used as an online surface control. 
 
This methodology was applied to the four prioritised clones at 6-well plate scale (section 
2.3.3.4.4). Figure 4.2-10 illustrates the cTnI binding profile for the four clones. Indicated on 
the graph are the time points REarly and RLate which were used to derive the percentage left 
values for the four clones using Equation 4.2-1 (8G4: 59.4%, 20B3: 54.2%, 8G7: 52.6%, 
11C10: 51.9% and Hytest 228: 53.1%). Of crucial importance from this analysis was the 
binding of the mAbs to the native protein in-solution. This orientation was more 
representative of the scenario in which the selected mAb would be deployed. The mAbs 
were also observed to perform comparably to the commercial standard mAb (Hytest 228). 
 
Equation 4.2-1: Calculation of percentage (%) left values in Biacore™ ‘off-rate’ experiments 
 
Where R is the response units (RU). „Early‟ was defined as 10 seconds after the end of the cTnI injection (end 
of the association phase) and „late‟ as the response after several minutes dissociation in relation to the early 
time point. See Figure 4.2-10 for graphical representation of REarly and RLate. 
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Figure 4.2-10: Biacore™ 3000 'off-rate' analysis of four selected hybridomas for the cTnI protein 
This normalised graph (minus mAb capture level and non-specific interactions) indicates the association and 
dissociation of cTnI. Fixed time intervals Rearly and Rlate (7.5 minutes dissociation) are indicated on the graph. 
The response values (RU) at these time points were used in Equation 4.2-1 to calculate % left values.  
 
The four clones were scaled-up to T75 flasks and subsequently cloned by limiting dilution 
as described in section 2.3.3.5. The other non-prioritised clones were banked, as described 
in section 2.3.3.6.3. Once cloned by limiting dilution, five clones from each parent were 
selected from direct binding ELISA data (not shown). Nineteen of the twenty selected 
hybridomas continued to secrete antibody through expansion (11C10#5 became non-viable) 
and were tested predominantly by ELISA as described for the primary expansion (data not 
shown). The 19 clones were analysed side-by-side with the Hytest equivalent antibody 
(mAb 228) on Biacore™ 3000 in the capture approach. Figure 4.2-11 shows the subtracted 
sensorgrams for all the clones and the commercial antibody. The response at the early time 
point (~600 seconds) and the late time point (~1020 seconds) was then expressed as % left 
values as calculated from Equation 4.2-1 and contained in Table 4.2-2. The analysis 
showed that all the 20B3 sub-clones performed best, with values from 61.50 to 63.26%, 
and compared well with the Hytest mAb (66.66%). To further differentiate between the 
20B3 sub-clones (#1-5) a dilution series of supernatants was prepared to assess the 
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antibody expression levels between the daughter clones (section 2.3.3.4.1). Figure 4.2-12 
shows no appreciable difference in expression levels and so 20B3#5, with a marginally 
greater percentage left value, was selected and expanded for further cloning by limiting 
dilution (section 2.3.3.5). 
 
 
Figure 4.2-11: Biacore™ 3000 percentage left ranking of twenty clones for cTnI protein binding  
This normalised (minus mAb capture level) reference subtracted graph indicates the association and 
dissociation of cTnI at fixed time intervals. Rearly was defined as 10 seconds after the end of the cTnI injection 
and Rlate as the dissociation after 7 minutes in relation to Rearly.  
 
Table 4.2-2: Percentage left values for nineteen hybridomas from Biacore™ 3000-based experiment 
Clone # 
Percentage (%) Left 
8G4 8G7 11C10 20B3 Control 
1 47.13 50.18 58.39 61.50 
66.66 
 
2 47.14 53.10 58.28 61.58 
3 47.90 51.82 57.98 62.00 
4 49.99 52.80 58.44 62.68 
5 49.96 52.86 - 63.26 
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Figure 4.2-12: Direct binding ELISA-based analysis of hybridoma antibody expression levels 
In a direct binding ELISA format three dilutions of supernatant (1 in 4, 1 in 40 and 1 in 400) were prepared in 
1% (w/v) PBSTM and applied to a cTnI-coated (1μg/mL), blocked (5% (w/v) PBSM) plate. The bound mAb 
levels were detected using an anti-mouse-Fc-specific HRP-labelled secondary antibody. This allowed 
comparison of the antibody production levels between the five 20B3 daughter clones. The graph illustrates no 
major differences in expression levels between these closely related progenies. Clone #5 was selected for 
expansion and cloning by limiting. 
 
4.2.2.3 Additional screening of the hybridoma progeny 
 
After the second cloning by limiting dilution carried out on 20B3, the hybrids were then 
evaluated in a sandwich ELISA capturing various concentrations of cTnI and bound protein 
was detected using an anti-epitope-3 HRP-labelled antibody (Hytest 16A11) as described in 
section 2.3.3.4.5. Figure 4.2-13 shows the cTnI concentration dependant signal obtained for 
all the captured mAbs over a significant cTnI concentration range with no non-specific 
interaction between the mAbs and reporter antibody. This demonstrated the ability of the 
antibodies to recognise the antigen in a number of formats and, in particular, one 
mimicking its envisaged endpoint assay application. Clone E (20B3.5.E) was isotyped 
using Pierce™ Rapid Isotyping kit and the selected monoclonal was found to by IgG1κ as 
shown in Figure 4.2-14 (section 2.3.3.4.6). 
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Figure 4.2-13: Sandwich ELISA for cTnI using hybridoma supernatant 
Supernatants directly from hybridoma wells were applied to an ELISA plate to form the antibody capture 
surface. Hytest 228 (2μg/mL) was also immobilised to serve as a positive control. Various cTnI 
concentrations were applied to the immobilised monoclonal antibodies. A buffer only control (0μg/mL cTnI) 
was also applied to ensure there was no non-specific interactions with the monoclonal antibodies. Captured 
cTnI was probed using an anti-eptiope-3 HRP-labelled secondary antibody which completed the sandwich 
format. A cTnI dependent profile for each antibody surface was obtained. 
 
 
Figure 4.2-14: Isotype determination of monoclonal antibody 20B3 
This rapid kit allowed isotype determination for both the heavy and light chains directly from crude 
supernatant. The supernatants were diluted in sample diluent and applied to the bottom of the lateral flow 
cassette. There were three cassettes (2 heavy and one light) which contain control lines and areas 
corresponding to a specific isotype. The presence of the control and test lines indicates a valid positive result. 
The mAb was determined to be an IgG1κ. 
 
  
4–24 
 
  
To ensure clonality, 20B3.5.E was cloned out by limiting dilution for a third and final time. 
The resulting hybridomas were considered to be truly monoclonal at this stage. To examine 
differences in expression levels all the output clones were diluted in a comprehensive 10-
fold dilution series (1 in 3  1 in 300,000) and assayed by direct binding ELISA against 
cTnI (section 2.3.3.4.1). Figure 4.2-15 illustrated relatively uniform expression levels for 
all twenty sub-clones of 20B3. 
 
 
Figure 4.2-15: Analysis of the expression levels of individual hybridomas by direct binding ELISA 
All the clones had comparable absorbance and were considered to be similar due to their common origin. 
cTnI was coated across an ELISA plate to which diluted supernatants were applied. Bound mAb was detected 
with anti-mouse-Fc-specific HRP-labelled secondary antibody. 
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As a final analysis six of the clones were evaluated in a competitive analysis format (as 
indicated in Figure 4.2-15). Competitive analysis was carried out during the initial scale-up 
and screening using free peptide and cTnI (cTnI data not shown). Six clones were selected 
from the expression analysis of the 20 clones above and were initially titred to obtain the 
optimal supernatant dilution to carry out the competitive analysis (Figure 4.2-16-A). Two 
of the clones were diluted accordingly and mixed 1:1 with a range of free peptide (Figure 
4.2-16-B) and free cTnI (Figure 4.2-16-C) concentrations. Figure 4.2-16-B shows the 
competition profile with free peptide-2 for the selected hybrids and the control antibody 
Hytest 228. The two clones perform well, but the relatively low AU for the Hytest 228mAb 
results in a poorer competitive profile potentially indicating its limited usefulness. Figure 
4.2-16-C shows the competition profile with free cTnI where there is no competition of the 
two selected clones or the 228 mAb. This mirrors the behaviour of all the clones and the 
control when tested early in the first scale-up and screening campaign.  
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Figure 4.2-16: Titre and competitive analysis of selected monoclonal antibody 20B3 
A) Titre of all six clones plus Hytest 228 mAb to assess optimal supernatant dilution to use in 
subsequent competitive assay. 
B) Competitive analysis of selected two clones in direct comparison to Hytest 228 mAb for free peptide. 
The mAbs demonstrate sensitivity for the peptide. 
C) Competitive analysis of the two selected clones in direct comparison to Hytest 228 mAb for cTnI 
protein. 
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The control mAb and the selected mAbs behave equally in this assay. As shown previously, 
the selected clones can recognise cTnI directly bound, in sandwich ELISA and in a capture 
format on Biacore™ 3000. This suggests that for binding either the antibody/antigen must 
be immobilised in some way and may involve charge-determined properties that have a 
significant effect on binding. Accordingly, clone #12 was carried forward for large-scale 
antibody production and purification. The route to selection of the various sub-clones of 
20B3 is outlined in Figure 4.2-17. 
 
 
Figure 4.2-17: Route to the selection of lead monoclonal antibodies from the analysis strategy employed 
From the initial master plate position (plate: 20 position: B3) three sequential limiting dilution steps through 
continuous culture resulted in the isolation of various daughter clones. 
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4.2.3 Purification of the monoclonal antibody 20B3 
 
Large-scale expression of mAb 20B3 was carried out over a number of weeks in T175 
flasks permitting the collection of approximately 30mL conditioned media per flask twice a 
week. This conditioned media was retained at 4
o
C until 500mL media was collected (with 
the addition of 0.02% (w/v) NaN3). The „antibody-rich‟ media was concentrated using an 
Amicon® stir cell system (GE Healthcare) with a molecular weight cut-off membrane 
(100kDa). This facilitated reduction of the supernatant volume to a manageable level for 
purification (10mL). Purification was carried out using protein G (reviewed by Darcy and 
co-workers [129]) (recombinant: sepharose™ fast flow – Sigma®) which was selected for 
its medium antibody-binding protein interaction for this isotype (see appendix, Figure 
8.1-8), as outlined in section 2.3.3.7.1. The entire concentrated supernatant was applied to 
the settled resin, followed by washing and elution by acidic pH. Post elution the protein-
containing fractions were collected (Figure 4.2-18), combined (~2.5mL) and desalted on a 
PD-10 (GE Healthcare) column. Significant protein-containing fractions (Figure 4.2-18) 
were pooled and concentrated using a Vivaspin™ column (30kDa MW cut-off).  
To assess the success of the purification, samples from the column „flow-through‟, washes 
and desalted protein were analysed by 12.5 % (w/v) SDS-PAGE and WB. Figure 4.2-19 
shows the success of the purification protocol and the purified sample was compared to 
goat IgG. Bands corresponding to intact IgG, the heavy and light chains were observed in 
the purified fraction. To examine the purity of the final preparation, samples of the purified 
mAb were analysed by size exclusion chromatography (SEC) (section 2.3.3.7.2). SEC 
allowed separation of molecules as consequence of their size not molecular weight and was 
carried out in aqueous buffers that allowed retention of biological activity. To establish the 
ideal concentrations for use, three different concentrations of mAb (high, low and medium) 
were applied to the column and compared to a set of protein standards. Figure 4.2-20 shows 
the elution profile of the purified mAb and was overlaid with a second chromatogram of 
protein standards. From the figure, the purified mAb overlaps well with the IgG protein 
standard and no other significant peaks were observed. This simple one step purification 
successfully yielded a very pure monoclonal antibody preparation. Typically, this type of 
purification from 500mL conditioned media gave 6-8mg of protein (12-16μg/mL of culture 
media). 
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Figure 4.2-18: Elution profiles for protein G and PD10 columns used in the purification of 20B3 
Absorbance (280nm) measurement of the eluted fractions collected from protein G and PD-10 desalt columns. 
Significant protein-containing fractions as visualised here were combined and carried forward to next stage of 
purification. 
 
Figure 4.2-19: SDS-PAGE and WB analysis of the purification steps for monoclonal antibody, 20B3 
The figure shows the SDS-PAGE (A) and WB (B) probed with anti-mouse-Fc-specific HRP-labelled 
antibody. The lanes were labelled as follows; PR
+
: Prestained protein ladder, lane 1: goat IgG control, lane 2: 
purified mAb 20B3, lane 3: column wash 2, lane 4: column wash 1, lane 5: flow-through 2 and lane 6: flow-
through 1. From the results 20B3 was demonstrated to have purified successfully using protein G. 
A 
 
 
 
B 
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Figure 4.2-20: SEC-HPLC analysis of the 20B3 monoclonal antibody following purification 
Protein standard peaks; 1: bovine thyroglobulin, 2: immunoglobulin, 3: myoglobin, 4: uridine. Analysis was 
carried out on SHIMADZU Prominance HPLC using a Phenomenex BioSep-SEC-S2000 column (dimensions 
300 x 7.8mm 5micron) at 20
o
C. The buffer was 1X PBS and the analysis was carried out at 0.5μL/minute. 
 
To ensure that the purification conditions did not compromise the activity of the purified 
mAb, a series of ELISAs were carried out. Initially, the mAb was titrated against cTnI in a 
direct binding ELISA (section 2.3.3.4.1) in parallel to the Hytest mAb228 (Figure 4.2-21). 
The mAb (8.76mg/mL) titred out at approximately 1 in 30,000 compared to the commercial 
mAb228 (9.3mg/mL) titring at approximately 1 in 70,000. Figure 4.2-22, a sandwich assay 
(section 2.3.3.4.5), illustrates mAb 20B3 and mAb 228 as capture reagents for various 
concentrations of cTnI. Bound cTnI was detected using an anti-epitope-3 HRP-labelled 
secondary antibody (16A11) and mAb20B3 again compares well with the equivalent 
commercial antibody. In this non-optimised assay format both antibodies can detect cTnI 
concentrations between 70-100ng/mL. 
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Figure 4.2-21: Titrations of purified the 20B3 and Hytest 228 antibodies 
Reciprocal antibody dilutions in 1 % (w/v) PBSTM titrated against cTnI-coated onto the surface of a 
microtitre plate. The purified mAb titred in a similar fashion to the commercial standard and indicated no 
adverse loss of activity due to the purification strategy. 
 
Figure 4.2-22: Sandwich ELISA using the 20B3 antibody and equivalent control antibody for cTnI 
MAb 20B3 and Hytest 228 were coated onto the surface of an ELISA plate capturing cTnI over a relatively 
wide concentration range (0.2 to 2000ng/mL). Captured cTnI was detected using the Hytest anti-epitope-3 
HRP-labelled mAb (Hytest 16A11). Both the Hytest and „in-house‟ monoclonal antibody (20B3) behave 
similarly. 
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4.2.4 Determination of antibody affinity on Biacore™ 3000 
 
The determination of affinity, by a capture approach, was hampered by non-specific 
interaction between the cTnI antigen and the antibody used to capture 20B3. This was a 
typical event when batches of cTnI (commercial) were changed and was a result of the 
inconsistencies between purification batches and highlights the significance of the antigen 
quality issues. This did not manifest as a problem in ranking experiments, but in true 1:1 
binding any additional interactions represent a significant barrier to efficient modelling of 
affinity. 
To overcome this, the 20B3 mAb was directly immobilised to a Biacore™ 3000 chip (see 
section 2.3.3.8). Due to the stabilisers and preservatives (e.g. BSA) present in the 
commercial antibody it could not be immobilised and compared in this format. However, 
determination of the kinetic constants for the mAb was of interest. Figure 4.2-23 is a 
sensorgram of the immobilisation of mAb 20B3 to the chip surface. The dextran was 
activated using EDC-NHS and the mAb (20μg/mL) injected across the flow cell linking the 
antibody to the surface. The surface was capped to block any un-reacted sites and 
regenerated twice. This resulted in a 20B3 mAb surface of approximately 5000RUs. In this 
fashion the kinetics were examined in the simplistic 1:1 Langmuir binding interaction 
(Figure 4.2-24).  
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Figure 4.2-23: Immobilisation of monoclonal antibody 20B3 onto the surface of a Biacore™ 3000 chip 
Flow cell (FC) 2 of a CM5 dextran (research grade) chip was activated by EDC-NHS for 10 minutes and the 
antibody linked via primary amine groups to the surface. Un-reacted sites were capped using ethanolamine-
HCl, pH 8.5 and regenerated with two 30 second pulses of 10mM NaOH. A total of 5027.1 RU of mAb was 
covalently linked to the surface, as indicated by the multi-directional arrow compared to the flow cell baseline 
(gold line). 
 
Kinetic constants were modelled on the curves with 1:1 Langmuir binding with drifting 
baseline model and local Rmax parameter. This was carried out using the dedicated 
BiaEvaluation software. The simplest model (and therefore the most reliable) did not fit the 
data well and the drifting baseline degree of freedom was required to accurately model the 
data (Figure 4.2-24). From the chi
2
 (χ2) value (0.137) the fits were found to be good and 
even residual distribution reinforces the „goodness‟ of the fit. From the kinetic evaluation 
the derived constants are outlined in Table 4.2-3. 
 
Table 4.2-3: Kinetic constants derived for monoclonal antibody 20B3  
 20B3 
ka (M
-1
s
-1
) 1.27 x 10
6
 
kd (s
-1
) 2.33 x 10
-4
 
KD (M) 1.84 x 10
-9
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Figure 4.2-24: Kinetic analysis of the 20B3 antibody-immobilised surface 
Kinetic analysis of interaction between cTnI and the mAb 20B3. Four cTnI concentrations were used in the 
analysis (12.5, 6.25, 3.125 and 0nM) to fit the kinetics using 1:1 Langmuir binding model with drifting 
baseline (black line). The residuals (below) show the „goodness‟ of the fits with even distribution of the data 
points. The following kinetic parameters were derived; ka: 1.266x10
6
Ms
-1
, kd: 2.325x10
-3
s
-1
 and KD: 1.836x10
-
9
M with χ2 value of 0.137. 
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4.3 Chapter conclusions 
 
The 20B3 antibody was developed by fusion of a SP2/0-Ag14 myeloma fusion partner with 
splenocytes from a mouse showing a significant titre to cTnI in a synthetic epitope-based 
immunisation regime. Screening the resultant progeny was undertaken combining direct, 
sandwich and competitive ELISA formats, HT-epitope mapping and „off-rate‟ ranking. The 
ability to acquire rapid information in a timely manner dramatically increased the chances 
of success, minimising sources of error not related to chromosome loss or competition by 
non-secreting cells. Adopting an „information-rich‟ approach allowed the successful 
isolation of a panel of antibodies specific for the N-terminal epitope-2 region of cTnI. From 
112 positive clones identified, a single progeny of 20B3 was isolated as the optimal anti-
cTnI mAb generated in this campaign. The antibody was successfully purified in large 
quantity, tested in direct binding and sandwich assay formats before evaluation of its 
affinity on Biacore™ 3000. The mAb20B3 was found to have an affinity of 1.84nM 
demonstrating the isolation of a high-affinity reagent ideal for use for cardiovascular risk 
assessment.  
The development of an antibody by the traditional hybridoma approach demonstrated was 
primarily dictated by the differential response of the host animal during the immunisation 
regime. Interestingly, but inexplicably the synthetic peptide-2 conjugate only raised cTnI-
specific responses in mouse. This was in direct contrast to the synthetic peptide-1 conjugate 
which raised a cTnI-specific response exclusively in chicken. Owing to the extremely high 
titre obtained the chances of developing a hybridoma were favourable and mitigated against 
the „sampling problem‟ encountered when amplifying variable domains from mouse 
repertoires. The sampling problem referred to is the use of complex, degenerate primer 
mixes to amplify variable domains which can introduce a sampling bias preferentially 
selecting dominant variable domains. This sampling issue is greatly reduced in avian hosts 
due to the simplistic nature of the genes encoding for avian antibodies. Also, the patent-free 
status of hybridoma technology surpasses patent issues that surround the use of 
recombinant antibodies in downstream POC-device development. However, by adopting 
the hybridoma approach to antibody generation a finite pool of candidate clones were 
developed which require continuous attention, analysis and culture without the ability to 
„shelve‟ the clones at any stage prior to achieving monoclonality.  
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The continuous nature of hybridoma generation requires significant support in terms of 
analysis and the utility of HT-screening tools for hybridoma characterisation is abundantly 
clear. The HT-SPR-based analysis took in the order of 6 hours to analyse hundreds of 
hybridoma supernatants with minimal manipulation and reagent consumption. However, 
the epitope-mapping strategy adopted was a relatively suboptimal approach to harness the 
parallel processing power of the instrument. The instrument and screening technology was 
recently acquired and exploiting its power was balanced with ensuring maximal value in 
terms of prepared surfaces and reagents. At the time of screening the hybridoma 
supernatants, the instrument was also in use mining a recombinant anti-cTnI protein library 
for epitope-specificity. The ease at which the instrument could be switched between 
bacterial lysate and crude supernatant analysis, using only one prepared surface, facilitated 
analysis of hundreds of individual monoclonal and recombinant antibodies. In fact, in many 
analyses the hybridomas and recombinant lysates were analysed in the same run. A more 
generic approach to hybridoma screening using a capture surface would have facilitated 
acquisition of a greater wealth of information. However, the transition to recombinant 
library screening with the same surface would not have been possible. In laboratories where 
many hybridoma screening campaigns are routinely undertaken, a single surface created on 
a multiplex instrument like the Biacore™ 4000 would aid selection by providing real-time 
interaction analysis in a time-scale to promote efficient scale-up, typically analysing 386 
clones in 12 hours [121].  
The 20B3 hybridoma also represents a potential source of genetic material for isolation and 
formation of a recombinant library. Using recombinant technologies it is possible to 
significantly modify the properties of the antibody in ways not possible with monoclonal 
antibodies. This would be advantageous as it would allow the evolution of affinity by in 
vitro mutagenesis, to drive down the possible assay limit of detection using ultra-sensitive 
antibodies. Additionally, the ability to tailor the biophysical properties of the antibody, in a 
retrospective fashion from the hybridoma, would greatly enhance the plasticity of the 
molecule for differing assay formats and applications [6]. 
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Chapter 5: Recombinant Antibodies 
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5.1 Introduction to recombinant antibodies for diagnostic-based 
applications 
5.1.1 Applications and potential 
 
Although numerous useful diagnostic kits exist for a multitude of disease states, such as 
cardiac disease [130] and biological threat detection [54, 131, 132], few biosensor devices 
employing recombinant antibody technology are commercially available. Biosensors have 
huge potential in the areas of clinical diagnosis/monitoring, environmental and food safety, 
biothreat analysis on the battlefield and counter-terrorism [133]. In addition, POC testing 
can obviate long delays by providing relatively short testing times. However, for POC and 
other biosensor-based detection devices to become mainstream, current biological formats 
require reductions in size, sample and reagent volume requirements coupled with 
significant advances in reliability, ease-of use for multi-analyte determinations and high-
throughput capabilities [134]. Table 5.1-1 outlines some examples of recombinant 
antibody-based biosensors incorporated on various transduction platforms.  
 
Table 5.1-1: Examples of recombinant antibody-based biosensors for important applications 
Analyte Antibody Format Transducer Ref. 
Disease 
 HIV-1 virion infectivity factor scFv Piezoelectric [135] 
 Listeria monocytogenes 
scFv 
scFv (phage bound) 
SPR 
Amperometric 
[136] 
[137] 
 Severe acute respiratory syndrome virus scFv Imaging Ellipsometry [138] 
Bio-warfare 
 Venezuelan equine encephalitis virus scFv Potentiometric [139] 
 Bacillus anthracis S-layer protein scFv Resonant Mirror [140] 
Haptens 
 Morphine-3-glucuronide scFv SPR [141] 
Contaminants 
 Aflatoxin B1 scFv SPR [142] 
 Parathion (insecticide) scFv Piezoelectric [143] 
 Atrazine scAb Amperometric [144] 
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5.1.2 Emergence of recombinant antibody technology 
 
In the late 1980s, the use of vectors in bacterial expression systems demonstrated that 
correctly folded antibody fragments could be produced [145, 146]. Since then, recombinant 
antibody fragments have been produced in mammalian [147, 148], insect [149, 150], yeast 
[151], plant [152] and „cell-free‟ systems [153]. A factor limiting several of these 
expression systems is the inability to express large amounts of active protein. The relative 
advantages and disadvantages of each expression system is reviewed by Verma and co-
workers [154]. There are two main sources of antibody genes; V-gene repertoires 
rearranged from animal or human donors and synthetic antibody V-gene repertoires 
constructed de novo, in vitro [58]. Cloning of antibody fragments into such systems begins 
with the isolation of mRNA coding for the V-genes from donor cells [155, 156]. Such 
sources of mRNA include hybridomas, peripheral blood lymphocytes, spleen and bone 
marrow cells [157]. The mRNA is in turn reverse transcribed into cDNA [156] and the 
subsequent amplification of the antibody genes is then carried out by PCR-based methods. 
This strategy for recombinant antibody generation clones all the mRNA molecules 
encoding for the antibody genes present in the mRNA pool. For the antibodies to be useful 
it is imperative that the antibody genes be cloned reliably [157]. Hoogenboom and co-
workers [58] and Azzazy and co-workers [156] have provided comprehensive reviews of 
recombinant antibody libraries and their screening. 
 
5.1.3 Antibody fragments and formats 
 
Prior to the development of recombinant antibody technologies, antibody fragments were 
generated by proteolytic cleavage yielding F(ab`)2 and Fab. The ability to generate 
fragments of antibodies that retain their stability and specificity is essential. Recombinant 
technologies have facilitated the generation of a number of distinct antibody fragments 
(Figure 5.1-1) with desirable attributes and specificities for use in diagnostic applications. 
The smallest fragment of the whole antibody practically used is the Fv which consists of 
the VH and VL domains associated via a disulphide bond. Stability problems at lower 
concentrations were overcome by incorporating a flexible peptide linker into the Fv 
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fragment generating the single chain Fv (scFv) [158, 159]. Typically, a flexible (Gly4Ser)3 
linker is used due to its tendency not to form secondary structures and the fact that it is 
found naturally in the M13 pIII protein and, is well tolerated in phage display. However, it 
was demonstrated that selection based on linker mutations can influence production, 
stability and recognition properties of the scFv [160]. Diabody production by incorporating 
a shorter polypeptide linker (5–12 amino acids) forces the association of two scFv 
molecules [161]. Genetically encoding alkaline phosphatase (AP) as a fusion to the scFv 
facilitates direct detection of bound antibody fragments [162, 163]. Dimeric scFv consists 
of two scFv fragments brought together via a naturally dimeric protein [157, 164]. An 
interesting variation on the dimeric scFv is a bifunctional scFv comprised of AP-labelled 
scFv [156, 157, 165]. Once these antibody fragments are generated, an appropriate or 
tailored selection method is used to isolate high-affinity antibodies from a vast library. 
 
 
Figure 5.1-1: Recombinant antibody formats 
The Fv consists of the VH (red) and VL (green) chains. The scFv consists of the Fv with a flexible linker 
joining the terminal ends of the VH to VL (or VL to VH). A scAb incorporates a human constant κ light chain or 
similar species-specific constant domain to the terminal of the VL or VH chains. The Fab consists of the Fv 
with both constant heavy and light chains. F(ab`)2 involves linking two Fab fragments by disulphide bonds (it 
can also be achieved by proteolytic cleavage of an IgG molecule). A dimeric scFv is generated by fusion of 
two scFv molecules via a naturally dimeric protein. A dimeric bifunctional scFv incorporates an alkaline 
phosphatase (AP) label to facilitate direct detection. The locations of the antigen binding sites are indicated by 
the yellow triangles. 
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5.1.4 Antibody libraries 
 
Antibody libraries mirror what would naturally be present in individuals allowing them to 
generate antibodies against antigens that might be encountered during normal everyday life. 
This is the basis of our immune response and permits our survival despite the prevalence of 
many pathogens, toxins and life-threatening infections. The availability of combinatorial 
libraries is of major importance in antibody engineering. These libraries may be generated 
from immunised hosts (animal or human) or are available from academic or industrial 
sources (naïve or non-immunised libraries). The isolation of antibodies from such libraries 
is achieved by non-covalent interaction between the library member and its cognate 
antigen. Efficient high-throughput screening has enabled scientists to screen large libraries 
thus enhancing the probability of enriching for highly-specific antibodies [166, 167]. This 
capability has also allowed engineering of antibodies with improved affinity, stability and 
facilitated the possibility of „tailor-made‟ antibodies for a wide range of applications. 
 
5.1.5 Advantages of display technology 
 
The advent of display techniques has enabled the generation of very large antibody 
libraries, thus increasing the probability of selecting antibodies with high-affinity and 
specificity [168]. In phage display, the antibody fragment is fused to a phage coat protein 
which provides a link to the encapsulated genetic information [169]. This physical link 
between the phenotype and genotype simplifies the selection of binders in the antibody 
library [12]. In contrast, in ribosome display the mRNA, ribosome and nascent antibody 
form a stable, stalled antibody–ribosome–mRNA (ARM) complex allowing for RT-PCR-
mediated recovery of specific fragments [153, 170]. Table 5.1-2 outlines the attributes of 
phage (plasmid library) and ribosome display (mRNA/PCR fragment) [171]. 
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Table 5.1-2: Phage and ribosome display compared 
 Phage Display Ribosome Display 
Largest Library Size 10
10 
[172] 10
13 
[58]
 
potentially 10
14 
[173] 
Recovery of selected binders Various (Figure 5.1-3) RT-PCR  (Figure 5.1-4) 
Diversification Mutagenesis Mutagenesis (in situ) 
Transformation and cloning Required Not required 
Highest affinity mAb reported Picomolar [174] Picomolar [175] 
Table adapted from [171]. 
 
Other display technologies include yeast [176, 177], bacterial [178] and mRNA display 
[179, 180]. A major advantage of the use of combinatorial display libraries is the generation 
of an immunised repertoire of antibodies from practically any species [181]. However, 
hybridoma technology applied to rabbit [182], cow [183], chicken [184] and human [185] 
lymphocytes has shown some success. The ability to generate antibodies recognising 
human epitopes, e.g. in biomarkers of diseases, is essential for many diagnostic tests and 
for therapy. Generally this can be achieved in a range of species, but the antigenicity is 
often dependent on how phylogenetically distant the species are from humans [88]. To date 
antibody libraries have been generated from a number of species including human [186], 
mouse [187], chicken [88, 188], rabbit [189, 190], camelids [191], shark [192], cattle [193] 
and sheep [194]. The availability of naïve and synthetic repertoires facilitates the 
generation of antibodies without the need for immunisation of animals, since such libraries 
can recognise a wide range of antigens [195]. The ability to generate recombinant 
antibodies to target-specific antigens, for example those demonstrated in Table 5.1-3, is 
crucial for the efficient development of the biorecognition elements for biosensor- and 
POC-based devices. 
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Table 5.1-3: Examples of recombinant antibodies generated to specific targets 
Target Analyte Ref. 
Human Disease 
 Cardiac disease Cardiac troponin (cTn) [196] 
  C-reactive protein (CRP) [167] 
  Heart-type fatty acid binding protein (h-FABP) [90] 
  Myeloperoxidase [197] 
 Hormones Thyroid stimulating hormone (TSH) [198] 
Haptens 
 Environmental Atrazine [199] 
 Illicit drugs Morphine-3-glucuronide [200, 201] 
Animal Disease 
 Foot and mouth Non-structural protein 3ABC [202, 203] 
 Mastitis  N-acetyl-beta-D-glucosaminidase [204] 
 Bovine immunodeficiency virus Capsid protein [205] 
Security 
 Biological warfare pathogen Brucella melitensis [206] 
Contaminants 
 Food stuffs Aflatoxin B1 [59, 207] 
  Halofuginone [208] 
  Salmonella Typhimurium (OmpD) [209] 
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5.1.6 Phage display 
5.1.6.1 Introduction 
 
Phage display has become a widely exploited selection platform for antibodies since it was 
first described in 1985 by Smith and co-workers [210]. Use of the novel bacteriophage 
lambda expression system facilitated rapid identification of antibodies, and was suggested 
as a method to supersede hybridoma technology [211]. McCafferty and co-workers initially 
isolated an antibody from a large combinatorial library [212], and due to its robust nature 
phage display has become the „work-horse‟ of antibody isolation [213]. Library diversities 
of up to 10
10 
have since been achieved [58]. Antibody selections performed on immobilised 
antigen [214, 215], antigen-coated magnetic beads in-solution [216-218], Biacore™ [219, 
220], surface-displayed targets [221, 222], mammalian tissue culture [223] and in vivo 
approaches [223, 224] have all been successfully used in phage display. 
 
5.1.6.2 The principle of phage display 
 
Filamentous phage particles encapsulate single stranded DNA (ssDNA) and are capable of 
infecting Escherichia coli cells. Filamentous phage (Figure 5.1-2) infect and replicate 
without killing the host cell, unlike lytic phage (e.g. T4) [225]. The phage coat is composed 
of 5 different proteins (pIII, pVI, pVII, pVIII and pIX) [89, 213].  The pVIII (~50 amino 
acids) is the major coat protein and covers the surface of the phage cylinder. The 
hydrophobic 33 amino acid pVII (5 particles) and the 32 amino acid pIX proteins are 
located at one proximal end of the phage particle. The other end contains the pVI (112 
amino acids) and pIII (406 amino acids) [89]. The pIII consists of the N1, N2 and CT 
domains. The interaction of the phage with the cell is mediated by the pIII protein 
(specifically N1 and N2 domains) and phage biology is well understood and documented 
[213, 226, 227]. The N1 domain is required during infection of the cell facilitating 
translocation of DNA into the cytoplasm and the N2 region is responsible for binding to F 
pilus, while the CT domain is essential for the formation of a stable phage particle [89, 
213]. Antibodies consist of heterodimeric heavy and light chain variable domains that 
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combine to form the antigen-binding site and phage display of such a scFv is depicted in 
Figure 5.1-2. The two variable domains are linked by a polypeptide linker and integrated 
into the phage genome as a fusion to the gene of the pIII protein. 
 
 
Figure 5.1-2: Phage display of a single chain fragment variable antibody 
ScFv is displayed as a fusion to the pIII phage coat protein retaining a link between the antibody phenotype 
and the encapsulated genetic information. The phage remains infective to E. coli via pIII-mediated 
attachment to F pili. pIII proteins consist of N1 and N2 domains responsible for interaction with the F pilus 
of the cell and insertion of the phagemid DNA into the cytoplasm. 
 
The development of phagemid vectors [214] has taken over from the initial use of phage 
vectors [211] due in part to the simplified transition to soluble expression of the antibody 
fragment, using an amber stop codon mutation between the geneIII (or pIII) and the 
antibody chain [156, 228]. This facilitates antibody fragment expression without continued 
fusion to the phage pIII by use of non-suppressor strains of E. coli [156, 228, 229]. Phage 
systems are also limited as fusions of large polypeptides to the amino acid terminus of the 
coat protein, lead to compromised protein function [230]. Phagemid systems permit the 
display of polypeptides that could not be displayed in simple phage systems by fusion to 
alternative coat protein genes encoded on the phagemid vector. This attenuates the effects 
of the fusion protein as the wild-type coat proteins are available from the helper-phage 
[230]. Table 5.1-4 outlines considerations to be taken into account when choosing phage or 
phagemid methods of recombinant antibody production.  
Phagemid vectors contain E. coli and phage origins of replication. The phagemid DNA is 
packaged in the phage coat and propagated by super-infection with helper-phage [213]. 
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This infection step allows the phagemid vector in the cell to be packaged into the phage 
particle in an identical way to phage DNA. The helper-phage serves to provide the proteins 
and enzymes necessary for phage replication and also the structural proteins required for 
encapsulation. To prevent over expression of the helper-phage genome, commercially 
available helper-phage contain a defective origin of replication (M13KO7 or VCSM13) 
and/or packaging signal [89, 213, 225].  
Selection of such displayed antibodies is achieved by multiple rounds of binding to a target 
which selectively enriches phage with the relevant cognate antibody fragment expressed on 
their surface (Figure 5.1-3) [229]. Specific phage are eluted and re-infected into E. coli for 
sequential rounds of bio-panning [213] or soluble expression of antibody in non-suppressor 
strains which facilitates downstream purification and characterisation of the selected 
antibody fragments [156, 227]. 
 
Table 5.1-4: Phage and phagemid systems compared for antibody production 
Phage Phagemid 
Better suited to peptide display Suited to antibody display 
Large proteins effect pIII production and 
assembly 
Carries the fusion-coat protein to be displayed 
(e.g. pIII) 
Large proteins present on pIII can affect 
infectivity  
Large inserts are better maintained 
Lower transformation efficiency Higher transformation efficiency 
Misfolding of large proteins more likely 
Multiple copies of gene inserts per phage 
particle (valency) 
No requirement for helper phage Requires helper-phage to select 
Avidity effects – lower affinity antibodies Monovalent display – higher affinity antibodies 
Sub-cloning required for soluble expression Direct expression of soluble antibody 
Not suited for affinity maturation Suited for affinity maturation 
This table was adapted from [89, 227, 231]. 
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5.1.6.3 Selection considerations for successful phage display 
 
Despite phage display of antibodies being widely practiced and mainstream in many 
molecular laboratories [58], the successful selection of specific antibodies remains a 
challenge [176]. The selection conditions exploited (Figure 5.1-3) can dramatically 
influence the quality of the selected antibody fragment and not all standard conditions lead 
to the selection of phage-displaying antibodies-specific to the target antigen. Selection aims 
to isolate high-affinity antibodies. However, the level of display may preferentially recover 
the antibody with the highest display level (avidity) on an individual phage particle. 
Monovalent display has been utilised to combat this phenomenon [58, 225, 231].  
After transformation, the phage selection cycle illustrated in Figure 5.1-3 (steps 2–6) is 
sequentially repeated in order to isolate specific phage-displayed antibodies. In theory, only 
one round of selection from a phage library should be necessary. However, in practice non-
specific binding of „sticky‟ phage limits the enrichment that can be achieved. Typically 
between two and five rounds of bio-panning are required to isolate specific antibody-
displaying phage as the ratio of binders to non-binders before and after each round of 
selection varies from 5- to 1000-fold [231]. Selection conditions such as elution strategy, 
stringency of washing, use of solid- or solution-phase methodologies, antigen form and the 
number of cycles (increasing cycles leading to decreased diversity) impact on the quality of 
the isolated antibody and require significant consideration [232, 233]. 
Antigen presentation is of particular importance and several presentation strategies are 
outlined in Figure 5.1-3. Conformational changes as a consequence of direct 
immobilisation on solid supports [156] or the use of peptide antigens, may result in the 
selection of antibodies that fail to recognise native epitopes in the context of the whole 
target molecule. Schier and co-workers have shown that affinity-driven selections of 
mutated scFv on immobilised antigen preferentially selected spontaneously dimerising 
scFv, with higher apparent KD values, due to avidity effects compared to selection on 
biotinylated antigen with streptavidin-coated magnetic beads [215]. This demonstrated the 
dramatic influence of solid and solution-phase modes of selection, impacting upon the type 
and binding characteristics of the isolated antibodies. Lowering the antigen concentration in 
successive rounds of selection enriches for higher-affinity antibodies in a similar fashion to 
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B-cell selection in vivo [58, 231]. Low-concentration selections are employed to select 
antibodies with the highest affinity avoiding multimer formation [231]. Selection can also 
be tailored to favour affinity or „off-rate‟ kinetics by gradual limitation of available antigen 
[229], limiting interaction time of the phage with the antigen, performing solution phase 
selection or competitive interaction with free antigen. To isolate specific, high-affinity 
antibodies the first round of selection should be regarded as an enrichment step, as 
excessive stringency leads to a decrease in the library diversity [227]. The multiplicity of 
infection of the helper-phage is also of considerable importance ensuring that each antibody 
is represented within the library. It is imperative to add sufficient phage (10–20:1) to infect 
the whole library and failure to do so in the initial amplification of the library leads to a 
reduction in diversity [234]. 
Suitable blocking agents to reduce non-specific binding are required and typical agents are 
semi-skimmed milk powder, bovine serum albumin (BSA) and keyhole limpet 
haemocyanin (KLH). Inclusion of detergents such as Tween™-20 in washing steps and in 
the phage preparation contributes to reducing non-specific interactions [231]. Initially, each 
phage is represented in low numbers and washing should be less stringent to allow recovery 
of all antigen-bound phage. After the initial cycle, the stringency can be increased as the 
phage particles populate the library in higher numbers and it is necessary to exert selective 
pressure to isolate strong binders [231]. When bio-panning with immobilised antigen 
washing is  performed by rinsing the wells or the immunotube with an increasing number 
of washes per round with a wash solution, e.g. PBS containing 0.05-0.1% (v/v) Tween®-20 
[233]. Bio-panning in-solution typically involves using magnetic beads coated with the 
biotinylated antigen to capture phage-displaying antibodies [231]. Subsequently, the beads 
are washed and then recovered using a magnet. Bio-panning by cell surface display (e.g. 
surface/membrane proteins) requires centrifugation and re-suspension in wash solution 
[231]. 
Elution of specific-phage can be achieved in a number of ways (Figure 5.1-3). Elution by 
altering pH uses acidic (e.g. glycine-HCl, pH 2.2 [235, 236]) or basic (e.g triethylamine 
[232, 237]) solutions followed by immediate neutralisation with a suitable reagent. 
Neutralisation is critical to prevent protein denaturation. It is also necessary to optimise 
elution as increasingly stringent elution may be required as antibody affinity increases 
[220]. Elution, without breaking the antigen-antibody interaction, can be facilitated by 
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trypsin [238], cleavage of a protease-sensitive site [239], NHS-SS-biotin cleavage by DTT 
[240] or use of commercially available paramagnetic beads containing a nuclease-cleavable 
DNA linker between the bead and streptavidin [241]. These methods for site-specific 
cleavage provide a means of decreasing background phage elution. Interaction between the 
phage and the E. coli cell can also be evoked to elute phage through the natural affinity for 
F pili [237]. 
 
 
Figure 5.1-3: Overview of phage selection strategies 
The iterative selection strategy shown is a multistep process. V-gene assembly by PCR allows cloning of 
the recombinant antibody library into E. coli. Subsequent rescue by helper-phage permits the propagation 
of the phage antibody library (scFv is shown). Antigen presentation is a key consideration and there are 
many modes of antigen-phage-antibody interaction. Serially increasing the stringency of washing after 
antigen presentation selects those phage displaying antibodies with highly-specific binding properties. 
Elution strategies are also illustrated. This figure was adapted from [176]. 
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5.1.7 Ribosome display 
5.1.7.1 Introduction 
 
Ribosome display is a totally „cell-free‟ method of selection and evolution of proteins that 
is not limited by any cell-based transformation steps [242-245]. It is an in vitro selection 
method for the isolation of proteins and peptides from large libraries  that was successfully 
applied to the affinity maturation of antibodies using eukaryotic and prokaryotic systems 
[246]. The use of ribosome display overcomes current limitations for protein selection 
technologies as diversity is not limited by transformation efficiency, but by the physical 
number of ribosome molecules present and differing mRNA molecules available in vitro. 
Ribosome display couples the individual emerging protein (phenotype) with its 
corresponding mRNA (genotype) by the formation of stable protein–ribosome–mRNA 
(PRM) complexes, and after selection, PCR amplification of corresponding DNA for 
concurrent selection or diversification [247]. 
 
5.1.7.2 The principle of ribosome display 
 
The generation of antibody–ribosome–mRNA (ARM) complexes [170] was developed 
from two experimental achievements: i) the production of single chain antibodies in vitro 
using rabbit reticulocyte lysate [248] and ii) the experimental demonstration that nascent 
proteins can remain stably associated with their mRNA as a polypeptide–ribosome–mRNA 
(PRM) complex in the absence of a stop codon or with the inclusion of antibiotics [249, 
250]. The generation of the ARM complex, illustrated in Figure 5.1-4, allows the stalled 
complex to be selected for by interaction of the nascent protein with its cognate antigen. 
This captured complex permits the recovery of the genetic information directly from the 
ribosome-bound mRNA [170]. Ribosome display has two important functions: i) it allows 
selection, using proofreading polymerases and antigen-coated beads or plates [251] and ii) 
evolution of antibody affinity. The combination of both of these functions facilitates the 
selection of specific antibodies from a combinatorial library with simultaneous evolution of 
the protein by successive diversification of the pool with each round [153, 179, 252, 253]. 
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The ribosome display construct is generally composed of the T7 promoter, a ribosome-
binding site, a translational enhancer (such as the β-globin gene of Xenopus laevis), a 
translational initiation signal (such as Shine-Dalgarno for prokaryotic systems or Kozak 
sequence  for eukaryotic systems) and an open reading frame (ORF) in which the library is 
fused to a C-terminal polypeptide spacer without a stop codon [244, 250, 253, 254]. The 
absence of a stop codon is crucial as it facilitates recovery of the intact, stalled ARM 
complex. Spacer length is of importance as it facilitates folding of the nascent protein by 
ensuring exit from the ribosomal tunnel. Typically, at least 20–30 amino acids are required 
and a spacer of 116 amino acids was shown to be more efficient in displaying proteins 
[255]. The spacer also provides a known sequence for designing primers for the RT-PCR 
recovery of the selected library [247]. Commonly used spacer sequences include human 
antibody light chain (Cκ) and filamentous phage geneIII [244, 255]. The inclusion of 5' and 
3' stem loop structures serve to improve mRNA stability by protecting it against 
degradation by RNases [253, 256]. 
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Figure 5.1-4: Overview of the principle of ribosome display 
Overview of eukaryotic ribosome display, selection and evolution of antibody affinity. Selection is based 
on the formation of the antibody-ribosome-mRNA (ARM) complex by stalling the ribosome. The complex 
can then be isolated by affinity interaction with biotinylated antigen. RT-PCR then allows for the in situ 
recovery of the mRNA encoding for specific ARM complexes. Affinity evolution can be facilitated by the 
use of error prone PCR (random), chain shuffling (random) or site directed mutagenesis. This figure was 
adapted from [170, 247, 256]. 
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5.1.7.3 Considerations for successful ribosome display 
 
For antibody generation using ribosome display the folding efficiency is affected by 
inclusion of transcription stabilisers, as transcription requires reducing conditions whereas 
translation requires oxidising conditions. Hence, the enzymatic activity of transcription (T7 
RNA polymerase) requires monitoring in the absence of reducing reagents and, where 
reducing agents are used for transcription, oxidising conditions are required for the 
subsequent translational step [256, 257]. Time, temperature and the inclusion of various 
additives for in vitro translation impact upon the yield and efficiency of ribosomal display. 
These effects are summarised briefly in Table 5.1-5. 
 
Table 5.1-5: Factors affecting translational efficiency in ribosome display 
Translational  
Factor 
Effect 
Temperature 
Enzymatic activity of polymerase. 
Degradation of mRNA by RNases. 
Folding efficiency of synthesised protein. 
Time 
Longer translational times required in eukaryotic versus prokaryotic systems. 
Critical in uncoupled systems as mRNA is continually produced. 
Accumulation of small MW molecules from hydrolysis of triphosphates with 
longer translation times. 
Time-dependent inactivation of α-subunit of initiation factor 2 (eIF-2) by Ca2+. 
Additives  
Protein disulphide isomerise (PDI) catalysing the formation of disulphide bonds. 
10sRNA inhibition by anti-sense DNA-oligonucleotides. 
Adapted from [153, 242, 253, 256, 257]. 
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5.1.8 Mutagenesis strategies for evolution of antibody affinity 
 
Mutagenesis introduces errors or changes in the genetic blueprint which gives rise to 
modified proteins, products or functions. Mutagenesis is an efficient method applied to 
directed molecular evolution. Evolution in vitro is a powerful tool for protein generation 
and refinement with improvements in binding affinity, folding efficiency and enhanced 
thermodynamic stability demonstrated [258]. Mutagenesis of genes is generally carried out 
using two broad strategies. Site-directed mutagenesis introduces errors focused in a 
particular region (e.g. CDR or antibody conserved regions). Alternatively, random 
mutagenesis causes mutations scattered across the gene in a stochastic manner by use of 
error prone PCR and/or DNA shuffling. Figure 5.1-5 outlines mutagenesis strategies for 
affinity improvement of selected antibodies by manipulation of the V-genes [6, 242]. 
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Figure 5.1-5: Overview of mutagenesis strategies for the evolution of antibody affinity 
Strategies for the introduction of mutations for altering/improving the affinity of recombinant antibodies. 
Advantageous (red) and deleterious (green) mutations are shown. Error prone strategies introduce 
mutations randomly across the gene. With increasing number of PCR cycles more mutations are 
introduced. The useful mutations can be masked by deleterious ones and DNA shuffling of the light (and/or 
heavy) chains offers a solution by cleaving the gene with DNaseI and allowing the gene to randomly 
reassemble (shotgun approach). Site directed mutagenesis of the CDR incorporates degenerate primers to 
introduce mutations in the antigen recognition sites. This figure was adapted from [258]. 
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5.1.9 Genetically coded-tags for biosensor development 
 
The inclusion of certain known peptide tags in recombinant antibody expression vectors 
offers a rapid and reliable method of purification and characterisation [259]. These tags 
may also prove useful as capture sites in biosensor development.  
Oligohistidine tagging of antibody fragments has long been hugely beneficial for enhancing 
the purification process [260], but may also be useful in non-covalent coupling of the 
antibody to sensor surfaces using anti-histidine monoclonal antibodies [261], or potentially 
direct coupling to sensor surfaces, as demonstrated by Lori and co-workers [262]. The anti-
HA (YPYDVPDYA) tag derived from influenza virus is extensively used in recombinant 
protein technology as a useful tag for capture methodologies [167]. FLAG (DYKDDDDK) 
residues incorporated into antibody fragments have utility as a useful „capture‟ methods for 
recombinant protein characterisation. Mersich and co-workers demonstrated the detection 
of FLAG-tag fusion proteins facilitated by the use of anti-FLAG monoclonal antibodies in 
a SPR-based system [263]. The AviD tag is a neutrAvidin- (or avidin)-specific moiety that 
has useful applications in the immobilisation and purification of recombinant proteins 
[264]. Despite the absence of examples of biosensors utilising this specific AviD tag, there 
are many reports of the use of avidin, streptavidin and neutrAvidin surfaces or beads 
immobilising biotinylated antibodies for use in biosensors [265-267]. Purification using 
streptavidin-binding peptide (SBP tag) has also been demonstrated as a useful approach 
[268]. The SBP tag interacts specifically with streptavidin, but is a weaker interaction than 
between biotin and avidin. Hence, dissociation can be controlled and this SBP tag was 
utilised in surface preparation as demonstrated in both SPR- [269] and TIRF-based [270] 
systems. 
Additionally, site-specific modification made possible by recombinant antibody techniques 
permits the incorporation of unnatural amino acids (e.g. selenocysteine [271]) or reactive 
amino acids (e.g. cysteine) into the antibody construct. This is of considerable value for 
specific ordered immobilisation or labelling of diagnostically-relevant antibodies for 
efficient incorporation into POC or biosensor devices. 
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5.1.10 High-throughput screening of antibody libraries 
 
The real value of large and highly diverse recombinant libraries can only be efficiently 
exploited if the most judicious and discriminatory selection and enrichment regimes are 
employed [272]. This is particularly true in the case of extremely large ribosome displayed 
libraries and especially following focused in vitro directed evolution campaigns that can 
generate large pools of closely related yet heterogeneous clones. In order to exhaustively 
„mine‟ such libraries it is important to ensure that a suitably comprehensive number of 
individual clones, rather than a small representative subset, are analysed. Interestingly, 
some of the most useful means of accomplishing such high-throughput data-rich ranking of 
binding interactions is provided by the newest generation of multiplexed SPR-based 
biosensors. Currently, the GE Healthcare Biacore™ 4000 instrument offers extremely high-
sensitivity kinetic ranking of ligand interactions [121, 167]. It can accommodate multiple 
96- or 384-well plates in temperature-controlled integrated rack housing. Four flow cells, 
each containing five interaction spots, employ hydrodynamic addressing to control 
interaction flow paths. Dedicated LIMS integration software facilitates compatibility with 
existing LIMS systems that are now increasingly established in high-throughput screening 
labs. The ProteOn XPR36 system from Bio-Rad is a unique 6×6 multichannel SPR 
platform that enables automated multiplex analysis of up to 36 biomolecular interactions in 
one experiment [273-275]. The powerful parallel processing abilities of the ProteOn 
XPR36 and 4000 are apparent, but the cost associated with running and the acquisition of 
such instruments is substantial [127]. An alternative system from ICx Nomadics 
(www.discoversensiq.com), the SensiQ Pioneer, is an SPR-based three flow cell and fully 
automated system that maintains affordability [276]. Interestingly, the system removes the 
need for manual preparation of individual concentrations in an experiment, but rather 
employs a continuous concentration gradient allowing the kinetic evaluation of 192 clones 
over a concentration range of 2-3 orders of magnitude [277]. The availability of such truly 
high-throughput instruments represents a powerful capacity for candidate screening. In 
addition, the capability to assess key binding events with many interaction partners in real-
time and in parallel is of considerable value.  
It is worth also mentioning that numerous emerging parallel instruments/technologies 
which are versatile alternatives to more refined HT-SPR systems are available [127]. Planar 
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protein arrays bring existing methods, for example ELISA, into the forum of HT and 
parallel. Several commercial systems exist and the development of SPR imaging brings 
together the advantages of traditional SPR with HT capabilities [278]. The Octet from 
ForteBio is another such system in which biolayer interferometry monitors biomolecular 
interactions. The system does not have the same sensitivity as the Biacore or ProteOn 
XPR36 instruments, however, its disposable tips obviate the requirement to regenerate and 
additionally the system operates without micro-fluidics making it an interesting 
complementary technology [274].  
Several experiments carried out by Abdiche and co-workers compare a number of SPR 
platforms, namely Biacore™ 3000 (GE healthcare), Octet (ForteBio) and ProteOn XPR36 
(Bio-Rad) in several blocking assay configurations [279]. Such epitope-based analysis 
allows binning of antibodies with similar epitopes. These assays are amenable to high-
throughput analysis where often the affinity of the interaction is not the primary concern, as 
affinity can be engineered, but rather antibodies targeting specific-epitopes are of 
paramount interest. Blocking assays can also answer the question “does the binding of one 
molecule to a second prevent a third binding event?” The study demonstrates three 
interaction configurations (tandem, premix and classical sandwich) and the epitope bins 
correlated well when tested in each interaction configuration and on each analytical system 
[279]. Finally, the 20 country-wide benchmark study of affinity-based biosensors 
conducted to determine the variability in biosensor studies, by Rich and 150-colleagues, 
demonstrates the worldwide usage of SPR [280]. This publication employed a wide-breath 
of instruments from the Biacore™ range (A100, T100, S51, 3000, 2000, 1000, X100, 
flexichip and X), ProteOn XPR36, Octet and SensiQ to name a few. The data presented 
highlights the reliability of the systems in kinetic determination with individual user-
designed experiments using a common interaction partner set (Fab fragment and GST-
tagged antigen) on a range of surfaces [280].  
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5.1.11 Avian and mammalian repertories as sources of antibody libraries 
 
IgY is the typical low molecular weight antibody of several species (Table 5.1-6) and an 
evolutionary ancestor of IgG and IgE which are found only in mammals [281-283]. The 
chicken IgY, like IgG, consists of four polypeptide chains, but it differs by the presence of 
an additional constant heavy domain (Cν1 – Cν4) with an additional carbohydrate moiety, as 
illustrated in Figure 5.1-6. IgY by virtue of its lack of a hinge region, has significantly 
reduced flexibility in comparison to IgG. Its limited flexibility is derived from proline-
glycine rich regions around the Cν1-Cν2 and Cν2-Cν3 domains [281]. 
 
Table 5.1-6: Properties of IgG and IgY 
 IgG IgY 
Species Mammals Birds, reptiles, amphibians and lungfish 
Molecular weight (kDa) 150 180 
Isoelectric point (pI) 6.4-9.0 5.7-7.6 
Concentration (mg/mL) 10-12 (serum) 15-25 (Egg Yolk) 
Number of constant domains 4 (3 H and 1 L) 5 (4 H and 1 L) 
Hinge  Yes No 
Complement binding Yes No 
Rheumatoid factor binding Yes No 
Fc receptor binding Yes No 
Mediates anaphylaxis No Yes 
Binding to protein A Yes No 
Binding to protein G Yes No 
This table was adapted from [283, 284]. 
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Figure 5.1-6: Illustration of the structural differences between IgG and IgY 
IgG (left) is composed of four constant heavy domains with a single carbohydrate site (red dot) on each heavy 
chain. In contrast, the additional constant domain introduces a second carbohydrate site (yellow and purple 
dots). The flexible hinge region in the evolutionary ancestor (IgY) is absent and thus restricts flexibility in 
comparison to IgG. 
 
Of considerable advantage is the simplicity of the germline genes in the avian immune 
system (single VH and VL germlines) in comparison to the primary antibody repertoire 
diversity mechanism in most vertebrates. In the chicken system, diversity is not achieved 
by a diverse set of Ig variable (V), diversity (D) and joining (J) gene segments as is the case 
in the mammalian system. Diversity is achieved rather by gene conversion (7-10 random 
conversions or transplantation of upstream pseudogene blocks) of single functional Ig V 
and J segments of both the heavy and light chains causing rearrangement of genes during 
the developmental stage of B-cells in the Bursa of Fabricius (Figure 5.1-7) [281, 283, 285]. 
In the IgH loci, 80-100 pseudo-VH genes and in the IgL loci, 26 pseudo-VL genes exist 
upstream of the functional V gene segment which are unable to undergo recombination 
with the (D)J gene segment due to lack of a 5' promoter and a functional recombination 
signal sequence (RSS) [282]. Although a limited number of genes are involved, gene 
rearrangement of heavy VH-DH-JH and light VL-JL followed by subsequent gene conversion 
results in a large combinatorial diversity (~3 x 10
9
) for chicken [282]. This limited Ig V 
functional gene pool is advantageous for recombinant antibody generation as it affords 
ready sampling of the entire antibody repertoire with a small primer set. This saves on time 
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and resources, in addition to ensuring that rare transcripts are not lost due to primer 
inefficiencies that are associated with complex primer mixes used to clone the mammalian 
antibody repertoire [286]. Many targets, especially those with therapeutic potential, are 
highly conserved in the evolution of mammals. This renders the immune response limited 
at best in both mice and rabbits as a result of immunological tolerance conferred during 
foetal development [88]. The use of chickens is advantageous in this respect as human 
proteins may be significantly different from those in the avian system giving rise to greater 
immunogenicity. Furthermore, several other advantages exist in terms of diagnostic 
applications and those are summarised in Table 5.1-7.  
 
 
Figure 5.1-7: Overview of the process of gene conversion in chicken Ig genes 
Both the VH and VL germline sequences undergo a process known as gene rearrangement as an initial stage of 
antibody generation. In the H germline, a functional VH domain is comprised of unique VH and Jμ gene 
segments with one of a family of Dμ elements (~15). In the L germline, only one light chain exists (λ) and 
every light chain is composed of the same Vλ-Jλ arrangement which in itself generates minimal diversity. 
Inter-chromosomal gene conversion in immature B-cells gives rise to massive diversity by translocation of 
pseudogene sequences into the V-genes. Typically the closest pseudogene is used more frequently in gene 
conversion, but in the light chain the pseudogenes are distributed across a 20kb region preceding the VL gene 
[282]. 
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Table 5.1-7: Advantages of exploiting the avian immune system for diagnostic antibody generation 
Avian Antibodies Benefit Reference 
Simplistic genes 
Single primer sets. 
Efficient sampling of immune repertoire. 
[88, 282, 285-288] 
Phylogenetically distant 
Respond strongly to mammalian protein 
antigens. 
[285, 286, 289] 
Stable at higher core 
temperature (41
o
C) 
Stable antibodies (half-life in order of 
months). 
[281] 
Increased CDRH3 Length Potential for greater diversity. 
Personal 
observations, [290] 
Lacking Fc effector 
function 
Advantageous in diagnostic tests – reducing 
interference and false positives. 
[281, 291, 292] 
Multiple antigen 
immunisations tolerated 
Multiple V-gene specificities available from a 
single animal and reducing costs. 
[289] 
High antibody yield in egg 
Non-invasive, plentiful source of polyclonal 
Ab. 
[281, 282] 
High ratio of B-cells 
(100x compared with 
mouse) 
Rich source of V-gene mRNA, facilitates 
efficient sampling of V-gene repertoire. 
[285] 
Not yet used in therapeutics 
No HAMA responses – reduction in instances 
of false positives. 
[281] 
Increased levels of antibody 
produced 
Reduction in number of laboratory animals 
required leading to reduced costs. 
[281] 
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5.2 Results of the generation and isolation of recombinant antibodies 
against epitope-1 of cTnI 
 
Recombinant antibody-based techniques for the development of highly tailored specific 
antibodies for cTnI epitopes one and three were evaluated. The epitope recalcitrance found 
with whole protein-based immunisation strategy was overcome with a focused, synthetic 
peptide immunisation regime for epitope one in common with the generation of the 20B3 
monoclonal antibody. In contrast, epitope three-specific scFvs were readily isolated from 
an immunisation campaign using the commercial cTnI protein. The more established and 
routine methodology of phage display was opted for over ribosome display due to nature of 
the panning experiments undertaken where complex antigen presentation methodologies 
required a robust selection methodology.  
The main rationale behind the use of chickens in the course of this project was the 
phylogenetic distance from man leading to greater cTnI protein heterogeneity (Figure 
5.2-1). In the epitope one and two region human and mouse have identical amino acid 
compositions. In chicken, the amino acid sequence differs by four residues in this region 
and that was postulated to lead to increased immunogenicity. Epitope-specificity has 
proven recalcitrant in a whole protein-based immunisation regime for epitope one which 
could possibly be explained by the identical amino acid sequence in chicken and man. 
Again in the approach taken, native epitope recognition was paramount in the synthetic 
peptide-based immunisation strategy.  
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Figure 5.2-1: Alignment of human, mouse and chicken cardiac Troponin I  
Chicken shows an increased level of heterogeneity compared to human cTnI in contrast to the murine protein. 
The alignment was generated with the clustalW program using the sequences from the universal protein 
resource knowledge base (UniProtKB - http://www.uniprot.org/uniprot/) with the sequnces TNNI3_Human 
(P19429), TNNI3_Mouse (P48787) and cTnI_Chick (Q6S7R6). Amino acid identity is indicated by the 
symbols as follows; “*” identical, “:” conserved and “.” semi-conserved. Significant regions of the protein are 
conserved across the speicies. However, chicken shows amino acid variance in the regions of interest for 
development of cTnI epitope-specific antibodies.  
 
5.2.1 Anti-epitope-1 wild-type scFv development 
5.2.1.1 Immunisation  
 
Throughout immunisation (section 2.3.4.1) the development of the antibody response to the 
antigen was evaluated using the biotinylated peptide and cTnI using a direct binding ELISA 
(section 2.3.4.1). Prior to the final boost and sacrifice the antiserum titre was determined. 
Serum was diluted (1 in 150 to 1 in 2,952,450) in 1% (w/v) PBSTM and the response 
against cTnI determined to be in excess of 1 in 20,000 with the titre against the biotin-
peptide approaching 1 in 100,000. The difference in titre was attributed to several factors; 
i) a high proportion of the antibody response to the synthetic epitope does not 
recognise the epitope in the context of the cTnI protein, 
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ii) there was no accurate way to normalise for coating of neutrAvidin and 
subsequent capture of the peptide-biotin conjugate. With 4 binding sites per 
neutrAvidin there could be an excess of peptides compared to a single epitope 
per cTnI molecule. 
In spite of this, the response to cTnI was encouraging and owing to the simplicity of the 
avian immune system efficient sampling of the entire repertoire was ensured by the 
relatively small number of PCRs required to build the library.  
 
 
Figure 5.2-2: Avian antiserum titration for a chicken sensitised with the peptide-1-KLH conjugate  
Avian host (designation Y.22.03.09) sensitised against peptide-1 of cTnI and N-terminal pro-brain natriuretic 
peptide (NT-proBNP). Serum was collected from an adult Leghorn chicken (male) 10 days after boosting, 
diluted in 1% (w/v) PBSTM and bound IgY (chicken antibody) detected using anti-chicken-Fc-specific HRP-
labelled antibody. The graph indicates a significant antibody response for the synthetic peptide and crucially 
for the peptide in the context of the cTnI epitope. NT-proBNP, another cardiac marker, was also immunised 
taking advantage of the chickens tolerance of multiple immunogens. A notable NT-proBNP response was 
observed. 
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5.2.1.2 Library construction by PCR 
5.2.1.2.1 Amplification of variable heavy and light chains 
 
Post sacrifice, RNA extraction and cDNA synthesis (section 2.3.4.2), the variable domains 
from the avian bone marrow (BM) and spleen (SP) were amplified (section 2.3.4.4). 
Initially, the MgCl2 concentration for the PCR was optimised for the VL and VH of both the 
BM and SP. MgCl2 optimisation allows for optimal yield with greatest specificity. The 
yield is influenced by activity of the Taq polymerase and the magnesium ion-dependent 
incorporation of dNTPs, which also affects the specificity of primer for the template. The 
PCR products for each variable domain at each MgCl2 concentration for both the BM and 
SP were resolved on 2% (w/v) agarose gels. These indicated similar yield, shown by 
discrete-specific band formation at approximately 450bp for VH and 350bp for VL (Figure 
5.2-3). With the apparent null effect on yield, the lowest MgCl2 concentration was used in 
the subsequent large-scale reactions (Figure 5.2-4). Post large-scale amplification the 
correct size amplicons were isolated by gel extraction and clean up (as per the 
manufacture‟s guidelines). Both the VL and VH were brought together by the inclusion of a 
flexible serine glycine linker [(G4S)4] in a splice-by-overlap extension (SOE) PCR (section 
2.3.4.4.2).  
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Figure 5.2-3: Optimisation of spleen and bone marrow VL and VH amplification from cDNA 
Visualisation of the effect of MgCl2 concentration on 2% (w/v) agarose gels. The amplification of BM and SP 
variable domains from chicken was initially optimised by magnesium chloride titration (MgCl2). 1Kb
+
; DNA 
ladder, 1.5-4.0mM MgCl2 concentration gradient. Negative reactions for each MgCl2 concentration in the 
absence of cDNA showed no non-specific bands. Successful variable domain amplification was achieved with 
1.5mM MgCl2 for both the SP and BM. 
 
Figure 5.2-4: Large-scale VH and VL amplification from cDNA 
MgCl2-optimised large-scale amplification of VL and VH from SP (top) and BM (bottom) of Y20.03.09 
chicken. In both cases VL amplicons were observed at ~350bp and VH amplicons at ~450bp.  A negative 
control PCR showed no contaminating bands. The 1Kb
+
 ladder allowed approximation of DNA fragment size 
following resolution on a 2% (w/v) agarose gel. 
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5.2.1.2.2 SOE-PCR of variable heavy and light chains 
 
The purified variable domains were incorporated in equimolar ratios into the SOE product 
corresponding to the scFv fragment (approximately 750-800bp) using the CSC-F and CSC-
B primers (section 2.3.4.4.2). At this stage of the library construction process a high fidelity 
enzyme, Hi-Fi Taq, was used to ensure correct formation of the scFv fragment. Hi-Fi Taq 
requires inclusion of MgSO4 in the PCR. The concentration was initially optimised and 
found to yield sufficient specific product at 1.5mM. The large-scale reactions were 
visualised on 2% (w/v) agarose gel and showed a diffuse band (Figure 5.2-5-A) that was 
discrete enough to be isolated and purified (Figure 5.2-5-B). 
 
 
Figure 5.2-5: Splice-by-overlap extension (SOE) PCR of avian bone marrow and spleen VH and VL 
Resolution of the PCR products was carried out on 2% (w/v) agarose gels. 
A) Optimised large-scale SOE-PCR for SP (top) and BM (bottom) 
An equimolar mix of VL and VH was overlapped by virtue of the overlap extension tails on the VL reverse and 
VH forward primers. Both the SP and BM show the formation of a specific band at ~800bp corresponding to 
the scFv SOE product. Negative control reactions show no non-specific products were amplified.  
B) Purified SOE-PCR products: 
SOE-PCR products after gel extraction and purification were visualised to ensure that a clean band was 
isolated from the large-scale SOE-PCR.  
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5.2.1.2.3 Construction of scFv library in the pComb3xSS vector 
 
The pComb3xSS vector was made available by Professor Carlos Barbas III of the Scripps 
Institute, La Jolla, California, USA. The vector is a variant of pComb3x (accession number 
AF268281) containing a stuffer fragment (Figure 5.2-6). The vector contains both E. coli 
and phage origins of replication and can act as a shuttle vector for DNA encoding scFv (or 
Fab) fragments between E. coli cells and expression of the scFv on the surface of phage as 
a fusion to the geneIII protein. The vector was initially transformed into dcm
-
/dam
-
 E. coli 
for vector purification (section 2.3.4.3). To ensure the vector was intact and functional, 
small-scale restriction digestions were carried out and the vector was visualised on a 0.5% 
(w/v) agarose gel (Figure 5.2-7). SfiI digestion confirmed the presence of a ~1672bp stuffer 
fragment and concurrent SacI digest generated linear vector. 
 
 
Figure 5.2-6: pComb3xSS vector map 
The pComb3xSS vector is approximately 4973bp with both E. coli and phage origins of replication. 
Significant elements of the vector are highlighted. The stuffer fragment is located between the two SfiI sites. 
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Figure 5.2-7: Test digestion of pComb3xSS vector 
Examination of the vector prior to any library building, on a 0.5% (w/v) agarose gel. The undigested vector 
was resolved to ensure vector integrity. SfiI digestion results in drop out of the stuffer fragment at 
approximately 1650bp with SacI linearising the ~4973bp vector. Test digestions were compared to a 1Kb
+
 
DNA ladder. 
 
Large-scale digestion of the vector to incorporate the anti-epitope-1 scFv library (section 
2.3.4.4.3) was carried out in a stepwise, triple digestion protocol (Figure 5.2-8). Digestion 
of the vector with SfiI may result in a significant amount of intact stuffer fragment or 
undigested vector, leading to library contamination, as observed in previous experiments 
despite de-phosphorylation of the cut vector (personal communication: Dr. Stephen Hearty 
and Dr. Barry McDonnell). To overcome this, subsequent digestion of the vector with XhoI 
and XbaI further degraded the stuffer fragment into three products (SfiI –XbaI, XbaI – 
XhoI and XhoI – SfiI see Figure 5.2-6) where only two were large enough (underlined) to 
be observed on a 0.5% (w/v) agarose gel (Figure 5.2-8). In addition, Antarctic phosphatase 
treatment of the entire vector digestion results in a de-phosphorylated vector, thus further 
preventing re-ligation. The fully digested, treated and purified pComb3xSS vector was 
visualised on 0.5% (w/v) gel showing a single band at approximately 3300bp (Figure 
5.2-9).  
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Figure 5.2-8: Large-scale triple digestion of pComb3xSS vector 
Undigested pComb3xSS (lane 1), SfiI digested (lane 2) and triple digested (lane 3) reactions are shown. 
Triple digestion involved further degradation of the stuffer fragment (already SfiI digested) with XhoI and 
XbaI (flow diagram). The triple digestion (lane 3) reduces the potential for contamination of the downstream 
library building process. The digestions were resolved on a 0.5% (w/v) agarose gel and were compared to a 
1Kb
+
 DNA ladder. 
 
Figure 5.2-9: Purified triple digested pComb3xSS vector 
Unpurified triple digestion (lane 1) and purified vector (lane2) were resolved on a 0.5% (w/v) agarose gel. 
Post triple digestion, the vector backbone was purified by gel excision and clean-up resulting in a pure 
preparation of SfiI ready vector. The digestions were compared to a 1Kb
+
 DNA ladder. 
 
Successful SfiI digestion of the SOE products was confirmed on a 2% (w/v) agarose gel 
(Figure 5.2-10) with cleavage of the restriction site plus the (GAG)6 sequence readying the 
insert for ligation into the triple digested pComb3x vector (section 2.3.4.4.4). Post ligation 
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the antibody libraries (BM and SP) were transformed into electrocompetent E. coli 
generating a combined library size of 9.0 x 10
8 
members which was subsequently rescued 
with helper-phage for bio-panning. The background re-ligation/contamination of this 
library was found to be zero, or at least less than 1000, as confirmed by control titring of 
vector religation reaction without insert. This highlights the success of the triple digestion 
methodology in combination with de-phosphorylation of the pComb3xSS vector during the 
library building process, generating a specific and uncompromised antibody library. 
 
 
Figure 5.2-10: SfiI digestion of avian anti-peptide-1 scFv SOE-PCR inserts 
Unpurified SP (lane 1) and BP (lane 3) and purified SfiI digested SP (lane 2) and BM (lane 4) SOE-inserts are 
shown. Examination of the SOE-PCR products post digestion on a 2% (w/v) agarose gel allowed visualisation 
of the digestion success due to the slight shift in the position of the product, compared to the undigested 
insert. 1Kb
+
: DNA ladder. 
 
 
5.2.1.3 Phage display of the anti-epitope-1 scFv library 
 
The library was evaluated in a highly stringent antigen presentation manner to maximise 
the probability of selecting scFvs for compatible assay pairing with the 20B3 mAb, in 
addition to ensuring high-affinity and specificity. The phage library was interrogated by 
capture of cTnI using the previously established anti-epitope-2 monoclonal antibody 20B3 
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(Figure 5.2-11-A). Integrating this „pairs-by-selection‟ approach mitigates the requirement 
to mine for antibody pairings post bio-panning (section 5.1.10). This has advantages in 
terms of time-saving, ensuring compatible pair isolation and removing the need to re-select 
or screen should an antibody to only one dominant epitope be selected (i.e. no second pair 
available). Prior to carrying out this bio-panning approach, the concentration of the 20B3 
mAb to use as a capture for cTnI was determined in a sandwich-type ELISA with 
comparison to the commercial antibody, Hytest mAb228 (section 2.3.4.5.1.1). This 
confirmed adequate capture density to efficiently evaluate the library and enrich for 
epitope-1-specific binders in very close proximity to the anti-epitope-2 mAb (Figure 
5.2-11-B).  
Notably, from the results obtained for the antibodies 20B3 (50μg/mL) and Hytest 228 
(2μg/mL) capturing equal cTnI concentrations, with a fixed dilution of 19C7 (Hytest anti-
epitope-1 HRP-labelled antibody), there was substantial a difference in absorbance values. 
This may be attributed to inaccuracies in the „in-house‟ protein determination compared to 
the commercially sourced protein. Overlapping of the „in-house‟ mAb epitope compared to 
the epitopes defined in Hytest catalogue also may have contributed to the result (Figure 
5.2-11-C). Where the Hytest antibody pair (anti-epitope-2 capture and anti-epitope-1 
reporter) were used there was a 5 amino acid spacer between the defined epitopes for both 
these antibodies. In contrast, where 20B3 was used as a capture reagent the epitope 
designed overlaps with the defined epitope for Hytest anti-epitope-1 mAb. 
A high density (50μg/mL) of 20B3 capturing an excess of TnI (75μg/mL) for the first two 
rounds of bio-panning was adopted (section 2.3.4.5.3) to ensure enrichment of the library. 
To complement the stringency element introduced by this presentation strategy, a further 
level of selective pressure was introduced by gradual limitation of the concentration of 
antigen available for binding, but fixing the number of washes throughout (Table 2.3-12). 
Analysis of the input and output titres provides some information in relation to the 
successful shuttling of phage from input to output, as indicated in Table 5.2-1. Inbuilt into 
the selection campaign, was consideration for assay parameters such as temperature (room 
temperature) and blood collection regimes (presence of EDTA).  
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Figure 5.2-11: Antigen presentation strategy and optimisation for bio-panning of the anti-epitope-1 
library 
A) Bio-panning presentation: Stringent conditions for anti-epitope-1 library members to bind to cTnI 
were created by this antigen capture approach. MAb 20B3 (yellow) was coated onto the ELISA plate 
surface capturing cTnI and presenting the protein to the scFv library (multiple colours) displayed on 
phage particles (green). This rigorous format ensured the isolation of compatible assay pairings. 
B) Optimisation of bio-panning conditions: Varying concentrations of monoclonal 20B3 were coated on 
to an ELISA plate to capture cTnI. Bound cTnI was detected using anti-epitope-1 HRP-labelled mAb 
(Hytest 19C7). For comparison purposes the commercial antibody Hytest 228 was also used as a 
capture reagent. 
C) Graphical explanation of the difference in signal obtained for the two captures mAbs: Capture with 
Hytest 228 and probe with Hytest 19C7 contains a 5AA spacer between the defined epitopes. The 
„in-house‟ monoclonal epitope (which was used as the immunogen) overlaps with the 19C7 mAb-
defined epitope and may cause an element of steric hindrance.  
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Table 5.2-1: Bio-panning input and output titres for anti-epitope-1 scFv 
 Input Titre (cfu) Output Titre (cfu) % Recovery 
R1 1.1 x 10
12 
2.9 x 10
6
 2.6 x 10
-4
 
R2 9.6 x 10
11
 2.6 x 10
6
 2.7 x 10
-4
 
R3 8.2 x 10
11
 4.2 x 10
5
 5.1 x 10
-5
 
R4 5.6 x 10
11
 1.3 x 10
6
 2.4 x 10
-4
 
 
Post-panning, the selected antibody-displaying phage from each round of selection were 
evaluated in a polyclonal-phage ELISA for enrichment against cTnI in its presented, 
immobilised and synthetic forms (section 2.3.4.6.1). To increase confidence in the result, 
negatives such as the capture monoclonal, blocking solution and KLH (carrier) were 
included. The presence of specific-antibody-displaying phage was detected by an anti-M13 
HRP-labelled secondary antibody. Figure 5.2-12 illustrates the dramatic increase in 
specific-antibody-displaying phage at round four, suggesting enrichment of scFv-
harbouring phage within the panned library. This specific signal was directed to no less 
than three different formats of the epitope: cTnI (native), KLH-peptide-1 (synthetic 
epitope) and mAb presented cTnI. There was minimal or no background binding to any of 
the included controls. Round four phage were subsequently infected into mid-exponential 
E. coli Top 10F' for expression of soluble scFv fragments (section 2.3.4.7) and taken 
forward into the screening campaign (section 2.3.5.1). 
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Figure 5.2-12: Polyclonal-phage ELISA after four rounds of stringent bio-panning 
The phage preparations were assayed for specific binding against a number of positive and negative elements. 
Phage from each round was diluted 1 in 5 in 1% (w/v) PBSTM and 100μl applied to each well. Bound phage 
were detected using anti-M13 HRP-labelled secondary antibody. The ELISA plate was developed using TMB 
and the absorbance read after quenching with 10% (v/v) HCl at 450nm. The graph shows the dramatic 
increase in phage-displaying specific scFvs for the various formats of the epitope. 
 
 
5.2.1.4 Screening of anti-peptide-1 scFv library post selection 
 
Three hundred single colonies were isolated and grown up for screening (section 2.3.5.1). 
The screening approach was carried out at two levels. At the genetic level to assess the 
diversity of the rigorously panned library and at the protein level to asses binding in two 
ways: i) capture ELISA and ii) Biacore™ 4000 HT-ranking by „off-rate‟ analysis. The 
acquired data, most notably on the refined HT-system, offered a wealth of information to 
judiciously aid the screening process.  
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5.2.1.4.1 Genetic fingerprint analysis of a subset of scFvs 
 
The initial DNA-based analysis employed the restriction enzymes BstNI and AluI (below) 
to randomly cut the scFv gene generating a genetic fingerprint (section 2.3.5.1.1). 
Variations in the recognition site patterns as a result of DNA sequence diversity provided a 
rapid and cost effective method to examine a relatively good number of clones.  
 
BstNI 
W= A or T  
AluI 
 
 
A colony pick PCR of the scFv insert showed 100% presence of DNA of the correct size 
(Figure 5.2-13 - 18/18). Subsequent digestion with the two enzymes and resolution on a 2% 
(w/v) agarose gel resulted in a fingerprint-specific for each clone analysed (Figure 5.2-13). 
Of those clones, 12 unique clone types were identified based on the size and number of the 
resulting bands. Type „Di‟ (Alphabetic = group from BstNI digestion and roman numerals 
= group from AluI digestion) was found to be the dominant clone (Table 5.2-2). 
 
Table 5.2-2: Genetic fingerprint identification of eighteen selected clones 
Clone # Clone Type Occurrence % of Population 
1,6 Ai 2 11.1 
2 Bii 1 5.6 
3 Ciii 1 5.6 
4,9,11,14,18 Di 5 27.8 
5,12 Ci 2 11.1 
7 Eiv 1 5.6 
8 Cv 1 5.6 
10 Dvi 1 5.6 
13 Fvii 1 5.6 
15 Cviii 1 5.6 
16 Dix 1 5.6 
17 Gx 1 5.6 
 
Total 18 100.0 
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Figure 5.2-13: Genetic fingerprint analysis of eighteen clones after four rounds of bio-panning 
L = 1Kb
+
 DNA ladder. Lanes 1-18 = selected single colony picks from which the scFv insert was amplified 
using CSC-F and CSC-B primers (top). Subsequently, the purified inserts were restriction fingerprinted with 
BstNI (middle) and AluI (bottom) to investigate the diversity in the DNA sequence of the clones isolated after 
stringent bio-panning. 
 
5.2.1.4.2 Screening of anti-peptide-1 scFv in a functional assay format 
 
Initial protein-specificity screening was performed as a preliminary evaluation of the 
success of the bio-panning procedures undertaken. Analysis by direct binding ELISA for 
cTnI, the peptide conjugate and KLH as a control was carried out as described in section 
2.3.5.1.2. The subsequent functional screening was designed to consist of a sandwich assay 
format using mAb 20B3 as a capture reagent and kinetic evaluation using HT-Biacore™ 
4000 system.  The direct binding screen showed 98% binding-specificity for cTnI and 
KLH-peptide-1 with no background binding to KLH (Figure 5.2-14). A positive clone was 
defined as having a peptide and protein response greater than an absorbance of 0.2A.U. The 
screen highlighted the success of the bio-panning strategy, but was merely a pre-screen for 
the more rigorous analysis. 
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Figure 5.2-14: Initial screening of one anti-epitope-1 scFv bio-panned library output plate 
This direct binding ELISA permitted approximate determination of the percentage of positive binders for 
cTnI, the peptide-1 conjugate and control KLH. Virtually all the clones bound to both cTnI and the peptide. 
cTnI, KLH-P1 and KLH were coated on three ELISA plates, blocked with 5% (w/v) PBSTM, to which 
diluted crude supernatants from overnight expressed single colonies were applied. Specific scFv were 
detected using an anti-HA HRP-labelled secondary antibody. 
 
 
The second screen was instigated to challenge the scFvs in a sandwich format with the 
mAb 20B3. In this analysis the lysates were applied to plates on which the mAb 20B3 was 
coated to capture two concentrations of cTnI. This allowed comparison of the scFvs 
sensitivity for differential antigen concentrations. Figure 5.2-15 shows the response to both 
cTnI concentrations and to the negative control (0nM cTnI) for 4 out of 5 plates. From the 
graphs, varying degrees of response to the high and low cTnI concentrations was observed. 
With the exception of 3 clones (Plate #1 – 51, #5 – 29, #5 – 58 and #5 – 59) non-specific 
interaction with the 20B3 mAb was not observed. 
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Figure 5.2-15: Sandwich ELISA screening for positive clones selected during anti-epitope-1 scFv bio-
panning 
Using the „in-house‟ monoclonal 20B3 to create a capture surface, two concentrations of cTnI were applied to 
the immobilised mAb. In addition, a non-specific binding control plate (mAb coated only) was prepared. The 
crude lysates for four plates were diluted in 1% (w/v) PBSTM and applied over the three plates. Bound scFv 
were detected using an anti-HA HRP-labelled secondary antibody. The graphs above are a plot of clone 
number versus absorbance at 450nm for each cTnI concentration and for the mAb only control. 
 
This response was then evaluated as a ratio which was developed based on experiments 
which ranked hybridomas in a time-resolved fluorescence assay carried out by Diago and 
co-workers [293]. The signal from the 6nM cTnI concentration was divided by the response 
for the 36nM concentration. This was plotted on a graph by clone number (Figure 5.2-16). 
Not all the clones had binding responses and resulted in very low ratio values. Clones with 
high 36nM binding signals and low 6nM signals resulted in a lower ratio value, for 
example highlighted clone #201 (purple): 6nM = 0.15AU and 36nM = 0.71AU gave a ratio 
of 0.215. In contrast, clone #270 (blue): 6nM = 0.97AU and 36nM = 1.180AU resulted in a 
higher ratio value of 0.871. Several other high performing clones were highlighted (green) 
in addition to the commercial control mAb 19C7 (red). This was a useful analysis to assist 
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in ranking a significant number of clones. However, some variability between plates (e.g. 
clones 1-60 on plate #1 compared to clones 241-300 on plate #5) was apparent with the 
control mAbs giving different ratio values between the plates (see “1+” = 19C7 ratio on 
plate #1 compared to the other highlighted controls in Figure 5.2-16). This was likely to be 
an artefact of variance in the washing steps as the plates were washed manually, and the 
analyses was performed over several days (1 set of plates per day). Use of a plate washer 
may assist in normalising such variability in addition to the assay being carried out within a 
day. To assist the ranking of these clones in a functional assay rather than a single cTnI 
concentration, a combination of 6-fold differing concentrations allowed the data to be 
presented in a useful way to aid the selection process by way of comparing scFv 
sensitivities to lower cTnI concentrations. 
 
 
Figure 5.2-16: Ranking of anti-epitope-1 scFv based upon their binding ratio in a sandwich assay 
Plot of 6nM signal divided by 36nM signal in 20B3-cTnI capture sandwich assay format for four out of the 
five plates of single colonies. This ratio permits ranking based on the ability of the scFv-clone to detect lower 
cTnI levels. Higher performing clones (#180, 249, 260 and 270) are indicated with a lower performing clone 
(#201) alongside the commercial equivalent mAb 19C7. Higher ratios are attributed to clones with greater 
sensitivity to lower cTnI concentrations. 
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5.2.1.4.3 High-throughput ranking of anti-peptide-1 scFv 
 
In the selection campaign for the mAb 20B3 the ability to rank by a capture approach on 
the HT-Biacore™ was not feasible. In the screening campaign described for the scFv, the 
full parallel processing power of the instrument was harnessed and brought to bear on the 
panel of 300 anti-epitope-1 scFvs. 
The scFvs were ranked by percentage left analysis in a capture format (section 2.3.5.1.3). 
Figure 5.2-17-A diagrammatically illustrates the flow cell setup. There are four flow cells 
each with five independently addressable and monitored spots within the system. An anti-
HA pAb surface was created by immobilisation of approximately 6000RUs of the antibody 
onto spots 1, 2, 4 and 5. Crude lysates from overnight expressed clones were diluted in 
running buffer (HBS-EP
+
) and scFv captured on the outside spots (one scFv on spot one 
and another on spot five). cTnI (50nM in HBS-EP
+
) was passed over the entire surface with 
spots two and four acting as online references. The clones were ranked by the RU level at 
two time points (stability early and stability late). Stability late was set 12 minutes after 
stability early to allow for dissociation to occur. Figure 5.2-17-B is the raw sensorgram data 
acquired from a single run of 300 scFv clones. ScFv capture on spots one and five of each 
flow cell can be seen with a stabilisation step prior to zeroing the baseline. The binding of 
cTnI was then acquired before regeneration of the surface with 20mM NaOH. 
Figure 5.2-18 is a plot of stability early versus stability late for the 300 clone screen and 
100% left (or no dissociation) is signified by the diagonal blue line. The majority of clones 
resided within three sub-populations. Those with percentage left values ≥ 60%: high (1) and 
low (2) expressers and the remainder of the clones with percentage left values < 60% (3). 
High and low expressing clones were differentiated by the stability early values where 
greater levels of scFv capture gave higher cTnI binding responses. This was verified by the 
scFv capture level plot (Figure 5.2-19). In this case the high-level captured scFv # 23 and 
lower level captured scFv #17 are highlighted. In the stability early versus late plot (Figure 
5.2-18) both clones were also highlighted and were both in the percentage left ≥ 60% 
category. However, they exist in the high and low expresser groups, respectively. This extra 
information was useful for aiding the decision making process allowing for the 
identification of higher expressing clones. The data was also presented in a percentage left 
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plot versus clone number in Figure 5.2-20. This plot has value in identifying more stable 
binding events amongst a large panel of clones. 
This screening approach demonstrates the wealth of information was be garnered from the 
HT-based methodology in a single analysis run. Using the cTnI antigen at all times ensured 
confidence in the antibody-antigen interaction in a conformation not compromised by direct 
immobilisation effects.  
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Figure 5.2-17: High-throughput screening by capture format on Biacore™ 4000 used for scFv analysis 
A) Overview of the experimental flow cell setup: The surface was composed of polyclonal anti-HA 
antibody on spots 1, 2, 4 and 5 of each flow cell (FC). The outer spots (1 and 5) were the active spots 
where recombinant antibodies were captured from crude lysate (two per FC by four FCs = 8/cycle). 
A fixed antigen concentration was then passed over the captured scFv with the inner spots (2 and 4) 
acting as online reference spots. 
B) Raw sensorgram data: Initially, the scFv were captured on spot 1 (1st peak on curve) and spot 5 (2nd 
peak) of each flow cell. This was followed by a stabilisation step before zeroing the baseline and 
injection of cTnI (antigen binding). After 12 minutes dissociation the flow cells were regenerated for 
the next cycle (*) with 20mM NaOH. 
A 
B 
  
5–49 
 
  
 
Figure 5.2-18: High-throughput stability early versus stability late ranking of anti-epitope-1 scFv 
A plot of stability early versus stability late values for each of the 300 clones illustrated the overall stability of 
the binding events. From the graph, three distinct populations were identified - red circle: lower expressing 
clones with % left values ≥ 60, green circle: higher expressing clones with % left vales ≥ 60 and those clones 
with % left values < 60. The blue diagonal line signifies a percentage left value of 100% where no 
dissociation has occurred. 
 
Figure 5.2-19: High-throughput scFv capture level plot for anti-epitope-1 scFv 
Plot of the scFv capture level by clone number shown for 300 clones in the analysis. High capture level clone 
#23 and lower capture level clone #17 were highlighted. The capture level can be related to expression as all 
clones were cultured in equal volumes and diluted in the same fashion. 
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Figure 5.2-20: High-throughput percentage left plot for anti-epitope-1 scFv 
Percentage left values were calculated using Equation 4.2-1. Percentage left values were plotted versus clone 
number and broken into three groupings ≥ 40, 50 and 60% (green horizontal lines) 
 
Vast amounts of data were acquired in a relatively short timeframe where the analysis of 
300 clones took <12 hours. Combined with the functional sandwich assay screening 
substantial information was available to rationally select a panel of clones to carry forward. 
Table 5.2-3 is the correlated data for the top 58 performing clones from the HT-screening. 
This was then related to functional sandwich assay screen and a decision made on the top 
three clones (bold and red) to send for sequencing. As the plate position for the Biacore™ 
4000 (where all 96-wells were used) was different from the original single colony plate 
(inner 60-wells only) the relevant plate positions are also tabulated for clarity. An 
additional clone that did not appear in the HT-screen (as it captured well, but had a fast 
cTnI dissociation rate), but did perform well in the functional assay screen was also 
selected for sequencing (clone_218). This trend occurred frequently on clones captured on 
spot five of the flow cells (FC) and suggested a bias in the instrument as all the clones that 
had performed superiorly were those captured on spot one (spot one FC:1 = plate position 
A, FC:2 = B, FC:3 = C and FC:4 = D compared to spots five of the four FC coming from 
plate positions E, F, G and H. Note: HT plate positions in Table 5.2-3). 
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Table 5.2-3: Rationalised selection of anti-epitope-1 scFvs 
Clone # % left Positive by Sandwich ELISA HT Plate Position Original Plate Position 
1 56.38 YES 1A2 1B3 
3 62.59 YES 1A3 P1B4 
4 57.43 YES 1A4 P1B5 
7 53.63 YES 1A7 P1B8 
10 50.47 YES 1A10 P1B11 
15 65.45 YES 1B5 P1C6 
16 64.75 YES 1C6 P1C7 
17 62.40 YES 1B7 P1C8 
22 65.30 YES 1C1 P1D2 
23 66.88 YES 1C3 P1D4 
24 62.32 YES 1C4 P1D5 
28 54.32 YES 1C8 P1D9 
32 57.85 YES 1D1 P1E2 
34 57.44 YES 1D4 P1E5 
93 65.21 - 2B3 P2E4 
95 62.50 - 2B5 P2E6 
96 63.64 - 2B6 P2E7 
98 64.30 - 2B8 P2E9 
99 58.49 - 2B9 P2E10 
106 59.82 - 2C6 P2F7 
107 59.71 - 2C7 P2F8 
108 59.94 - 2C8 P2F9 
110 56.78 - 2C10 P2F11 
113 51.65 - 2D3 P2G4 
117 61.79 - 2D7 P2G8 
118 60.79 - 2D8 P2G9 
166 60.31 YES 3A6 P3F7 
167 59.54 YES 3A7 P3F8 
168 56.63 YES 3A8 P3F9 
169 56.71 YES 3A9 P3F10 
173 50.29 YES 3B3 P3G4 
175 67.52 YES 3B5 P3G6 
177 66.34 YES 3B7 P3G8 
180 62.33 YES +++ 3B10 P3G11 
182 55.93 YES 3C2 P4B3 
183 57.07 YES 3C3 P4B4 
186 65.80 YES 3C6 P4B7 
188 62.47 YES 3C8 P4B9 
190 64.75 YES ++ 3C10 P4B11 
192 52.54 YES 3D2 P4C3 
196 64.62 YES 3D6 P4C7 
197 62.40 YES 3D7 P4C8 
199 58.62 YES 3D9 P4C10 
249 55.19 YES 4A9 P5B10 
256 54.06 YES 4B6 P5C7 
257 67.97 YES 4B7 P5C8 
259 59.54 YES 4B9 P5C10 
260 62.11 YES ++ 4B10 P5C11 
261 54.32 YES 4C1 P5D2 
262 64.43 YES 4C2 P5D3 
263 60.34 YES 4C3 P5D4 
265 59.24 YES 4C5 P5D6 
266 56.24 YES 4C6 P5D7 
267 65.02 YES 4C7 P5D8 
269 61.10 Non-Specific 4C9 P5D10 
270 63.18 YES ++ 4C10 P5D11 
271 62.16 YES 4D1 P5E2 
272 54.33 YES 2D2 P5E3 
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5.2.1.5 Sequence analysis of four selected scFvs 
 
Examination of the four sequences (section 2.3.8.1) indicated a „jackpot library‟ with 100% 
sequence similarity (Figure 5.2-21). This „jackpot‟ is a desirable outcome, because in a 
library of 9 x 10
8
 members the probability of the same sequence appearing at random is low 
[12]. This was a relatively small cohort of clones to sequence. However, after four stringent 
rounds of selection and rigorous, specific screening it was anticipated that the diversity 
would be narrow given the focussed immunisation and stringent bio-panning regimes. This 
„jackpot‟ result further validates the procedures followed.  
It is widely accepted that the CDRH3 has by far the greatest sequence diversity compared 
to the remaining five CDRs and makes a significant contribution to antigen contact [6]. The 
CDRH3 in this case was 15 amino acids in length and dominated by serine (3/15), glycine 
(4/15), aspartic acid (4/15) and single tyrosine/isoleucine residues. Interestingly, the 
CDRL1 (14 amino acids) contains many tyrosine (5/14) and glycine (5/14) residues. The 
tyrosine residue content of the CDRs is attributed to specific antibodies in synthetic 
libraries with glycine, serine and tyrosine being dominant in naïve loops. Tyrosine, 
tryptophan and arginine residues are capable of mediating a wide-array of intermolecular 
interactions which are desirable in the composition of the CDRs. The frequency of 
tryptophan and arginine residues increases in antibodies having undergone affinity 
maturation, but it is tyrosine side-chains that mediate ~25% of antigen contacts. 
Furthermore, small residue prevalence in the CDR loops confers conformational flexibility 
which is crucial for effective antigen recognition [294]. With this in mind, almost all the 
CDRs are dominated by the small amino acids serine, glycine and aspartic acid. Four of the 
six CDRs contain tyrosine residues with the CDRL1 and CDRH2 showing higher 
frequencies.  Interestingly, only two arginine residues occur in the CDRs (L1 and L2). In 
CDRL2, at this position the arginine residue was observed in many chicken-derived 
antibodies irrespective of the antigen (personal observation). The CDRL1 appears to be 
quite long i.e. longer than observed for other protein antigen binding clones developed in 
DCU including other avian and rabbit anti-cTnI antibodies. Of the 14 amino acids making 
up that CDR, tyrosine and the smaller amino acids (glycine, serine and aspartic acid) are 
abundant with only a single arginine residue. Based upon what is known about flexibility 
and tyrosine/arginine content this would suggest that CDRL1 may be important for avian 
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anti-cTnI peptide one binding. In the absence of any structural data this observation 
remains a supposition. 
 
Figure 5.2-21: Alignment of four selected wild-type scFv for sequence comparison 
The CDRs are highlighted using the Kabat numbering system. Conserved CDR flanking regions are 
highlighted (bold and underlined). Light chain CDRs 1-3 are indicated in blue with the heavy chain CDRs in 
red. Other highlighted regions: linker; gold, hexahistidine tag; green and HA-tag; purple. Sequences aligned 
using ClustalW at http://www.uniprot.org/. 
 
It must be noted that scFv 218 which did not perform well in the HT-screening was 
identical in sequence as the other clones. It did perform well in the functional sandwich 
assay, but the rapid dissociation of cTnI in HT-analysis resulted in omission of the clone 
from selection. While no instrument issues/failures were found at the time (as the A100) 
when the machine was upgraded to Biacore™ 4000 a flow valve issue was found. In my 
opinion this introduced the selective bias noted in the screening of these clones (as one 
clone compared directly on spot one and five of the same flow cell also gave different 
dissociation rates). Post upgrade to Biacore™ 4000 positive hits came from all spots as 
demonstrated in the numerous plate positions in Figure 5.2-31. 
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5.2.2 Mutagenesis of anti-epitope-1 scFv 
 
The primary decider of assay specificity and sensitivity is the antibody. The issue of 
specificity was well defined early in the antibody generation process by way of the epitope-
focused immunisation and selection strategies. To ensure optimal sensitivity, the affinity of 
the antibody was of crucial importance. In vitro mutagenesis offers a rapid methodology to 
increase the diversity of the selected libraries and mine for improved clones by phage 
display. 
 
5.2.2.1 Overview of the mutagenesis strategy 
 
The mode of mutagenesis selected for this library was a conservative chain shuffle, 
considered an optimal approach for immune repertories, as the chances of recapitulating the 
immune B-cell VL-VH pairing is statistically low [295].  Chain shuffling involves 
randomisation of the VL-VH pairing by re-combination of the one V chain with either the 
original or an alternative source of the other V gene. In the case of the anti-epitope 1 scFv 
180, it was light-chained-shuffled against the catalogue of light chains from the original 
library, thus generating a second library (Figure 5.2-22-A) as described in section 2.3.4.5.4. 
This secondary library (3.1 x 10
8 
members) based around the wild-type (WT) VH contained 
many combinations of light chains from the immune catalogue with further diversity 
potentially introduced by errors during PCR amplifications. It is known from crystal 
structure determination and for genetic reasons that the VH dominates antibody binding 
interactions and thus a light chain shuffle was an optimal method to improve the antibody 
binding energies [12]. The secondary library contains many combinations both specific and 
non-specific for cTnI in common with the primary library, in essence the libraries overlap 
greatly (Figure 5.2-22-B) and the selection strategy required significant modification to 
increase the statistical chances of finding new, higher-affinity VH-VL combinations.  
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Figure 5.2-22: Overview of light chain shuffling mutagenesis strategy for the wild-type scFv library 
A. The parental scFv (180) heavy chain was isolated by PCR and recombined with a catalogue of light 
chains from the original library variable domain amplification, generating a secondary library. The 
recombined library was then subjected to bio-panning by phage display.  
B. This secondary library, biased by the VH of the WT, contained many combinations of the light chains 
previously found in the primary library, but may also contain new light chain combinations not 
selected for in the WT campaign. Additional diversity could be introduced by the error rate of the 
polymerase potentially leading to new clones. This is diagrammatically represented by the bubble 
plot and highlights the significant overlap of the two libraries demonstrating the requirement for a 
new selection strategy to favour the isolation of improved affinity clones. 
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To favour an increased statistical probability of finding advantageous VL-VH combinations, 
solution-phase bio-panning was chosen as the optimal approach to select for specific 
mutants (section 2.3.4.5.4). With solid-phase selection, it is problematic to accurately 
control the concentration of the available antigen during selection experiments [89]. This is 
primarily due to the uncontrollable mechanism of absorption of proteins onto the surface of 
microtitre plates. Solution-phase bio-panning was a superior methodology in terms of 
selection of affinity improved mutants. In this case the concentration was precisely 
controlled during the phage-displayed antibody and free antigen interaction. Biotinylated 
peptide one was employed in the selection experiments. This was carried out by incubating 
the library with sequentially reduced concentrations of antigen. The specific phage 
displayed scFvs were subsequently recovered from the mixed population using 
streptavidin-coated paramagnetic beads followed by washing and infection into E. coli for 
the next round of bio-panning (Figure 5.2-23).  
 
 
Figure 5.2-23: Solution-phase bio-panning for anti-epitope-1 mutant scFv 
The chain shuffled library was displayed on phage and incubated with biotin conjugated peptide-1 in-solution. 
Bound peptide-phage antibody complexes were recovered using streptavidin-coated paramagnetic beads and a 
magnet followed by washing away of non-specific phage. The specific-phage were eluted by trypsin treatment 
and infected into E. coli for repeated rounds of bio-panning with decreasing free peptide concentrations. 
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Prior to bio-panning the capture of the WT clone and mAb 19C7 (HRP-labelled) by the 
biotinylated peptide-1 was evaluated (section 2.3.4.5.1.2). A dilution series of free-peptide 
was incubated with a fixed scFv (pure) or 19C7 concentration and recovered using 
streptavidin-coated paramagnetic beads. Post washing the bound scFv was detected using 
an anti-HA HRP-labelled secondary antibody and the signal developed using TMB. The 
signals were quantified by transferring the TMB to a microtitre plate (Figure 5.2-24) 
facilitating absorbance determination at 450nm. From the graph the lowest concentration of 
peptide (0.1nM) showed loss of signal for the WT scFv, with the Hytest 19C7 signal 
virtually abolished at 1nM. Owing to the relative low instance of each clone in the mutant 
(MT) library, the selection strategy that was employed mimicked the methodology 
demonstrated in these optimisation experiments (Table 2.3-13). This ensured that all 
peptide-binding antibodies were captured and enriched prior to significant challenge with 
low peptide concentration (0.1nM). 
 
 
Figure 5.2-24: Pre-panning optimisation of peptide concentrations for in-solution bio-panning 
The WT scFv and control mAb (19C7) were incubated with free peptide-1 and recovered using paramagnetic 
beads. The recovered bead-peptide-antibody complexes were incubated with TMB. The inset pictures show 
the 10nM and 0nM peptide concentrations for both Hytest (blue) and scFv 180 (red) after incubation with 
TMB. Visually the zero peptide concentration gave little or no colour change while the 10nM peptide showed 
strong colour development. The developed TMB for each concentration was then transferred to an ELISA 
plate for quantitation. This permitted optimisation of the bio-panning conditions prior to selection. 
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5.2.2.2 Library construction by PCR 
 
The light chain shuffled library was constructed in the same manner as the WT library. The 
catalogue of VL chains was prepared in large-scale, as previously optimised and described 
in section 2.3.4.4. In this instance the VH was amplified from the scFv 180 plasmid directly 
using the VH primer set (Table 2.3-4). The MgCl2 concentration was optimised for this 
process prior to large-scale amplification. Figure 5.2-25 illustrates the specific bands 
amplified with 1.5mM MgCl2 and this was used for the large-scale amplification. Finally, 
the VH and catalogue of VL were overlapped by SOE-PCR, as previously described using 
the optimised conditions (section 2.3.4.4.2) keeping the BM and SP VL separate (Figure 
5.2-26). The SOE-PCR was then ligated into pCom3xSS vector, as described for the WT 
library, and transformed into E. coli XL1 blue in preparation for bio-panning (section 
2.3.4.4.4).  
 
 
Figure 5.2-25: VH amplification from wild-type gene 
A) Optimisation of the VH amplification from the selected scFv 180 plasmid. MgCl2 was titrated from 
1.5mM to 4.0mM and demonstrated no significant increase in yield of the amplified product at 
~450bp. 
B) The large scale amplification of the VH was carried out at 1.5mM MgCl2 as the optimised 
concentration. 
The amplified products were resolved on 2% (w/v) agarose gels and in both cases negative reactions (no 
template DNA) were included. The size of the amplified products was estimated by comparison to the 1kb
+
 
ladder. 
 
  
A B 
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Figure 5.2-26: Mutant library SOE-PCR   
The SP and BM catalogue of VL chains were „stitched‟ together with the VH chain from the WT scFv by SOE-
PCR. This resulted in the formation of a band at approximately 800bp corresponding scFv gene segment (VL-
linker-VH). This product was subsequently digested with SfiI and ligated into the pComb3xSS vector for 
transformation. The SOE-PCR products were resolved on a 2% (w/v) agarose gel. 1Kb
+
: DNA ladder. 
 
5.2.2.3 Bio-panning of the anti-epitope-1 mutant library 
 
The transformed MT library was composed of both the SP and BM VL catalogues which 
were pooled post transformation, yielding a library of 3.1 x 10
8
 members. The scFv 
fragments were rescued by helper-phage and displayed on filamentous phage surface. The 
solution-phase bio-panning strategy outlined in section 2.3.4.5.4 was exploited 
incorporating the optimised bio-panning conditions and stringencies that are delineated in 
Table 2.3-13. After four rounds of bio-panning the phage preparations for each round were 
analysed by polyclonal-phage ELISA (section 2.3.4.6.2). Figure 5.2-27 demonstrates the 
immediate enrichment for both cTnI and KLH-P1 after one round of bio-panning and 
reinforces the need to perform at least one selection to enrich even a heavily-biased library. 
Despite gradual limitation of free antigen the enrichment sequentially increases for cTnI. 
Based on this strong positive polyclonal-phage ELISA, the round four phage population 
was infected into mid-exponential E coli. Top 10F' for expression of soluble scFv and 
brought forward to screening (section 2.3.4.7). 
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Figure 5.2-27: Polyclonal-phage ELISA for the light chain shuffled library  
The phage preparations were assayed for specific binding against cTnI and the KLH-peptide-1 conjugate to 
demonstrate anti-epitope-1 scFv enrichment. Phage from each round was diluted 1 in 5 with 1% (w/v) 
PBSTM and the WT scFv (boxed) was also included as a positive control. Bound phage were detected using 
anti-M13 HRP-labelled secondary antibody and bound scFv with anti-HA HRP-labelled secondary antibody. 
Specific phage-displayed antibodies for cTnI (epitope one) were enriched after a single round of bio-panning. 
Even in such a biased library the transformed unpanned library signal was low due to the low representative 
numbers of each clone present. 
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5.2.2.4 Mutant screening for improved affinity clones 
 
The mutant library generated contained a large pool of closely related yet heterogeneous 
clones that required differentiation from the WT in an efficient way. The primary screening 
regime (section 2.3.5.2) again utilised direct binding and sandwich ELISAs and the HT 
power of the Biacore™ 4000, but in this case applying some of the lessons learned and 
„tricks of the trade‟ to garner more information per run. For example, zero antigen 
concentrations for each clone on Biacore™ 4000 allowed estimation of very crude ka/kd 
and the newly described „2 over 2‟ kinetic evaluation permitted further refinement of the 
kinetics of the interactions in a HT-fashion. Use of the purified scFv 180 as a benchmark 
throughout the analysis allowed clear differentiations to be drawn in „side-by-side‟ 
comparison to the MT lead candidates.  
Initially, the 192 clones were evaluated in direct binding and sandwich assays (section 
2.3.5.2.1). Figure 5.2-28 shows a significant population of positive clones in both sandwich 
(77.6%) and cTnI direct binding ELISA (81.3%). In general, most of the scFv that bound to 
cTnI directly also recognised the antigen presented by the 20B3 mAb. However, 
approximately 3.7% failed to bind the presented antigen (~7 clones) and thus represented 
sub-optimal VL-VH combinations for efficient pairing with the 20B3 mAb. The analysis 
was valuable as it demonstrates the success of the „in-solution‟ selection campaign. The 
information acquired in this experiment does not provide a means to separate the clones in 
terms of improvement in affinity. However, this positive result allowed confident 
progression into HT-ranking of the clones on Biacore™ 4000. 
 
 
  
5–62 
 
  
 
Figure 5.2-28: Functional assay screening of mutant scFv for immobilised and captured cTnI protein 
cTnI was presented using the 20B3 mAb. ScFvs from crude lysates were applied to the captured antigen and 
bound scFv detected using an anti-HA HRP-labelled secondary antibody. A significant proportion of the 
population recognised cTnI in this presented form. In parallel, the same scFv supernatants were applied 
directly to wells coated with cTnI antigen and detected with the same secondary antibody. Again the majority 
of clones bound to the antigen specifically. This analysis alone gives a positive result to the bio-panning 
experiment, but lends no information to rank the clones in terms of improved affinity mutants. 
 
The second more „information-rich‟ screening method relied on the parallel processing 
power of the Biacore™ 4000. Figure 5.2-29 is the sensorgram data for the 192 mutant 
scFvs, analysed with a fixed concentration of cTnI in a capture approach (as described in 
Figure 5.2-17-A). The inclusion of a zero antigen concentration corrected for the 
dissociation of each captured scFv from the anti-HA surface and allowed the MT screen to 
evaluate each scFv by basic binding kinetics in a very HT-fashion (section 2.3.5.2.2.1). 
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Figure 5.2-30 is an „on/off-rate‟ map of the 192 MT clones and the WT clone. A plot of this 
type allows affinity isotherms to be graphically represented giving an insight to the 
effective kd/ka. With little variance in the ka a dramatic „slowing‟ of the kd was apparent. 
Given that KD (affinity) = kd/ka, this dramatic improvement in kd was advantageous, giving 
rise to a sharp improvement in the affinity values, as approximated from the position 
relative to affinity isotherms. The clones were also compared by % left analysis in the same 
experiment. By inclusion of the WT clone a threshold % left value of ~63.6% was applied. 
Figure 5.2-31 illustrates the dramatic improvement in percentage left value, indicating 
improved stability of the binding events. Only 15 clones (7.8%) showed reduced percentage 
left values in comparison to the WT. For the vast majority of clones the percentage left 
values increased above 70% up to a maximum of 94.8%.   
 
 
Figure 5.2-29: High-throughput (HT) screening of the mutant scFv on the Biacore™ 4000 
Reference subtracted sensorgram data of the screening process. In each cycle individual scFvs were captured 
on spot 1 (1
st
 peak) and 5 (2
nd
 peak) followed by injection of both 0nM and 100nM cTnI. Inclusion of a zero 
for each scFv clone allows evaluation of the binding kinetics in a preliminary way by assigning association 
(A) and dissociation (D) curves. Regeneration of the surface (*) was achieved using 20mM NaOH. 
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Figure 5.2-30: 'On/off-rate’ map of phage selected scFv mutants for anti-epitope-1 
From the Biacore™ 4000 experiments crude association (ka) and dissociation (kd) constants were modelled. 
The plot of ka and kd gives rise to the affinity isotherm map shown above. The affinity isotherms are indicated 
by diagonal red lines and allow visualisation of approximate affinity (M). The circle indicates the area where 
the WT lies on the plot. Visually there appears to be very little variance in ka introduced by the light chain 
shuffle. However, a spread in the kd was noticeable where the mutant clones predominantly move to 
significantly slower kd values (directional arrow). 
 
Figure 5.2-31: HT ‘percentage-left’ ranking of scFv mutants in comparison to the wild-type clone  
In the same HT-experiment as the „on/off-rate‟ map, the binding level early versus binding level late data was 
plotted as percentage left graph. This shows the stability of the binding event with a notable increase to a 
higher binding stability for the mutants compared to the WT (red line). 
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To delve further into this affinity improvement a relatively small subset of clones at the 
highest affinity range (14 clones) and one not so high (1 clone) plus the WT were taken into 
a „2 over 2‟ kinetic experiment (section 2.3.5.2.2.2). This involved the capture of two 
different densities of the scFvs from the crude lysates, as illustrated in Figure 5.2-32. Data 
was then acquired for three antigen concentrations (0, 25 and 75nM cTnI) and provided a 
greater number of curves per clone for the software to fit kinetic constants. This resulted in 
improved reliability of the calculated values while retaining HT nature of the analysis. An 
example of the reference subtracted, fitted curves for two scFvs is illustrated in Figure 
5.2-33. The curves were fitted with the 1:1 Langmuir binding model and a sharp 
„flattening‟ of the dissociation phase observed for the mutant example. Figure 5.2-34 plots 
the extrapolated ka and kd values highlighting the dramatic shift in affinity towards 10
-15
M. 
Although this was an exciting result the extremely high-affinity for the clones here was 
somewhat suspicious in magnitude and raised concerns about underlying antigen quality 
issues contributing to the derived kd.  
 
 
Figure 5.2-32: Flow cell setup for ‘2 over 2’ kinetic experiment  
A polyclonal anti-HA surface was created within the flow cell. In this setup two scFvs are captured from 
diluted lysates; one scFv on spots 1 and 2 and a second scFv on spots 4 and 5. The lysates were diluted such 
that two different densities of scFv were captured; high density on spots 1 and 5 and low density on spots 2 
and 4. Three cTnI concentrations (0nM, 25nM and 75nM in 1XHBS-EP
+
) were passed over the two capture 
densities and were referenced against the unmodified surface on spot 3. Two densities of each clone 
interacting with three cTnI concentrations formed the basis of kinetic constant determination with the 1:1 
Langmuir binding model. In the four flow cell system eight clones were evaluated per cycle. 
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Figure 5.2-33: '2 over 2' kinetic curves for wild-type and one selected mutant 
Representative reference subtracted curves from the „2 over 2‟ experiment. A: scFv 180 and B: scFv 2B12 
with the high (red) and low (blue) density scFv capture levels for two cTnI concentrations (the 0nM cTnI 
curve was subtracted automatically by the software). The association and dissociation curves (blue lines) for 
each scFv were fitted with kinetic curves (black lines, a 1:1 Langmuir binding model) using a local fit. The 
fits were found to be good with χ2 values of 0.56 for the WT and 1.0 for the MT. The corresponding affinities 
for all 15 selected clones and the WT were then plotted in Figure 5.2-34. 
 
Figure 5.2-34: Plot of ka and kd from the ‘2 over 2’ experiment for anti-epitope-1 mutant selection 
The accuracy of the ka and kd values was improved by the „2 over 2‟ screening format while continuing to 
evaluate a significant number of scFvs. The ka and kd values were determined by fitting of the kinetic curves 
(as illustrated in Figure 5.2-33) and plotted on the graph. The affinity isotherms are indicated by diagonal 
broken red lines and again demonstrate little variance in ka, but significant kd improvement. The WT scFv is 
highlighted by the black circle. 
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5.2.2.5 Comparison of wild-type and mutant clones 
 
From the „2 over 2‟ kinetic evaluation, six clones were selected for full kinetic 
characterisation alongside the WT clone. The next section describes the challenges that 
presented themselves in acquiring accurate kinetic information and the approach taken to 
improve the quality of the interaction using the FABP-P1&2 fusion protein. Subsequent 
sections outline the route to selection of the „best‟ clone largely based on the kinetic 
evaluations and inhibition analyses. 
 
5.2.2.5.1 Full kinetic evaluation of the scFvs 
 
Table 5.2-4 lists the clones selected for further kinetic analysis on Biacore™ 4000. 
Table 5.2-4: Mutant clones selected for further characterisation 
Clone Percentage left (%) Crude Analysis of KD (M) ‘2 over 2’ KD (M) 
2B11 94.8 1.21 x 10
-13
 6.80 x 10
-14
 
1E12 60.8 2.83 x 10
-11
 6.60 x 10
-16
 
2B12 93.1 1.84 x 10
-14
 3.20 x 10
-14
 
2B9 93.1 2.50 x 10
-13
 2.65 x 10
-13
 
2B6 92.9 2.85 x 10
-13
 1.98 x 10
-14
 
2B2 93.4 1.07 x 10
-12
 5.77 x 10
-14
 
WT 63.6 - 1.12 x 10
-10
 
 
Full kinetic analyses were carried out for the six MT clones and the WT (section 
2.3.5.2.2.3) with optimised dilutions for capture and cTnI concentrations to ensure that the 
Rmax was < 100RU. The cTnI concentration range used was: 12.0, 6.0, 3.0(x2), 1.5 0.75, 
0.38, 0.19 and 0nM. Figure 5.2-35 shows the reference (buffer only) subtracted curves 
fitted locally by the Biacore™ software. A clear flat line for dissociation (kd) was observed 
for each of the six MT clones which was indicative of high-affinity. Figure 5.2-36 shows 
the scFv 2B12 and the WT side-by-side illustrating the visual improvement in the „off-rate‟ 
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and thus suggests that the MT was a higher-affinity clone than the WT.  Fitting kinetic 
constants on the dissociation phase proved extremely difficult owing to the apparent high-
affinity of the clones. Significant and wildly varied kd were obtained in inter- and intra-day 
analysis. This may be attributed to the fact that determination of the affinity of the clones 
had reached the limitations of the instrument. However, the quality of the commercially 
sourced TnI may also introduce non-1:1 binding effects, which at these very slow kd values 
caused this variation and the resultant, dramatic apparent improvement in kd. 
  
 
Figure 5.2-35: Full kinetic evaluation of selected scFv mutants on Biacore™ 4000 
Clones were analysed over a broad range of serial cTnI concentrations (120.19nm). Kinetic fits were 
applied by the system software with 1:1 Langmuir binding model using local fit option. Blue curves represent 
the reference subtracted data acquired for each concentration, the black lines represent the fitted association 
and dissociation curves. Red curves are those rejected by the system software due to the positive slope after 
the end of the association phase.   
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Figure 5.2-36: Kinetic comparison of wild-type and mutant scFv 2B12 
Clones were analysed over a broad range of serial cTnI concentrations as in Figure 5.2-35. Kinetic fits were 
applied by the system software with 1:1 Langmuir binding model using local fit option. Blue curves represent 
the double referenced data acquired for each concentration, black lines represent the fitted association and 
dissociation curves. Red curves are those rejected by the system software due to the positive slope after 
association. The underlying dot plots show the residuals for the data. This allows assessment of bias and 
represents the „goodness‟ of the 1:1 model fit. The data points for scFv 180 represent an even spread and 
indicates no significant bias. The equivalent residual plot for the mutants indicated some bias in the 
association phase (elliptical trend) suggesting the fit data quality was not truly optimal. 
 
From all the kinetic data acquired throughout the screening campaign and the full 
comparison, no real conclusion in terms of a „hard number‟ could be attributed to the MT 
clones. However, the side-by-side nature of all the analysis ensured that any effects of 
antigen quality were at least consistent and allowed the conclusion to be drawn that the MT 
clones selected were certainly improved compared to the WT. A different analysis was 
required to efficiently rank the clones in a less ambiguous way. 
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5.2.2.5.2 Inhibition analysis of selected clones 
 
To answer many of the questions left unanswered by the kinetic evaluation, a rigorous 
inhibition format comparison was undertaken to assess any changes in terms of the half-
maximal inhibitory concentration (IC50) value (section 2.3.6). IC50 refers to the effective 
antigen concentration required to decrease antibody binding by 50% at equilibrium. 
Lysates were initially titred against cTnI to obtain the optimal working dilution for an 
inhibition ELISA (Figure 5.2-37-A). Each scFv was incubated with a range of free cTnI 
concentrations (2000.39nM) and then converted to a ratio of signal obtained/signal at 
zero cTnI (A/A0).  Figure 5.2-37-B shows the full complement of selected scFv and their 
associated inhibition profiles in comparison to the WT scFv. It was apparent that there was 
a shift towards a lower IC50 value for the mutants and as IC50 is proportional to KD this 
suggests that the clones are indeed of improved affinity. Clones 2B12 and 1E12 were re-
analysed with the WT over a more focussed concentration series in the inhibition ELISA. 
Figure 5.2-37-C reaffirms the previous result showing an improvement in IC50 value for 
clone 2B12 (~6nM) over the WT (~10.5nM).  
This encouraging result indicated that clone 2B12 had superior inhibition assay 
performance compared to the WT, reinforcing the suggested affinity improvement found 
with the full kinetic analysis. The confirmation of discrete kinetic constants remained a 
high priority. 
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Figure 5.2-37: Titre and competitive analysis of wild-type and mutant scFvs for cTnI and free peptide 
A. Titration of scFvs against cTnI by ELISA: Supernatants were serially diluted in 1% (w/v) PBSTM 
and applied to individual wells. Bound scFv was detected using anti-HA HRP-labelled secondary 
antibody. Optimal dilutions of lysate were determined for each clone to give an absorbance of 
1.0AU. 
B. Inhibition ELISA for six scFvs and the wild-type: scFv was mixed 1:1 with various concentrations of 
free cTnI at the optimal scFv dilution derived from A. Post incubation the mix of the various scFvs 
and free TnI concentrations were applied to the cTnI-coated wells. Unbound scFv was available to 
bind to the surface-immobilised cTnI. The results here indicated a generalised shift wards lower IC50 
value compared to the WT. 
C. Two mutants and WT were re-analysed in the inhibition format: IC50 for WT ~10.5nM, 1E12 ~10nM 
and 2B12 ~6nM 
From this analysis an improvement in inhibition assay performance was observed and scFv 2B12 was selected 
as the best clone isolated from the MT screening campaign. 
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5.2.2.5.3 Purification of scFv from bacterial culture 
 
Both the WT and MT scFv were purified, as described in section 2.3.1.9, using the 
simplified PBS-based buffers delineated in section 2.1.4.6.2. The scFv were purified by 
virtue of the 6xHis tag encoded on the pComb3x vector by IMAC. The purification was 
carried out from 400mL cultures induced overnight (0.5mM IPTG). Both clones expressed 
well with minimal optimisation of culture conditions (results not shown). It was noted that 
a significant amount of protein was eluted, especially in the case of the MT scFv (Figure 
5.2-38) over the WT (Figure 5.2-39-A), in the washes (W1 and W2). The presence of 0.5% 
(v/v) Tween®20 may have caused this to occur, whereas the first wash contained many 
contaminating bands the W2 fraction appeared to be extremely clean. The W2 fraction for 
2B12 was concentrated/buffer exchanged alongside the pure fraction. These concentrated 
samples were re-analysed by SDS-PAGE (Figure 5.2-38-B) and showed a very pure protein 
preparation. For the analysis of the scFv 180 purification, the W2 fraction was concentrated 
alongside the pure fraction and run on the SDS-PAGE to ensure maximal recovery of 
expressed protein (Figure 5.2-39). In this case the loss of protein in the washes was 
significantly less pronounced, but significant. In both cases the pure fractions eluted (by 
acidic elution) and concentrated W2 fractions yielded significant quantities of protein of 
acceptable purity. Protein concentrations were obtained by A280 on a ND-1000™ and 
outlined in Table 5.2-5.  
 
Table 5.2-5: Purified scFv protein determination 
 Clone 180 
(Pure) 
Clone 180 
(W2) 
Clone 2B12 
(Pure) 
Clone 2B12 
(W2) 
Total protein (mg)  1.68mg 0.58mg 1.00mg 0.73mg 
μg protein per mL culture  5.7μg/mL 4.3μg/mL 
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Figure 5.2-38: Purification of 2B12 scFv (mutant) by immobilised metal affinity chromatography 
(IMAC) 
SDS-PAGE analysis of 2B12 scFv purification steps. The lanes are labelled as follows; FL: filtered lysate, F1: 
flow-through 1, W1: wash 1, W2: wash 2 and pure samples. PR
+
 is the prestained protein ladder. 
A) In the large-scale purification, samples of each step of the process were analysed. A notable amount 
of protein was washed from the column (W1 and W2) and appeared to be quite pure in the W2 lane. 
This fraction was concentrated from 5mL to 1mL alongside the eluted pure sample  
B) The concentrated pure and W2 fractions were re-analysed by SDS-PAGE. This showed that a large 
amount of pure protein was present in the W2 fraction.  
 
Figure 5.2-39: Purification of scFv 180 (wild-type) by IMAC 
SDS-PAGE analysis of 180 scFv purification steps. The lanes are labelled as follows; FL: filtered lysate, F1: 
flow-through 1, W1: wash 1, W2: wash 2, W2 conc.: concentrated W2 and pure samples. PR
+
 is the 
prestained protein ladder. As observed in the MT purification (above) specific protein was eluted in the 
washes (W1 and W2) to a much lesser extent. By concentration of the W2 sample a significant amount of 
protein was recovered. 
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5.2.2.5.4 Improved kinetic characterisation using fatty acid binding protein fusion 
 
Kinetic analyses for the WT and MT scFv was carried out using the FABP-P1&2 fusion 
protein (developed in section 3.2.4) to overcome the unreliability of the kinetic evaluation 
obtained with the cTnI protein (section 5.2.2.5.1). Kinetics were carried out on the 
Biacore™ 4000 (section 2.3.7) and permitted each scFv to be analysed on two spots for the 
full analyte concentration range (250.39nM) in a single run. The analyses were carried 
out on a minimum of three separate occasions with independently prepared analyte samples 
(total number of independent analysis = 6). 
Figure 5.2-40 is an example of the full kinetic profile for scFv 180 and 2B12 using the 
FABP-P1&2 fusion. Visually the fits are very good with chi
2
 (χ2) values of 0.34 and 0.68, 
respectively combined with good even residual distribution. In addition, the replicate 
measurements (3.13nM cTnI) were indistinguishable re-enforcing the reliability of the 
analysis. Table 5.2-6 outlines fully the kinetic constants obtained. The clones are 
statistically different from each other in terms of affinity. The scFv 180 was found to have a 
KD of 99.2±12.6pM and scFv 2B12 approximately 27% lower at a KD of 72.4±11.1pM. 
This overall improvement in KD was attributed to a slowing of the kd and was somewhat 
countered by a marginal impairment in ka. The kinetic constants derived using this ligand 
indicated a less dramatically improved kd (Figure 5.2-37), but the data sets were easily 
modelled and accurate statistical analysis (t-Test: two-sample assuming equal variances) 
was carried out to give reliable affinities (Table 5.2-6). 
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Figure 5.2-40: Full kinetic evaluation of wild-type and mutant scFv with the FABP-peptide fusion 
Example of the kinetic profile obtained on Biacore™ 4000 for each scFv using the global fit 1:1 Langmuir 
binding model. Serially doubling dilutions of FABP-peptide fusions were assayed (250.39nM) including 
one concentration in duplicate (3.13nM) and double referenced against both an equivalently immobilised 
reference spot and zero antigen concentration. Residuals are indicated for each data point below the kinetic 
sensorgram indicating the „goodness‟ of the fit. 
 
Table 5.2-6: Derived kinetic constants for wild-type and mutant scFv using FABP-peptide fusion  
 scFv 180 scFv 2B12 
ka (M
-1
s
-1
) 2.76x10
6 
± 5.18x10
5
 1.70x10
6 
± 1.06x10
5
 
kd (s
-1
) 2.70x10
-4
 ± 3.43x10
-5
 1.22x10
-4
 ± 1.50x10
-5
 
KD (pM) 99.2 ± 12.6 72.4 ± 11.1 
n 6 8 
Significance (p) 0.001 0.001 
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5.2.2.5.5 Thermal challenge assay to asses for improved thermostability 
 
To assess how the amino acid changes affected the stability of the proteins, a rapid thermal 
challenge method was adopted from the literature. High-throughput thermal stability 
screening has been suggested as a useful tool to isolate stable scFv variants in the area of 
bispecific and bivalent antibodies. This is especially important in this field as the stability 
of the scFv is often a limiting factor in its production, quality and yield [91]. In work by 
Miller and co-workers [92], improved thermally stabilised scFvs were identified by a 
statistical knowledge-based mutagenesis campaign where single mutations resulted in up to 
a 14
o
C difference in melting temperature (Tm). The approach compared scFv variants by a 
T50 binding assay which gave a rapid and useful insight to the thermal characteristics of the 
scFv variants (section 2.3.9).  
This approach was adopted in the characterisation of the WT and MT scFvs as a rapid 
means to assess the impact of the mutations observed between them. The assay involved 
heating equivalent protein concentrations over a 30
o
C temperature range for 90 minutes. 
Immediately after this, the scFvs were diluted 1 in 2 in 1% (w/v) PBSTM and assayed 
against cTnI for retained binding. The signals obtained were expressed as a percentage of 
retained binding activity compared to the non-heat treated samples. Figure 5.2-41 
demonstrates the difference in T50 binding activity for both WT and MT scFv. A shift of 
4
o
C for the MT was observed (WT: 58
o
C and MT: 62
o
C) suggesting improved 
thermostability.  
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Figure 5.2-41: Comparison of the stability of the scFvs 180 and 2B12 by thermal challenge 
Both clones were adjusted to equivalent protein concentrations and their thermal resistance evaluated by 
thermal challenge assay. Retention of binding activity to cTnI was correlated with temperature and the effect 
of the mutations introduced by the light chain shuffle appeared to improve the thermo-stability of the mutant. 
 
5.2.2.5.6 Sequence comparison of the two scFvs 
 
To ascertain the structural basis behind the determined improvement in affinity, the scFvs 
were sequenced by Source BioScience DNA Sequencing, St. James Hospital, Dublin. 
Sequencing was carried out using the pComb3x sequence primer pair (Table 2.3-4). From 
the derived sequence the biochemical properties (Table 5.2-7) were estimated using the 
PROTEIN CALCULATOR v3.3 [296]. 
 
Table 5.2-7: Biochemical properties of wild-type and mutant scFv 
 ScFv 180 ScFv 2B12 
Molecular Weight (kDa) 28.40 28.56 
Number of Amino Acids 276 276 
Estimated pI 5.97 6.20 
Charge at pH7.00 -4.5 -3.5 
Extinction Coefficient at 280nm (M
-1
 cm
-1
) 46040 46040 
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Figure 5.2-42 is the alignment (section 2.3.8.1) of the WT and MT scFv with the CDRs and 
significant features highlighted as per the caption. Noticeably, no mutations occurred in any 
of the VL CDRs, which might have been expected due to the observed affinity 
improvement. In the light chain there are two mutations in the framework (FR) preceding 
the CDRL1 (GE and EK). Additionally, a PCR introduced mutation in the framework 
of the VH preceding CDRH1 was introduced (LV). These mutations were combined with 
a change to the linker amino acid structure brought about by use of the published primer 
sequences [88] which are known to code for the linker GQSSRSSSSGGGSSGGGG in 
place of the correct primer encoding the linker GGSSRSSSSGGGGSGGGG. 
 
 
Figure 5.2-42: Sequence alignment of mutant and wild-type antibodies 
The CDRs are highlighted using the Kabat numbering system. Conserved CDR flanking regions are 
highlighted (black, bold and underlined). Light chain CDRs 1-3 are indicated in blue with the heavy chain 
CDRs in red. Other highlighted regions: linker; gold, hexahistidine tag; green and HA-tag; pink. Sequences 
were aligned using ClustalW at http://www.uniprot.org/. 
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The effect of the framework mutations was modelled from the sequence information using 
the online web antibody modelling (WAM) program for the prediction and 3D modelling of 
antibody Fv structure (section 2.3.8.2). This type of modelling was somewhat limited as the 
system uses human Fv sequences to predict structure. Such knowledge-based and ab initio 
methods are valuable to assess the changes introduced to the framework region of the 
mutant library, but apply human antibody structures to the avian antibody. 
Figure 5.2-43-A is an overlaid predicted model of the wild-type and mutant clones. The 
CDRs are coloured for easy visualisation. In the model, the CDR spatial relationships can 
be observed with the CDRH3 protruding higher than the other CDRs, but angled towards 
the CDRL3 which can be more clearly observed in the top-down view of the CDR pocket 
(Figure 5.2-43-B). In the top-down view, the other CDRs can be seen to run around the 
periphery of the binding pocket with some turns in the loops towards the CDRs L3 and H3. 
Figure 5.2-43-C shows the CDR view through the heavy and light chains which again 
highlights the dominant „lean‟ of CDRH3 towards the LC. 
Figure 5.2-44 focuses on the mutated amino acids. The backbone and CDRs are shown 
with their side chain groups and hydrogen bonds illustrated by the green dashed lines for 
both the LC and the HC. In the light chain the glycine (GGA) to glutamate (GAA) mutation 
retained the hydrogen bonds in that area and the second mutation, glutamate (GAG) to 
lysine (AAG), also showed no change in the hydrogen bond composition of the LC. The 
HC mutation, leucine (CTG) to valine (GTG), again failed to introduce any new or disrupt 
any existing hydrogen bonds.  
 
  
5–80 
 
  
 
Figure 5.2-43: Predicted hypothetical model of 180 and 2B12 scFvs 
A) Front on view: Heavy and light chain (without linker) illustrating CDR loops/domains. The model 
was generated using web antibody modelling (WAM - http://antibody.bath.ac.uk/index.html) and 
was visualised using SPDB deep-view and rendered using POV-Ray programs.  
B) Top-down view onto the CDR region: the High CDRH3 loop was the dominant feature of the CDR 
landscape.   
C) View through heavy and light chains: again the dominant protrusion of CDRH3 can be seen and the 
twist structure in the CDRL1 is apparent. 
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Figure 5.2-44: Modelled mutations for the wild-type and mutant scFvs with displayed side chains 
A) The modelled light chains for the WT (left) and MT (right) scFvs. The hydrogen bond (green dashed 
lines) landscape was not augmented by the introduced mutations (coloured in yellow). 
B) The modelled heavy chains for the WT (left) and MT (right) scFvs. Again no augmentation in the 
hydrogen bond (green dashed lines) landscape was observed, by the introduced mutations (coloured 
in red). 
 
  
5–82 
 
  
Overall the modelling suggests no change in backbone structure or introduction of new 
hydrogen bonds. However, the mutations appear to be towards more bulky amino acids 
with changes from hydrophobic to polar negative (GE) and polar negative to positive 
(EK) resulting in a slight overall effect on the pI of the protein (WT: 5.97 MT: 6.20 at pH 
7.0 from Table 5.2-7). This selection of a MT clone with bulkier amino acids may have 
been facilitated by use of the peptide in the bio-panning procedure. The extraneous parts of 
the protein were not present (all areas other than epitope one) and the scFv selected did not 
seem to cause a disadvantageous steric hindrance for binding to cTnI. In fact quite the 
opposite was suggested, as was observed from the kinetics. The flexible linker was not 
modelled here, but it is possible that the amino acids within the linker may interact with 
each other stabilising the scFv differently (Thermal stability, section 5.2.2.5.5) since the 
linker composition is not equivalent in both scFvs. Linker mutations have previously been 
demonstrated to impact antibody production, stability and recognition properties [160]. 
Attempts were made to model the interaction of the cTnI-derived peptide and the scFv 
using the FlexX program. However, the number of amino acids and areas of the scFv to 
which the peptide docked were substantial and no one „correct‟ model could be isolated by 
in silico docking. The same is true in attempts to dock the cTnI molecule using the Patch 
dock program. As the model of cTnI was based on only one incomplete crystal structure in 
complex, the scFv were seen to dock in many areas of the protein. In the absence of crystal 
structure determination the residues involved in mediating antibody-antigen interaction and 
the possible structural differences between the scFv remains an unknown. 
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5.2.3 Investigation of crystal structure of recombinant proteins 
 
Understanding protein structure and function is of paramount concern to scientists to 
understand the interactions between proteins, for example between an antibody and an 
antigen. Such limitations of in silico modelling of the scFv fragments (section 5.2.2.5.6) 
indicated that our understanding of the antibody 3D structure is limited, and particularly so 
for those antibodies derived from avian immune repertoires. Searching the PDB with 
keywords such as “single chain fragment variable” or “scFv” yields 263 and 44 hits, 
respectively. Of those hits the majority of the structures obtained are 2.0-3.0Å in resolution 
with few in the 1.5-2.0Å, high-resolution range. Further refining the search to Gallus Gallus 
(chicken) all the structures relate to avian lysozyme predominantly in complex with many 
species of antibody (current as of 15 June 2011). Therefore, the fundamental structure of 
avian derived antibodies would be of benefit to the scientific community and would 
enhance our combined knowledge of antibody structure.  The key to obtaining good quality 
crystal structures is a pure protein preparation that is homogenous, soluble, mono-dispersed 
and stable. To achieve this multistep purification protocols are typically required. Given 
that the scFvs generated in this thesis were stable and soluble proteins they were ideal 
candidates to carry out initial investigations into crystal structure. The wild-type and mutant 
scFv were of considerable interest to determine the structural features leading to the 
demonstrated affinity and assay improvements. However, initial coarse screening 
conditions did not lend themselves to efficient crystal formation for all constructs as the 
process of generating protein crystals is „trial and error‟ rather than a precise science. Due 
to time constrains it was not possible to investigate all of the protein constructs fully. The 
wild-type scFv 180 was the only protein optimised further for crystal formation due to the 
appearance of crystals in coarse screening experiments which allowed for optimisation 
trials to be setup and some preliminary diffraction data collection. This section describes 
the work carried out to optimise crystal production for the wild-type 180 scFv in 
collaboration with Professor James Whisstock‟s group at Monash University, Melbourne, 
Australia.  
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5.2.3.1 Crystal structure determination by X-ray crystallography 
 
Protein structure determination by X-ray crystallography allows the determination of 
protein structures at the atomic level and has the potential to greatly assist our 
understanding of protein function. The protein data bank (PDB) houses some 45,000 
macromolecular structures largely determined by crystallographic methods [297]. To study 
atomic structures a crystal is needed as the diffraction of a single molecule would not 
produce a signal strong enough to be measured. To achieve an „amplification‟ of the 
diffraction pattern structural biochemists rely on the formation of ordered, three-
dimensional molecular arrays or crystals [298], indeed the bottleneck to obtaining high-
resolution structures is the generation of suitable crystals. Proteins can be coerced into 
forming crystals when placed in the appropriate conditions where the protein undergoes 
slow precipitation from the aqueous phase. This causes the protein to align into repeating 
„unit cells‟ through the adoption of a consistent orientation known as a crystal lattice. The 
lattice is formed by non-covalent interactions and forms the basis for examination of the 
atomic structure by X-ray crystallography. For good diffraction the goal of the 
crystallisation process is to produce well ordered crystals of high purity protein. 
 
5.2.3.1.1 Basic X-ray diffraction instrument setup 
 
X-ray diffraction is a key technology for analysis of the arrangements of atoms within a 
crystal. Since it is possible to form crystals composed of salts, metals, proteins, peptides 
and DNA, the technique has become invaluable in the structural biochemists 
armamentarium and provides fundamental insights into structure for many fields. The basic 
instrument setup is described in Figure 5.2-45. Essentially a crystal mounted on the 
goniometer is rotated as it is continuously bombarded with focused X-rays producing a 
diffraction pattern of spots picked up by a detector (known as reflections). By compiling 
these various two-dimensional images a three dimensional electron density model can be 
created. The data set which is built from many different images contains spots relating to 
the electron density calculated by Fourier transforming the diffraction intensities. The data 
is indexed (matching electron density variations to spots), merged and scaled (matching 
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relative strengths of the spots in various images) and combined to give the total electron 
density (phasing). To achieve these steps powerful computer programs are relied upon to 
obtain and refine the determined structural information combination with complementary 
chemical information. The resolution of the images obtained is critical to obtaining precise 
structural features of the protein. High resolution protein structures are common place in 
the PDB with resolutions at the sub-atomic level possible. Table 5.2-8 demonstrates the 
relationship between the resolution (Å) and the features that can be obtained from 
diffraction data. 
 
 
Figure 5.2-45: Instrument setup for collection of X-ray diffraction patterns 
Rotating anode X-ray generator produces the primary X-ray beam (yellow line) which is focused onto the 
crystal mounted on the goniometer by focusing mirrors. The crystal is cooled by the cryo-stream to 100K. The 
focused beam strikes the cooled crystal and diffracts. The diffraction pattern is detected by an area detector. 
Green arrows represent rotational abilities of various components. Image was adapted from 
http://pruffle.mit.edu/atomiccontrol/education/xray/xray_diff.php 
 
Table 5.2-8: Relationship between resolution of X-ray diffraction and the structural features obtained 
Resolution (Å) Structural features observable on a good map 
5.5 Overall shape of the molecule. 
3.5 The main chain (ambiguous). 
3.0 Partial resolution of side chains. 
2.5 Resolution of side chains and plane of peptide bond. 
1.5 Atoms located to ± 0.1Å. 
0.77 Bond lengths. 
Table taken from [299]. 
  
5–86 
 
  
5.2.3.2 Results  
5.2.3.2.1 Refinement of protein purity 
 
Typically multistep purification protocols were not undertaken for scFv purification due to 
the fact that they were readily purified by IMAC. In the literature, protein purity required 
for the generation of crystal structures is reported from >90% to >98% by SDS-PAGE and 
so a very high purity is paramount. ScFv 180 purifications were typically of a purity >95% 
estimated by SDS-PAGE from IMAC (Figure 5.2-39). Accordingly, the scFv (180) was gel 
filtered using S75 10/30 column on the AKTA Explorer FPLC (GE Healthcare) to ensure 
that it was mono-dispersed, free from low molecular weight contaminants and further 
characterised as a single species by matrix-assisted laser-desorption/ionisation (MALDI) 
time of flight (TOF) mass spectrometry (MS). From the gel filtration chromatogram (Figure 
5.2-46) it was seen that the protein, after IMAC purification and storage, contained a 
mixture of monomer and higher order aggregates. The necessity for the protein to be mono-
dispersed and homogenous is critical for high quality crystal lattice formation. Despite 
storage for numerous days on ice at 4
o
C post gel filtration the monomeric protein did not 
revert to aggregated/dimeric forms (data not shown). This gel filtration step also allowed 
the protein to be buffer exchanged into 1X TBS (with 0.02% (w/v) NaN3) as phosphate salt 
crystals from PBS would contaminate any crystal tray setup. Interestingly, in experiments 
to gauge the state of the protein purified from cytoplasmic versus periplasmic extractions 
(see appendix Figure 8.1-15 for scFv periplasmic purifications), it was observed that 
cytoplasmic extractions yielded predominantly dimers and higher order aggregates (data 
not shown) even in cell-lines such as Rosetta 2 gami that are designed to promote disulfide 
bond formation in the cytoplasm.  The purified monomeric scFv was then analysed by 
MADLI-TOF MS confirming its purity and accurate determination of the protein molecular 
weight (28,545Da) as illustrated by the m/z plot in Figure 5.2-47. MALDI-TOF MS is a 
routine technique to identify proteins, a capability central to life sciences. The use of TOF 
rather than tandem TOF-TOF or other tandem detectors was the most suitable analysis 
method for determination of accurate mass in a high-throughput fashion [300]. Now that 
the protein satisfied the key requirements to generate reliable high quality crystals 
(homogenous, soluble, mono-dispersed and stable) it was concentrated to approximately 
6mg/mL to take forward to coarse screening for crystallisation conditions. 
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Figure 5.2-46: Gel filtration chromatogram for IMAC-purified scFv 180 
Gel filtration profile of scFv 180 after IMAC purification. Protein peaks were observed at 8-11mL for 
dimer/aggregates and 11.5-13mL for monomeric scFv. Protein was monitored by A280nm. The single 
monomeric fractions were then pooled and concentrated to approximately 6mg/mL. 
 
Figure 5.2-47: Mass and purity determination for scFv 180 by MALDI-TOF MS 
Species determination was carried out using MALDI-TOF (courtesy of Monash University) to accurately 
determine the mass of the scFv species in the purified sample. IMAC and gel filtered protein (6mg/mL) in 1X 
TBS (0.02% (w/v) NaN3) was used to prepare the spectrum in positive ionisation mode. The spectrum shows 
typically well resolved peaks representing the [M+2H]
2+
 (half mass) and [M+H]
+1
 (mass) of the sample. ScFv 
180 was observed to be a single species with a mass of 28.545kDa.  
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5.2.3.2.2 Screening conditions for crystal formation 
 
Manual trays were prepared by the hanging drop method and automated robotic trays by the 
sitting drop method, as illustrated in Figure 5.2-48. Vapour diffusion occurs when a drop 
composed of a mixture of sample and reagent is placed in vapour equilibration with a liquid 
reservoir of reagent (Figure 5.2-48). The lower reagent concentration in the drop causes 
water vapour to leave the drop to achieve equilibrium and eventually ends up in the 
reservoir. As water leaves the drop, the sample undergoes an increase in relative 
supersaturation and both the sample and reagent increase in concentration. Equilibration is 
reached when the reagent concentration in the drop is approximately the same as that in the 
reservoir [301]. Typically with this process the success rate is relatively low. Therefore, 
many conditions are screened and where changes occur, such as precipitation, they can be 
further altered by adjustment of protein concentrations or precipitant composition. There 
are a wide range of kits for different types of proteins/complexes to optimise crystallisation 
experiments. Hampton Research (HR) is the leading provider of theses crystallisation 
screening kits (summarised in appendix, Table 8.1-2). Each kit provides a differing set of 
crystallants, buffer composition, pH, salts and other additives to comprehensively coarse 
screen for conditions to promote crystallisation of proteins.   
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Figure 5.2-48: Drop methods for crystal screening 
The hanging drop method involved mixing the antibody solution with precipitant and turning the cover slip 
over before sealing on the reservoir using petroleum jelly. The sitting drop method was carried out by the 
automated crystal system depositing 100nL drops of protein and precipitant onto a small well located to the 
side of the reservoir. Supersaturation occurs as water leaves the drop and the precipitant concentration ([ppt]) 
moves to equilibrium with the precipitant concentration in the reservoir as described by the equation (inset). 
This figure was adapted from [301]. 
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5.2.3.2.2.1 Manual tray crystal screening and diffraction 
 
Manual trays were setup in 24-well plates by the hanging drop method (Figure 5.2-48), as 
described in section 2.3.10.2.1. Each day the trays were manually inspected noting the 
changes that occurred for example; formation of precipitation, phase contrast and absence 
of change. After 17 days, a low density of crystals formed in the manual screen for scFv 
180 in condition number 40 (0.1M Na-citrate pH 5.6, 20% (v/v) 2-propanol and 20% (w/v) 
PEG-4000). The crystals were imaged using a light microscope (Figure 5.2-49) and were 
typical of a protein crystal. However, only two crystals formed in the droplet which was 
likely to be attributed to the low scFv concentration (6mg/mL). With the protein that 
remained it was not possible to bring the protein concentration higher without the need to 
re-express and purify (time limits for the visit). However, fine screen trays were setup 
around the conditions found as described in section 2.3.10.3. The crystal was extracted 
from the drop and X-ray diffracted as described in section 2.3.10.4. Figure 5.2-50 shows 
the generated diffraction pattern collected. The dark spots are the diffraction pattern (or 
reflections) due to scattering of the X-rays that interact with the atoms in the protein crystal 
lattice. From this image, rotated through 90
o
, strong reflections were observed with weaker 
shadows in an irregular pattern that suggests a somewhat disordered lattice, overlapping 
second crystal or cracking of the crystal when placed at 100K without a cryo-protectant. In 
this case fine screening is required to improve a) the lattice order b) the crystal size/number 
and c) the resolution of the diffraction.  The crystallisation conditions were fine screened by 
varying the pH of the buffer, the 2-propanol and the PEG-4000 percentages as outlined in 
the plate layout grid described in section 2.3.10.3 (Table 2.3-16). The trays were placed at 
20
o
C and are currently awaiting crystal formation. 
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Figure 5.2-49: Formation of a crystal of scFv 180 in a manually prepared screen 
The Sigma basic screen condition number 40 (0.1M Na-citrate pH 5.6, 20% (v/v) 2-propanol and 20% (w/v) 
PEG-4000) gave rise to the formation of the crystals, shown above, after 17 days incubation at 20
o
C. The two 
overlapping crystals were promising protein crystals and were allowed to grow further as spikes on the top 
right are typical of a growing protein crystal. 
   
Figure 5.2-50: X-ray diffraction pattern of scFv 180 crystal from the manual tray 
X-ray diffraction pattern obtained using the Rigaku U-3HBR rotating anode generator with helium purged 
OSMIC focusing mirrors as an X-ray source and the data are collected using an R-AXIS IV++ detector at 
Monash‟s X-ray diffraction laboratory. The diffraction pattern confirms the crystal was protein and was of a 
low resolution at approximately 3.5-4Å. 
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5.2.3.2.2.2 Robotic (Crystalmation) crystal screening and diffraction 
 
Monash University houses an automated crystallography suite which was available to use 
during the collaborative visit maximising the limited amount of scFv by nano-dispensed 
spots. The automated suite consists of the Rigaku CrystalMation system which is a fully 
integrated platform for protein crystallisation. Robotic trays were setup in 96-well plates by 
the sitting drop method (Figure 5.2-48), as described in section 2.3.10.2.2. 
After 3 days, a low density of crystals formed PEG/ION screen position B10 (0.2M 
Potassium formate and 20% (w/v) PEG-3350) as shown in Figure 5.2-51. The crystals were 
allowed to grow for a further 12 days which resulted in the formation of a second crystal 
and were diffracted as described in section 2.3.10.4. In the case of this crystal of 180 scFv 
the diffraction pattern was much more ordered and the quality of the lattice superior to the 
previous crystal. Again some smearing of the reflections was observed which was 
attributed to cracking of the crystal in the cryo-stream or the presence of the second crystal 
behind the primary one (twinning). In this case the resolution was approximately 3Å. As for 
the previous crystal the conditions required modification to yield higher quality crystals and 
crucially more crystals to carry out numerous diffractions with cryopreservation. 
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Figure 5.2-51: Formation of a crystal of scFv 180 in position B10 of PEG/1ON screen 
The PEG/ION condition B10 (0.2M Potassium formate and 20% (w/v) PEG-3350) gave rise to the formation 
of the crystals, shown above, after 3 days incubation at 20
o
C.  
 
Figure 5.2-52: X-ray diffraction pattern of scFv 180 crystal from condition B10 of PEG/ION screen 
X-ray diffraction pattern obtained using the Rigaku U-3HBR rotating anode generator with helium purged 
OSMIC focusing mirrors as an X-ray source and the data are collected using an R-AXIS IV++ detector at 
Monash‟s X-ray diffraction laboratory. The diffraction pattern confirms the crystal is protein and medium low 
resolution at approximately 3Å. Again the slight shadow of the diffraction pattern (red arrow) is indicative of 
non-uniform lattice or cracking of the crystal 
 
  
  
5–94 
 
  
5.2.3.3 Future work to determine the crystal structure of scFv 
 
The results outlined for scFv 180 demonstrate successful optimisation of the coarse 
conditions required to generate protein crystals during a four week period, facilitated by a 
collaborative visit to Monash University, Melbourne, Australia. In the case of scFv 180, 
two conditions were found in the coarse screening to support the formation of crystals. In 
both cases, the abundance of the formed crystals was low presumably due to low protein 
concentrations and a relatively slow supersaturation process. The 0.2M sodium formate 
with 20% (w/v) PEG-3350 crystal was the most promising crystal in terms of its ordered X-
ray diffraction profile. However, further optimisation of the conditions for efficient crystal 
formation was required. In the case of the 0.1M Na-citrate pH 5.6, 20% (v/v) isopropanol 
with 20% (w/v) PEG-4000 crystal, which was larger in size, a less well ordered, but strong 
diffraction profile was observed under X-ray. In the case of this crystal conditions, at the 
time of leaving Monash, they were fine screened further and the trays are currently 
incubating. 
The results generated represent a significant advance towards determination of the crystal 
structure of the scFv 180 and the skills acquired can now be used as a template to examine 
the other proteins constructs. The work is envisaged to form part of a grant proposal to 
return to Monash for a significantly longer period of time to investigate and further refine 
the crystals and to ascertain the conditions required for the remaining proteins. 
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5.3 Isolation of recombinant antibodies against epitope-3 of cTnI 
 
Early in the lifetime of this work a previously prepared and panned avian scFv immune 
library was made available by Dr. Stephen Hearty and this library was developed with a 
cTnI protein-based immunisation protocol and panned against the whole protein molecule. 
Exhaustive mining of this library yielded a number of scFv-specific for the cTnI protein. As 
the body of work presented here focussed on particular epitopes crucial to the specificity of 
the envisaged cardiovascular risk test, initial studies characterised a subset of these scFv 
against the various epitope regions. This short section focuses on the isolation of the scFv 
„4G5‟ and its utility for incorporation into immunoassays as a „tracer or probe‟ antibody.  
 
5.3.1 Identification of anti-epitope 3 scFv from the screened library 
 
From a high-throughput robotics-based screening of a scFv library from cTnI protein 
immunised chicken several clones were identified by IC50 screening. This involved robotic 
titring of the clones (480) against cTnI (1μg/mL) to determine optimal lysate dilutions for 
competitive analysis. This was carried out on a custom built Tecan Evo Freedom robot and 
subsequently, the competitive analysis carried out as normal by the robotic system. A high-
throughput Excel macro file was used to tabulate the data into an output of IC50 to rank the 
clones (Figure 5.3-1). As an initial screen was carried out against the cTnI protein it 
provided no insight into epitope-specificity.  
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Figure 5.3-1: Customised macro for anti-epitope-3 scFv ranking experiments 
This is an example of a one plate competitive readout from the macro, written by Dr. Paul Leonard. Clones 
were labelled negative if A0 was < 0.2 and the IC50 values for the clones grouped (central columns) and the 
actual IC50 value given on the RHS.  
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The issue of specificity was addressed by employing the custom-designed biotinylated 
peptides to mine a small subset of the screened library for epitope-specific antibodies. In a 
direct binding ELISA, the supernatants were diluted and applied in series to wells coated 
with the peptides. Figure 5.3-2 shows that the clones were either cTnI protein-specific 
outside of the epitope regions targeted or they were epitope-3-specific. No clones were 
found to react to either epitopes 1 or 2. Indeed exhaustive mining of this library by others, 
in a number of formats on the Biacore™ 4000 (when it was acquired), failed to yield any 
epitope-1 or 2-specific antibodies (data not shown). None-the-less successful identification 
of an anti-epitope-3 scFv (4G5) was achieved in this analysis. The epitope has utility as a 
tracer or reporter targeting epitope for specific assay, employing the N-terminal-specific 
antibodies as capture reagents. 
To further analyse the scFv it was compared in an inhibition ELISA format (section 
2.3.6.2) in comparison the Hytest equivalent antibody 16A11. Figure 5.3-3 demonstrates 
the comparable performance in the inhibition format for the isolated scFv 4G5 and for the 
Hytest mAb 16A11. 
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Figure 5.3-2: Epitope-specificity mapping of the scFv isolated from a cTnI protein-based avian library 
Twenty seven clones were analysed against the synthetic biotinylated peptides in a direct binding ELISA 
format using the neutrAvidin. Each scFv lysate was assayed against all four peptide regions and cTnI. As was 
observed from the graph a number of false positives were carried through the initial robotic screening, likely 
caused by suboptimal setup. Additionally, 3 clones reacted with peptide 1 and 2 without reacting to cTnI 
(3F9, 3G12 and 4D11). As expected quite a few clones reacted to cTnI, but not at the specific epitopes (1B1, 
1B2 1F5, 4H4, 4A7, 4C7 and 4F12). A significant number of epitope-3-specific scFv were identified from the 
analysis (4C1, 4F5, 4G5, 4H5, 4C6).  
 
Figure 5.3-3: Inhibition analysis of identified anti-epitope-3-specific clone 4G5 
Comparison of clone 4G5 selected from the immunised library and the equivalent commercial standard 
antibody 16A11 HRP-labelled mAb. Both clones behave comparably with IC50 values approximated at 
800ng/mL for 4G5 and 600ng/mL for Hytest 16A11. 
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5.3.2 Purification of anti-epitope-3 scFv from bacterial culture 
 
From the derived sequence of 4G5 (see appendix Figure 8.1-14 ) the biochemical properties 
(Table 5.3-1) were estimated using the PROTEIN CALCULATOR v3.3 [296]. 
 
Table 5.3-1: Biochemical properties of the anti-epitope-3 scFv 
 4G5 
Molecular Weight (kDa) 28.16 
Number of Amino Acids 275 
Estimated pI 7.12 
Charge at pH7.00 0.4 
Extinction Coefficient at 280nm (M
-1
 cm
-1
) 45450 
 
Purification of the scFv from bacterial expression was carried out (section 2.3.1.9) on a 
number of occasions, but continuously gave poor yields of functional antibody from IMAC 
purifications. SDS-PAGE and WB analysis (section 2.3.1.11 and 2.3.1.12) of the 
purification fractions collected showed successful purification of scFv (data not shown). 
However, a significant proportion was not retained on the column despite repeated 
applications of the flow through to the IMAC resin. Typically from a 400mL induced 
culture only 0.3mg of pure scFv could be obtained (0.75μg/mL).  Despite numerous 
expression optimisation experiments and purification modifications the yield of protein 
remained prohibitively low. The possibility of re-formatting the scFv to scAb (section 
2.3.11) was envisaged to help improve the levels of expression by the addition of skp 
chaperone (see appendix, Figure 8.1-7) as yields of scFv were previously shown to be 
improved by addition of a constant domain [206].  
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5.4 Chapter conclusions 
 
A synthetic epitope-based immunisation strategy successfully yielded a strong chicken 
response-specific for the native cTnI protein. A large scFv library was constructed and 
subjected to stringent selection based on presentation of the cTnI protein. This unique, 
defined presentation strategy asked several distinct questions of the scFv library i) to bind 
to a particular epitope of cTnI and ii) to do so in the presence of a second bound antibody. 
The bio-panned population was screened in a HT-fashion applying percentage left analysis 
with insights into expression levels in a single run. This data was combined with a novel 
differential cTnI concentration sandwich assay which provided assessment of each of the 
clones individual sensitivity to lower cTnI concentrations. Ultimately, the stringently bio-
panned and rigorously screened library yielded a single „jackpot‟ antibody sequence. The 
WT antibody (scFv 180) was immediately mutated by a conservative light chain shuffle 
and subjected to in-solution-based bio-panning to mine for higher affinity scFvs. The 
mutant clones were screened in truly HT-manner assessing kinetic parameters (ka and kd) 
and ranking the stability of the binding events by percentage left analysis at all times in 
direct comparison to the WT antibody. This information combined with „2 over 2‟ and full 
kinetic evaluation led to the isolation of several very high-affinity clones which were 
superior to the WT in side-by-side analyses. The superior performance of the MT scFvs 
was further confirmed by inhibition profiling and assignment of definitive affinity values 
(KD) to the WT (99.2pM) and selected MT (72.4pM) using the „in-house‟ recombinantly 
expressed and purified FABP-P1&2 fusion protein. 
In silico modelling sought to determine the structural reasons behind the higher affinity and 
proven increased thermostability between the WT and selected MT scFvs. These improved 
properties were not attributed to changes in the protein structure or introduction of 
stabilising hydrogen bonds, but by subtle modification of protein charge and an increase in 
the bulk of the amino acids. The nature of these structural differences was of considerable 
interest and the investigation into the crystal structures of the protein constructs was an 
exciting avenue to explain the improved cTnI-binding profiles. Despite the crystal structure 
studies being in their infancy, the fundamental basis behind the structure of avian 
antibodies, in particular the WT and MT, have the potential to add significantly to our 
collective knowledge of basic structural biology. 
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An existing library constructed from a chicken sensitised with the whole cTnI protein was 
assessed for epitope-specificity using custom designed biotinylated peptides. The spread of 
epitope-specificity demonstrated in this screening highlighted the challenges to generating 
epitope-specific antibodies from whole protein-based immunisation regimes. The 
immunodominance of epitope-3 was apparent and led to poor epitope reactivity for the N-
terminal epitopes-1 and -2. The recalcitrance of these crucial epitopes represented a 
significant challenge to the generation of highly-specific, high-affinity antibodies and these 
results formed the basis of the rationale behind synthetic epitope-based immunisation 
protocols. Anti-eptiope-3 scFv were successfully isolated and a single clone (4G5) 
evaluated in comparison to the commercial equivalent. Issues surrounding the purification 
of the scFv were investigated as the yields were prohibitively low. This was envisaged to be 
significantly augmented by domain reformatting experiments introducing the chicken 
constant domain (section 6.2.2). 
Demonstrated throughout the generation and isolation of recombinant antibodies was the 
flexibility of this type of antibody technology. In a relatively small time scale a scFv library 
was constructed from an avian repertoire of modest serum titre, rigorously bio-panned and 
immediately taken forward into a mutagenesis strategy to further refine the affinity where 
one well equalled one antibody. The success of the two bio-panning campaigns for anti-
epitope-1 scFv development further validates the synthetic epitope methodology of 
antibody generation. The successful application of recombinant antibody technology here 
further supports the decision to move away from monoclonal antibody generation 
hybridoma technology, albeit a decision forced by the differential responses to cTnI in 
chicken and mouse-based peptide immunisations. Critical to the success of the subsequent 
screening campaigns was the rational, well thought-out bio-panning experiments tailored to 
select for the most optimal antibody pairings for cTnI-diagnostic applications. The selected 
antibodies exemplify the most desirable outcome from the selection campaigns. The ability 
to access these high-value and high-affinity reagents was supported by the capability to 
exhaustively mine large numbers of clones in a HT, assay-relevant manner. The availability 
of multiplexed, highly-parallel processing power of the Biacore™ 4000 instrument 
significantly contributed to finding these antibodies. During the screening campaign, multi-
parameter data was acquired which was most notably highlighted in the mutant screening 
campaign.  
 
6–1 
 
  
 
 
 
 
 
 
 
 
 
 
Chapter 6: Recombinant antibodies – assay development: benefits 
and pitfalls 
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6.1 Foreword  
 
Some key parameters exist for the successful exploitation of antibodies in POC-based 
applications. These include sensitivity, selectivity, stability, immobilisation (i.e. orientation 
on the surface), labelling and antibody size (impacts on the density of the bio-layer of the 
POCT test). Recombinant antibodies are an attractive technology to optimise these factors, 
but chemical modification of scFv fragments can limit their broader utilisation. Some 
modifications, such as the SNAP-tag offer a methodology to control the site and 
stoichiometry of modification [302]. Genetic modification facilitates improvements in 
selectivity, stability, size (sections 5.1.3 and 5.1.4) and, in addition, such novel antibody 
fragments can aid effective immobilisation [200]. High-throughput screening (section 
5.1.10) and display libraries facilitate improvements in sensitivity due to the ability to 
screen much larger recombinant antibody libraries (Section 5.1.5). The use of coupling 
chemistries and genetic insertion of tags for immobilisation (section 5.1.9) are valuable in 
assisting the orientation and immobilisation of such antibodies. The ability to alter 
properties such as the size and affinity of antibodies has led to the development of novel 
antibodies which have potential uses in diagnostics (see Table 5.1-3). Commercially 
available monoclonal antibody-based POC-tests exist, for example in the diagnosis of 
cardiovascular disease, and include: Abbott‟s i-STAT® (cTnI) [303], Roche‟s CARDIAC 
proBNP assay [304] and those listed in Table 1.3-3. The area of POC-testing for cTnI 
monitoring is dominated by the use of monoclonal and polyclonal antibodies with no 
commercially available, approved recombinant examples available. An article published by 
Ylikotila and co-workers highlights the utility of recombinant Fab fragments, derived from 
the Hytest® catalogue of mouse monoclonal antibodies, notably for the ability to site-
specifically label the fragments [305]. The specificity, and to a large degree the sensitivity, 
of all these assays is dictated by the biorecognition element [18, 306] and hence, the ability 
to develop more sensitive and robust systems is reliant on the modification of antibodies to 
improve these attributes. The capacity to enhance recombinant antibodies with respect to 
their selection, modification and subsequent applications in biosensors is of critical 
importance. 
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6.2 Results 
6.2.1 Comparison of wild-type, mutant and Hytest antibodies 
 
The final assessment of the purified scFv was carried out in a „side-by-side‟ analysis with 
the Hytest anti-epitope one antibody (19C7) by inhibition analysis (section 2.3.11). All 
three proteins were titred and optimal concentrations for the inhibition assay identified 
(Hytest: 1 in 4,000; scFv 180: 1 in 2,000 and scFv 2B12: 1 in 60,000). A serially diluted 
(doubling) concentration range of cTnI (10,000ng/mL  0.019ng/mL) was utilised to 
compare the clones by IC50. The analysis was carried out in duplicate and with three 
independently prepared antibody and inhibitor preparations.  Figure 6.2-1 shows the 
dramatic superiority of the scFv in this assay format compared to the Hytest standard. The 
mean IC50 values for the WT and MT clones were 3.2 and 9.0-fold improved, respectively, 
compared to the mAb. The very conservative light chain shuffle, and the subsequently 
introduced mutations, led to a 2.7-fold improvement in assay performance between the WT 
and MT scFv. In addition, the proteins were easily purified in sufficient quantity and purity 
for analysis. The highly-specific, highly-sensitive reagents generated represent a significant 
step towards improved cTnI diagnostics and lend themselves readily to incorporation into 
much higher sensitivity cTnI risk determination platforms. To realise this potential 
application the limitations of the use of small fragments come into play, for example 
immobilisation leading to antibody denaturation and labelling of scFv causing loss of 
binding or blocking the compatible pair interaction. The latter was a phenomenon seen with 
the amine-coupling of fluorescent dyes to scFv 2B12. The antibody retained its reactivity 
for cTnI, but the sandwich assay using the mAb 20B3 was compromised. To address these 
issues reformatting of the scFv was an attractive methodology to increase the molecular 
surface of the molecule and facilitate site-specific functionalisation. 
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Figure 6.2-1: Comparison of wild-type and mutant scFv to Hytest anti-epitope-1 antibody 
IC50 value comparison of WT, MT and commercial antibodies.  IC50 values were obtained from three 
independent analyses (in duplicate) of an optimised inhibition ELISA (inset). Average IC50 values were 
plotted on a bar chart with standard deviations applied. Hytest mAb (19C7) had a mean IC50 of 1883ng/mL, 
the WT scFv 180 an IC50 of 583ng/mL and the MT scFv 2B12 an IC50 of 210ng/mL. The analysis shows the 
clear superiority of the recombinant antibodies generated in the course of this work. The MT scFv shows 
additional improvement over the WT. 
 
6.2.2 Reformatting recombinant antibodies 
 
Modification of the scFv format to improve potential application in a diagnostic setting was 
undertaken. Introduction of the Cλ domain from chicken cDNA was of interest to facilitate 
improved stability and immobilisation or orientation and selective labelling via the cysteine 
residue (Figure 6.2-2). Labelling experiments using commercially available amine coupling 
kits resulted in a steric hindrance for scFv binding to the antigen in a sandwich assay format 
(results not shown). With all the substantial effort to develop compatible assay pairings this 
presented a significant challenge. The ability to specifically label, using the reactive 
cysteine residue incorporated into the scAb format (Figure 6.2-2), offered a selective 
method to position the labelling site away from the binding site of the antibody. 
  
6–5 
 
  
 
 
Figure 6.2-2: Reformatting scFv to include chicken constant light domains 
Reformatting of the scFv to the scAb format. An additional chicken constant light (CL) domain was added to 
the VH of the scFv (VL-VH format) by cloning the scFv into the pMopac16 vector with the HuCκ replaced with 
chicken Cλ. The co-expression of the periplasmic chaperone skp on the pMopac16 vector (Figure 8.1-7) 
enhanced expression of most clones. 
 
The scFvs 2B12 and 4G5 were reformatted to scAb and scAb-cys as a result of the findings 
above. The first step to convert the scFv to scAb was switching of the pComb3x SfiI sites 
to a pMopacCλ compatible restriction site pair. This was carried out by PCR amplification 
using primers to „switch‟ the restriction sites (Table 2.3-18). Figure 6.2-3 shows the 
successfully amplified PCR products for scFv 2B12 and 4G5 from their pComb3x vectors. 
The purified products were digested, ligated into the pMopacCλ vector and transformed as 
described in sections 2.3.12.1 and 2.3.1.4.  
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Figure 6.2-3: PCR modification of SfiI sites in 2B12 and 4G5 scFv 
Resolution of PCR amplifications from purified plasmid on a 2% (w/v) agarose gel. Discrete bands 
representing the modified SfiI scFv inserts were observed at approximately 800bp for 2B12 and 4G5. The 
DNA size was approximated by comparison to 1Kb
+
 DNA ladder. A negative reaction (NEG) ensured no 
contamination of the reaction components. 
 
Single colonies were isolated for both the scAb constructs and expressed in small-scale to 
identify functionally active protein expression by ELISA and SDS-PAGE/WB (data not 
shown). Large-scale expression was undertaken and the protein lysed from E. coli cells as 
described in section 2.3.1.7. The proteins were purified as per the generic protocol in 
section 2.3.1.9 using the PBS-based buffers prepared as outlined in section 2.1.4.6.2. Figure 
6.2-4 shows two significant results. The 2B12_scAb expressed and purified extremely 
efficiently which was due to the presence of the SKP chaperone on the vector. In excess of 
12mg of protein was purified from a single 400mL overnight induced culture compared to 
~3mg in the same culture volume for the scFv format. The second dramatic result is the 
comparably sub-optimal expression of the 4G5_scAb construct. Under the same culture 
conditions it failed to express well (see Figure 6.2-4; FL lane in the WB) and led to very 
low protein purification yields (comparable to those in scFv format). For comparison 
purposes the 2B12_scAb-cys was expressed and the purified protein is shown in Figure 
6.2-5, illustrating a dramatic decrease in protein expression as can be expected due to the 
presence of a free cysteine. However, the protein can still be purified better than the 
4G5_scAb. Examination of the hydrophobicity plot and amino acid sequence for 4G5 (see 
appendix Figure 8.1-14) does not reveal any obvious reasons for its low expression. 
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Attempts to optimise the expression of 4G5_scAb like 4G5 scFv failed to increase the yield 
of purified protein (data not shown). The issue of rare codon usage was thought to 
contribute to the sub-optimal expression of the scFv and the scAb formats for 4G5. This 
was investigated by analysis of the DNA sequence. The 2B12 scFv was found to contain 15 
rare codons with 4G5 containing only 12, by comparison. This suggests that the rare codon 
usage was present, but did not affect the 2B12 scFv. Introduction of the avian Cλ introduced 
an additional 6 rare codons for E. coli, but did not seem to effect the 2B12 construct as 
dramatically as the 4G5 construct. To overcome any potential limitations of E. coli rare 
codon usage for 4G5 it was transformed into Rosetta2 cells for analysis of expression due 
to supply of rare codon tRNA by the cell. In this case expression could not be dramatically 
improved. It may be useful to clone this scFv into a dedicated expression vector, such as 
pET26b, to tightly control the expression as 4G5 may prove to be toxic to the cells or 
unstable under the control of the leaky lac operon that is present on the pComb3x and 
pMoPac vectors. 
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Figure 6.2-4: SDS-PAGE and Western blotting of scAb purification steps 
The fractions from each stage of IMAC purification were analysed by SDS-PAGE (top) and WB (bottom). 
The lanes are labelled as follows; PR
+
: protein ruler, UFL: unfiltered lysate, FL: filtered lysate, F1-3: flow-
through, W1-5: wash-steps and pure protein. The WB‟s were probed with an anti-HIS HRP-labelled antibody. 
A) The 2B12_scAb protein was purified very successfully as confirmed by the presence of a very large 
band in the „pure‟ lane. When probed with the anti-HIS HRP-labelled antibody in the WB, the 
protein was seen to express extremely well (UFL lane), was retained on the IMAC resin (F1-3) and 
little was lost during washing (W1-2). 
B) The 4G5_scAb, by comparison, purified poorly. This was attributed to low expression levels of the 
protein as demonstrated by the weak band in the „FL‟ lane of the WB. 
 
Figure 6.2-5: SDS-PAGE and Western blotting of 2B12_scAb-cys purification steps 
The fractions from each stage of IMAC purification were analysed by SDS-PAGE (top) and WB (bottom).. 
The lanes are labelled as follows; PR
+
: protein ruler, UFL: unfiltered lysate, FL: filtered lysate, F1-3: flow-
through, W1-5: wash steps and pure protein. The WB was probed with an anti-HIS HRP-labelled antibody. 
The presence of the free cysteine on the scAb_cys construct resulted in diminished expression. However, the 
protein was purified in amounts sufficient for characterisation and assay development. 
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6.2.3 Initial development of plate-based assays 
 
The optimal assay pairings were initially investigated using the 20B3 mAb as the capture 
reagent. In this case an anti-HA HRP- or anti-HA Cy5-labelled secondary antibodies were 
employed to remove the need to directly label the scFv format by virtue of targeting the 
HA-tag. The tests were carried out to assess greatest cTnI sensitivity achievable using the 
possible pairings available. The available antibodies were paired as follows:   
20B3mAb with 2B12 scFv 
20B3mAB with 4G5 scFv 
20B3mAb with cTnI-specific scFv 
Figure 6.2-6 illustrates suboptimal assay sensitivity where the mAb capture was postulated 
as a potential weakness in developing a highly-sensitive assay format. The high-affinity of 
the 2B12 scFv made it a very attractive alternative to mAb20B3 as a capture reagent. With 
its conversion to scAb format it was possible to capture cTnI and probe the available 
reporter scFv (4G5 or cTnI-specific scFv). From the observed performance of the cTnI-
specific scFv (Dr. B. Vijayalakshmi Ayyar.) it was decided to combine it with the 
2B12_scAb in a demonstration fluorescent-linked immunosorbent assay (FLISA). Figure 
6.2-7 shows the dramatic improvement in sensitivity using the fluorescently labelled anti-
HA-Cy5 (Rockland Labs.) and the scAb in a sandwich configuration with the undefined 
epitope cTnI-specific scFv. This non-optimised assay can detect cTnI down to ~50-
100ng/mL. The success of the FLISA was anticipated to be improved further by 
optimisation of the plate-based assay and use of anti-HA IR®800-labelled antibodies to 
facilitate in serum detection. However, the development of assays was compromised by 
batch to batch variability in antigen quality. 
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Figure 6.2-6: Optimisation of capture and reporter reagent combinations for a cTnI sandwich assay 
20B3 capture and various scFv reporter combinations were assayed to determine the optimal pairing for 
development of a sensitive sandwich assay. cTnI was captured over a large concentration range and the 
detected with anti-cTnI-epitope scFv 4G5 (epitope-3) and 2B12 (epitope-1) and the anti-cTnI-specific scFv 
(undefined epitope). The scFv were detected using an anti-HA HRP-labelled secondary antibody. 
 
Figure 6.2-7: Demonstration FLISA for a cTnI  sandwich assay 
Reformatting the 2B12 scFv to scAb facilitated direct immobilisation of the high-affinity anti-epitope-1 
antibody to the surface of the FLISA plate. cTnI from 1μg/mL to 0.02ng/mL was captured and detected by 
anti-cTnI scFv with anti-HA Cy5-labelled reporter antibody. The assay was significantly more sensitive than 
with the mAb capture and by virtue of using a fluorescence detection system in conjunction with a higher-
affinity capture reagent. 
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6.2.4 Assays compromised by antigen variability 
 
The assays described above were carried out using combinations of the 2B12_scAb with 
anti-cTnI scFv or 4G5 scFv and mAb 20B3 paired with the 2B12 scFv, 4G5 scFv or cTnI 
scFv. Initially the coating concentrations of the capture antibodies were investigated. 
However, no signals were obtained for any analysis pairing despite modification of the 
coating buffers and concentrations of the reagents (data not shown). To investigate this 
further a number of test ELISAs using the antibodies in combination with the commercially 
sourced antibodies as controls were carried out providing an insight into the behaviour of 
the antibodies with the new batch of antigen. Figure 6.2-8 demonstrates the behaviour of 
mAb 20B3 and Hytest 228 in comparison to 2B12_scAb. In both cases the capture by anti-
epitope-2-specific reagents did not generate a signal, whereas the anti-epitope-1-specific 
capture worked well with the Hytest mAb 16A11. The only difference between these assays 
and those carried out previously (in section 6.2.3 and for mAb screening in section 4.2.2 
and rAb generation in sections 0) was the cTnI batch from the commercial source. This lead 
to the realisation that the antigen quality was affecting the assay as previously reported in 
the literature [94]. The cTnI was tested by SDS-PAGE and WB using all the commercial 
and „in-house‟ antibodies. In the SDS-PAGE and WB all the antibodies reacted with the 
antigen (Figure 6.2-9) in much the same pattern as the original batch quality check (Figure 
3.2-1). This suggests that the solubilised commercial cTnI antigen had adopted a different 
conformation which resulted in diminishment of the capacity of the anti-epitope-2 mAbs to 
bind to it in-solution.  
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Figure 6.2-8: Test of capture reagents including the positive control mAb 228 with the new batch of 
cTnI  
Analysis of the cTnI batch by sandwich ELISA. MAb20B3, Hytest mAb228 and 2B12_scAb were coated 
(20μg/mL) onto wells of an ELISA plate and captured 2μg/mL cTnI in 1% (w/v) PBSTM. The captured cTnI 
was then probed with Hytest 16A11 HRP-labelled mAb. The analysis shows that combinations of anti-
epitope-2 mAbs and reporter gave no signal in contrast the anti-epitope-1 scAb and 16A11 combinations 
which gave a strong signal. This suggests the antigen has adopted a new conformation or has undergone 
degradation. 
s  
Figure 6.2-9: Test of new cTnI batch by SDS-PAGE and WB 
Analysis was carried out using a battery of anti-epitope antibodies. SDS-PAGE (LHS) of cTnI from Life 
Diagnostics. Multiple transfers of the resolved gel were prepared in series and probed with various antibodies. 
Hytest control antibodies 19C7 (epitope 1), 228 (epitope 2) and 16A11 (epitope 3), and in-house 20B3 
(epitope 2) and 2B12 (epitope 1). 19C7 and 16A11 were both HRP-labelled and were directly detected. MAbs 
228 and 20B3 were detected using an anti-mouse HRP-labelled secondary antibody and recombinant antibody 
2B12 was detected using anti-HA HRP-labelled secondary antibody. PR
+
: Prestained protein ladder 
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6.3 Chapter conclusions 
 
The developed recombinant anti-epitope-1 scFv were demonstrated to have far superior 
affinity compared to the industry standard monoclonal antibody from Hytest. The basic 
light chain shuffled mutant was shown to be further improved over the wild-type in the 
inhibition ELISA format. The development of truly high-affinity reagents, for deployment 
in diagnostics test systems was a critical component. However, it is the first stage of ultra-
sensitive detection and requires significant support from the assay platform and signal 
amplification components of the POC format. 
Issues relating to the small size, aggregation potential, stability, labelling potential and 
unsuitability to direct immobilisation of the scFv validates the requirement to reformat the 
antibodies. Introduction of a single constant domain in the scAb format has the potential to 
dramatically improve the expression potential and increases the „real-estate‟ area of the 
antibody to be exploited without compromising high-affinity binding. The presence of the 
reactive cysteine residue has applications for ordered immobilisation of the capture 
reagents and facilitates labelling of the antibody at the C-terminus away from the 
functionally vital area, the binding pocket. These requirements were highlighted in the 
experiments carried out to evaluate the effects of directly labelling the scFv. The specific-
labelling and immobilisation of the constructs is currently under optimisation, but was 
successfully applied to the immobilisation of the 2B12_scAb_cys on AFM cantilevers 
using hetero-bifunctional linkers. 
As was observed from the initial antibody pairing experiments, the availability of a number 
of antibody combinations was valuable in developing the working demonstration assay for 
cTnI detection. Use of the monoclonal antibody 20B3 in its current form demonstrated 
lower sensitivity for cTnI than the reformatted 2B12_scAb. It was therefore of considerable 
importance to isolate the variable domains from the hybridoma and refine the affinity by 
recombinant antibody-based methodologies.  
The promising assay development process centred on the tested pairings and was thwarted 
by variation in commercially sourced batches of cTnI which was previously reported in the 
literature as a barrier to standardised cTnI-based cardiovascular assays [94]. The variability 
in the reactivity of the anti-epitope-2 monoclonal antibodies between the sandwich assay 
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and the Western blotting analysis suggests that the antigen adopted a different confirmation 
in-solution and was likely to be causing occlusion of the epitope-2 domain. This was not 
seen in the previous batch and further highlights the need for a consistent stable and 
representative antigen or reference standard.  
The initial optimisation of the assay pairs and reformatting experiments were undertaken to 
pre-develop an electro-chemiluminescent (ECL) assay [307]. The development of the ECL 
assay was an avenue of interest as a novel means to detect ultra-low concentrations of cTnI 
which was based on results previously obtained using anti-CRP antibodies. The use of ECL 
has the potential to dramatically increase assay sensitivity by removal of the excitation light 
source decreasing the background signal. The use of super-critical angle fluorescence 
(SAF) was a second avenue of assay development which focuses light on a single region of 
a parabolic chip reducing the bulk fluorescence in the sample and efficiently collecting 
light for the sample zone even from a single flurophore [308]. The SAF platform 
potentially addresses the unmet need for fast and sensitive concentration measurements at 
low cost and could be useful in POC testing [309]. Both these assay avenues required 
optimised assay pairings and the introduction of labels-specific to the assay format. The 
issues highlighted for the labelling and immobilisation of the antibodies were addressed by 
simple yet novel reformatting experiments. The potential development of these novel 
assays was compromised by the variance in quality of the antigen. The use and 
development of a common cTnI assay calibrator has received much attention and rigorous 
investigation. Harmonisation of different cTnI assays and standards appears to be a 
complicated process due intractably to the different recognition patterns of different anti-
cTnI antibodies used in the assays. Hytest® provides a native cTn ternary complex in liquid 
form which has received recommendation for use by the American Association for Clinical 
Chemistry (AACA). Additional rigorous characterisation of this material was developed by 
the National Institute of Standards and Technology (NIST) as even minor variances in 
structure of the material can distort the reactivities and hence analytical performance of the 
material [94]. Despite these barriers the high-affinity antibodies developed are essential for 
ultra-sensitive assay formats, which is the ultimate goal. The relatively simplistic transition 
of the scFv to both scAb and scAb_cys formats significantly improved stability and 
orientation while imparting a modular capacity to design and develop highly tailored 
biorecognition entities for POC testing. 
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Chapter 7: Concluding remarks and discussion 
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Acute coronary syndrome is the single greatest killer in the western world placing a 
massive healthcare and social burden on world economies. The importance of early 
intervention cannot be emphasised strongly enough in order to provide the patient with an 
opportunity to change their lifestyle and circumvent the health issues associated with 
cardiac muscle damage. Due to the massive impact of cardiovascular events, significant 
research has focussed on the development of reliable methods to detect these events, 
preferably upstream of irreversible myocardial necrosis. However, many of the potential 
biomarkers purported to be indicative of future cardiovascular events remain inconclusively 
proven. The cardiac troponins are the only biomarkers of cardiovascular disease accepted 
clinically as definitive indicators of a cardiovascular event and the challenges faced by 
medical practitioners in diagnosing CVD are still substantial. 
Cardiac troponin I, a biomarker of myocardial damage, was targeted for the development of 
highly-specific antibodies for the generation of a low cost point-of-care device. The choice 
of cTnI as a target, was complicated by its structural and sequence similarity to its skeletal 
isoform, its existence in complex and modified forms and interferences from serum 
proteins during analysis. To circumvent these challenges a rational epitope targeting 
approach was adopted to develop antibodies-specific to the N-terminal cardio-specific 
region of cTnI. 
In Chapter 3, the cTnI antigen was introduced and limitations due to the quality of the 
antigen available from commercial sources highlighted. The limitations of protein-based 
immunisation regimes for generating epitope-specific antibodies were discussed, and the 
principles of the design and use of synthetic peptide-based immunisation regimes were 
proposed. To overcome the cTnI quality issues, for efficient antibody generation and 
characterisation, recombinant expression of various forms of the antigen were investigated. 
The expression and purification of recombinant TnI was complicated by the protein‟s high-
charge. It was successfully expressed, but formed insoluble inclusion bodies and the 
production strategy was refined to use truncated forms of the protein. The research 
culminated in the generation of a novel cTnI epitope fusion to fatty acid binding protein 
which proved to be stable and soluble with the requisite epitopes available for binding in 
the correct conformations representative of the native antigen. The fusion protein was 
successfully applied for the characterisation of the recombinant antibodies. This construct 
has potential as a novel fusion partner for „difficult-to-express‟ proteins and peptides. The 
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use of recombinant protein expression proved to be a multi-facetted process requiring 
constant adaption in strategy and approach. Given the wealth of structural and genetic 
information available on many diagnostically-important proteins a rational, knowledge-
based approach to antigen design should be undertaken where an antigen is in scarce 
supply, and also to efficiently support the generation of highly-specific and well 
characterised antibodies. In any antibody generation project, the quality of the antigen is 
paramount.  
The use of hybridoma technology for the generation of antibodies was an attractive 
approach due to the patent status of the technology. By not patenting hybridoma 
technology, Kolher and Milstein ensured that significant and successful applications of the 
methodology to diagnostics and therapeutics ensued. In Chapter 4, development of the 
nanomolar affinity IgG1κ monoclonal antibody (20B3) to cTnI was described. It was 
rigorously evaluated using numerous assay configurations to ensure the optimal assay 
capture antibody was selected from the hybridoma screening campaign. However, the use 
of mouse-derived antibodies in diagnostic applications can have potential problems with 
regard to interferences from circulating human-anti-mouse-antibodies and other activated 
complement components [93, 291, 292]. 
The limitations of mouse monoclonal antibodies for human diagnostics favour the 
development of antibodies from alternative immune repertoires, for example the chicken. 
The modularity and plasticity of recombinant antibodies was an attractive approach and 
was introduced in Chapter 5. Recombinant antibody technology surpasses the traditional 
hybridoma methodology by permitting access to the genes encoding for the antibodies from 
virtually any species. Chicken in particular have received attention as excellent hosts for 
diagnostic antibody development [291, 292], twinned with the relative ease at which the 
simplistic avian genes can be accessed for efficient recombinant antibody development. 
Chapter 5 outlines the successful development of an anti-epitope-1-specific scFv and its 
subsequent mutagenesis, resulting in the isolation of an improved mutant derived from 
genetic engineering approaches. The chapter also exemplifies the benefits of high-
throughput systems to screen and affinity rank large numbers of clones from recombinant 
antibody libraries. Using in silico methodologies no structural changes in the antibodies 
could be discerned and this led into initial studies to ascertain the crystal structure of the 
parental and mutant scFvs. Recombinant antibodies, such as the scFv, are not without their 
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limitations for diagnostic-based applications. These include the propensity to aggregate and 
denature if coated onto surfaces and labelling limitations. However, the modular nature of 
recombinant antibody formats facilitated their development and tailoring for the intended 
application. 
In chapter 6, the superiority of the developed anti-epitope-1 scFv (WT and MT) in direct 
comparison to the equivalent industry standard monoclonal antibody was described. The 
available antibodies and formats were tested for optimal pairing to ensure that the antibody 
orientation in the assay facilitated the highest sensitivity possible. In light of these results, 
the limitations of using scFv formats in assays were addressed and initially overcome by re-
formatting experiments to introduce constant domains to form the scAb and site-targetable 
scAb_cys constructs. Such antibody formats could ideally be employed in ECL and SAF-
based assays whereby the enhanced signal generation could greatly improve sensitivity.  
The research described in the course of this thesis demonstrates the merit in applying a 
rational design-based approach to antibody generation and antigen targeting. The approach 
can be applied to any antibody generation campaign and is valid for this particularly 
complex antigen. 
This research was an integral component of a large research effort in the Biomedical 
Diagnostic Institute (BDI) to optimise all key components of assays for disease markers. 
This included high-level signal enhancement technologies (e.g. use of high-brightness 
nanoparticles and specially designed optical detection systems) and novel microfluidics-
based surface optimised chips. Due to the high-affinity and modular nature of the 
antibodies they have major potential as model antibodies to demonstrate the capacity of 
these technologies to generate ultra-sensitive assays and this process is ongoing with 
significant industrial inputs. For the development of a low-cost, highly-specific and 
sensitive point-of-care test for cTnI diagnosis, the issues of affinity and specificity of 
antibodies have been comprehensively addressed for the platforms currently in 
development. Accordingly, significant industrial interest in these antibodies has ensued. 
Advanced licensing agreements for the antibodies and technologies developed in this 
research are in place with the BDIs industrial partners (Merck Millipore and Biosurfit) and 
material is currently in the process of transfer. 
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The comprehensive and integrated approach taken in this research for optimising each 
element of the antibody generation process is unique. Each stage of antibody development 
from the design of the antigen to screening and down-stream re-engineering and 
optimisation of the antibodies was thoroughly and rigorously designed to maximise 
success. This process is the key reason that the thesis presents some of the highest affinity 
tailored antibodies generated to date for cTnI. 
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8.1 Supporting material 
 
Table 8.1-1: Restriction enzymes and recognition sequences 
5'3' cut site is indicated by ^ and complementary 3'5' by the _ (sequence not shown). 
Enzyme Recognition Sequence 
BamHI G^GATC_C 
NcoI C^CATG_G 
SacI G_AGCT^C 
SfiI GGCCN_NNN^NGGCC 
NotI GC^GGCC_GC 
XhoI C^TCGA_G 
XbaI T^CTAG_A 
HindIII A^AGCT_T 
 
ATGGTGGACGCTTTCCTGGGCACCTGGAAGCTAGTGGACAGCAAGAATTTCGATGACTAC 
 M  V  D  A  F  L  G  T  W  K  L  V  D  S  K  N  F  D  D  Y  
ATGAAGTCACTCGGTGTGGGTTTTGCTACCAGGCAGGTGGCCAGCATGACCAAGCCTACC 
 M  K  S  L  G  V  G  F  A  T  R  Q  V  A  S  M  T  K  P  T  
ACAATCATCGAAAAGAATGGGGACATTCTCACCCTAAAAACACACAGCACCTTCAAGAAC 
 T  I  I  E  K  N  G  D  I  L  T  L  K  T  H  S  T  F  K  N  
ACAGAGATCAGCTTTAAGTTGGGGGTGGAGTTCGATGAGACAACAGCAGATGACAGGAAG 
 T  E  I  S  F  K  L  G  V  E  F  D  E  T  T  A  D  D  R  K  
GTCAAGTCCATTGTGACACTGGATGGAGGGAAACTTGTTCACCTGCAGAAATGGGACGGG 
 V  K  S  I  V  T  L  D  G  G  K  L  V  H  L  Q  K  W  D  G  
CAAGAGACCACACTTGTGCGGGAGCTAATTGATGGAAAACTCATCCTGACACTCACCCAC 
 Q  E  T  T  L  V  R  E  L  I  D  G  K  L  I  L  T  L  T  H  
GGCACTGCAGTTTGCACTCGCACTTATGAGAAAGAGGCA 
 G  T  A  V  C  T  R  T  Y  E  K  E  A   
 
Figure 8.1-1: DNA and amino acid sequence of hFABP (Val
2
 to Ala
133
) 
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ATGGCGAACTACCGCGCTTATGCCACGGAGCCGCACGCCAAGAAAAAATCTAAGATCTCC 
 M  A  N  Y  R  A  Y  A  T  E  P  H  A  K  K  K  S  K  I  S  
GCCTCGAGAAAATTGCAGCTGAAGACTCTGCTGCTGCAGATTGCAAAGCAAGAGCTGGAG 
 A  S  R  K  L  Q  L  K  T  L  L  L  Q  I  A  K  Q  E  L  E  
CGAGAGGCGGAGGAGCGGCGCGGAGAGAAGGGGCGCGCTCTGAGCACCCGCTGCCAGCCG 
 R  E  A  E  E  R  R  G  E  K  G  R  A  L  S  T  R  C  Q  P  
CTGGAGTTGGCCGGGCTGGGCTTCGCGGAGCTGCAGGACTTGTGCCGACAGCTCCACGCC 
 L  E  L  A  G  L  G  F  A  E  L  Q  D  L  C  R  Q  L  H  A  
CGTGTGGACAAGGTGGATGAAGAGAGATACGACATAGAGGCAAAAGTCACCAAGAACATC 
 R  V  D  K  V  D  E  E  R  Y  D  I  E  A  K  V  T  K  N  I  
ACGGAGATTGCAGATCTGACTCAGAAGATCTTTGACCTTCGAGGCAAGTTTAAGCGGCCC 
 T  E  I  A  D  L  T  Q  K  I  F  D  L  R  G  K  F  K  R  P  
ACCCTGCGGAGAGTGAGGATCTCTGCAGATGCCATGATGCAGGCGCTGCTGGGGGCCCGG 
 T  L  R  R  V  R  I  S  A  D  A  M  M  Q  A  L  L  G  A  R  
GCTAAGGAGTCCCTGGACCTGCGGGCCCACCTCAAGCAGGTGAAGAAGGAGGACACCGAG 
 A  K  E  S  L  D  L  R  A  H  L  K  Q  V  K  K  E  D  T  E  
AAGGAAAACCGGGAGGTGGGAGACTGGCGCAAGAACATCGATGCACTGAGTGGAATGGAG 
 K  E  N  R  E  V  G  D  W  R  K  N  I  D  A  L  S  G  M  E  
GGCCGCAAGAAAAAGTTTGAGAGC 
 G  R  K  K  K  F  E  S  
  
Figure 8.1-2: DNA and amino acid sequence of rTnI (Asp
25
 to Ser
210
) 
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The pET vectors are sourced from Novagen and the detailed maps were accessed at 
http://www.merck-chemicals.se/life-science-research/vector-table-novagen-pet-vector-
table/c_HdSb.s1O77QAAAEhPqsLdcab?PortalCatalogID=merck4biosciences&CountryNa
me=Ireland 
 
 
Figure 8.1-3: pET26a-c(+) 
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Figure 8.1-4: pET28a-c(+) 
 
 
Figure 8.1-5: pET32a-c(+)  
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Figure 8.1-6: pUC57 
Downloaded from: http://www.genscript.com/site2/document/1400_20060331011034.JPG 
 
 
Figure 8.1-7: pMoPac vector 
Taken from [206]. 
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Figure 8.1-8: Properties of antibody binding proteins A, G and L 
Figure taken from Piercenet.com an excellent resource for technical information. Technical document 
reference number TR0034.3 (www.piercenet.com). 
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Figure 8.1-9: 1kb plus ladder from Invitrogen. 
 
Figure 8.1-10: Fermentas Page-Ruler Plus MW maker. 
Left – early maker, right marker modified by company for improved visualisation. Both were utilised in the 
course of the thesis. The main variation is the 27kDa to 25kDa band change and the green colour applied to 
10kDa marker. 
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Figure 8.1-11: N-end rule for protein degradation in E. coli 
Adapted from [107]. Amino acids highlighted in red signify de-stabilising effects on the protein and amino 
acids in green signify those with stabilising effects on the protein. 
 
 
Figure 8.1-12: Venn diagram  of amino acid properties  
Downloaded from: http://www.dsimb.inserm.fr/~debrevern/VENN_DIAGRAM/aa_venn_diagram.png. 
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Figure 8.1-13: Amino acid structure and properties 
Downloaded from http://www.neb.com/nebecomm/tech_reference/general_data/amino_acid_structures.asp. 
 
Table 8.1-2: Protein crystallisation screening kits 
Kit Crystallisation Screen Type 
Crystallisation Basic Kit for Proteins (Sigma) Primary: Empirical.  
Index (HR) Primary: Diverse reagent.  
Crystal Screen (HR) Primary: Sparse matrix biased. 
PEGRx (HR) Primary/Secondary:  pH and polymer. 
PEG/ION (HR) Primary/Secondary: PEG, ion. 
Salt Rx (HR) Primary/Secondary: Salt and pH. 
Wizard I, II and III (Emerald) Primary: Sparse Matrix, pH buffer and salt. 
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Figure 8.1-14: Amino acid sequence of the avian-derived scFv 4G5 
 
 
Figure 8.1-15: Gel filtration profiles for the scFvs purified by IMAC from periplasmic extraction 
Predominantly monomeric fractions were purified by IMAC as illustrated by the major peak. Higher order 
fractions or aggregates were much less prominent in comparison to cytoplasmic prepared purifications. 
LTQPSSVSAN PGETVKIACS GSGGSYGWYQ QKSPGSAPVT VIYYNNNRPS DIPSRFSGSK  60   
SGSTATLTIT GVQAEDEAVY FCGGWDSSTY TGIFGAGTTL TVLGQSSRSS GGGGSSGGGG  120  
SAVTLEESGG GLQTPGGTLS LVCKGSGFTF SSVNMFWVRQ APGKGLEFVA GINTGAGSGT  180  
NYAPAVKGRA AISRDNGQST VRLQLNNLRA EDTATYFCAK SSYQCSGDYC WGHPGTIDAW  240  
GRGTEVIVSS TSGQAGQHHH HHHGAYPYDV PDYAS                             275  
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